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ABSTRACT 
ROLES OF SURFACTANT AND BINARY POLYMERS ON DISSOLUTION 
ENHANCEMENT OF BCS II DRUGS FROM NANOCOMPOSITES AND 
AMORPHOUS SOLID DISPERSIONS  
 
by 
Md Mahbubur Rahman 
Drug nanocomposites and amorphous solid dispersions (ASDs) are two major 
formulation platforms used for the bioavailability enhancement of BCS Class II drugs. 
The major drawback of nanocomposites is their inability to attain high drug 
supersaturation during in vitro (<50% relative supersaturation) and in vivo dissolution.  
On the other hand, formulating an amorphous solid dispersion (ASD) with high drug 
loading (>20%) that releases drug rapidly, while generating and maintaining high 
supersaturation over at least three hours is challenging. The goal of this thesis is to 
develop a fundamental understanding of the impact of anionic surfactants–polymers 
on in vitro drug release from nanocomposites and ASDs, while addressing the above 
challenges. To achieve this goal, the following objectives are set: (1) compare 
griseofulvin (GF, drug) release from spray-dried nanocomposites and ASDs with 
identical formulation that has low GF:polymer (HPC/Soluplus) mass ratio (1:1 to 1:5) 
and an anionic surfactant (SDS),  (2) examine the presence/absence of SDS on drug 
release from nanocomposites, (3) develop rapidly supersaturating ternary ASDs of 
GF with HPC/Sol and SDS as a minor component, (4) investigate GF release from 
ternary ASDs of GF with a hydrophilic, wettability-enhancing polymer (HPC/PVP-
VA64) as a minor component and an amphiphilic polymer as drug precipitation 
inhibitor (Soluplus), and (5) apply the fundamental knowledge generated for GF to 
another BCS Class II drug, itraconazole (ITZ).   
 
ii 
Spray-drying of aqueous GF nanosuspensions with 1:5 GF:Sol–0.125% SDS 
has led to formation of a novel class of nanocomposites, HyNASDs, which have 
notable amorphous GF content (~5–20%). Their dissolution has generated 300% 
supersaturation within 20 min that is largely maintained after 3 h (250%). Such 
remarkable drug supersaturation is made possible by strong intermolecular 
interactions/miscibility between GF–Soluplus at 1:5 ratio and ensuing fast kinetic 
solubilization of GF nanoparticles upon contact of HyNASDs with water. While 
HyNASDs do not generate as high saturation as ASDs (480%), they can be rendered 
competitive to ASDs upon further optimization. The supersaturation generation by 
HyNASDs is affected by presence of SDS either in the formulation or in the 
dissolution medium, drug–polymer interactions/miscibility as well as the size of the 
drug (nano)crystals in the polymeric matrix. Incorporating even 1.23% SDS in Sol-
based ASDs has led to dramatic increase in supersaturation (max. 570%), but it has 
no notable improvement for HPC-based ASDs. SDS provides Sol-based ASDs with 
enhanced wettability and augments Sol in solubilizing GF, without interfering with 
Sol’s ability to inhibit GF recrystallization. Combination of Sol with HPC/VA64 has 
led to a trade-off between rapid drug release and high supersaturation. A strong 
synergistic effect exists for the ASD with 11:1 Sol:VA64. The inclusion of a 
hydrophilic polymer as a minor component in an amphiphilic, precipitation-inhibiting 
polymer of a ternary ASD exhibited optimal drug release. General findings from GF 
regarding HyNASD formation and impact of SDS are applicable to ITZ as well. 
Overall, this thesis has generated fundamental knowledge about the impact of SDS 
and binary polymers on improved in vitro release of BCS Class II drugs. 
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CHAPTER 1 
INTRODUCTION 
 
1.1  Motivation 
It is estimated that approximately 40% of the marketed drugs and 75% of the new 
drug candidates coming out of the drug discovery pipeline are poorly water soluble 
(Di et al., 2009; Kipp, 2004; Lipinski, 2002). Due to their poor aqueous solubility, 
intestinal absorption of these drugs turns out to be rate-limiting, which leads to low 
bioavailability eventually (Fasano, 1998; Müllertz et al., 2010). Over the years, 
significant number of research has been carried out and directed toward developing 
various formulation/processing strategies to enhance the dissolution performance of 
these drugs. These strategies include production of prodrug (Rumondor et al., 2016), 
salt formation (Elder et al., 2013; Rahman et al., 2012), micelle formation (Letchford 
and Burt, 2007), cyclodextrin complexes (Aleem et al., 2008; Srivalli and Mishra, 
2016), lipid-based systems (Hauss et al., 1998; Humberstone and Charman, 1997), 
drug nanocrystals (Li et al., 2016a; Merisko-Liversidge et al., 2003), amorphous solid 
dispersions (ASDs) (Nakagami, 1991; Serajuddin, 1999) etc. Among all these 
approaches, increasing the surface area by reducing drug particle size (drug 
nanocrystals) and increasing saturation solubility of the drug through the formation of 
ASD have achieved prevalence both in the academia and industry to enhance 
dissolution rate/bioavailability of poorly-water soluble drugs.  
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1.1.1  Background on Drug Nanocrystals and Their Production  
In pharmaceutics literature, drug nanocrystals are defined as crystals with a size in the 
nanometer range; usually ranging from 10 nanometers to 1000 nm (Keck and Müller, 
2006). Since the nanoparticles have tremendously higher specific surface area 
compared to the micron-sized particles, drug nanoparticles can provide significant 
dissolution rate and bioavailability enhancement to a multitude of poorly water-
soluble drugs (Singh et al., 2011; Tanaka et al., 2012).  The classical Noyes–Whitney 
equation (Noyes and Whitney, 1897b) could help to explain the improvement in drug 
dissolution rate, dm/dt, due to the particle size reduction and ensuing increase in 
surface area (Equation 1.1): 
( )sAD C Cdm
dt h
− 
= 
 
 
(1.1) 
where m is mass of drug dissolved at time t, A is the surface area of the particles, D is 
the diffusion coefficient, h is the diffusion layer thickness, Cs is the saturation 
solubility, and C is the instantaneous concentration in the bulk dissolution medium. In 
addition to the significant enhancement of the particle surface area, the diffusion layer 
thickness (h) also decreases significantly as particle size decreases (Galli, 2006). 
Furthermore, the particle size of drugs could also influence their saturation solubility 
in the bulk solution, which can be explained by the Ostwald–Freundlich equation 
(Equation 1.2) (Shchekin and Rusanov, 2008).                         
2
log
2.303
SC V
C RT r


 
= 
 
 
(1.2) 
where CS is saturation solubility, C∞ is solubility of large particles, σ is interfacial 
tension, V is atomic volume, R is gas constant, T is absolute temperature, ρ is density 
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of the solid, and r radius of the small particle. According to Equation (1.2), the 
reduction of particle size especially to sizes below 100 nm increases the saturation 
solubility CS (Shegokar and Müller, 2010). This indicates that not only do 
nanoparticles affect the dissolution rate by higher specific surface area and reduced 
diffusion layer thickness, but also they allow for higher saturation solubility CS. 
(Kesisoglou et al., 2007) have also demonstrated 10–15% solubility increase with the 
reduction of drug particle size down to 100 nm. Others reported similarly higher 
solubility of the ultrasmall particles and nanoparticles (Junghanns and Müller, 2008b; 
Shegokar and Müller, 2010).  
Among various methods used for the production of drug nanoparticles (Li et 
al., 2016a), wet stirred media milling (WSMM) has found the most common use in 
the pharmaceutical industry owing to its unique advantages: WSMM is organic 
solvent free, scalable, and environmentally benign. Moreover, WSMM allows for 
production of nanosuspensions with high drug loading, which exhibit low excipient 
side effects. Also, it has continuous processing capability and can be applied 
universally to any poorly water-soluble drug (Afolabi et al., 2014; Bhakay et al., 
2018b; Kesisoglou et al., 2007; Li et al., 2016a; Merisko-Liversidge and Liversidge, 
2008). Nanosuspensions also have the advantage of higher mass packing (higher 
dose) per injection volume and improved physical stability owing to the use of 
stabilizers such as polymers and/or surfactants (Müller and Peters, 1998; Rabinow, 
2004). Several marketed products such as Rapamune® (Pfizer (Wyeth), New York 
City, NY, USA), Emend® (Merck, Kenilworth, NJ, USA), Tricor® (AbbVie, North 
Chicago, IL, USA), Megace® ES (PAR Pharmaceuticals, Woodcliff Lake, NJ, USA), 
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and Invega® SustennaTM (Janssen, Beerse, Belgium) made use of wet media 
milling. 
In the common recirculating mode of WSMM operation, micron-sized drug 
particles in an aqueous solution of stabilizers, usually polymers and/or surfactants, 
circulates from a holding tank passing through the milling chamber, exiting through a 
screen, and returning to the holding tank. During the milling operation, the milling 
media (beads) are retained in the milling chamber by the screen. Due to high speed 
rotation of the rotor/stirrer, turbulent motion is induced in the suspension, and the 
mechanical power consumed is dissipated during frequent bead–bead collisions 
(Eskin et al., 2005). The drug particles captured between the beads are subjected to 
stress, which is concentrated on the cracks already present in the material and causes 
crack propagation, ultimately leading to breakage of the particles (Schönert, 1988) 
and eventually production of nanoparticles.  
1.1.2   Typical Issues in the Production–Drying of Drug Nanosuspensions   
Despite its advantages, WSMM is not devoid of any issues during the production of 
drug nanoparticles. A major issue is the aggregation–growth tendency of the milled 
drug particles in the aqueous suspensions during milling or storage (Li et al., 2016a). 
Formation of aggregated particles negates the advantage associated with the large 
surface area of the drug nanoparticles. Usually, two major competing mechanisms 
operate during the milling of the drug particles: breakage of the drug particles due to 
mechanical stresses and aggregation due to highly attractive inter-particle forces (van 
der Waals, hydrophobic forces, etc.) (Bhakay et al., 2013b). Additionally, Ostwald 
ripening may occur causing drug nanocrystals to grow (Bitterlich et al., 2014). 
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Ostwald ripening can be defined as a process where differences in solubility, as a 
function of particle sizes, leads to a transport of dissolved drug from small to larger 
particles causing growth over time. Therefore, physical stability of the drug 
nanosuspensions by various stabilizers (Cerdeira et al., 2010; Wu et al., 2011), also 
known as dispersants, is required during milling and storage for proper downstream 
processing and adequate shelf-life. 
Selection of proper stabilizers with optimum concentration plays a major role 
in formulating a stable drug nanosuspension. Inadequate concentration of stabilizers 
may not be able to prevent aggregation of drug nanoparticles, while excess in 
concentration may facilitate Ostwald ripening. Electrostatic interactions, steric forces, 
entropic forces, and van der Waals forces among the nanoparticles usually determine 
the physical stability of the drug nanosuspension (Wu et al., 2011). Drug particles 
dispersed within a liquid continuous medium are stabilized by steric, electrostatic 
mechanisms or combination of both i.e., electrosteric mechanism (see Figure 1.1), 
owing to adsorption of polymers and/or surfactants on drug particle surfaces (Basa et 
al., 2008; Bilgili et al., 2016; Merisko-Liversidge and Liversidge, 2011; Van 
Eerdenbrugh et al., 2008c). Nonionic polymers or nonionic surfactants (e.g., 
poloxamers, cellulosic derivatives, polysorbates, and povidones etc.) usually provide 
steric stability by preventing the particles from getting into the range of attractive van 
der Waals forces. Electrostatic stabilization is usually imparted by ionic surfactants, 
e.g., sodium dodecyl sulfate (SDS), dioctyl sulfosuccinate sodium salt (DOSS), and 
benzethonium chloride (BKC). In electrosteric stabilization, nonionic polymers or 
surfactants and ionic surfactants stabilize the particles, acting simultaneously.   
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Figure 1.1  Schematic of physical stabilization mechanism in drug nanosuspensions:  
(a) steric stabilization imparted by nonionic polymers; (b) electrostatic stabilization 
imparted by anionic surfactants; and (c) electrosteric stabilization imparted by both 
nonionic polymers and anionic surfactants. 
 
Usually, solid dosage forms are preferred over suspensions due to 
convenience and easiness of their use by patients. Therefore, nanosuspensions 
produced via WSMM are dried and converted into nanocomposites microparticles or 
simply nanocomposites, which are ultimately incorporated into standard dosage 
forms such as tablet, capsule, sachets (Basa et al., 2008; Bhakay et al., 2014a; Van 
Eerdenbrugh et al., 2008b), and polymeric strip films (Bhakay et al., 2016; Krull et 
al., 2016; Krull et al., 2015; Sievens-Figueroa et al., 2012; Susarla et al., 2015). 
Drying of nanosuspensions can be achieved via spray-freeze drying (Cheow et al., 
2011; Wang et al., 2012), freeze drying (De Waard et al., 2008; Layre et al., 2006), 
spray drying (Azad et al., 2015b; Lee, 2003), vacuum drying (Choi et al., 2008; Kim 
and Lee, 2010), as well as granulation with, or coating onto, inert excipient particles 
(Basa et al., 2008; Bhakay et al., 2014b). 
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Unfortunately, drug nanoparticles tend to form aggregates during both milling 
and drying of the drug suspensions (Bhakay et al., 2013a; Lee, 2003), causing the loss 
of surface area of the drug. It must be noted that the same dispersants (soluble 
polymers and surfactants) used to prevent nanoparticle aggregation also act as matrix 
former in the dried nanocomposites and modulate drug release during 
dissolution/redispersion (Bhakay et al., 2018b; Li et al., 2016b; Li et al., 2016c). 
However, depending on the formulation, drug nanoparticles may not be fully 
recovered from the dried composites during redispersion and dissolution, which will 
slow down the drug dissolution and reduce the bioavailability from such nanoparticle-
based formulations (Bhakay et al., 2013a; Bhakay et al., 2018b; Chaubal and 
Popescu, 2008). Here, redispersion refers to the dispersion of the drug composites in 
various physiologically relevant fluids like water, and preservation of the milled drug 
particle size. Various redispersion methods were studied extensively by Bhakay et al. 
(2013b, 2018a). Slow/incomplete recovery of drug nanoparticles from the 
nanocomposites was observed when a steric stabilizer or ionic stabilizer was used 
alone in the precursor griseofulvin (drug) suspension (Bhakay et al., 2013b; Lee, 
2003). Drug particles were fully recovered only when steric stabilizer and ionic 
stabilizer were used in combination (e.g., Basa et al., 2008; Bhakay et al., 2013b)) or 
when swellable dispersants were co-milled along with the drug (Azad et al., 2015b; 
Bhakay, 2014; Bhakay et al., 2018a). 
In the production of drug nanosuspensions/nanocomposites, the most widely 
used dispersants are the soluble polymers (Bhakay et al., 2018b; Li et al., 2016a). 
Among different properties of the polymers, molecular weight (MW) has a great 
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impact on the steric stabilization of the drug suspensions. It also regulates the 
suspension/solution viscosity (Adamson and Gast, 1997; Choi et al., 2008; Ploehn 
and Russel, 1990), mechanical properties of films (Rowe, 1986), and drug release 
from polymer-based dosages (Mittal et al., 2007). Similarly, use of different polymers 
or polymers with different MW is expected to determine the extent of aggregation in 
drug nanosuspensions and nanocomposites. Interestingly, only few studies examined 
the impact of different polymers and different MW of the same polymer on drug 
nanosuspension stabilization and dissolution enhancement systematically, which 
requires further investigation. On the other hand, despite being an effective 
dispersant, surfactants may pose several challenges such as aggregation of the drug 
nanoparticles in suspensions during milling/storage (Cerdeira et al., 2010; Knieke et 
al., 2013), micellar solubilization of the drug (Yalkowsky and Roseman, 1981) and 
particle growth via Ostwald ripening during milling and/or storage (Ghosh et al., 
2011; Knieke et al., 2013; Verma et al., 2011). Additional challenges associated with 
the use of anionic surfactants include incompatibilities with other ionic molecules, 
sensitivity to pH, salt or temperature changes, GIT irritation (Gupta and Kompella, 
2006; Liversidge and Cundy, 1995), and even toxicity when used in excess 
(Liversidge and Cundy, 1995), especially for inhalation applications (Lebhardt et al., 
2011; Suzuki et al., 2000). In view of all the aforementioned issues, during 
formulation development, surfactant usage should be minimized to mitigate all 
potential negative impact.  
Besides all the challenges mentioned above regarding the drug nanoparticle-
based formulations, limited supersaturation capability of nanocomposites appears to 
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be the greatest impediment to the bioavailability enhancement and their 
competitiveness to ASDs. Throughout the thesis, supersaturation refers to relative 
supersaturation defined as S = (C/Cs –1), where C is the drug concentration in a 
dissolution medium and Cs refers to the thermodynamic aqueous solubility of the 
crystalline drug at the same temperature. While in the prevalent pharmaceutical 
terminology, particles with sizes less than 1 µm are considered nanoparticles 
(nanocrystals); in most published work, the median/mean size is in the range of 100–
400 nm (see the review by Li et al., 2016a) and fewer publications reported true drug 
nanoparticles with a median/mean size below 100 nm (e.g., Li et al., 2015). As 
mentioned in Section 1.1.1, owing to their high curvature, nanocrystals with sizes 
<~100 nm tend to show high saturation solubility, which also enhances the 
dissolution rate, and this phenomenon can be explained via the Kelvin and the 
Ostwald–Freundlich equation (Equation 1.2) (Muller et al., 1998). The higher 
apparent solubility that originates from the greater curvature of <~100 nm 
nanocrystals than that of the micron-sized crystals was estimated to be ~10–15% 
(Kesisoglou and Wu, 2008); however, up to 50% increase in apparent solubility was 
also reported (Muller and Peters, 1998). In general, the potential benefit of 
nanocrystals in terms of supersaturation is mostly left without consideration in the 
field of bioavailability enhancement (Peltonen et al., 2018), which requires more 
investigation.  
1.1.3  Amorphous Form of Drugs  
Enhanced dissolution rate, improved bioavailability, safe dose escalation, elimination 
of food effects, and improved safety, efficacy and tolerability profiles are some of the 
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numerous advantages of drug nanocrystals (Junghanns and Müller, 2008a). However, 
with all these advantages, nanocrystal formulations are severely limited in their 
bioavailability enhancement capability due to low aqueous solubility of drug 
nanocrystals. Often for drugs with very low aqueous solubility, the achieved increase 
in dissolution rate via size reduction is limited and insufficient to provide significant 
enhancement of bioavailability (Müller et al., 2011). Another platform approach for 
bioavailability enhancement of poorly water-soluble drugs is the production of 
amorphous form of the drug. Amorphous drugs lack distinct intermolecular 
arrangement that leads to crystalline structure. They exhibit lower thermodynamic 
stability and higher apparent solubility then their crystalline counterparts. The 
solubility advantage of the pure amorphous compared with its crystalline form could 
be theoretically estimated using Equation (1.3) (Hancock and Parks, 2000):                        
Gamorphous
RT
crystal
e


 
= 
 
 
(1.3) 
where σamorphous/σcrystal is the ratio of the solubility of amorphous form to the stable 
crystalline from, ΔG is the free energy difference between the amorphous and 
crystalline forms, R is the universal gas constant, and T is the temperature in Kelvin. 
The free energy difference can be determined from Hoffman equation (Equation 1.4) 
(Hoffman, 1958).  
2
f
m
H T T
G
T
  
 =  
(1.4) 
where ΔHf is the enthalpy of fusion, T is the operating temperature, Tm is the melting 
point temperature, and ΔT is the difference between Tm and T.  
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Unfortunately, taking advantage of amorphous form of poorly water-soluble 
drugs is challenging since pure amorphous drugs are inherently metastable: they can 
simply convert to crystalline form during processing and storage (recrystallization in 
the solid state) (Marsac et al., 2006; Shamblin et al., 1999; Wu and Yu, 2006; Yu, 
2001) as well as during dissolution (recrystallization in the liquid dissolution 
medium) (Alonzo et al., 2010). Usually, pure amorphous products are undesirable to 
scale up due to their highly unstable nature and higher energy state. To resolve this 
stability issue, drugs are dispersed molecularly in an amorphous polymeric matrix, 
known as amorphous solid dispersions (ASDs), which imparts stability (prevention of 
recrystallization) to amorphous form of the drug during storage and dissolution. 
Polymers can provide stability through a number of mechanisms including reduction 
in the drug molecules’ mobility, increase in the glass transition temperature (Tg) of 
amorphous drug via ASD formation and anti-plasticization exerted by the glassy 
polymer matrix (Crowley and Zografi, 2002; Cui, 2007; Shah et al., 2013; Van den 
Mooter et al., 2001), and strong drug–polymer intermolecular interactions such as 
hydrogen bonding, hydrophobic interactions, etc. (Kestur and Taylor, 2010; Kestur et 
al., 2011). Since the apparent solubility of the amorphous form is higher than its 
crystalline counterpart, ASDs can offer significant enhancement in the dissolution 
rate and supersaturation generation under non-sink conditions resulting in 
bioavailability enhancement of the drugs with very low aqueous solubility (Ambike 
et al., 2005; Six et al., 2004; Yamashita et al., 2003). Usually, types of the carrier 
matrix, molecular level interaction of drug–polymer, the extent of recrystallization 
inhibition during storage and dissolution, drug:polymer ratio, and manufacturing 
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process play important roles in the production and stabilization of ASDs (Li et al., 
2017a; Qian et al., 2010; Thakral and Thakral, 2013).  
1.1.4  Production of Amorphous Solid Dispersions (ASDs) 
Processes used for the production of ASDs can be broadly classified into two major 
categories: solvent-based processes and fusion/melting-based processes (Brough and 
Williams, 2013). In the fusion/melting-based processes, drug and polymeric carriers 
are melted together at a temperature above their melting or glass transition 
temperature, then the molten liquid is solidified by rapid cooling. Due to the rapid 
cooling, drug molecules do not have sufficient time and molecular mobility to 
crystallize while being trapped inside the highly viscous polymeric matrix (Brough 
and Williams, 2013), which leads to molecular dispersion of the drug inside the 
polymer or formation of a solid drug–polymer solid solution. The resultant solid is 
then crushed or milled to obtain a desired particle size. The main advantage of the 
fusion/melting-based processes is that they do not require any solvent. However, an 
important prerequisite for ASD formation is the miscibility of the drug and polymer 
in the molten state to obtain a homogenous mixture. Thus, for a successful 
formulation, a polymeric carrier that shares similar physicochemical properties with 
the drug would be more suitable (Vo et al., 2013). Despite having found significant 
use in pharmaceutical industry, the most serious limitation of the fusion/melting-
based processes is that they can only process drugs and polymers that are not 
thermally degradable at the elevated temperatures required for proper processing 
(Vasconcelos et al., 2016). Another issue is that if the drug and polymer are not 
miscible at the processing temperature; phase separation of the drug during cooling is 
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highly likely. Hot melt extrusion (HME) has become the standard fusion-based 
process to produce ASDs (Baghel et al., 2016).   
Solvent-based processes entail preparing a solution of both drug and polymer 
in a single solvent or solvent mixture followed by removal of the solvent(s) to yield a 
solid dispersion. This technique enables molecular level mixing of the drug and 
polymer, which could be beneficial to the drug–polymer miscibility and stability of 
the product. It addresses the main issue associated with the melting method relating to 
the decomposition of drugs and carriers at high temperature because solvent can be 
removed at relatively low temperatures. An important prerequisite of the solvent-
based process is the solubilization of the drug and polymer in the same solvent 
mixture (Leuner and Dressman, 2000). However, finding out a suitable non-toxic 
solvent is not always an easy task because carriers are hydrophilic in nature, whereas 
drugs are hydrophobic. Another disadvantage of this method is residual solvent after 
evaporation, which often requires a secondary drying process such as oven drying, 
microwave drying, etc. to achieve an acceptable solvent content required by 
regulations and maintain physical stability by avoiding any plasticization effect of the 
residual solvent (Brough and Williams, 2013; Janssens and Van den Mooter, 2009). 
Spray drying (Langham et al., 2012; Paradkar et al., 2004) and freeze drying 
(Kagotani et al., 2013; Schersch et al., 2010) are two widely used processes for the 
production of ASDs in the solvent-based process. Freeze drying or lyophilization is a 
process comprised of freezing the drug–polymer solution followed by the reduction 
of surrounding pressure allowing sublimation of the frozen solvent (Brough and 
Williams, 2013; Van Drooge et al., 2006). In the spray drying process, a drug–
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polymer solution is atomized into a hot gas chamber that causes fast evaporation of 
the solvent, resulting in sudden increase in viscosity and encapsulation of the drug 
molecules in amorphous form into the polymeric matrix (Vehring, 2008). The fast 
drying and presence of the amorphous polymer matrix prevents nucleation and 
growth of drug crystals, thus enabling molecular level dispersion of the amorphous 
drug in the polymeric matrix. 
1.1.5  Challenges Involved with Amorphous Solid Dispersions (ASDs) 
Despite several advantages of ASDs, the number of commercially available products 
is not as high as one would anticipate or desire (see Table 1.1). The most important 
problem is the poor stability of the amorphous drug during production, storage, and 
dissolution. In general, recrystallization of the amorphous drugs occurs in two stages: 
nucleation followed by crystal growth via diffusion or rearrangement of the drug 
molecules (Baird and Taylor, 2012). Thus, for the physical stability, molecular 
mobility of the drug–polymer is an important factor for the stability of the amorphous 
drug. Moisture acts as a plasticizer and often reduces the Tg of ASD and thus 
increases molecular mobility (Duddu and Sokoloski, 1995; Hancock and Zografi, 
1994). Since polymer absorb moisture during storage, the storage at high relative 
humidity (RH) can accelerate drug recrystallization (Rumondor et al., 2009). High 
storage temperature, especially closer to the glass transition temperature of the ASD, 
could be another reason for accelerated recrystallization of the drug due to enhanced 
molecular mobility (Alhalaweh et al., 2015; Shibata et al., 2014).  
Besides storage instability, maintenance of supersaturation during the 
dissolution of ASDs is another major challenge. During dissolution, drug may phase 
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separate in the form of liquid–liquid phase-separated (LLPS) droplets, or may convert 
to crystalline nanoparticles, which will lead to a significant reduction of the 
supersaturation and inability to maintain high extent of drug dissolution (Ilevbare and 
Taylor, 2013). Crystallization from amorphous formulations is complex and may 
occur either directly from the solid matrix upon contact with the dissolution medium 
or from a supersaturated solution generated during dissolution under non-sink 
conditions (Alonzo et al., 2010). Polymers play a critical role in altering the 
crystallization kinetics of the drug from both the matrix (Ewing et al., 2014) and 
solution phase (Raghavan et al., 2001), enabling supersaturation generation and 
maintenance when the polymer is judiciously selected in the formulation (Alonzo et 
al., 2011; Alonzo et al., 2010; Suzuki and Sunada, 1998). Multiple factors such as 
polymer type, drug–polymer miscibility and interactions, and physical stability of the 
amorphous drug have significant effect on the dissolution performance of ASDs 
(Craig, 2002; Serajuddin, 1999). Therefore, a number of complex factors needs to be 
considered during the evaluation of dissolution performance of ASDs including the 
drug:polymer ratio, the relative dissolution rate of the components, and the 
crystallization behavior of the drug during dissolution. In order to understand the 
mechanisms of drug release from ASDs and to optimize polymer selection, it is 
essential to evaluate the relative impact of the polymer on crystal nucleation and 
growth. 
 
 
 
16 
 
Table 1.1 List of Commercially Available Medicines Manufactured by Amorphous 
Solid Dispersion (ASD) Technique Containing Poorly Water-soluble Drugs 
Trade Name Generic Name 
Processing 
Technologya 
Company  
(Year of Approval)b 
Cesamet® Nabilone SE Meda Pharma (1985) 
ISOPTIN® SR Verapamil ME 
Ranbaxy Laboratories 
(1987) 
Sporanox®  Itraconazole 
FB bead 
layering 
Janssen (1992) 
Prograf® Tacrolimus SD Astellas Pharma (1994) 
NuvaRing® 
Etonogestrel/ 
Ethinyl Estradiol 
ME Merck (2001) 
Kaletra® Lopinavir/Ritonavir  ME AbbVie (2007) 
Intelence® Etravirin SD Janssen (2008) 
Modigraf® Tacrolimus SD Astellas Pharma (2009) 
Zortress® Everolimus SD Novartis (2010) 
Norvir®  Ritonavir ME AbbVie (2010) 
Onmel® Intraconazole ME Merz Pharma (2010) 
INCIVEKTM Telaprevir SD Vertex (2011) 
Zelboraf® Vemurafenib 
Solvent/ 
anti-solvent 
precipitation 
Roche (2011) 
Kalydeco® Ivacaftor SD Vertex (2012) 
Noxafil® Posaconazole ME Merck (2013) 
Astagraf XL® Tacrolimus WG Astellas Pharma (2013) 
Belsomra® Suvorexant ME Merck (2014) 
Harvoni® Ledipasvir/Sofosbuvir SD Gilead Sciences (2014) 
Viekira XRTM 
Dasabuvir/Ombitasvir/ 
Paritaprevir/Ritonavir 
ME AbbVie (2014) 
Epclusa® Sofosbuvir/Velpatasvir SD Gilead Sciences (2016) 
Orkambi® Lumacaftor/Ivacaftor SD Vertex (2016) 
VenclextaTM Venetoclax ME AbbVie (2016) 
Zepatier® Elbasvir/Grazoprevir SD Merck (2016) 
MavyretTM 
Glecaprevir/Pibrentasv
ir 
ME AbbVie (2017)c 
aFB: Fluidized Bed; ME: Melt Extrusion; SD: Spray Drying; SE: Solvent Evaporation; WG: Wet 
Granulation. 
bBased on US Food & Drug Administration (FDA), 2016 (Huang and Williams, 2018; Jermain et al., 
2018). 
cBased on European Medicines Agency: Public Assessment reports, 2016 (Huang and Williams, 2018; 
Jermain et al., 2018).     
 
Although the higher free energy of the amorphous form may theoretically 
achieve a solubility level that is order of magnitude higher than that of its crystalline 
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counterpart, this high free energy also works as the driving force for spontaneous 
recrystallization from the solid state or supersaturated solution upon dissolution 
(Marsac et al., 2006). Usually, in the conventional ASDs, drug is molecularly 
dispersed or solubilized in a polymeric carrier (binary system) (Konno et al., 2008). 
However, significant improvement in the performance of drug ASDs has been 
reported recently for ternary ASDs consisting of drug–binary polymers (Xie and 
Taylor, 2016) or drug–polymer–surfactant (Ghebremeskel et al., 2007). Several 
reports have shown the improved dissolution performance and storage stability due to 
the presence of surfactant in the ASD formulation over the formulation w/o 
surfactants (Ghebremeskel et al., 2007; Goddeeris et al., 2008; Joshi et al., 2004; Li et 
al., 2013; Sotthivirat et al., 2013, Feng et al., 2018). It is claimed that presence of 
surfactant in the ASD formulation increases the drug wettability by reducing the 
interfacial energy barrier between the drug particles and the dissolution medium and 
it can inhibit drug precipitation in the aqueous medium (Jung et al., 2016). On the 
other hand, detrimental effects of the surfactants have also been reported in literature 
during dissolution of ASDs due to the competitive interaction between drug–
polymer–surfactant resulting in promoted recrystallization of the drug from 
supersaturated solutions (Chen et al., 2016; Liu et al., 2016; Deshpande et al., 2018). 
In fact, sometimes by increasing the solubility and reducing the surface tension of the 
growing crystals, surfactants might promote precipitation in vivo negating the 
supersaturation maintenance of the drug (Rodríguez‐hornedo and Murphy, 1999). 
Therefore, to say the least, the roles/impact of surfactant in the dissolution of drug 
ASDs are elusive, and the use of surfactants can be detrimental/beneficial depending 
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on the specific drug–polymer–surfactant system and composition. Hence, further 
investigation of the roles of surfactants in the wettability enhancement and 
recrystallization inhibition of drugs along with polymers is warranted.  
Conventionally, ASD has been regarded as a simple binary component system 
in which the drug acts as a solute and the polymer acts as a solvent (Meng et al., 
2017). However, a successful ASD formulation must be resistant to recrystallization 
during processing and storage. Moreover, ideally having a high drug load, it should 
generate and maintain high supersaturation during in vivo dissolution (Davis, 2018). 
Meeting all these criteria using a single polymer (binary ASD) could be very 
challenging; hence, an upsurge of research into ternary ASDs in the recent years is 
notable (Davis, 2018). Significant improvement in the performance of drug ASDs has 
already been reported recently by using ternary systems such as drug–binary 
polymers (e.g., Xie and Taylor, 2016a) and drug–polymer–surfactant (e.g., 
Ghebremeskel et al., 2007). The use of binary polymers in a ternary drug ASD has 
been the focus of recent studies for further improvement of drug dissolution. In the 
ternary ASD system (binary polymer), the dissolution profile is regulated by the 
characteristics of individual polymers (Ohyagi et al., 2017). Some polymers enable 
rapid drug release, while others can efficiently inhibit recrystallization in the 
polymeric matrix and the dissolution medium during the in vitro or in vivo dissolution 
(Zhang et al., 2018). However, in the ternary ADSs, various polymers with different 
hydrophilicity/amphiphilicity and drug recrystallization inhibition capability have 
been combined to improve the dissolution performance of ASDs (Prasad et al., 2016; 
Xie and Taylor, 2016a; Yoshida et al., 2012). Another driver for ternary ASDs 
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besides dissolution enhancement is improved storage stability and long-term drug 
recrystallization inhibition (Albadarin et al., 2017; Davis et al., 2018).  
In the rest of Chapter 1, the remaining challenges and knowledge gaps 
regarding various aspects of drug nanocomposites and ASDs that are used in the 
dissolution enhancement of poorly water-soluble drugs are presented and how each 
chapter of this dissertation will address them will be indicated. 
 
1.2  Remaining Challenges and Knowledge Gaps 
1.2.1  Comparative Assessment of Various Dispersants and Their Molecular 
Weight in Nanosuspension Stabilization and Dissolution Rate Enhancement 
Particle size growth and aggregation occur in drug suspensions during wet media 
milling, storage, and downstream processing, and the extent of such phenomena must 
be reduced as they reduce drug surface area available for dissolution (Bilgili et al., 
2016; Knieke et al., 2014). To prevent gross physical instability, drug 
nanosuspensions are usually dried into nanocomposites that are then incorporated into 
standard solid dosage forms such as tablets and capsules (Basa et al., 2008; Bhakay et 
al., 2018b; Van Eerdenbrugh et al., 2008c). This approach also helps to achieve 
patient compliance because solid oral dosage forms incorporating drug nanoparticles 
are preferred over drug nanosuspensions. Among different drying techniques, spray-
drying is preferred over other techniques due to several advantages such as its 
continuous and scalable nature, its ability to produce micron-sized particles with large 
surface area (Kemp, 2011), and its potential in producing high drug-loaded 
nanocomposites (Azad et al., 2015b; Bhakay et al., 2014a). Although high drug 
loading in dried powders can be achieved by both freeze drying and spray drying 
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(Azad et al., 2015b; Niwa and Danjo, 2013), spray drying is inherently continuous 
having a one-step process, and is more energy and time efficient compared to freeze 
drying (Chin et al., 2014). Hence, spray drying is selected here as the drying method 
for converting drug nanosuspensions into nanocomposites. 
Although preparation of drug nanoparticles in the form of wet-milled 
suspensions and their drying into nanocomposites has been shown to be an effective 
approach for enhancing the dissolution rate of various poorly water-soluble drugs 
(Bhakay et al., 2018b; Li et al., 2016a), several challenges remain in formulation 
design. To prevent aggregation during milling and ensure physical stability of the 
suspensions, dispersants such as polymers, sugars, and surfactants are added to the 
suspensions where they function as stabilizers (Bhakay et al., 2018b; Chin et al., 
2014; Kesisoglou et al., 2007). Unfortunately, depending on the concentration and 
types of dispersants used in the formulation, drug nanoparticles may still form 
aggregates in the wet-milled suspensions due to attractive inter-particle forces (van 
der Waals, hydrophobic forces, etc.) (Li et al., 2016a; Malamatari et al., 2018); 
further aggregation may occur during drying (Bhakay et al., 2014a; Kim and Lee, 
2010; Li et al., 2016d). It must be noted that the same dispersants used to prevent 
nanoparticle aggregation also act as matrix former in the dried nanocomposites and 
modulate drug release during dissolution/redispersion (Bhakay et al., 2018b; Li et al., 
2016a; Li et al., 2016b). Overall, the anticipated advantage of producing drug 
nanoparticles in terms of dissolution enhancement may not be achieved fully due to 
the aggregation of the drug particles upon milling and drying (Bose et al., 2012; Choi 
et al., 2008) and slow nanoparticle recovery from the nanocomposite matrix (Bhakay 
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et al., 2014a; Li et al., 2016b).  
Among various classes of dispersants, surfactants have been commonly used 
because they enhance drug wettability, reduce surface tension, and provide 
electrostatic stabilization (Bhakay et al., 2018b; Gupta et al., 2013; Li et al., 2018a). 
However, there could be several issues with use of surfactants in drug 
nanosuspensions such as aggregation of drug nanoparticles (Knieke et al., 2013; Li et 
al., 2016d), particle size growth due to Ostwald ripening during milling and/or 
storage (Ghosh et al., 2011; Knieke et al., 2013), and micellar solubilization of the 
drug (Yalkowsky and Roseman, 1981). Additional challenges for anionic surfactants 
include incompatibilities with other ionic molecules; sensitivity to pH, salt, and 
temperature changes; GIT (gastro intestinal tract) irritation (Gupta and Kompella, 
2006; Liversidge and Cundy, 1995); and toxicity when used in excess (Liversidge 
and Cundy, 1995), especially for the inhalation applications (Lebhardt et al., 2011; 
Suzuki et al., 2000). Various formulation strategies can be used to mitigate these 
issues with surfactants. One strategy is to use a combination of a surfactant with a 
water-soluble adsorbing polymer, thereby reducing surfactant usage (Bhakay et al., 
2018b; Bilgili and Afolabi, 2012; Bilgili et al., 2016; Niwa et al., 2011). Another 
strategy is to develop surfactant-free formulations that contain other classes of 
dispersants either alone or in combination (Bhakay et al., 2018b; Chin et al., 2014). 
For example, water-soluble polymers such as hydroxypropyl cellulose (HPC), 
hydroxypropyl methyl cellulose (HPMC), polyvinylpyrrolidone (PVP), and 
polyethylene glycol (PEG) can be used alone or in combination with other water-
soluble dispersants such as sugars (e.g., sucrose, lactose) and sugar alcohols (e.g., 
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mannitol, sorbitol) (Abdelwahed et al., 2006; Chin et al., 2014; Kesisoglou et al., 
2007), water-insoluble dispersants such as microcrystalline cellulose, anhydrous 
dicalcium phosphate, and montmorillonite (Van Eerdenbrugh et al., 2008a), and 
swellable crosslinked polymers such as sodium starch glycolate and croscarmellose 
sodium (Azad et al., 2015b; Bhakay et al., 2014b).  
Polymers are the most widely used dispersants in drug 
nanosuspensions/nanocomposites (Bhakay et al., 2018b; Li et al., 2016a). Polymer 
molecular weight (MW) affects steric stabilization in drug suspensions and 
suspension/solution viscosity (Adamson and Gast, 1997; Choi et al., 2008; Ploehn 
and Russel, 1990), mechanical properties of films (Rowe, 1986), and drug release 
from polymer-based dosages (Mittal et al., 2007). More specifically, use of different 
polymers or polymers with different MW is expected to determine the extent of 
aggregation in drug nanosuspensions and nanocomposites. Interestingly, only few 
studies examined the impact of different polymers and different MW of the same 
polymer on drug nanosuspension stability systematically. For example, ITZ was wet 
ball-milled for 4 days in aqueous solution of HPC with MW in the range ~10–50 
kg/mol inside a vial (Choi et al., 2008). This study concluded that lower MW HPC is 
more effective for faster particle size reduction, while suspensions with all HPC 
grades were stable. However, they did not study the impact of MW on drug 
dissolution. Nabumetone and halofantrine suspensions with HPMC and PVP were 
wet media milled for 6 h in a mixer mill (Sepassi et al., 2007); however, drying of the 
suspensions and dissolution testing were not performed. Their study suggests that 
only lower MW HPMC (<50 kg/mol) led to drug suspensions having mean particle 
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sizes less than 1 µm. Unfortunately, studies like (Choi et al., 2008; Sepassi et al., 
2007) that used low-energy mills as opposed to high-energy (wet stirred media) mills 
do not truly reflect the impact of different polymers or MW on steric stabilization and 
reduction of drug aggregate formation. In wet media milling, breakage kinetics and 
extent of drug particle breakage depend on the viscosity of the drug suspensions, 
which is affected by the type/MW of the polymer (Li et al., 2016a). The use of higher 
MW polymer and/or higher polymer concentration causes more pronounced viscous 
dampening and slower breakage (Bilgili and Afolabi, 2012; Sepassi et al., 2007). 
While viscous dampening occurs in any wet media mill, low-energy mills are 
particularly sensitive to viscous dampening; drug nanoparticles may not even be 
produced with high MW polymers even after prolonged milling (see e.g., Sepassi et 
al., 2007). Hence, such studies drew somewhat confounded conclusions about the 
impact of polymer MW due to significant impact of viscous dampening. In the study 
presented in Chapter 2, a wet stirred media mill was used instead, which reduces the 
sensitivity to viscous dampening and helps to better elucidate the roles of polymer 
MW. 
Itraconazole (ITZ), an antifungal drug, has been used for the treatment of 
local and systemic mycoses. As it is a hydrophobic model BCS Class II drug with 
high permeability and poor water solubility (<1 ng/mL) (Peeters et al., 2002), several 
research groups (Azad et al., 2016; De Smet et al., 2014; Parmentier et al., 2017; 
Sarnes et al., 2014; Van Eerdenbrugh et al., 2008d) produced ITZ-loaded 
nanocomposites to improve its dissolution rate. These studies used surfactants along 
with other dispersants in the nanocomposite formulations; the highest drug loading 
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that achieved immediate drug release (>80% in 20 min) was 63% (Van Eerdenbrugh 
et al., 2008d). Therefore, in Chapter 2, the impact of various polymers/MW on ITZ 
nanosuspension stabilization and ITZ release from spray-dried ITZ nanosuspensions 
is investigated. This investigation could yield significant insight into the roles of 
polymers and allow for design of high-drug loaded, fast-dissolving, surfactant-free 
nanocomposites. 
1.2.2  Drug Nanocomposites With High Supersaturation Capability and Their 
Comparison to ASDs in Dissolution Enhancement 
As mentioned in Section 1.1.2, hydrophilic/amphiphilic polymers and/or surfactants 
are added to the suspensions as stabilizers to suppress the aggregation during and 
after WSMM (Li et al., 2016b; Wang et al., 2013). In general, drug:stabilizer mass 
ratio has been optimized based on several considerations. At low concentration of 
stabilizers, drug nanoparticle aggregation cannot be suppressed (Knieke et al., 2013; 
Li et al., 2016c); while if used in excess, stabilizers especially surfactants may 
promote Ostwald ripening (Ghosh et al., 2011; Verma et al., 2011). Also depending 
on the molecular weight of the polymer, too high concentration of the polymer can 
cause significant viscous dampening, leading to slower breakage kinetics during 
milling (Bilgili and Afolabi, 2012; Knieke et al., 2013) as well as downstream 
processing issues (Bhakay et al., 2018). Finally, stabilizer concentration should be 
minimized to achieve high drug loading in the final solid dosages, while still 
achieving physical stability in the milled suspensions (Bhakay et al., 2018b; Li et al., 
2016b). In view of these considerations, it is no surprise to find that a drug:polymer 
mass ratio much higher than 1 has been widely reported in several papers: 1:0.5 to 
1:0.05 (Kesisoglou et al., 2007; Wang et al., 2013),  1:0.8 to 1:0.02 (Chang et al., 
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2015), and 1:1 to 1:0.02 (Van Eerdenbrugh et al., 2008c). A quick review of recent 
literature (see Table 1.2) also suggests a similarly high drug:polymer mass ratio, i.e., 
1:1 to 1:0.01, in drug nanosuspensions used in the preparation of spray-dried 
nanocomposites. 
As mentioned in Section 1.1.2, drug nanosuspensions prepared via WSMM 
are usually dried and converted into nanocomposite microparticles or shortly 
nanocomposites. Pharmaceutical formulators need to resolve two major issues 
regarding the drug release from nanocomposites. First, depending on the stabilizer 
formulation in the precursor nanosuspensions, primary drug nanoparticles may not be 
effectively recovered from the nanocomposites during the dissolution (Azad et al., 
2015b; Bilgili et al., 2018). This may be attributed to the poor physical stability of the 
drug nanosuspensions (extensive aggregation) prepared by WSMM and/or inability of 
the nanocomposite matrix to release drug nanoparticles fast enough (Azad et al., 
2015b; Bhakay et al., 2013a; Bilgili et al., 2018; Li et al., 2016c). These issues have 
been largely addressed (see Bhakay et al., 2018b and the references cited therein), 
e.g., by using strongly adsorbing/interacting polymers (Bilgili et al., 2018), soluble 
excipients like sugars and sugar-alcohols (Iurian et al., 2017; Medarević et al., 2018), 
combination of a polymer with a surfactant (Bhakay et al., 2014a; Li et al., 2016b), 
and combining an adsorbing polymer with colloidal superdisintegrants (Azad et al., 
2015b; Li et al., 2018b).  
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Table 1.2  Formulations and Drug–Polymer Content of Nanosuspensions Used for the Preparation of Spray-Dried 
Nanocomposites in Recent Studies  
Drug  Drug content  
(% w/v) 
Polymeric stabilizerb  Drug:polymer mass 
ratio 
References 
Naproxen 1.0 HPMC 1:0.5 Kumar et al. (2014)  
Lovastatin 0.5a PVP K12, K30, K17, and PVA 1:0.2 Zhang et al. (2014)  
Griseofulvin 10a HPC SL 1:0.25 Azad et al. (2015)  
Naproxen 1.0, 3.0, and 5.0 HPMC E15 1:0.2–1:0.6 Kumar et al. (2015)  
Griseofulvin 5.0 HPC SL 1:0.25 Shah et al. (2016)  
Allisartan Isoproxil 5.0 PVP K30 1:0.01–1:0.03 Hou et al. (2017)  
Mefenamic Acid 5.0a HPC SSL 1:0.15 Konnerth et al. (2017)  
Aprepitant 2.5 Pharmacoat 603 and HPC SSL 1:0.5, 1:1 Toziopoulou et al. (2017)  
Carvedilol 8.3 HPC SL 1:0.1–1:0.4 Medarevic et al. (2018)  
Fenofibrate 10.0a HPC 1:0.25 Aleandri et al. (2018)  
Itraconazole 10.0a HPC SL 1:0.25–1:0.65 Li et al. (2018)  
Itraconazole  10.0a HPC L and HPC SL 1:0.45 Bilgili et al. (2018)  
aWith respect to the total weight of the suspension liquid (% w/w); bHPMC: hydroxypropyl methylcellulose, HPC: hydroxypropyl cellulose, PVA: polyvinyl 
alcohol, PVP: polyvinylpyrrolidone. 
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Unfortunately, the second major challenge, i.e., the low supersaturation 
generation capability of drug nanocomposites in in vitro and in vivo dissolution has 
not been resolved. Interestingly, even though all studies mentioned in Table 1.2 
reported significant increase in drug release from the spray-dried nanocomposites as 
compared with as-received drug micro-crystals and their physical mixtures with the 
excipients, none of these studies investigated or reported any supersaturation 
generation in the dissolution tests. In fact, the low drug supersaturation from 
nanocomposites is the primary reason for pharmaceutical formulators to opt for ASDs 
for bioavailability enhancement of high-dose poorly soluble drugs. As mentioned in 
Section 1.1.3, as the apparent solubility of the amorphous form is much greater than 
its crystalline counterpart, ASDs provide high extent of drug release above 
thermodynamic solubility and significant supersaturation (Ambike et al., 2005; Six et 
al., 2004; Yamashita et al., 2003) unlike drug nanocomposites.  
Surprisingly, although both drug nanocomposites and ASDs have been used 
as two major platforms for dissolution enhancement, a head-to-head comparison of in 
vitro drug release from these two solid dosage forms having identical formulation is 
not available in the literature. Typically, to establish the dissolution enhancement 
owing to the use of nanocrystals, nanocomposites were compared with the as-
received crystalline drug as well as physical mixtures of the as-received drug with the 
same formulation of the nanocomposites (Bhakay et al., 2014a; Hecq et al., 2005). 
Likewise, ASDs were compared to the as-received drug microparticles and/or drug 
microparticles in tablets/capsules in terms of dissolution enhancement (Jung et al., 
1999; Six et al., 2004). In some cases, nanosuspensions, not dried nanocomposites, 
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were compared with ASDs, but not in a head-to-head manner. For instance, Fakes et 
al. (2009) investigated the bioavailability enhancement of a BCS class II drug, BMS-
488043, using a 10% (w/w) drug nanosuspension with 2% (w/w) hydroxypropyl 
cellulose (HPC-SL) and 0.1% (w/w) sodium lauryl sulfate (SLS). They also prepared 
the drug ASD by spray drying and flash evaporation techniques at different 
drug:polymer (polyvinyl pyrrolidone, PVP) ratios. In the case of spray drying, 40:60 
drug:PVP was used for the formulation development and further characterization, 
whereas 90:10 drug:PVP ratio was selected in the case of flash evaporation. The 
nanosuspension and two amorphous formulations containing 20% and 40% drug were 
compared to a wet-milled crystalline drug in a capsule in a crossover beagle dog 
study. While having different formulations, the ASDs showed superior bioavailability 
enhancement compared with the nanosuspension, as expected from the relatively high 
drug supersaturation capability of the ASDs with respect to the nanosuspension. In a 
recent study (Li et al., 2017), a nanoextrusion process was used to compare 
griseofulvin (GF) nanocomposites with ASDs.  GF nanosuspensions prepared via 
WSMM were extruded with additional polymers and simultaneously dried in a twin-
screw extruder. This nanoextrusion process with two different polymers, i.e., HPC 
(partially miscible with GF) and Soluplus (Sol, miscible with GF), led to the 
formation of GF nanocomposite and GF ASD, respectively. The researchers 
demonstrated that for 100 mg GF dose, GF–Sol ASD led to 340% (relative) 
supersaturation whereas GF–HPC nanocomposite only achieved 60% supersaturation. 
While this finding corroborates the well-known shortcoming of nanocomposites vs. 
ASDs in drug supersaturation generation, a direct and scientifically fair head-to-head 
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comparison of drug release from nanocomposites vs. ASDs having identical 
polymer/formulation is still lacking in the literature. Finally, none of the previous 
studies on spray-dried GF nanocomposites (Azad et al., 2015b; Bhakay et al., 2014a; 
Shah et al., 2016) reported or investigated GF supersaturation in the dissolution 
medium. 
Chapter 3 presents how drug nanocomposites and ASDs with identical 
formulation can be prepared using the spray drying process, which enables us to 
compare their drug release in a head-to-head manner, unlike all previously mentioned 
studies. The main objective is to improve the supersaturation capability of drug 
nanocomposites in dissolution tests significantly using a relatively low drug:polymer 
mass ratio (high polymer loading), i.e., 1:1 and 1:3, as compared with high 
drug:polymer mass ratio like 3:1 in typical nanosuspension formulations (Table 1.1), 
and compare their dissolution performances to those of the ASDs.  
1.2.3  Roles of Surfactant in Drug Release from Spray-Dried Nanocomposites 
A quick review of recent literature on spray-dried drug nanosuspensions that contain 
polymer–anionic surfactants as stabilizers (see Table 1.3) suggests a high 
drug:polymer mass ratio, i.e., 1:0.5 to 1:0.1, with minimal use of anionic surfactants 
with respect to drug (1:0.1 to 1:0.0025). Selection of such low concentrations of 
anionic surfactants, usually below their critical micelle concentration (CMC), has 
been mostly driven by two considerations: (i) significant growth of drug nanoparticles 
could occur due to Ostwald ripening above CMC (Ghosh et al., 2011; Verma et al., 
2011) and (ii) anionic surfactants are relatively toxic and can cause gastrointestinal 
tract irritation, if used at high concentrations (Gupta and Kompella, 2006; Liversidge 
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and Cundy, 1995).  
As discussed in Section 1.2.2, the low supersaturation generation capability in 
dissolution tests has not been resolved or addressed adequately. For example, even 
though all studies reported in Table 1.3 indicated significant increase in drug release 
from the spray-dried nanocomposites with surfactants as compared with as-received 
drug micro-crystals and/or their physical mixtures with the excipients, they, except 
Zuo et al. (2013), did not investigate or report any supersaturation generation in the 
dissolution tests. The dissolution data in Zuo et al. (2013) suggest up to ~50% 
(relative) supersaturation of fenofibrate from spray-dried nanocomposites in 0.15% 
sodium dodecyl sulfate (SDS) solution, which is in line with supersaturation levels 
from traditional nanocomposites (Li et al., 2017b; Müller and Peters, 1998). It is fair 
to assert that low drug supersaturation from nanocomposites is still the primary 
reason for pharmaceutical formulators to opt for ASDs for bioavailability 
enhancement of poorly soluble drugs. Hence, a new approach for boosting the 
supersaturation capability of nanocomposites to make them competitive to ASDs is 
warranted.  
Being motivated by the use of low drug:polymer mass ratios from 1:1 to 1:9 in 
drug ASDs (Baghel et al., 2016; Singh and Van den Mooter, 2016) unlike the high 
drug:polymer ratios (1:0.8 to 1:0.02) in traditional drug nanocomposites (Chang et al., 
2015; Kesisoglou et al., 2007; Van Eerdenbrugh et al., 2008c; Wang et al., 2013), as 
also depicted in Table 1.3, in Chapter 4, drug nanocomposites with relatively high 
polymer loading are presented. Judicious choice of polymers that have relatively low 
aqueous viscosities even at high concentrations allowed for preparation of drug 
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nanosuspensions and their spray-drying without processing issues. To avoid potential 
toxicity issues associated with anionic surfactants, SDS, the most common anionic 
surfactant, was used at 0.125% w/v in the drug suspensions, below its CMC (0.24% 
w/v (Moroi et al., 1974)). Chapter 4 also presents the impact of SDS during in vitro 
drug release from the nanocomposites. 
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Table 1.3  Formulations and Drug–Polymer–Anionic Surfactant Content of Aqueous Drug Nanosuspensions Used for the 
Preparation of Spray-Dried Nanocomposites in Recent Studies  
Drug  Drug 
content  
(% w/w) 
Polymeric stabilizer and 
gradeb  
Surfactantb Drug:polymer: 
surfactant mass  
ratio (–) 
References 
Miconazole 20 HPC LF, HPMC E15 SDS 1:0.25:0.0025 Cerdeira et al. (2013) 
Itraconazole 20 HPC LF, HPMC E15 SDS 1:0.25:0.0025 Cerdeira et al. (2013) 
Fenofibrate 10a HPMC E5 SDS 1:0.2:0.003 Zuo et al. (2013) 
Griseofulvin 10 HPC SL SDS 1:0.25:0.05 Bhakay et al. (2014) 
Azodicarbonamide 10 HPC SL SDS 1:0.25:0.05 Bhakay et al. (2014) 
Lovastatin 0.5 PVP K12/K17/K30, PVA SDS 1:0.2:0.05 Zhang et al. (2014)  
Griseofulvin 10 HPC SL SDS 1:0.25:0.05 Azad et al. (2015)  
Itraconazole 1a PVP K40 SDS 1:0.1:0.01–1:0.3:0.05 Kumar et al. (2015) 
Griseofulvin 5a HPC SL DS 1:0.25:0.01 Shah et al. (2016)  
Hesperetin 1 HPMC SC 1:0.5:0.1 Liu et al. (2018) 
Glibenclamide 1 HPMC SC 1:0.5:0.1 Liu et al. (2018) 
Resveratrol 1 HPMC SC 1:0.5:0.1 Liu et al. (2018) 
Rutin 1 HPMC SC 1:0.5:0.1 Liu et al. (2018) 
Quercetin 1 HPMC SC 1:0.5:0.1 Liu et al. (2018) 
Aprepitant 2.5a HPMC E15, HPC SSL SDS 1:0.5:0.1, 1:1:0.04 Toziopoulou et al. (2017)  
Carvedilol 8.3a HPC SL SDS 1:0.1:0.01–1:0.4:0.01 Medarevic et al. (2018)  
Fenofibrate 10 HPC SDS 1:0.25:0.05 Aleandri et al. (2018)  
Itraconazole  10 HPC L, HPC SL SDS 1:0.25:0.02 Bilgili et al. (2018)  
aWith respect to the total volume of the suspension liquid (% w/v); bDS: docusate sodium; HPMC: hydroxypropyl methylcellulose, HPC: hydroxypropyl 
cellulose, PVA: polyvinyl alcohol, PVP: polyvinylpyrrolidone; SC: sodium cholate; SDS: sodium dodecyl sulfate. 
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1.2.4  Roles of an Anionic Surfactant in Drug Release from Spray-Dried ASDs 
In most of the recent studies (see Table 1.4), anionic surfactants like sodium dodecyl 
sulfate (SDS) have been used as a carrier along with polymers in ASDs so as to 
solubilize the drug; hence, surfactants form a high mass fraction of the ASDs. This is 
not surprising as the use of surfactants and surfactants–polymers as carriers has been 
an emerging trend in the last two decades (Vasconcelos et al., 2007). When polymers 
alone cannot achieve high kinetic solubilization, they are augmented with copious 
amounts of surfactants which can solubilize drugs through micellar solubilization and 
surfactant–polymer complex formation (Jung et al., 2016; Liu et al., 2016; Xia et al., 
2016). Although the role of anionic surfactants in wettability enhancement of drugs is 
commonly accepted and mentioned, Table 1.4 suggests that this aspect either for 
anionic surfactants like SDS alone or along with polymers has been rarely examined 
and quantified, especially in relation to the drug release from ASDs. For example, 
(Lu et al., 2014) investigated the impact SDS, the most commonly used anionic 
surfactant, in the wettability enhancement of simvastatin (SV) and its relation to the 
dissolution rate of the SV–polyvinyl pyrrolidone (PVP) solid dispersion via separate 
measurements of contact angle and water absorption into a packed powder bed. 
While they reported the positive impact of SDS inclusion on drug wettability and 
drug release form the solid dispersions, they did not investigate the impact of SDS on 
the supersaturation maintenance/recrystallization kinetics. Similarly, the impact of 
anionic surfactants on drug supersaturation maintenance has not been routinely 
studied in separate desupersaturation–recrystallization kinetic studies unlike in Chen 
et al. (2018), Deshpande et al. (2018) and Feng et al. (2018). Moreover, several 
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studies have indicated that SDS had deleterious impact on drug supersaturation 
maintenance as it promoted drug recrystallization in the presence of polyvinyl 
pyrrolidone-vinyl acetate (PVP-VA) (Liu et al., 2016) and crystal growth in the 
presence of PVP (Mosquera-Giraldo et al., 2014).  
As SDS was intended as a carrier/solubilizer in most of the studies in Table 
1.4, the drug:SDS mass ratios in ASDs are typically in the range of 1:0.2 to 1:3, 
except in few studies  (Dave et al., 2013; Kim et al., 2018; Lu et al., 2014; Truong et 
al., 2015; Yan et al., 2012) that did not investigate the impact of SDS on drug 
wettability and recrystallization kinetics. In other words, SDS has been rarely used as 
a minor component, e.g., 1:0.05 or 20:1 drug:polymer mass ratio. In view of the 
existing literature, it is fair to state that the impact of SDS, as a minor component of 
the ASD, on both drug wettability enhancement and drug crystallization 
inhibition/supersaturation maintenance in the presence of polymers, specifically 
hydroxypropyl cellulose (HPC) and Soluplus (Sol), has not been systematically 
examined. It is hypothesized that the use of SDS as a minor component along with a 
drug-miscible polymer, which can provide solubilization and supersaturation 
maintenance, could boost supersaturation from the ASDs via mainly wettability 
enhancement and some additional drug solubilization, without having any deleterious 
effect on drug recrystallization. Another driver for the use of SDS as a minor 
component of ASDs is that anionic surfactants are relatively toxic and can cause 
gastrointestinal tract irritation (Gupta and Kompella, 2006; Kim et al., 2016), 
especially if used at high concentrations in ASDs with high drug doses.    
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Table 1.4  The Formulation Composition of Drug ASDs with Sodium Dodecyl Sulfate (SDS) in Recent Studies and Survey of the 
Use of  Wettability and Desupersaturation Tests 
Drug Drug 
loadinga  
(% w/w) 
Polymerb Drug:Polymer:SDS Wettability 
testing 
DeS 
testingc 
References 
Ketoprofen 10% PEG 1:8:1 No No Mura et al. (2005) 
Tacrolimus 10% CMC-Na 3:24:3 No No Park et al. (2009) 
Docetaxel 5–9%  PVP K30 1:9:1–1:19:1 No No Moes et al. (2011) 
Valsartan 50–67%  HPMC 3:1.25:0.25–3:2:1 No No Yan et al. (2012) 
Sulfathiazole 33–50% PVP K29/32 1:1:0.1–1:1:1 No No Dave et al. (2013) 
Simvastatin 33% PVP K29/32 1:3:0.02–1:3:0.06 Yes No Lu et al. (2014) 
Sorafenib 20–50%  Soluplus 1:0.9:0.1–1:4.5:0.5 No No Truong et al. (2015) 
Tacrolimus 20–33% HPMC 1:1:1–1:1:3 No No Jung et al. (2016) 
Felodipine 23% Soluplus 1:3:0.2–1:3:0.4 No Yes Chen et al. (2018) 
Itraconazole 50% Soluplus, PVP VA64 2:1:1 No Yes Deshpande et al. (2018) 
Itraconazole 20% HPMC-AS 1:3.75:0.25–1:2.75:1.25 No Yes  Feng et al. (2018) 
Sirolimus 16–48%  HPMC 1:1:0.05–1:5:0.1  No No Kim et al. (2018) 
Nifedipine 14–40%  Kolliphor, Soluplus 1:1:0.5–1:4:2  No No Muralichand and 
Bhikshapathi, (2018) 
a% w/w with respect to the total weight of the total solid content. 
bCMC-Na: Carboxymethylcellulose-sodium; HPMC: hydroxypropyl methylcellulose; HPMC-AS: hydroxypropyl methylcellulose-acetyl succinate; PEG: 
polyethylene glycol; PVP: polyvinyl pyrrolidone; PVP-VA: polyvinyl pyrrolidone-vinyl acetate. 
cDeS testing: Desupersaturation testing 
 
3
5
 
 
 36 
 
Unlike all previous studies, the study presented in Chapter 5 aims to examine 
the impact of a common anionic surfactant, SDS, as a minor component of a drug–
polymer–SDS ASD, on in vitro drug release while elucidating its roles in wettability 
enhancement and recrystallization inhibition in the presence of HPC/Sol. 
1.2.5  Synergistic Effects of Binary Polymers in ASDs in Drug Supersaturation  
Several recent reports (see Table 1.5) have shown improved dissolution performance 
and storage stability of the ternary ASDs (binary polymers with drug) over binary 
ASDs (single polymer with drug). Al-Obaidi and Buckton (2009) studied the 
dissolution performance and storage stability of binary and ternary griseofulvin (GF) 
ASDs produced by hydroxypropyl methylcellulose acetate succinate (HPMCAS) and 
poly[N-(2-hydroxypropyl) methacrylamide] (PHPMA) in the dissolution performance 
and storage stability. Although the ternary ASD provided significant storage stability 
due to the stronger GF interactions with both HPMCAS and PHPMA via hydrogen 
bonding, there was no improvement observed during dissolution compared to the 
binary ASDs. Xie and Taylor (2016b) optimized the dissolution performance of a 
high drug loaded ASD containing celecoxib (CXB) by using binary polymers. 
Polyacrylic acid (PAA), a hydrophilic polymer, was used to achieve rapid drug 
release, while hydroxypropyl methylcellulose (HPMC) or HPMCAS were used to 
inhibit CXB recrystallization, thus maintaining the supersaturation during dissolution. 
The ternary ASDs with certain ratios of HPMC and PAA achieved rapid release as 
well as crystallization inhibition at 30% CXB loading. The optimum formulation was 
reported to have 3:6:1 mass ratio for both CXB–PAA–HPMCAS and CXB–PAA–
HPMC, which achieved fast CXB release and high supersaturation generation–
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maintenance. Xie and Taylor (2016a) also investigated the effectiveness of polyvinyl 
pyrrolidone (PVP) K12, PVP K29/32, HPMC, and HPMCAS in inhibiting CXB 
crystallization via desupersaturation experiments and compared the CXB release rate 
and crystallization tendency of CXB in various binary and ternary ASDs. HPMC and 
HPMCAS were more effective than PVP K12 or PVP K29/32 in maintaining 
supersaturation. The dissolution results from binary ASDs suggest that the CXB 
release was substantially faster from PVP-based ASDs than HPMC/HPMCAS-based 
ASDs. However, poor crystallization inhibition ability of PVP K12 and PVP K29/32 
resulted in faster desupersaturation compared to HPCM/HPMCAS. Ternary ASD 
with 4:1 PVP:HPMCAS/HPMC exhibited slower CXB release than PVP-based 
binary ASD, but no desupersaturation was observed during dissolution time period 
(16 h).  
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Table 1.5  Binary Polymers Used in the Preparation of Ternary Drug ASDs via Solvent Evaporation Techniques 
Drug Drug 
loadinga  
(% w/w) 
Polymer1 
(P1)b 
Polymer2 
(P2)b 
Drug:P1:P2  
Mass Ratio (–)c 
Wettability 
study 
DeS 
testd 
References 
Griseofulvin 50 HPMCAS PHPMA 1:0.5:0.5 No No Al-Obaidi and Buckton, (2009) 
Cilostazol 20 HPMC PVP 1:2:2–1:3:1 No No Park et al. (2013) 
API 30 PVP PLGA 1:1.5:0.8 No No Meeus et al. (2015) 
Celecoxib 50 PVP HPMCAS 1:0.8:0.2 No Yes Xie and Taylor, (2016a) 
Celecoxib 50 PVP  HPMC 1:0.8:0.2 No Yes Xie and Taylor, (2016a) 
Celecoxib 10–50 PAA HPMCAS 1:0.4:0.6–1:8:1 No Yes Xie and Taylor, (2016b) 
Celecoxib 30–50 PAA HPMC 1:0.5:0.5–1:2:0.3 No Yes Xie and Taylor, (2016b) 
Itraconazole 10–30 Soluplus HPMCP 1:4.5:4.5–1:1.3:1 No No Davis et al. (2017) 
Griseofulvin 20 HPMC EUD 1:2:2 No Yes Ohyagi et al. (2017) 
Ibuprofen 20 PVP VA64 HPMCP 1:2:2 No No Ziaee et al. (2017) 
Itraconazole 30 Soluplus HPMCP 1:1.3:1 No No Davis et al. (2018) 
Lovastatin 25 Soluplus HA 1:1.5:1.5  No Yes Guan et al. (2019b) 
Lacidipine 16.7  Soluplus GA 1:3.75:1.25  No Yes Guan et al. (2019a) 
a% w/w with respect to the total weight of the solid content. 
bEUD: Eudragit, GA: gum Arabic, HA: hyaluronic acid; HPMC, hydroxypropyl methylcellulose, HPMCAS: hydroxypropyl methyl cellulose acetate 
succinate,  HPMCP: hydroxypropyl methyl cellulose phthalate, PEG: polyethylene glycol, PHPMA: poly [N-(2-hydroxypropyl)methacrylate], PLGA: 
Poly(lactic-co-glycolic acid), PAA: polyacrylic acid, PVP: polyvinyl pyrrolidone, PVP VA: polyvinyl pyrrolidone-vinyl acetate. 
cThe ratios refer to the polymer1:polymer2 mass ratio. All formulations had 1:3 drug:total polymer mass ratio whether a single polymer or binary polymers 
were used. 
dDeS test: desupersaturation test.  
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Guan et al. (2019b) investigated the synergistic effect of Soluplus (Sol) and 
hyaluronic acid (HA) on the in vivo and in vitro dissolution and supersaturation 
maintenance of lovastatin (LOV). In their study, HA was used as a crystal growth 
inhibitor and the Sol was used as a nucleation inhibitor. Desupersaturation test 
confirmed the synergistic effect of HA–Sol combination on the supersaturation 
maintenance of LOV. Significant enhancement in the dissolution performance was 
achieved by the ASD with binary polymers (Sol–HA) than the ASDs with single 
polymer. The possible reason for the synergistic effect of the binary polymer was 
explained by the Sol–HA complex formation where HA could insert into the Sol 
micelles and interact with Sol via hydrogen bonds providing both electrostatic and 
steric stabilization against nucleation and crystal growth from the supersaturated drug 
solutions. Guan et al. (2019a) investigated the synergistic effect of a nucleation 
inhibitor (Sol) and a crystal growth inhibitor (gum arabic, GA) on the in vitro–in vivo 
performance of lacidipine from ASD formulation. Although significant improvement 
in supersaturation maintenance was not observed, synergistic effect in equilibrium 
solubility enhancement and dissolution performance was observed with Sol–GA mass 
ratio 3:1 even after 3 months of accelerated storage condition. The authors explained 
that the complex micelle of Sol–GA could provide a softer core with improved 
solubilizing ability, resulting in improved equilibrium solubility of the drug. Davis et 
al. (2017) produced ternary ASDs of ITZ–Sol–HPMCP and studied the storage 
stability and dissolution performance by varying the drug–polymer compositions. 
After one year of storage at accelerated condition, all the ternary formulations had 
amorphous ITZ confirming storage stability. Dissolution studies indicated that the 
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formulations with higher Sol content exhibited faster dissolution and higher extent of 
ITZ supersaturation. Ohyagi et al. (2017) investigated the synergistic role of polymer 
blending on dissolution performance of GF ASDs. The ternary ASD of GF–HPMC–
Eudragit (EUD) showed faster drug release with a significantly higher supersaturation 
than the GF–HPMC and GF–EUD ASDs. In their study, to produce a ternary ASD, 
first a polymer blend was produced by spray drying of HPMC and EUD, and then this 
spray-dried polymer blend was spray-dried again with GF to produce ternary ASD. 
The authors reasoned that the hydrogen bond formation due to the intermolecular 
interactions between HPMC and EUD likely helped to improve the dissolution 
performance of ternary ASDs over binary ASDs.   
The recent studies overall suggest that ternary ASDs that make judicious use 
of binary polymers can outperform binary ASDs with a single polymer in one or more 
of the following performance metrics: storage stability, rapid drug release, and high 
supersaturation generation with prolonged maintenance. Among all studies, the work 
of Xie and Taylor, (2016a, b) is quite intriguing and has offered a new strategy for 
ternary ASDs. The inclusion of an effective crystallization inhibitor (HPMC, 
HPMCAS) as a minor component in a hydrophilic polymer (PVP, PAA), which 
enables rapid drug release, of a ternary drug ASD can achieve both rapid drug release 
and high, sustained drug supersaturation during in vitro dissolution. The study 
presented in Chapter 6 explores if this strategy works for ternary griseofulvin (GF) 
ASDs with binary polymer combination of HPC/PVP-VA64 (hydrophilic polymer) 
and Sol (amphiphilic polymer, possible crystallization inhibitor).  
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1.3  Dissertation Outline 
This dissertation has been organized into various chapters as follows:  
1) Chapter 2 assesses the impact of polymers on the aggregation of wet-milled 
itraconazole and their dissolution from spray-dried nanocomposites. The aim is to 
understand the impact of polymer type and molecular weight on nanoparticle 
stabilization and drug release from the nanocomposites. The fundamental 
knowledge generated could help formulators guide the rational formulation design 
of surfactant-free, stable nanosuspensions and fast dissolving spray-dried 
nanocomposites. 
2) Chapter 3 examines drug supersaturation generation during the dissolution of 
spray-dried griseofulvin nanocomposites vs. ASDs, which contain a low 
drug:polymer mass ration (high polymer loading). The characterization of the 
nanocomposites suggests the formation of molecularly dispersed drug 
surrounding the drug nanocrystals, a special class of nanocomposites we called 
hybrid nanocrystal–ASD (HyNASD).  
3) Impact of an anionic surfactant (SDS) in the formation and dissolution 
performance of HyNASDs with various drug:polymer mass ratios and different 
drug doses has been investigated and results/discussion are presented in Chapter 
4. The criticality of the anionic surfactant in high supersaturating HyNASDs has 
been indicated. 
4) In Chapter 5, impact of surfactant as a minor component of ASDs on drug release 
has been systematically investigated for various drug:polymer ratios and different 
drug doses. Despite being a minor component, anionic surfactant played a major 
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role in supersaturation from ASDs. 
5) In Chapter 6, synergistic effect of binary polymer combination in the drug 
supersaturation generation and maintenance from ASDs has been examined using 
combinations of two hydrophilic polymers that provide rapid drug release and an 
amphiphilic polymer that generates supersaturation and inhibits drug 
recrystallization. 
6) To generalize the observations and understanding from Chapters 3–5 that focused 
on griseofulvin, in Chapter 7, another poorly water-soluble drug, itraconazole 
(ITZ), has been used in HyNASDs and ASDs. HyNASD formation and its 
significant supersaturation effect as well as positive impact of SDS as a minor 
component of HyNASDs/ASDs has been corroborated.  
7) Finally, Chapter 8 provides the conclusions and recommendations for future work 
that originate from interesting research questions/issues identified during the 
course of this investigation.  
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CHAPTER 2 
IMPACT OF POLYMERS ON THE AGGREGATION OF WET-MILLED 
ITRACONAZOLE AND THEIR DISSOLUTION FROM SPRAY-DRIED 
NANOCOMPOSITES  
 
We explore the impact of various polymers and their molecular weight on the 
stabilization of wet-milled suspensions of itraconazole (ITZ), a poorly soluble drug, 
and its dissolution from spray-dried suspensions. To this end, ITZ suspensions with 
SSL, SL, and L grades of hydroxypropyl cellulose (HPC) having molecular weights 
(MWs) of 40, 100, and 140 kg/mol, respectively, hydroxypropyl methyl cellulose 
(HPMC E3 with 10 kg/mol), polyvinylpyrrolidone (PVP K30 with 50 kg/mol), 
sodium dodecyl sulfate (SDS, surfactant), and HPC SL–SDS were wet media milled 
and spray-dried. Laser diffraction results show that 2.5% HPC SL–0.2% SDS led to 
the finest ITZ nanosuspension, whereas without SDS, only 4.5% HPC with SL/L 
grades ensured minimal aggregation. Rheological characterization reveals that 
aggregated suspensions exhibited pronounced pseudoplasticity, whereas stable 
suspensions exhibited near Newtonian behavior. Spray-drying yielded 
nanocomposites with 60–78% mean ITZ loading and acceptable content uniformity. 
Severe aggregation occurred during milling/drying when 4.5% polymers with MW  
50 kg/mol were used; their nanocomposites exhibited incomplete redispersion due to 
slow matrix erosion and released ITZ slowly during dissolution test. Overall, high 
drug-loaded, surfactant-free ITZ nanocomposites that exhibited immediate release 
(>80% dissolved in 20 min) were prepared via spray-drying of wet-milled ITZ with 
4.5% HPC SL/L.  
 
44 
 
2.1  Materials and Methods 
2.1.1  Materials 
ITZ was purchased from Jai Radhe Sales (Ahmedabad, India). HPC, HPMC, and 
PVP are commonly used hydrophilic, water-soluble polymers that serve as steric 
stabilizers and dispersants in the preparation of drug nanosuspensions and 
nanocomposites (Bhakay et al., 2018b; Li et al., 2016a). SSL, SL, and L grades of 
HPC with MW of 40, 100, and 140 kg/mol, respectively, donated by Nisso America 
Inc. (New York, NY, USA), were used to examine the impact of MW. HPMC 
(Methocel E3 grade with 10 kg/mol MW) and PVP (Kollidon K30 grade with 50 
kg/mol MW) were donated by Dow Chemical (Midland, MI, USA) and BASF 
Corporation (Florham Park, NJ, USA), respectively. PVP K30 was selected because 
it has slightly higher MW than HPC SSL, while E3 grade of HPMC was used because 
such low MW HPMC (E3/E5) was commonly used in prior studies (e.g., (Bhakay et 
al., 2018b; Tuomela et al., 2014)). SDS, purchased from Sigma Aldrich (Milwaukee, 
WI, USA), is a commonly used anionic surfactant. Zirmil Y grade wear-resistant 
yttrium-stabilized zirconia (YSZ) with a median size of 430 µm (400 µm nominal 
size) was used as the milling media and purchased from Saint Gobain ZirPro 
(Mountainside, NJ, USA). 
2.1.2  Rational for Formulation Design and Wet Stirred Media Milling Process 
The formulations used in the preparation of drug suspensions are provided in Table 
2.1. Unless otherwise indicated, suspensions and nanocomposites are labeled with the 
concentration‒type of the dispersants in the suspensions. All percentages (%) refer to 
w/w with respect to the total weight of deionized water (200 g). ITZ concentration 
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was kept constant at 10%. Formulations F1–F3 allow us to examine the impact of 
HPC SL–SDS combination, which is known to be effective for stabilizing multiple 
drug nanosuspensions due to its synergistic effect (e.g., (Bilgili et al., 2016)), with the 
respective controls (SDS alone and HPC SL alone). Various surfactant-free 
suspensions with different polymers/grades having 4.5% concentration were also 
prepared (F4–F8). A higher polymer concentration (>4.5%) would reduce drug 
loading in the nanocomposites below 50%; hence, it was not considered. 
 
Table 2.1  Formulation of the Milled Suspensions and Drug Content in the 
Nanocomposites 
IDa 
Polymer 
type/grade 
MWb   
(kg/mol) 
  Suspension contenta Theoretical 
drug content  
(% w/w) d 
Actual drug 
content, RSD  
(% w/w, %) d 
Polymer  
(% w/w) c 
SDS 
(% w/w) c  
F1 -  - 0 0.2  98.0 NMe 
F2 HPC SL 100 2.5 0 80.0 77.8, 3.6 
F3 HPC SL   100 2.5  0.2  78.7 78.3, 4.7 
F4 HPC SL 100 4.5  0  69.0 68.3, 2.9 
F5 HPC SSL 40 4.5  0 69.0 61.0, 4.8 
F6 HPC L 140 4.5  0  69.0 67.4, 4.4 
F7 HPMC E3 10 4.5  0  69.0 59.5, 2.5 
F8 PVP K30 50 4.5  0  69.0 62.9, 5.1 
a ID is formulation identity 
b MW is Molecular Weight of the polymers 
c All suspensions have 10% ITZ. %w/w is with respect to the weight of deionized water (200g). 
d %w/w is the weight of ITZ with respect to the weight of nanocomposites;  
e Not measured.  
 
A shear mixer (Fisher Scientific Laboratory Stirrer, Catalog No. 14-503, 
Pittsburgh, PA) was used to disperse ITZ particles in aqueous dispersant solution. 
The resultant ITZ pre-suspensions were transferred to the holding tank of a Netzsch 
wet stirred media mill (Microcer, Fine Particle Technology LLC, Exton, PA, USA) 
(Figure 2.1a). Selection of the milling conditions was guided by our prior studies on 
wet media milling (Afolabi et al., 2014; Bilgili et al., 2016). 50 mL of the chamber 
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was filled with zirconia beads, and a screen with 200 µm opening was used to hold 
the beads in the chamber. The suspension was recirculated through the chamber at a 
rate of 126 mL/min via a peristaltic pump and was milled at a rotor speed of 4000 
rpm for 65 min. The milling chamber and holding tank were cooled by a chiller 
(Advantage Engineering Greenwood, IN, USA). Particle sizes of samples taken at the 
exit of the mill chamber were measured at different time intervals. A portion of each 
suspension was separated in a vial and stored for 7 days at 8 °C to assess the short-
term physical stability. 
2.1.3  Preparation of Nanocomposites via Spray Drying 
The milled ITZ suspensions were dried following one-day storage using a spray dryer 
(4M8-Trix, Procept, Zelzate, Belgium) running in a co-current flow set up (Figure 
2.1b). The length and the diameter of the spray dryer are 1.59 m and 0.15 m, 
respectively. The operating conditions were adapted from Azad et al. (2015b). The 
suspensions were atomized at 2 bar atomizing pressure using a bi-fluid nozzle having 
0.6 mm tip diameter. In each run, ~120 g milled suspensions were sprayed at 1.3–1.6 
g/min spray rate using a peristaltic pump (Makeit-EZ, Creates, Zelzate, Belgium). 
Drying air at 120 °C was fed co-currently at the top of the column at a rate of 0.37–
0.40 m3/min. The residence time was calculated to be ~4 s. After attainment of 
steady-state in about 15 min, the outlet temperature was measured to be 35–38 °C in 
different runs due to variable solids loading in different formulations (refer to Table 
2.1). A cyclone separator was used at 54–70 mbar differential pressure to separate the 
particles from the outlet air stream and divert them into a glass jar. The dried 
powders, i.e., the nanocomposites, were used for further characterization. 
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Figure 2.1  (a) Schematic of a wet stirred media mill in recirculation mode of 
operation and (b) schematic of a co-current spray dryer. (Figures are not drawn to 
scale.). 
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2.1.4  Particle Sizing and Imaging 
Particle size distributions (PSDs) of the suspensions were measured at various times 
during milling as well as after 1-day and 7-day refrigerated storage by laser 
diffraction using Coulter LS 13 320 (Beckman Coulter, Miami, FL). The steps 
involved in measuring PSDs of the suspensions were adopted from ref. (Bilgili et al., 
2016). During sample addition, intensity was maintained between 40–45%, while 
obscuration was below 8%. Mie scattering theory was used to compute the volume-
based PSDs in the software with refractive index value 1.68 for ITZ and 1.33 for 
deionized water (medium). Before each measurement, 2 mL suspension sample was 
diluted with 5 mL of the respective stabilizer solution using a vortex mixer (Fisher 
Scientific Digital Vortex Mixer, Model No: 945415, Pittsburgh, PA) at 1500 rpm for 
1 min.  
PSDs of the nanocomposites were measured by Rodos/Helos laser diffraction 
(LD) system (Sympatec, NJ, USA) based on Fraunhofer theory using the dry powder 
dispersion module. About 1 g of the sample was placed on the sample chute of the 
Rodos dispersing system. The chute was vibrated at 100% setting to feed the sample, 
and 1.0 bar dispersion pressure was imposed to suck in the falling powder through the 
sample cell of the laser diffraction system. In addition, nanocomposite particles were 
placed on a glass slide and visualized by Axio Scope.A1 polarized light microscope 
(Carl Zeiss Microscopy GmbH, Göttingen, Germany).  
Images of as-received ITZ and milled F3 suspension were taken using a LEO 
1530 SVMP (Carl Zeiss, Inc., Peabody, MA, USA) SEM. For dry as-received ITZ 
particles, a carbon tape was placed on an SEM stub and then the particles were placed 
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on top of the carbon tape. For F3 suspension, approximately 1.0 mL aliquot of the 
suspension sample was diluted to 30 mL with deionized water, mixed for 30 s with a 
vortex mixer, mounted on top of a silicon chip (Ted Pella Inc., Redding, CA, USA), 
and then placed on a carbon specimen holder (Li et al., 2016c). This sample was 
placed into a desiccator for overnight drying under vacuum condition. The final 
samples were then sputter coated with carbon using BAL-TEC MED020 (BAL-TEC, 
Balzers, Switzerland) to reduce possible charging during imaging. 
2.1.5  Apparent Shear Viscosity, Density, and Zeta Potential of the Suspensions  
The apparent shear viscosity of the milled suspensions was measured using R/S plus 
rheometer (Brookfield Engineering, Middleboro, MS, USA) with a water jacket 
assembly Lauda Eco (Lauda-Brinkmann LP, Delran, NJ, USA) (Afolabi et al., 2014). 
A coaxial cylinder with jacketed setup was used to impart a controlled shear rate on 
the samples from 0 to 1000 1/s in 60 s. The jacket temperature was kept constant at 
25 ± 0.5 °C. The raw data were analyzed using the Rheo3000 software (Brookfield 
Engineering, Middleboro, MA, USA). The viscosities of selected dispersant 
(stabilizer) solutions were also measured as they are needed in wettability study. For 
the 2.5% HPC SL–0.2% SDS sample with viscosity <10 cP, a rheometer with higher 
sensitivity/accuracy (Kinexus Ultra Plus Rotational Rheometer, Malvern Panalytical, 
Southborough, MA, USA) was used. 40 mm rotational parallel plates with 0.75 mm 
gap were used to provide a controlled shear rate on the sample from 0 to 1000 1/s. 
The simple power-law model was fitted to measured viscosity profiles of all 
suspensions (Equation 2.1): 
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1( ) na    −= =  
(2.1) 
where η and  are the apparent shear viscosity and shear rate, respectively, while a 
and n are the consistency index and power-law index, respectively. This model shows 
that n = 1 represents Newtonian flow behavior, n ˂ 1 represents shear-thinning 
(pseudoplastic) behavior, and n ˃ 1 represents shear-thickening (dilatant) behavior. 
The density () was measured thrice by weighing a 60 mL glass cylinder filled with 
the suspension and dividing by the volume.  
Using a Delsa Nano C zeta potential analyzer (Delsa Nano C, 
BeckmanCoulter, USA), zeta potentials of wet-milled ITZ particles and the milled 
suspensions with 2.5% HPC SL, 2.5% HPC SL–0.2% SDS, and 4.5% HPC SL were 
measured. The Delsa Nano C uses electrophoretic light scattering (ELS) for zeta 
potential determination; electrophoretic movement of charged particles was 
determined from the Doppler shift of scattered light under an applied electric field. 
2.1.6  X-Ray Powder Diffraction (XRPD) 
The crystallinity of as-received ITZ, physical mixture corresponding to F4 
formulation, and F4–F8 nanocomposites was analyzed using PXRD (PANalytical, 
Westborough, MA, USA), equipped with Cu Kα radiation (λ = 1.5406 Å). The 
samples were scanned at a rate 0.165 s-1 for 2θ ranging from 5 to 40°. To detect 
characteristic peaks more distinctly, another set of samples were prepared: wet-milled 
suspensions were centrifuged (Compact II centrifuge, Clay Adams® Brand, Sparks, 
MD, USA) at 3200 rpm for 90 min to separate the drug from the aqueous phase with 
excess polymer. The resultant solid phase was redispersed in deionized water 
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followed by another centrifugation. The final solid phase was overnight-dried in a 
vacuum hood before XRPD analysis. 
2.1.7  Thermal Characterization 
Thermograms of a physical mixture corresponding to F4 formulation as well as F2 
and F4–F8 nanocomposites were obtained by a Mettler–Toledo differential scanning 
calorimeter (DSC) (PolyDSC, Columbus, OH, USA). About 6 mg sample was placed 
in a sealed aluminum pan and loaded into the DSC. The samples were heated at a rate 
of 10 °C/min from 25 °C to 220 °C. Nitrogen gas was used as the purge gas and 
protective gas at a flow rate of 50 mL/min and 150 mL/min, respectively. Using the 
integrated software (STARe 10), peak melting point temperature Tm and fusion 
enthalpy ΔHm were determined. For the characterization of the residual water in the 
spray-dried nanocomposites, thermogravimetric analysis (TGA) was performed using 
a TGA/DSC1/SF Stare system (Mettler Toledo, Inc., Columbus, OH). About 6 mg of 
F4/F8 nanocomposites was placed in a ceramic crucible and heated from 25 °C to 
150 °C at a constant rate of 10 °C/min under nitrogen flow. 
2.1.8  Drug Wettability 
Drug wettability was investigated by analyzing the penetration rate of dispersant 
solutions into a packed bed of ITZ particles inside a cylindrical column according to 
the Washburn method (Hołownia et al., 2008; Washburn, 1921). An Attension Sigma 
700 (Biolin Scientific, Linthicum, MD, USA) set-up was used. Experimental method 
was adapted from Li et al. (2017), and readers are referred to Appendix A for details. 
Dispersant concentrations in the solutions were identical to those in the respective 
wet-milled suspensions in Table 2.1. The apparent shear viscosity η and surface 
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tension γ of the liquids were measured using R/S Plus Rheometer (Brookfield 
Engineering, Middleboro, MA, USA) and Attension Sigma 700 (Biolin Scientific, 
Linthicum, MD, USA), respectively. Only for the solutions having viscosity <10 cP 
(2.5% HPC SL, 4.5% HPC SSL and 4.5% PVP K30), η was measured using a 
Kinexus Ultra Plus Rotational Rheometer (Malvern Panalytical, Southborough, MA, 
USA). The ratio of the cosine of contact angles cosθds/cosθw that does not require a 
separate measurement of the constant C was calculated using the modified Washburn 
equation (Li et al., 2017). Here, θds and θw are the contact angles between ITZ and the 
dispersant solutions and between ITZ and deionized water, respectively. This ratio or 
its logarithmic value provides a rough measure of the drug wettability enhancement 
upon use of various dispersants in water. 
2.1.9  Redispersion of the Drug Nanocomposites 
The redispersion of the spray-dried powders was performed following the method in 
refs. (Bhakay et al., 2014a; Li et al., 2016b). About 0.5 g of nanocomposites was 
weighed and dispersed in a 60 mL beaker containing 30 mL of 3 g/L aqueous SDS 
solution (the same concentration as that of the dissolution medium) and stirred with a 
paddle-stirrer (CAT R18, Scientific Instrument Center Limited, Winchester, UK) at 
400 rpm for 60 min. ~0.5 mL aliquot of redispersed sample was taken at 2, 10 and 60 
min while stirring, and particle size was measured using laser diffraction. A droplet 
of each redispersion sample was dropped on a glass slide and dried immediately 
using a hot air gun. The Zeiss Axio Scope.A1 polarizing microscope was used to 
capture the image of the dried samples. 30 mL medium was selected purposefully so 
that the dispersants can fully dissolve, while releasing the ITZ nanoparticles/clusters 
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with minimal dissolution. Indeed, the maximum amount of ITZ that can dissolve is 
small (e.g., 0.11% of ITZ in F3 nanocomposites). 
2.1.10  Drug Content and Dissolution Performance of the Nanocomposites  
Actual drug content of the nanocomposite powders was measured by assay testing. 
100 mg of the spray-dried powders was dissolved in 20 mL dichloromethane (DCM), 
sonicated for 50 min to ensure complete dissolution of ITZ, and then stored overnight 
to settle any undissolved particles. An aliquot of 100 µl was taken from the 
supernatant and diluted to 10 mL with DCM. The absorbance of all the samples was 
measured at 260 nm wavelength via Ultraviolet (UV)-spectrophotometer (Agilent, 
Santa Clara, CA, USA). Six replicates were tested for each formulation to calculate 
mean drug content and percent relative standard deviation (RSD). 
Dissolution of as-received ITZ and spray-dried ITZ nanocomposites was 
performed via a Distek 2100C dissolution tester (North Brunswick, NJ, USA) 
according to the USP II paddle method. The dissolution medium was 1000 mL SDS 
buffer with 3.0 g/L concentration. This solution was selected because it provides a 
good discrimination of ITZ release among the nanocomposite formulations (Azad et 
al., 2016). The medium was maintained at 37 °C and stirred by a paddle at 50 rpm. 
Nanocomposites, equivalent to a dose of 20 mg of ITZ, were added to the medium, 
and 4 mL samples were taken manually at 1, 2, 5, 10, 20, 30, and 60 min. The 
absorbance of dissolved ITZ was measured via UV-spectroscopy (Agilent, Santa 
Clara, CA, USA) at 260 nm wavelength. Aliquots of the samples were filtered using a 
0.1 µm PVDF membrane type syringe filter to avoid any effect of undissolved drug 
during UV-spectroscopy. The medium solution without drug was used as the blank. 
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The amount of drug dissolved was measured using a calibration curve generated from 
drug concentration vs. absorbance (R2 = 0.9995 with p < 0.0001). ITZ release was 
reported as a function of dissolution time for an average of six replicates. >80% drug 
release in 20 min was regarded as a stringent criterion for immediate drug release 
(Azad et al., 2016; Bhakay et al., 2014b). 
ITZ dissolution data was fitted by Korsmeyer‒Peppas model (Ritger and 
Peppas, 1987a, b): 
n
tM M kt =  
(2.2) 
where k is a constant incorporating structural and geometric characteristics of the 
drug dosage form, n is the release exponent, indicative of the drug release 
mechanism, and Mt/M∞ is fractional drug release. While this model has been used to 
assess drug release mechanisms, it was simply used as an empirical kinetic model 
here because some of the assumptions behind the mechanistic model were not 
satisfied, which may potentially confound the interpretation of the release 
mechanisms. Since the drug release rate (d(Mt/M∞)/dt) is proportional to kn (Peppas, 
1985), kn provides a quantitative measure for comparing initial release rates from 
different dispersant formulations. 
Dissolution profiles of all nanocomposites were compared to those of F3 and 
F4 nanocomposites, separately, using difference (ƒ1) and similarity (ƒ2) factors 
(Boateng et al., 2009; Costa and Lobo, 2001). ƒ1 values up to 15 (0‒15) and ƒ2 values 
greater than 50 (50‒100) suggest statistical similarity of two profiles. 
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2.2  Results and Discussion 
2.2.1  Apparent Breakage Kinetics During Wet Media Milling 
The ITZ suspensions with various dispersants listed in Table 2.1 were wet milled in a 
stirred media mill. Figure 2.2 presents the temporal evolution of median particle size 
d50 and 90% passing size d90 of the milled suspensions, while Table 2.2 presents d50 
and d90 of the final (65 min) milled suspensions and their sizes after 7-day 
refrigerated storage. 
 
 
Figure 2.2  Temporal evolution of (a) median size d50 and (b) 90% cumulative 
passing size d90 during the milling of ITZ suspensions with 0.2% SDS (F1), 2.5% 
HPC SL (F2), 2.5% HPC SL–0.2% SDS (F3), 4.5% HPC SL (F4), 4.5% HPC SSL 
(F5), 4.5% HPC L (F6), 4.5% HPMC E3 (F7), and 4.5% PVP K30 (F8), respectively. 
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As-received ITZ particles (Figure 2.3) had d50: 15.5 µm and d90: 45.8 µm, 
measured via Rodos/Helos laser diffraction system. When milled with 2.5% HPC 
SL–0.2% SDS, the best stabilizing formulation in this study, d50 and d90 of ITZ 
particles monotonically decreased and attained a limiting, plateau size at 0.17 and 
0.24 µm, respectively (Figure 2.2). Figure 2.3a and 2.3b visually confirms the 
dramatic size reduction during high energy wet stirred media milling, which allows 
us to prepare ~230 g ITZ nanosuspension within 65 min vs. ~8 g ITZ suspension in 
several days by ball milling in a vial (Choi et al., 2008). Qualitative similarity 
between the particle sizes observed in Figure 2.3b and laser diffraction measurement 
signifies minimal aggregation in this suspension due to effective stabilization.  
During wet media milling, two mechanisms act simultaneously: breakage of 
the drug particles, fragments of already broken particles as well as aggregates 
(deaggregation) and aggregation of the particles (Bilgili et al., 2004; Choi et al., 
2008; Sommer et al., 2006). The PSD and characteristic particle sizes like d50 and d90 
evolve in accordance with the competition between the rates of these two opposing 
mechanisms, i.e., breakage and aggregation. The monotonic decrease in particle size 
for 2.5% HPC SL–0.2% SDS suggests that breakage was the dominant mechanism 
during the milling owing to efficient stabilization. On the contrary, aggregation of 
ITZ particles was the dominant mechanism during the milling with 0.2% SDS and 
4.5% PVP, and d50 and d90 either changed in a non-monotone fashion or even 
increased (Figure 2.2). Such interesting size increase and non-monotone behavior 
were also observed in previous wet media milling studies where either poor 
stabilization with dispersants occurred or no stabilizers were used (Bhakay et al., 
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2011; Bilgili and Afolabi, 2012). Previous studies (Bhakay et al., 2011; Monteiro et 
al., 2013) reported that primary drug nanoparticles, which were examined by SEM 
imaging, were produced by wet media milling even in the absence of dispersants, 
while large aggregates formed in the suspensions were measured by laser diffraction. 
For suspensions with other dispersants, the aggregation appeared to be slower than 
the breakage, and d50 and d90 decreased in time, but all suspensions showed varying 
extent of aggregation depending on the dispersant used (Figure 2.2). Without SDS, 
only 4.5% HPC (any grade) could ensure a d90 below 1 m. It should be noted that 
suspensions may undergo additional aggregation during the storage, which is 
discussed below. 
 
 
Figure 2.3  SEM images of ITZ particles: (a) before milling (marker size: 2 µm, 2 
K× magnification) and (b) after milling (F3, 2.5% HPC SL–0.2% SDS) (marker size: 
200 nm, 30 K× magnification). 
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2.2.2  Stabilization Mechanisms 
Let us now examine the impact of dispersants on the final milled particle sizes and 
their 7-day stability (Table 2.2). When 0.2% SDS (an anionic surfactant) was used as 
a stabilizer, an aggregated, coarse suspension with d50: 11.4 µm was formed. 
Apparently 0.2% SDS was not sufficient to provide strong electrostatic stabilization, 
and it also imparted lowest wettability enhancement among all the dispersants studied 
(Table 2.3). The use of 2.5% HPC SL led to submicron median size in the final 
suspension with d90: 1.82 µm, which could be explained by the adsorption of HPC on 
ITZ particles and ensuing steric stabilization (Choi et al., 2008) and slow-down of 
aggregation during milling. However, 2.5% HPC SL was not sufficient to prevent 
further aggregation that results from Brownian motion during the storage, and ITZ 
particle size dramatically increased over 7-day storage (Figure 2.4). Other 
suspensions did not exhibit such a drastic change in particle size upon 7-day storage. 
Zeta potentials of the wet-milled ITZ particles, the milled ITZ suspensions with 2.5% 
HPC SL and 4.5% SL were measured to be 0.25, –2.2, and 0.34 mV, respectively. 
Overall, the electrostatic charge of the ITZ particles in the milled suspensions was 
very low: nearly neutral particles within experimental accuracy. Considering that 
even short-term stability requires an absolute value of zeta potential greater than 20 
mV (Lakshmi and Kumar, 2010; Riddick, 1968), steric stabilization appears to be the 
dominant stabilization mechanism upon use of the polymeric dispersants in this study. 
An increase in HPC SL concentration from 2.5% to 4.5% likely allowed for greater 
HPC adsorption and formation of a thicker polymer layer on ITZ particles, which 
reduced aggregation potential of colliding particles. Adsorption of cellulosic 
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polymers (HPMC and HPC) onto drug nanoparticles are known to follow Langmuir 
or Freundlich adsorption isotherms (Bilgili and Afolabi, 2012; Knieke et al., 2013), 
which display greater adsorption at higher polymer concentration in the bulk solution. 
In addition, significant wettability enhancement upon use of HPC SL (Table 2.3) 
could have facilitated deaggregation during the milling. Overall, the use of 4.5% HPC 
SL largely mitigated aggregation and led to formation of a relatively stable 
suspension over 7 days (Figure 2.4). 
As compared with 4.5% HPC SL suspension, 4.5% HPMC E3 and 4.5% PVP 
K30 suspensions had larger ITZ aggregates, which could be explained by lower 
extent of polymer adsorption onto ITZ particles and ensuing poorer steric stabilizing 
action by the respective polymers. In fact, adequate stabilization of wet-milled ITZ 
suspensions required the use of 0.05%–0.2% SDS when HPMC E3 was used (Azad et 
al., 2016). Besides, while 4.5% PVP K30 has slightly higher MW (50 kg/mol) than 
4.5% HPC SSL (40 kg/mol), its stabilizing capability was inferior to HPC SSL, 
which suggests that the ITZ–specific polymer interaction through their functional 
groups determine the extent of polymer adsorption and modulate steric stabilization 
(Choi et al., 2008). While polymer adsorption on ITZ particles was not studied here, 
our results suggest that HPC appears to be a better steric stabilizer than PVP and 
HPMC. 
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Figure 2.4    Volume-based particle size statistics of the ITZ suspensions with 0.2% 
SDS (F1), 2.5% HPC SL (F2), 2.5% HPC SL–0.2% SDS (F3), 4.5% HPC SL (F4), 
4.5% HPC SSL (F5), 4.5% HPC L (F6), 4.5% HPMC E3 (F7), and 4.5% PVP K30 
(F8) after milling (65 min) and 7-day storage at 8 °C: (a) Median particle size d50 and 
(b) 90% cumulative passing size d90.    
   
 61 
 
Table 2.2  Particle Size Statistics of the Drug Suspensions After Milling and 7-day Storage and Those of the Spray-dried 
Nanocomposites 
 
Formulation  
ID 
Suspension  
composition a 
Particle size of the 
suspensions after milling 
(µm) 
Particle size of the 
suspensions after 7 days 
(µm) 
Nanocomposite particle 
size (µm) 
  d50±SD   d90±SD   d50±SD   d90±SD   d50±SD   d90±SD 
F1 0.2% SDS 11.4±0.44 28.5±0.57 5.32±0.10 17.4±0.41 8.43±1.18 18.7±1.80 
F2 2.5% HPC SL 0.27±0.02 1.82±0.04 8.23±0.02 53.5±2.40 13.9±0.04 26.4±0.11 
F3 2.5% HPC SL–0.2% SDS 0.17±0.00 0.24±0.00 0.17±0.00 0.24±0.00 11.3±0.26 21.2±0.33 
F4 4.5% HPC SL 0.20±0.00 0.32±0.00 0.21±0.00 0.34±0.01 16.2±0.01 32.3±0.17 
F5 4.5% HPC SSL 0.24±0.01 0.44±0.02 0.26±0.00 0.50±0.02 14.0±0.11 29.4±0.06 
F6 4.5% HPC L 0.19±0.00 0.25±0.00 0.20±0.01 0.31±0.00 23.5±0.18 49.2±0.67 
F7 4.5% HPMC E3 0.32±0.02 1.73±0.09 0.35±0.00 1.64±0.02 17.7±0.10 39.8±0.12 
F8 4.5% PVP K30 3.25±0.47 11.1±3.92 3.33±0.20 8.24±1.08 15.2±0.11 27.9±0.21 
aAll suspensions have 10% ITZ. %w/w is with respect to the weight of deionized water (200g). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6
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Table 2.3  Wetting Effectiveness Factor Calculated Using the Modified Washburn Method for Various ITZ–stabilizer Solution 
Pairs 
Formulation of the 
stabilizer solutiona 
Slope 
(g2/s) 
R2 
 
(-) 
Viscosity 
 
η(cP) 
Density 
 
ρ (g/mL) 
Surface 
tension 
γ (mN/m) 
log 
(cosθds/cosθw) 
(-) 
Water 6.47×10-06 0.995 0.89b 1.00 70.8 0 
0.2% SDS 1.20×10-03 0.999 0.94c 1.00 32.8 2.69 
2.5% HPC SL 5.00×10-04 0.999 4.59 1.01 42.4 2.81 
2.5% HPC SL–0.2% SDS 8.00×10-04 0.999 17.4 1.03 38.2 3.63 
4.5% HPC SL 2.20×10-03 0.999 13.4 1.01 42.3 3.92 
4.5% HPC SSL 5.10×10-03 0.999 4.13 1.00 43.0 3.78 
4.5% HPC L 1.40×10-03 0.998 24.3 1.02 41.8 3.98 
4.5% HPMC E3 3.40×10-03 0.999 6.10 1.01 42.8 3.77 
4.5% PVP K30 3.20×10-03 0.998 1.66 1.01 50.7 3.10 
a %w/w is with respect to the weight of deionized water. 
b Taken from ref. (Korson et al., 1969). 
c Taken from ref. (Kushner et al., 1952). 
 
 
 
6
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The combination of 2.5% HPC SL and 0.2% SDS led to the finest ITZ 
particles and a 7-day stable suspension. HPC–SDS provides synergistic stabilization 
during milling and storage for a multitude of BCS Class II drugs due to combined 
electrostatic stabilization (zeta potential of –9.7 mV) by negatively charged SDS and 
steric stabilization by adsorbed HPC, i.e., electrosteric stabilization (Bilgili and 
Afolabi, 2012; Bilgili et al., 2016; Peltonen and Hirvonen, 2010; Shete et al., 2016) 
besides wettability enhancement of the lipophilic drug (see Table 2.3) and associated 
deaggregation effectiveness provided by the combination (Li et al., 2018a). The 
significantly higher wetting enhancement ratio for 2.5% HPC SL–0.2% SDS as 
compared with 0.2% SDS and 2.5% HPC SL (Table 2.3) corroborates the synergy. 
Such synergistic effects have been reported previously (Basa et al., 2008; Lee et al., 
2008; Ryde and Ruddy, 2002). HPC and SDS interact, forming aggregates or micelle-
like SDS clusters bound to HPC (Winnik and Winnik, 1990). The formation of such 
clusters could be deduced from the higher viscosity of 2.5% HPC SL–0.2% SDS 
aqueous solution than those of 0.2% SDS and 2.5% HPC SL aqueous solutions 
(Table 2.3). These clusters can co-adsorb on particle surfaces (Berglund et al., 2003a, 
b; Evertsson and Nilsson, 1997), potentially facilitating adsorption of HPC (Cerdeira 
et al., 2010) and enabling electrosteric stabilization. It should be noted that in the 
absence of SDS, only HPC SL/L led to stable particle sizes close to those of the 
HPC–SDS combination (Figure 2.4). 
A comparison of the final milled particle sizes (Table 2.2) for suspensions 
with SSL, SL, and L grades of 4.5% HPC with 40, 100, and 140 kg/mol MW, 
respectively, suggests that higher MW HPC led to finer and more stable ITZ 
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suspensions. The apparent breakage was faster for the higher MW HPC than lower 
MW (Figure 2.2) because the rate of aggregation was slower in higher MW HPC. 
These findings suggest higher MW HPC is more effective for the stabilization of ITZ, 
which is in contrast with ref. (Choi et al., 2008). The authors of ref. (Choi et al., 
2008) highlight a thermodynamic consideration that polymers of higher MW have 
less entropy loss related to their freedom of motion, which results in a higher affinity 
to the drug surface and thus stronger adsorption and slower desorption (Morrison and 
Ross, 2002; Ploehn and Russel, 1990). Therefore, according to this thermodynamic 
consideration, a polymer with higher MW should provide better stabilization, which 
is contrary to the findings in ref. (Choi et al., 2008), but in line with our study. As 
argued in Introduction, unfortunately, studies like (Choi et al., 2008; Sepassi et al., 
2007) that used low-energy mills do not truly reflect the impact of different polymers 
or MW on steric stabilization and reduction of drug aggregate formation. The use of 
higher MW polymer and/or higher polymer concentration causes more pronounced 
viscous dampening (Bilgili and Afolabi, 2012), which slows down the breakage in 
low-energy mills more profoundly than in high-energy mills. Hence, such studies 
drew somewhat confounded conclusions about the impact of polymer MW due to 
pronounced impact of viscous dampening. Not only did high-energy, wet stirred 
media milling enabled faster production of ITZ nanoparticles than low energy mills 
used in ref. (Choi et al., 2008) for ITZ–HPC, but also it allowed us to elucidate the 
role of polymer MW in stabilization of drug nanoparticles, which in line with the 
thermodynamic consideration of polymer adsorption. 
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2.2.3  Rheology of the Milled Suspensions  
To further assess the aggregation state of the precursor suspensions, rheological 
characterization of the ITZ suspensions was performed as an orthogonal 
characterization method, similar to (Azad et al., 2015a; Li et al., 2018a). Figure 2.5 
illustrates the apparent shear viscosity profiles of the milled suspensions. The power-
law model was fitted to the apparent shear viscosity profiles, and the fitted 
consistency index a, power-law index (n), and R2 values are reported in Table 2.4. 
The p-values for the model fit and the estimated parameters are less than 0.05 and R2 
values are in the range of 0.94–0.99, which suggest that overall the power-law model 
fitted the data fairly well and both the model and its parameters were statistically 
significant. Milled ITZ suspensions that had high extent of aggregation, as revealed 
by laser diffraction measurement results (see Table 2.2), exhibited pronounced 
pseudoplastic behavior, as shown by the sharp decrease in viscosity with an increase 
in shear rate (Figure 2.5), n < 1 (~0.2–0.3), and high a values (Azad et al., 2015a; Li 
et al., 2018a). The milled suspensions with smaller aggregates (HPC SL/L) exhibited 
slight pseudoplasticity, tending toward near-Newtonian behavior (n ~0.9–1). 
Suspensions with higher HPC MW had smaller aggregates and displayed less 
pseudoplasticity (higher n and lower a). During the rheological characterization, 
suspension samples were subjected to increasing shear rate, and any aggregates 
present were deaggregated upon an increase in shear rate (Barthelmes et al., 2003; 
Bernhardt et al., 1999). Usually, aggregates occlude liquid in their void spaces, which 
raises the effective volume fraction of the solid in a suspension with fixed solids 
amount. Hence, deaggregation during the characterization upon an increase in shear 
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rate reduces the apparent shear viscosity (pseudoplasticity), and this effect was more 
pronounced for suspensions that exhibited a higher extent of aggregation. Overall, the 
rheological characterization supports our earlier finding that higher MW HPC is more 
favorable for ITZ stabilization because smaller aggregates formed during the milling, 
which led to less remarkable pseudoplasticity for the respective suspensions. 
 
 
Figure 2.5  Semi-log plots for apparent shear viscosity vs. shear rate of the milled 
ITZ suspensions with 0.2% SDS (F1), 2.5% HPC SL (F2), 2.5% HPC SL–0.2% SDS 
(F3), 4.5% HPC SL (F4), 4.5% HPC SSL (F5), 4.5% HPC L (F6), 4.5% HPMC E3 
(F7), and 4.5% PVP K30 (F8), respectively. 
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Table 2.4  Power-law Model Parameters Obtained from Fitting the Apparent Shear 
Viscosity Profiles of Various Milled ITZ Suspensions 
Formulation 
ID 
Suspension composition a n (-) a (cP.sn) R2 (-) 
F1 0.2% SDS 0.33 2230 0.974 
F2 2.5% HPC SL 0.30 3180 0.989 
F3 2.5% HPC SL–0.2% SDS 0.90 9.80 0.950 
F4 4.5% HPC SL 0.91 41.1 0.954 
F5 4.5% HPC SSL 0.84 44.0 0.984 
F6 4.5% HPC L 1.05 14.4 0.940 
F7 4.5% HPMC E3 0.24 6620 0.994 
F8 4.5% PVP K30 0.30 2960 0.988 
aAll suspensions have 10% ITZ. %w/w is with respect to the weight of deionized water (200g). 
 
2.2.4  Properties of the ITZ Nanocomposites 
The milled ITZ suspensions were spray-dried to prepare nanocomposites using a co-
current spray dryer. High ITZ loaded nanocomposites (60–78%) were produced via 
spray-drying (Table 2.1), and most of the nanocomposites had higher ITZ loading 
than those reported earlier (Azad et al., 2016; De Smet et al., 2014; Parmentier et al., 
2017; Sarnes et al., 2014; Van Eerdenbrugh et al., 2008d). All nanocomposites had 
RSDs less than 6.0%, suggesting pharmaceutically acceptable content uniformity. 
There was a slight variation in the theoretical and actual drug content, which can be 
attributed to preferential drug loss during handling/transfer after milling, poor 
separation of finer particles in the cyclone of the spray drier, and presence of some 
residual moisture after drying (Azad et al., 2015b). By measuring weight loss of the 
selected nanocomposites (F4 and F8) via TGA, mean moisture contents were 
determined. F4 and F8 nanocomposites had a residual moisture content of 2.1 ± 0.2% 
w/w and 1.8 ± 0.3% w/w, respectively, which confirms removal of most of the water 
from the milled suspensions during spray drying.  
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The optical microscope images (Figure 2.6) illustrate that rounded and nearly 
spherical nanocomposite particles were formed upon spray drying. The characteristic 
sizes of the nanocomposite particles, as measured by laser diffraction, display few 
trends (see Table 2.2). First, a comparison of F1–F3 nanocomposites to F4–F8 
nanocomposites suggests that the lower dispersant loading led to smaller 
nanocomposites. Formation of coarser nanocomposites upon use of higher dispersant 
loading was also observed in previous spray drying studies (Sun et al., 2015; 
Vatanara, 2015). For different grades of 4.5% HPC, the nanocomposites with a higher 
MW HPC had larger particles, especially for HPC L grade. Among F4–F8 
nanocomposites with 4.5% polymer (identical dispersant and total solids loading), the 
median sizes did not vary greatly (14–18 µm), with the exception for HPC L having 
the highest MW (24 µm).  
In DSC thermograms, the physical mixture with F4 formulation (10% ITZ–
4.5% HPC SL) and the nanocomposites exhibited a distinguished endothermic peak 
correspond to the melting of ITZ (Figure 2.7). The melting point temperature Tm and 
the fusion enthalpy ΔHm were lower for the nanocomposites than for the physical 
mixture. The observed reduction in Tm and ΔHm is most likely due to defect 
formation and accumulation during milling (Azad et al., 2015b; Monteiro et al., 
2013). Moreover, according to Gibbs‒Thomson equation (Wu and Nancollas, 1998), 
the melting temperature of a material is proportional to its cohesive energy, which 
indicates that nanoparticles with reduced cohesive energy require less energy for 
melting, thus, exhibiting lower Tm and ΔHm as compared to as-received 
microparticles. The reduction in Tm and ΔHm was more pronounced for HPMC E3 
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and PVP K30, which might be due to some amorphization on the surface of the drug 
particles and suppressed recrystallization during drying in the presence of these 
polymers. Kayaert and Mooter (Kayaert and Van den Mooter, 2012) also reported 
similar amorphization on the surface of drug nanoparticles during drying, depending 
on the drug–polymer interaction. 
 
 
Figure 2.6  Optical microscope images of the nanocomposites prepared from the 
milled ITZ suspensions with (a) 2.5% HPC SL (F2), (b) 2.5% HPC SL–0.2% SDS 
(F3), (c) 4.5% HPC SL (F4), (d) 4.5% HPC SSL (F5), (e) 4.5% HPC L (F6), (f) 4.5% 
HPMC E3 (F7), and (g) 4.5% PVP K30 (F8), respectively. The marker size is 20 µm 
in all images. 
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In DSC thermograms, the physical mixture with F4 formulation (10% ITZ–
4.5% HPC SL) and the nanocomposites exhibited a distinguished endothermic peak 
correspond to the melting of ITZ (Figure 2.7). The melting point temperature Tm and 
the fusion enthalpy ΔHm were lower for the nanocomposites than for the physical 
mixture. The observed reduction in Tm and ΔHm is most likely due to defect 
formation and accumulation during milling (Azad et al., 2015b; Monteiro et al., 
2013). Moreover, according to Gibbs‒Thomson equation (Wu and Nancollas, 1998), 
the melting temperature of a material is proportional to its cohesive energy, which 
indicates that nanoparticles with reduced cohesive energy require less energy for 
melting, thus, exhibiting lower Tm and ΔHm as compared to as-received 
microparticles. The reduction in Tm and ΔHm was more pronounced for HPMC E3 
and PVP K30, which might be due to some amorphization on the surface of the drug 
particles and suppressed recrystallization during drying in the presence of these 
polymers. Kayaert and Mooter (2012) also reported similar amorphization on the 
surface of drug nanoparticles during drying, depending on the drug–polymer 
interaction. 
XRPD diffractograms (Figure 2.8a) illustrate distinct, sharp peaks for as-
received crystalline ITZ vs. lack of peaks for the (amorphous) polymers. Regardless 
of the preparation procedure, milled ITZ suspensions after drying exhibited the same 
peaks as those of the as-received ITZ and the physical mixture with F4 formulation 
(10% ITZ–4.5% HPC SL) (Figure 2.8b and 2.8c). However, the peak intensities were 
reduced along with broadening after milling–drying, which could be attributed to the 
smaller drug particle sizes and high stresses imparted by the milling process (Van 
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Eerdenbrugh et al., 2008d) and coverage of ITZ by the polymeric matrix. Similar 
observations were reported for loviride nanoparticles (Van Eerdenbrugh et al., 2007). 
Removal of excess polymer in the milled suspensions by centrifugation followed by 
drying led to slightly sharper peaks with higher intensity, signifying the role of the 
excess polymer (Figure 2.8c vs. Figure 2.8b). Overall, XRPD and DSC results 
together suggest that the crystalline nature of ITZ was preserved after milling and 
drying despite the formation of defects and potentially small fraction of amorphous 
drug. 
 
 
Figure 2.7  DSC thermograms of as-received ITZ, physical mixture of F4 (blend of 
10% ITZ–4.5% HPC SL), as well as the nanocomposites prepared via spray-drying of 
the milled ITZ suspensions with 2.5% HPC SL (F2), 4.5% HPC SL (F4), 4.5% HPC 
SSL (F5), 4.5% HPC L (F6), 4.5% HPMC E3 (F7), and 4.5% PVP K30 (F8), 
respectively. 
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Figure 2.8  XRD diffractograms of (a) as-received ITZ, HPC SL, HPMC E3, and 
PVP K30; (b) physical mixture of F4 (blend of 10% ITZ–4.5% HPC SL) and spray-
dried milled ITZ suspensions with 4.5% HPC SL (F4), 4.5% HPC SSL (F5), 4.5% 
HPC L (F6), 4.5% HPMC E3 (F7), and 4.5% PVP K30 (F8); and (c) physical mixture 
of F4 (blend of 10% ITZ–4.5% HPC SL) and centrifuged–oven-dried milled ITZ 
suspensions with 4.5% HPC SL (F4), 4.5% HPC SSL (F5), 4.5% HPC L (F6), 4.5% 
HPMC E3 (F7), and 4.5% PVP K30 (F8). 
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2.2.5  Redispersibility of the Nanocomposites 
Figure 2.9 presents the characteristic particle sizes after 2 min, 10 min, and 60 min 
redispersion of the nanocomposites in the redispersion medium as well as the particle 
sizes of the ITZ suspensions after milling and one-day storage (prior to spray-drying). 
Figure A3 of Appendix A presents the optical microscope images of the above-
mentioned redispersed samples. Ideally, during the redispersion test, the dispersant 
(polymeric) matrix should erode fast while dissolving in water and release the ITZ 
particles/clusters. Note that the dissolution of ITZ particles was negligible during the 
redispersion test by design, unlike that in dissolution testing. The nanocomposite 
particles with 2.5% HPC SL, 4.5% HPC SSL, 4.5% HPMC E3, and 4.5% PVP K30 
did not erode at all or eroded extremely slowly, keeping their large size and 
morphology intact during the 60 min redispersion (Figure 2.9 and Figure A3).  These 
dispersants all had MW  50 kg/mol. Only the nanocomposites with 4.5% HPC (SL/L 
grades with 100/140 kg/mol MW) and 2.5% HPC–0.2% SDS exhibited fast erosion 
and recovered ITZ nanoparticles/clusters. The optical microscope images in Figure 
A3 qualitatively support the redispersion behavior quantified by the laser diffraction 
results. When redispersion was slow and incomplete, the rounded/spherical 
nanocomposite particles appeared in the images even after 60 min, whereas fast 
redispersion was associated with complete erosion of the nanocomposite matrix, 
leading to disappearance of the nanocomposite particles in the images. 
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Figure 2.9  Volume-based particle size statistics of the ITZ suspensions after milling 
(65 min), before spray drying (after 1 day of milling), and the nanocomposites 
redispersed in 3 g/L SDS solution for 2 min, 10 min, and 60 min: (a) Median particle 
size d50 and (b) 90% passing size d90. Suspension formulations contain 2.5% HPC 
SL(F2), 2.5% HPC SL–0.2% SDS (F3), 4.5% HPC SL (F4), 4.5% HPC SSL (F5), 
4.5% HPC L (F6), 4.5% HPMC E3 (F7), and 4.5% PVP K30 (F8). 
 
An interesting question arises as to how hydrophilic and freely water-soluble 
dispersants used in this study could not achieve fast redispersion for all 
nanocomposite formulations. Indeed, according to the modified Washburn 
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experiments (see Figure A1 of Appendix A), the polymeric dispersant solutions 
penetrated into pores of a packed ITZ bed much faster than water and improved ITZ 
wettability drastically as per higher values of the wetting effectiveness factor, i.e., 
log(cosθds/cosθw) (Table 2.3). Accordingly, upon use of dispersants in the 
nanocomposites, one would expect that (i) the redispersion/dissolution medium could 
penetrate into the pores of the nanocomposite particles generated upon dissolution of 
the water-soluble dispersants fast and (ii) any ITZ aggregates released from the 
nanocomposites could redisperse/dissolve in the redispersion/dissolution medium. 
However, the redispersion tests (see Figure 2.9) suggest that the significant 
wettability enhancement upon use of dispersants observed in the modified Washburn 
experiments (Table 2.3) did not translate into fast redispersion of the nanocomposites 
and fast recovery of the ITZ nanoparticles for some dispersants. For example, while 
the use of dispersants with high log(cosθds/cosθw) in the nanocomposites led to 
recovery of ultrafine particles during the redispersion (e.g., 2.5% HPC SL–0.2% 
SDS), this was not the case for 4.5% HPC SSL. 
In the Washburn method, a polymeric dispersant solution penetrated through 
the void space of packed ITZ particles, whereas in the redispersion test, the polymeric 
solution is expected to locally form around the nanocomposite upon dissolution of the 
polymeric matrix. It is likely that the polymer at the surfaces of the nanocomposite 
particles with 2.5% HPC SL, 4.5% HPC SSL, 4.5% HPMC E3, and 4.5% PVP K30 
did not locally dissolve to provide the “theoretical” wettability enhancement. Since 
ITZ is a highly hydrophobic drug, which is indicated by the log-partition coefficient 
(logP) value of 8.5 (Van Eerdenbrugh et al., 2008b), and it comprises 60%–78% of 
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the nanocomposites, the nanocomposite surface could be hydrophobic despite the 
presence of hydrophilic dispersants especially if the drug nanoparticles are not well-
dispersed in the polymeric dispersant matrix due to formation of aggregates. Note that 
the aforementioned nanocomposites had aggregated ITZ particles that were already 
formed in the precursor suspensions during milling–storage (Figure 2.9) and that were 
likely formed during the drying (for 4.5% HPC SSL). Aggregation of drug 
nanoparticles during drying have been reported by other researchers (Li et al., 2016c; 
Van Eerdenbrugh et al., 2008b): when used at insufficiently low concentration, 
dispersants (e.g., 2.5% HPC SL) could not provide a sufficient physical barrier 
between drug nanoparticles and their existing aggregates, and larger clusters, 
sometimes called agglomerates or hard aggregates, can form (Li et al., 2016c; Van 
Eerdenbrugh et al., 2008b). Although the exact mechanism leading to nanoparticle 
aggregation during drying is unknown (Van Eerdenbrugh et al., 2008b), the capillary 
pressure theory suggests that aggregation is due to the capillary forces encountered 
during the drying process (Wang et al., 2005); others attributed aggregation to 
polymer chain entanglement and/or potential micro-phase separation of polymeric 
stabilizer from particles upon increase in particle concentration with reduced water 
content (Kim and Lee, 2010; Lee et al., 2009; Vehring, 2008). In summary, the 
aggregates of hydrophobic ITZ particles on the surface of the nanocomposites appear 
to have prevented solubilization of the polymer, thus negating any potential 
wettability improvement thereupon, and leading to negligible/slow erosion. The 
nanocomposites with 4.5% HPC (SL/L grades with 100/140 kg/mol MW) and 2.5% 
HPC–0.2% SDS did not have small aggregates in the precursor suspensions; hence, it 
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is expected that the hydrophobic ITZ nanoparticles/aggregates were well-dispersed in 
the hydrophilic polymeric matrix, and the matrix wetted and eroded fast upon contact 
with the aqueous media, thus releasing the ITZ nanoparticles fast. 
2.2.6  ITZ Dissolution Enhancement 
The dissolution profiles of the as-received ITZ, the physical mixture of formulation 
F4, and the nanocomposites with various dispersants are presented in Figures 2.10 
and 2.11. The p-values for the Korsmeyer–Peppas model fit and the estimated 
parameters are less than 0.05, and R2 values are in the range of 0.92–0.99 (Table 2.5), 
both of which suggest that overall the model fitted the data fairly well and both the 
model and its parameters were statistically significant. The kn value was used to 
compare initial dissolution rates of various nanocomposites, while >80% ITZ release 
in 20 min was used as the main discriminating criterion for immediate release. The 
f1–f2 statistics suggest that the dissolution profiles of F3 and F4 nanocomposites were 
similar; all dissolution profiles were statistically different from those of F3 and F4 
nanocomposites (Section A.4 of Appendix A). 
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Table 2.5  Korsmeyer‒Peppas Model Parameters Obtained From Fitting the 
Dissolution Data 
Formulation 
ID a  
Formulation  
composition b 
Korsmeyer‒Peppas model  
n 
(-) 
k 
(%min
-n
) 
R2 
(-) 
 kn 
 (%min
-n
) 
F1 0.2% SDS 0.47 7.67 0.963 3.59 
F2 2.5% HPC SL 0.50 6.15 0.992 3.08 
F3 2.5% HPC SL–0.2% SDS 0.30 48.2 0.929 14.4 
F4 4.5% HPC SL 0.23 49.1 0.942 11.1 
F5 4.5% HPC SSL 0.42 14.2 0.978 5.96 
F6 4.5% HPC L 0.35 30.4 0.923 10.6 
F7 4.5% HPMC E3 0.37 17.6 0.982 6.55 
F8 4.5% PVP K30 0.54 10.7 0.952 5.71 
a Formulation is labeled based on the composition of the respective milled ITZ suspension formulation. 
bAll precursor suspensions have 10% ITZ. w/w is w.r.t. the weight of deionized water (200 g). 
 
2.2.6.1  General Trends.     Figure 2.10 shows that only 7.3% of as-received ITZ 
was released (dissolved) after 60 min. The slow ITZ dissolution was due to low 
surface area of as-received, coarse ITZ crystals (d50: 15.5 µm) and lipophilic nature of 
ITZ. The nanocomposites produced by spray drying of wet-milled ITZ suspensions 
led to significantly higher ITZ dissolution for any dispersant used as compared with 
as-received ITZ (Figures 2.10 and 2.11). Considering that only limited dissolution 
improvement was observed for a physical mixture of as-received, coarse ITZ 
particles–4.5% HPC SL, it is evident that ultrafine ITZ particles in the form of 
nanoparticles and, to some extent, their aggregates (refer to Table 2.2) present in a 
hydrophilic nanocomposite matrix, account for the significant dissolution rate 
enhancement. In general, the nanocomposites that exhibited fast erosion and 
redispersion (Figure 2.9) of the polymeric matrix released ITZ faster as compared 
with those that exhibited slow redispersion (Figures 2.10 and 2.11), which originated 
from the presence of aggregates in the respective nanocomposites. It is also important 
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to note that the redispersion of the nanocomposites with any dispersant formulation is 
expected to be faster in the dissolution test than in the redispersion test because the 
ITZ particles on the surface of the nanocomposites can dissolve in the dissolution test 
with 1000 mL medium, thus facilitating the redispersion. This explains why >75% of 
ITZ dissolved from the nanocomposites with 4.5% HPC SSL/HPMC E3/PVP K30 at 
60 min (Figure 2.11) despite their slow erosion during 60 min redispersion test 
(Figure 2.9). 
 
 
Figure 2.10  Drug dissolution from the nanocomposites prepared via spray-drying of 
the milled ITZ suspensions with 0.2% SDS (F1), 2.5% HPC SL (F2), 2.5% HPC SL–
0.2% SDS (F3), and 4.5% HPC SL (F4) as well as from physical mixture of 
formulation F4 (blend of 10% ITZ–4.5% HPC SL) and as-received ITZ. 
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Figure 2.11  Drug dissolution from the nanocomposites prepared via spray-drying of 
the milled ITZ suspensions with 4.5% concentration of HPC SL (F4), HPC SSL (F5), 
HPC L (F6), HPMC E3 (F7), and PVP K30 (F8) as well as from as-received ITZ. 
 
While the ITZ particle size in the nanocomposites is clearly a dominant factor 
in ITZ dissolution enhancement, a question arises as to whether nanocomposite 
particle size (refer to Table 2.2) can significantly affect the dissolution results. Note 
that 0.2% SDS nanocomposites (smallest nanocomposites) and 4.5% HPC L (biggest 
nanocomposites) exhibited one of the slowest (kn = 3.59 %min-0.47) and the fastest 
ITZ release (kn = 10.6 %min-0.35), respectively, among all nanocomposites, contrary 
to what one would expect if the nanocomposite particle size itself is a dominant factor 
for ITZ release. To answer this question more precisely, we also spray-dried the 
milled 4.5% HPC SL suspension (F4) using a larger nozzle tip opening (1.2 mm vs. 
0.6 mm) at lower atomization pressure (1.5 bar vs. 2.0 bar) as compared with the 
baseline drying conditions. The so-formed nanocomposite particles were coarser (d50: 
20.7 µm and d90: 40.6 µm) than the baseline 4.5% HPC SL nanocomposites (d50: 16.2 
 81 
 
µm and d90: 32.3 µm), both having identical dispersant formulation. The dissolution 
profiles (see Figure A.2 of Appendix A) indicate that despite ~30% increase in d50 
and d90, there is no statistically significant impact of the nanocomposite particle size 
on ITZ release (ƒ1 = 0.93 and ƒ2 = 91.8) within the particle size range studied. Hence, 
while there may be some confounding effect of the nanocomposite particle size, it is 
expected that the milled ITZ (aggregate) particle size and dispersant 
type/concentration have more dominant effects on the drug release.  
2.2.6.2  Impact of Various Dispersants.     Figure 2.10 shows that the 
nanocomposites with 0.2% SDS and 2.5% HPC SL released 48.1% and 49.2% of ITZ 
at 60 min, respectively. However, the drug release from both nanocomposites was 
still slow and immediate release (>80% in 20 min) was not achieved. On the other 
hand, immediate release was achieved when combination of HPC and SDS (F3) or 
higher concentration of HPC SL (F4) was used. In fact, the dissolution profile of 
4.5% HPC SL formulation is statistically similar to that of 2.5% HPC–0.2% SDS, 
which suggests the feasibility of preparing an equivalent surfactant-free 
nanocomposite. The dispersants were ranked-ordered based on the initial ITZ release 
rates, quantified by kn, as follows: 2.5% HPC–0.2% SDS > 4.5% HPC SL > 0.2% 
SDS > 2.5% HPC SL. These results can be explained by the faster redispersion 
behavior of the 4.5% HPC SL and 2.5% HPC–0.2% SDS nanocomposites and the 
smaller aggregate sizes in the respective milled/stored precursor suspensions. 
Figure 2.11 compares the ITZ release from the nanocomposites prepared with 
4.5% polymer alone in the milled suspensions. The nanocomposites were ranked-
ordered based on ITZ release in 20 min as follows: HPC SL  HPC L > PVP K30 > 
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HPMC E3 > HPC SSL. Only HPC SL/L grades with 100 kg/mol and 140 kg/mol 
MW, respectively, achieved immediate release because they had small aggregates in 
their precursor suspensions and exhibited faster redispersion than the other polymers 
and HPC SSL (Figure 2.9). These observations for HPC were also confirmed by the 
kn values of the respective nanocomposites:  HPC SL > HPC L > HPMC E3 > HPC 
SSL > PVP K30. It appears that there is an optimum HPC MW for the fastest ITZ 
release. Although the precursor suspension with HPC L had slightly smaller 
aggregates than that with HPC SL, the former exhibited slower ITZ release perhaps 
due to slower redispersion (see Figure 2.9). This may also be partly explained by the 
confounding effect of the nanocomposite particle size as HPC L nanocomposites 
were the biggest among all. The nanocomposites with low MW polymers, i.e., HPC 
SSL (40 kg/mol), PVP K30 (50 kg/mol), and HPMC E3 (10 kg/mol) exhibited slower 
ITZ release than HPC SL/L because of the large aggregates formed during milling, 
storage, and drying and the ensuing slower redispersion (Figure 2.9). Finally, the 
lowest extent of ITZ release at 20 and 60 min with HPC SSL could be related to 
formation of hard aggregates during drying, slow redispersion of the nanocomposites, 
and slow deaggregation of the hard ITZ aggregates in the dissolution medium (Li et 
al., 2016c). While the precursor suspension with PVP K30 had large ITZ aggregates, 
it appears that the aggregates emanating from the nanocomposites were dispersed in 
the dissolution test, leading to higher ITZ release in 20 and 60 min as compared with 
HPC SSL. 
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2.3  Conclusions 
This study has demonstrated that wet-milled stable 10% ITZ nanosuspensions 
showing near-Newtonian flow behavior can be prepared with 4.5% HPC SL/L (100 
and 140 kg/mol MW, respectively). At 4.5% concentration, HPC SSL (40 kg/mol), 
HPMC E3 (10 kg/mol), and PVP K30 (50 kg/mol) could not suppress ITZ 
nanoparticle aggregation, leading to significant pseudoplastic behavior. Contrary to 
previous studies that highlight the favorability of low MW polymers (Choi et al., 
2008; Sepassi et al., 2007) (specifically <50 kg/mol for ITZ–HPC (Choi et al., 
2008)), our study demonstrated that higher MW HPC (100 and 140 kg/mol) is more 
favorable for ITZ nanosuspension stabilization, which in line with the 
thermodynamic considerations of polymer adsorption. Spray drying of the ITZ 
suspensions yielded nanocomposites with 60–78% mean ITZ loading, which is higher 
than that in the ITZ nanocomposites produced in prior studies, and acceptable content 
uniformity. Severe aggregation occurred during the milling/drying when 4.5% 
polymers with MW  50 kg/mol were used. Their nanocomposites did not redisperse 
into ITZ nanoparticles/aggregates due to negligible/slow matrix erosion in the 
redispersion test; thus, they did not exhibit immediate release during the dissolution 
test. While the use of higher MW HPC (100 and 140 kg/mol) was more favorable 
from both nanosuspension stabilization and ITZ release perspectives, there exists an 
optimal MW. The fastest ITZ dissolution among the nanocomposites with 4.5% 
polymer was achieved by HPC SL (100 kg/mol). Moreover, the viscous dampening 
effect even in a wet stirred media mill could detrimentally slow down the breakage 
rate if polymers with higher MW (e.g., >150 kg/mol) were used. Overall, high drug-
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loaded, surfactant-free ITZ nanocomposites that exhibited fast redispersion and 
immediate release were prepared via spray-drying of wet-milled ITZ with 4.5% HPC 
SL/L. In a future study, higher MW grades (> 50 kg/mol) of HPMC and PVP will be 
used to examine if they could improve nanosuspension stability and ITZ release 
similar to HPC. Moreover, HPC with MW above 150 kg/mol will be used to examine 
the limits of wet stirred media milling in producing drug nanosuspensions fast, as 
such limiting conditions could occur due to pronounced viscous dampening.  
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CHAPTER 3 
DISSOLUTION ENHANCEMENT VIA DRUG HYBRID NANOCRYSTAL–
AMORPHOUS SOLID DISPERSION (HYNASD) VS. ASD 
 
As has been indicated in Chapter 1, drug nanocomposites (nanoparticle-based dosage 
form) and amorphous solid dispersions (ASDs) are two major approached to enhance 
the bioavailability of the poorly water-soluble drugs, both approaches have some 
advantages and disadvantages. A major shortcoming of drug nanocomposites as 
compared with amorphous solid dispersions (ASDs) is their limited supersaturation 
capability in the dissolution media. Chapter 3 aims to address this limitation of the 
drug nanocomposites by introducing a new class of drug nanoparticles called hybrid 
nanocrystal–amorphous solid dispersions (HyNASDs) and compare their 
performance to ASDs. A wet-milled griseofulvin (GF, BCS II drug) nanosuspension 
and a GF solution, both containing the same dissolved polymer–surfactant (SDS: 
sodium dodecyl sulfate) with 1:1 and 1:3 GF:polymer mass ratios, were spray-dried. 
Hydroxypropyl cellulose (HPC) and Soluplus (Sol) were used as matrix-forming 
polymers. XRPD, DSC, and Raman spectroscopy reveal that ASDs were formed 
upon spray-drying the solution-based feed, whereas nanocomposites and 
nanocomposites with >10% amorphous content, HyNASDs, were formed with the 
nanosuspension-based feed. Sol provided higher GF relative supersaturation, up to 
180% and 360% for HyNASDs and ASDs, respectively, in the dissolution tests than 
HPC (up to 50% for both) owing to Sol’s stronger intermolecular interactions and 
miscibility with GF and its recrystallization inhibition. Besides the higher kinetic 
solubility of GF in Sol, presence of GF nanoparticles vs. micron-sized particles in the 
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nanocomposites enabled fast supersaturation. This study demonstrates successful 
preparation of fast supersaturating (190% within 20 min) HyNASDs, which renders 
nanoparticle formulations competitive to ASDs in bioavailability enhancement of 
poorly soluble drugs.    
 
3.1  Materials and Methods 
3.1.1  Materials 
BP/EP grade micronized griseofulvin (GF) was purchased from Letco Medical 
(Decatur, AL, USA) and used as a challenging Biopharmaceutics Classification 
System (BCS) Class II drug because GF nanocrystals exhibit severe aggregation in 
suspensions, if improperly stabilized (Bilgili and Afolabi, 2012), and it is known to 
be a fast crystallizing drug (Baird et al., 2010). Its solubility in deionized (DI) water 
is ~8.9 mg/L at 25 °C and ~14.2 mg/L at 37 °C; it has a melting point Tm of 220 °C 
and a glass transition temperature Tg of 89 °C (Baird et al., 2010). Hydroxypropyl 
cellulose (HPC, SSL grade, Nisso America Inc., New York, NY) is a semi-crystalline 
polymer with low crystallinity and amorphous domains of very low Tg. It is widely 
used as a stabilizer during milling and matrix former in the nanocomposites (Azad et 
al., 2015b; Bhakay et al., 2014a). Soluplus (Sol, BASF, Tarrytown, NY)) is an 
amphiphilic graft copolymer produced from polyvinyl caprolactam–polyvinyl 
acetate–polyethylene glycol having a single glass transition temperature of 73 ± 2 °C 
(Terife et al., 2012). Sol has been commonly used to produce ASDs of various poorly 
water-soluble drugs (Ha et al., 2014). An anionic surfactant, sodium dodecyl sulfate 
(SDS), purchased from GFS Chemicals, Inc. (Columbus, OH) was used as a wetting 
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agent, which also helps to stabilize GF nanosuspensions. Acetone (ACS reagent, ≥ 
99.5%) was purchased from BDH Analytical chemicals, (VWR, GA) and used as a 
solvent to prepare solution-based feed to the spray dryer. In WSMM, Yttrium 
zirconia beads (Zirmil Y, Saint Gobain ZirPro, Mountainside, NJ, USA) with a 
median size of 430 µm were used.  
3.1.2  Preparation of Spray-Dried Powders 
Aqueous suspension-based (W:water) feeds and organic solution-based (S:solvent) 
feeds of GF were fed to the spray dryer for the preparation of drug nanocomposites 
and ASDs, respectively (Figure 3.1). Table 3.1 presents the formulations used in the 
precursor feeds. Drug concentration was kept constant at 2.5% (w/v). The GF 
concentration was calculated w.r.t. the total volume of the water in the suspension-
based feeds and the total volume of the solvent mixture (acetone–water) in the 
solution-based feeds, which was fixed at 240 mL. GF nanosuspensions were prepared 
with two different polymers (HPC/Sol) at 1:1 and 1:3 drug:polymer mass ratios to 
examine the impact of polymer type and polymer loading on GF release in dissolution 
tests. To elucidate the role of Sol, a nanosuspension with 3:1 GF:Sol (W-Sol-3:1) and 
a suspension of as-received (micronized) GF with 1:3 GF:Sol (W-M-Sol-1:3) were 
also prepared. In all formulations, SDS concentration was kept constant below the 
critical micelle concentration (CMC, 0.23%, w/v) at 0.125% (w/v) to minimize 
Ostwald ripening (Knieke et al., 2013).  
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Figure 3.1  Schematic illustration of the process setup: (a) wet-stirred media milling (WSMM) of drug in aqueous solution of 
polymer–surfactant for the preparation of the drug nanosuspension-based (W) feed, (b) mixing of drug, polymer, and surfactant in 
acetone–water mixture for the preparation of the drug solution-based (S) feed, and (c) co-current spray drying of each feed 
separately. Diagrams are not drawn to scale. 
8
8
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Table 3.1  Formulations of the Suspension-based (W) Feeds and Solution-based (S) 
Feeds Used in  Spray Drying 
Formulationa 
GF  
(% w/v)b 
Polymer 
(% w/v)b 
SDS  
(% w/v)b 
Water  
(mL) 
Acetone 
(mL) 
W-Sol-1:3 2.5 7.5 0.125 240 0 
W-Sol-1:1 2.5 2.5 0.125 240 0 
W-Sol-3:1 2.5 0.8 0.125 240 0 
W-HPC-1:3 2.5 7.5 0.125 240 0 
W-HPC-1:1 2.5 2.5 0.125 240 0 
S-Sol-1:3 2.5 7.5 0.125 40 200 
S-Sol-1:1 2.5 2.5 0.125 40 200 
S-HPC-1:3 2.5 7.5 0.125 40 200 
S-HPC-1:1 2.5 2.5 0.125 40 200 
aS denotes solution-based feed; W denotes nanosuspension-based feed; Sol denotes Soluplus; the  
ratios refer to the drug:polymer mass ratios. All formulations have 0.125% w/v SDS.    
b% w/v with respect to the total volume (240 mL) of the liquid (water/solvent). 
 
In the preparation of nanosuspension-based (W) feeds, a shear mixer (Fisher 
Scientific Laboratory Stirrer, Catalog No. 14-503, Pittsburgh, PA) was used to 
disperse as-received GF particles in the aqueous dispersant (HPC/Sol–SDS) solutions 
first. The resultant GF pre-suspensions were transferred to the holding tank of a 
Microcer wet stirred media mill (WSMM) (Netzsch Fine Particle Technology, LLC, 
Exton, PA, USA) with 80 mL milling chamber (Figure 3.1a). Milling conditions were 
adopted from our prior work on WSMM (Afolabi et al., 2014; Bilgili et al., 2016). 50 
mL of the milling chamber was filled with zirconia beads, and to hold the beads in the 
chamber a screen with 200 µm opening was used at the outlet of the chamber. The 
pre-suspension was recirculated through the chamber at a rate of 126 mL/min via a 
peristaltic pump and was milled at a rotor speed of 3200 rpm for 64 min. A portion of 
each suspension was separated in a vial and stored for 7 days at 8 °C to assess the 
short-term physical stability. Also, the milled suspensions were refrigerated at 8 °C 
for overnight before spray drying. 
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To prepare the solution-based (S) feeds, a mixture of acetone–water was 
purposefully selected to dissolve all components of the formulation (Figure 3.1b). To 
ensure a head-to-head comparison of the nanocomposites with ASDs, the 
formulations of the solution-based (S) feeds are kept identical to those of the 
suspension-based (W) feeds. 40 mL of deionized water was added to 200 mL acetone 
to prepare a total of 240 mL solvent mixture. After dissolving the drug–polymer–
surfactant into the binary solvent mixture using a magnetic stirrer, the solutions were 
sonicated for 30 min before feeding to the spray dryer.  
Using a spray dryer (4M8-Trix, Procept, Zelzate, Belgium) having a co-
current flow set-up (Figure 3.1c), GF suspensions and drug–polymer solutions were 
dried. The total length and the diameter of the spray dryer are 1.59 m and 0.15 m, 
respectively. To ensure complete drying, inlet temperature was selected above the 
boiling temperature of the respective pure liquids. Drying air at 120 °C flowing at 
0.37–0.40 m3/min and drying air at 75 °C flowing at rate of 0.27–0.30 m3/min were 
fed co-currently at the top of the dryer column to dry W feeds and S feeds (see Table 
2), respectively. 200 g suspension/solution of each formulation was sprayed at 2.0 
g/min rate using a peristaltic pump (Make-it-EZ, Creates, Zelzate, Belgium). A 
cyclone separator was used to separate the dried particles from the outlet stream into a 
glass jar.  Atomizing air pressure of 2.0 bar, a bi-fluidic nozzle with tip diameter of 
0.6 mm, and cyclone pressure of 55–60 mbar were selected based on prior experience 
(Azad et al., 2015b) and exploratory experiments. The dried particles obtained from 
the collection jar were transferred into double plastic bags and stored in a vacuum-
desiccator at room temperature for further characterization. 
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3.2  Characterization Techniques 
3.2.1  Particle Sizing 
Drug particle size distributions (PSDs) in the suspensions were measured by laser 
diffraction (LS 13 320, Beckman Coulter, Miami, FL) based on Mie scattering theory 
following the procedure described in ref. (Bilgili et al., 2016) at various times: right 
after milling, after 1-day and 7-day storage at 8 °C to in a refrigerator. The intensity 
was maintained between 40–50% while the obscuration was maintained below 8.0% 
for all measurements. Refractive index values are 1.65 for GF (drug) and 1.33 for 
deionized water (medium). Before each measurement, a 2.0 mL suspension sample 
was dispersed into 5.0 mL of the respective stabilizer solution using a vortex mixer 
(Fisher Scientific Digital Vortex Mixer, Model No: 945415, Pittsburgh, PA) at 1500 
rpm for one min prior to each measurement. 
The particle sizes of the spray-dried powders were measured by a 
Rodos/Helos laser diffraction system (Sympatec, NJ, USA) based on Fraunhofer 
theory following the procedure described in ref. (Li et al., 2016b). About 1 g of the 
powder sample was placed on top of the sample chute of the Rodos dispersing system 
and the sample chute was vibrated at a 100% setting, and 0.1 bar dispersion pressure 
was used to suck in the falling powder through the sample cell of the laser diffraction 
system. For further confirmation of the particle sizes, spray-dried particles were 
placed on a glass slide and observed by Axio Scope.A1 polarized light microscope 
(PLM, Carl Zeiss Microscopy GmbH, Göttingen, Germany).  
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3.2.2  Solid State Characterization and Drug–Polymer Interactions  
To analyze the crystallinity of the as-received GF, HPC, Sol, spray-dried powders, 
and physical mixtures of GF–polymer–SDS (same formulation as stated in Table 3.1), 
X-ray powder diffraction (XRPD) (PANanalytical, Westborough, MA, USA), 
provided with Cu Kα radiation (λ= 1.5406 Å) was used. The samples were scanned at 
a rate of 0.165 s-1 for 2θ ranging from 5° to 40°. The total area under three distinct, 
non-overlapping peaks of GF at characteristic diffraction angles of 13.2o, 14.6o, and 
16.5o was calculated for both the physical mixtures and the spray-dried powders using 
the equipment’s HighScore Plus software, which was then used to estimate the 
crystallinity. 
Differential scanning calorimetry (DSC) of the as-received GF, Sol, HPC, 
physical mixtures of GF–polymer–SDS, and spray-dried powders was performed 
using a Mettler-Toledo polymer analyzer (PolyDSC, Columbus, OH, USA) with 
integrated STARe 10 software. ~6.0–7.0 mg powder sample was placed in an 
aluminum pan with a hole in the lid and loaded into the DSC machine. As-received 
GF was heated at a rate of 10 °C/min from 25 °C to 250 °C. All other samples were 
heated from 25 °C to 70 °C and the temperature was held for 2 min at 70 °C, then 
cooled back to 25 °C to remove any residual solvent in the sample. In the final step, 
the samples were heated from 25 °C to 250 °C at 10 °C/min. Nitrogen gas was used 
as the purge gas and protective gas at a flow rate of 50 mL/min and 150 mL/min, 
respectively. Thermogravimetric analysis (TGA) was performed to measure the 
residual water/solvent content using a TGA/DSC1/SF Stare system (Mettler Toledo, 
Inc., Columbus, OH). ~6.0–7.0 mg of each spray-dried sample was placed in a 
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ceramic crucible and heated from 25 °C to 150 °C at a heating rate of 10 °C/min 
under nitrogen flow. 
Raman spectroscopy was conducted using a Fergie Imaging Spectrometer 
System (Princeton Instruments, Trenton, NJ) with a 500-mW external diode laser 
processing at 785 nm wavelength. Data acquisition time for all spectra was 15 s per 
scanned spectrum (100–1800 cm-1) and each spectrum acquired was averaged over 
two scans. The data was presented for the range of 1550–1800 cm-1 wavenumber. 
3.2.3  Characterization of Drug Recrystallization 
 To elucidate the role of drying rate on drug recrystallization during drying, a droplet 
of 20 µL of the solution prepared for the solution-based (S) feed was put onto a hot 
glass slide at 75 °C and kept for drying in quiescent air. After about one min drying, 
the slides were placed under the polarized light microscope (PLM) to observe if any 
drug recrystallization occurred. To elucidate GF recrystallization in the presence of 
water, a small portion of the spray-dried powders prepared using the solution-based 
(S) feed (S-HPC-1:3 and S-Sol-1:3) was gently pressed to form a loose compact, 
which was then mounted onto a microscopic glass slide, and placed under the PLM. 
20 µL of deionized water was added to the sample and the PLM images were 
captured at 0, 1, 2, and 5 min from the moment of water addition. 
3.2.4  Study of Nanoparticle Recovery From the Nanocomposites  
Aqueous redispersion of the nanocomposites was performed following a previously 
established method (Bilgili et al., 2018; Li et al., 2016b). About 0.5 g of the spray-
dried powders prepared using the nanosuspension-based (W) feeds was dispersed in 
30 mL of deionized water inside a 60 mL beaker and stirred at 500 rpm for 60 min 
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with a paddle-stirrer (CAT R18, Scientific Instrument Center Limited, Winchester, 
UK). ~1.0 mL aliquot of redispersed sample was taken at 2, 10 and 60 min while 
stirring, and particle size was measured using laser diffraction (LS 13 320, Beckman 
Coulter, Miami, FL). At the same collection times, a droplet of each redispersed 
sample was taken and dried immediately by dropping on a preheated glass slide on a 
hot plate at 100 °C. After drying, the PLM was used to capture images of the 
redispersed particles. The details of the experimental methods and results are 
presented in Appendix B. 
3.2.5  Drug Content and Dissolution Performance of the Spray-Dried Powders 
The drug content in the dried powders varied based on the drug:polymer mass ratios. 
To measure the actual drug content in the spray-dried powders, an assay testing was 
performed by dissolving 100 mg of the sample powders in 20 mL methanol under 30 
min of sonication, followed by overnight storage to ensure complete solubilization of 
the GF particles. An aliquot of 100 µL was taken from the GF solution and diluted up 
to 10 mL using methanol. The absorbance of the samples was measured at 292 nm 
using UV spectrophotometer (Agilent, Santa Clara, CA, USA), and the drug 
concentration was calculated from a pre-established calibration curve. Six replicates 
were tested for each formulation to calculate mean drug content along with the 
relative standard deviation (RSD).   
Drug release from the spray-dried powders and various physical mixtures 
(PMs) prepared by blending was determined via a Distek 2100C dissolution tester 
(North Brunswick, NJ, USA), following the USP II paddle method. 1000 mL 
deionized water at 37 °C was stirred at 50 rpm paddle speed. Spray-dried powder 
 95 
 
samples containing 100 mg GF (above the thermodynamic solubility of as-received 
GF particles) were weighed and added to the dissolution medium and 4 mL samples 
were taken out manually at 1, 2, 5, 10, 20, 30, 60, 120, 180, and 210 min. These 
aliquots were filtered through 0.1 µm PVDF membrane-type syringe filter before 
UV-spectroscopy measurements (similar to Bhakay et al. (2014a) and Li et al. 
(2017)). The filtered samples were diluted with 37 °C deionized water at a ratio of 1 
to 5 before UV measurement. Dissolved GF amount was measured by UV 
spectroscopy at 296 nm wavelength and calculated using a pre-established calibration 
curve. Deionized water was used as the blank before UV measurement and six 
replicates of each sample were performed. In this paper, relative % supersaturation is 
reported based on GF concentration at 210 min and thermodynamic solubility of as-
received GF particles, unless otherwise indicated. 
3.2.6  Supersaturation Maintenance Ability of the Polymers 
The supersaturation maintenance ability of HPC/Sol was examined in a separate 
desupersaturation test (similar to ref. (Konno et al., 2008)). A concentrated solution 
of GF in acetone was prepared by dissolving 100 mg of as-received GF in 20 mL 
acetone. This solution was subsequently added to 1000 mL of pre-dissolved HPC–
SDS/Sol–SDS solution with 100 µg/mL and 300 µg/mL polymer concentration, 
which maintained 1:1 and 1:3 drug:polymer mass ratio, respectively, in the USP II 
paddle type dissolution tester. The addition resulted in 92–99 µg/mL supersaturated 
solutions of GF initially, and any subsequent desupersaturation during the following 
210 min was tracked via GF concentration measurements. The experimental 
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conditions and concentration measurement were identical to those in the dissolution 
test. All measurements were carried out in triplicate. 
 
3.3  Results and Discussion 
3.3.1  Properties of GF Nanosuspensions Prepared via Wet Stirred Media 
Milling 
Four different GF suspensions were wet media milled using HPC/Sol at 1:1 and 1:3 
drug:polymer mass ratios in the presence of SDS. The median particle size d50 and 
90% passing size d90 of the final milled suspensions (after 64 min), after 1-day and 7-
day storage are presented in Figure 3.2. Unless properly stabilized, GF nanoparticles 
severely aggregate in aqueous suspensions, forming micron-sized particles (Bilgili 
and Afolabi, 2012).  The wet-milling of as-received (micronized) GF particles with 
d50: 9.74 µm and d90: 27.4 µm yielded nanosuspensions with d50 in the range of 0.14–
0.19 µm. The small changes in d50 and d90 during the 7-day storage suggest that the 
suspensions did not undergo drastic aggregation/growth during milling and storage. 
On the other hand, an increase in HPC concentration led to smaller aggregates and 
finer sizes. In a previous study, HPC–SDS was reported to have synergistic 
stabilizing effect on GF suspensions during milling and storage (Bilgili and Afolabi, 
2012) and stabilized multiple BCS Class II drug nanosuspensions (Bilgili et al., 
2016). HPC and Sol imparted steric stabilization by adsorbing on drug nanoparticles 
(Bilgili and Afolabi, 2012; Yang et al., 2014), while the anionic surfactant (SDS) 
enhanced GF wettability/deaggregation and helped to stabilize the GF 
nanosuspensions via electrostatic repulsion (Bilgili and Afolabi, 2012; Bilgili et al., 
2016). 
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Figure 3.2  Volume-based particle size statistics of the milled GF suspensions with 
1:1 and 1:3 GF:polymer mass ratios after milling (64 min) as well as 1-day storage 
and 7-day storage at 8 °C: (a) 10% cumulative passing size d10, (b) median particle 
size d50 and (c) 90% cumulative passing size d90. All suspensions have 2.5% w/v GF 
and 0.125% w/v SDS. 
 
3.3.2  Size, Morphology, and Drug–Moisture Content of The Spray-Dried 
Powders  
Drug nanosuspension-based (W) feeds produced by WSMM and drug–polymer 
solution-based (S) feeds with identical formulations were spray-dried separately. The 
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residence time in the spray dryer was short, i.e., 4.0 s and 5.0 s, for W feeds and S 
feeds, respectively.  Despite the relatively short residence time, the spray-dried 
powders were completely dried, as indicated by the TGA, which shows weight loss of 
~2.0% for the samples. The extremely large surface area generated by atomization of 
the feed coupled with the fast-convective heat–mass transfer at high air temperature 
enabled fast drying of the droplets. The mean (actual) drug content after spray-drying 
was higher for feeds with higher drug:polymer mass ratio (Table 3.2). RSD values 
were below 6%: 0.73–3.14%, which signifies pharmaceutically acceptable content 
uniformity. The slightly lower drug content as compared with the theoretical value 
can be attributed to preferential drug loss during handling/transfer after milling, poor 
separation of finer particles in the cyclone separator of the spray dryer, and presence 
of the residual moisture after drying (Azad et al., 2015b; Bilgili et al., 2018). The 
median sizes of the spray-dried powders were measured to be in the range of 6.89–
19.0 µm and 11.0–15.8 µm (Table 3.2) for W feeds and S feeds, respectively. An 
increase in polymer loading led to formation of coarser particles due to increase in 
total solids loading and higher viscosity of the feed (Basa et al., 2008; Bilgili et al., 
2018; Li et al., 2018b). The microscopic images (Figure 3.3) illustrate that spray-
dried particles have rounded–donut shapes, and their sizes are in rough agreement 
with the ranges mentioned in Table 3.2.  
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Table 3.2  Particle Size Statistics of the Spray-Dried Powders and Their Drug 
Content 
 
Formulationa 
Particle size statistics of the spray-
dried particles (µm) 
Actual drug 
content, RSD              
(% w/w, %) 
Theoretical 
drug content 
(% w/w) d10±SD d50±SD d90±SD 
W-Sol-1:3 9.29±0.1 19.0±0.1 33.6±0.1 21.2, 1.50 24.7 
W-Sol-1:1 4.48±0.1 10.1±0.1 21.9±0.2 42.0, 1.73 48.8 
W-Sol-3:1 1.66±0.1 6.89±0.3 15.3±0.4 64.4, 0.51 72.3 
W-HPC-1:3 6.37±0.1 16.5±0.6 40.0±0.1 22.3, 3.14 24.7 
W-HPC-1:1 5.24±0.1 12.9±0.1 34.2±0.1 42.5, 2.83 48.8 
S-Sol-1:3 4.11±0.0 12.3±0.0 33.2±0.1 21.5, 2.02 24.7 
S-Sol-1:1 5.03±0.1 11.0±0.1 20.2±0.0 42.3, 2.21 48.8 
S-HPC-1:3 6.48±0.0 15.8±0.6 31.3±1.0 24.4, 2.56 24.7 
S-HPC-1:1 7.05±0.2 13.0±0.9 26.9±0.8 41.7, 0.73 48.8 
aS denotes solution-based feed, W denotes nanosuspension-based feed, Sol denotes Soluplus; the  
ratios refer to the drug:polymer mass ratios. All formulations have 0.125% w/v SDS. 
 
 
 
Figure 3.3  Polarized light microscope images of the spray-dried particles prepared 
using the GF nanosuspension-based (W) feed and the GF solution-based (S) feed with 
1:3 GF:polymer mass ratios: (a) W-HPC-1:3, (b) S-HPC-1:3, (c) W-Sol-1:3, and (d) 
S-Sol-1:3. All images were taken at 50X magnification (scale bar: 20 µm). 
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3.3.3  Formation of Drug Nanocomposites/HyNASDs vs. ASDs Upon Spray 
Drying  
The solid state of GF in the spray-dried powders was investigated via XRPD (see 
Figure 3.4) and DSC (see Figure 3.5). Table 3.3 presents the summary of DSC 
thermal events and estimated crystallinity via XRPD. X-ray diffractograms depict that 
as-received GF exhibited intense peak characteristics of a crystalline material, 
whereas HPC/Sol exhibited halo pattern indicating amorphous structure (Figure 3.4a). 
The physical mixtures (PMs), prepared by blending, exhibited peaks at the same 
diffraction angles as those of as-received GF, albeit with reduced peak intensity 
(Figure 3.4b and 3.4c), which can be attributed to the dilution and surface coverage of 
GF microparticles with HPC/Sol, and the reduction is more discernible with 
increasing polymer concentration. Similar XRPD diffractograms to those of the PMs 
were observed for the spray-dried powders prepared using the suspension-based (W) 
feeds confirming that spray-drying of W feeds led to formation of nanocomposites 
that are mostly crystalline (Figure 3.4b and 3.4c). Interestingly, the diffractograms of 
the spray-dried powders with W feeds especially those with higher polymer loading 
(lower GF:polymer ratio) show clear peak broadening and peak intensity reduction as 
compared with those of PMs, beyond the aforementioned dilution effect. 
Surprisingly, wet milling followed by spray-drying led to reduction of crystallinity 
and formation of notable (~5–20%) amorphous drug (see Table 3.3). To the best 
knowledge of the authors, this level of amorphous content in drug nanocomposites is 
not common. It is well-established that wet media milling does not cause any 
detectable amorphization of as-received GF, in the absence of stabilizers, due to 
plasticization effect of water (Monteiro et al., 2013). In the presence of high polymer 
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loading in the nanosuspensions here, however, amorphization of GF took place 
during the spray drying.  
 
 
Figure 3.4  X-ray diffractograms of as-received GF, HPC, and Sol (a); physical 
mixtures (PMs) of GF–polymer–SDS and the spray-dried powders prepared using the 
GF nanosuspension-based (W) feed and GF solution-based (S) feed with various 
GF:polymer mass ratios: (b) HPC as the polymer and (c) Sol as the polymer. 
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Figure 3.5  DSC thermograms of as-received GF, HPC, and Sol (a); physical 
mixtures (PMs) of GF–polymer–SDS and the spray-dried powders prepared using the 
GF nanosuspension-based (W) feed and GF solution-based (S) feed with various 
GF:polymer mass ratios: (b) HPC as the polymer and (c) Sol as the polymer. 
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Table 3.3  Characteristic Temperatures–Enthalpy Values Obtained From DSC 
Thermograms and Crystallinity Estimated From XRPD Diffractograms 
Formulationa Tg  
(ºC)a,b 
Trc  
(ºC)a,b 
Hrc  
(J/g)a,b 
Tm  
(ºC)a,b 
Hf  
(J/g)a,b 
Crystallinity 
(%)b 
S-HPC-1:1 58.9 109 –20.0 213 40.6 6.5 
W-HPC-1:1 ND ND ND 211 28.7 95.5 
S-HPC-1:3 57.7 124 –1.71 200 10.5 ND 
W-HPC-1:3 ND ND ND 198 12.7 86.5 
W-Sol-3:1 ND ND ND 212 47.0 92.1 
S-Sol-1:1 74.6 127 –9.26 206 25.4 ND 
W-Sol-1:1 ND ND ND 204 22.7 86.3 
S-Sol-1:3 80.0 ND ND ND ND ND 
W-Sol-1:3 ND ND ND 186 7.37 81.3 
aS denotes solution-based feed, W denotes nanosuspension-based feed, Sol denotes Soluplus; the ratios 
refer to the drug:polymer mass ratios. All formulations have 0.125% w/v SDS. Other symbols: Tg, Trc, 
and Tm stand for temperature for glass transition, recrystallization transition, and melting point, 
respectively, while Hrc and Hf respectively stand for recrystallization enthalpy and fusion enthalpy.    
bND: not detected.  
 
Table 3.3 shows that despite being largely crystalline, the amorphous content 
in the spray-dried powders prepared via nanosuspension-based (W) feeds increased 
upon an increase in the polymer loading in the nanosuspensions. Moreover, higher 
amorphous content was observed in the Sol formulations than in the HPC 
formulations at the same drug:polymer mass ratio. These findings suggest that 
amorphous GF was formed due to GF–polymer molecular interactions and/or 
solubilization of the surface layer of nanoparticles by the polymer during the spray-
drying. It is likely that presence of GF nanoparticles with large surface area could 
have facilitated the formation of amorphous content around the GF nanoparticles. In 
other words, the polymeric matrix of the spray-dried particles encapsulates drug 
nanocrystals, surrounded by a layer of amorphous GF ASD in the polymeric matrix 
(see Figure 3.6b). Formation of amorphous content upon drying of drug 
nanosuspensions was first observed by (Kayaert and Van den Mooter, 2012), albeit to 
 104 
 
a much lower extent; however, the impact of such amorphous content on drug release 
from the nanocomposites has not been studied at all. As the dissolution tests will 
reveal below, despite being largely crystalline, these nanocomposites with high 
polymer loading (low drug:polymer ratio) allow for much higher supersaturation than 
traditional nanocomposites; hence, we refer to them as hybrid nanocrystal–ASD 
(HyNASD). The higher amorphous content in the Sol than in the HPC formulations 
could be related stronger molecular interactions of Sol with GF than HPC with GF 
and GF–Sol miscibility. It is suggested that if the solubility parameter difference 
between a drug and polymer is <7.0 MPa1/2, they are likely to be miscible; if the 
difference is >10 MPa1/2, they are considered immiscible (Forster et al., 2001; 
Greenhalgh et al., 1999). The solubility parameters of GF, HPC, and Sol are 12.2 
(Thakral and Thakral, 2013), 24.0 (Choi et al., 1994), and 19.4 (Kolter et al., 2012) 
MPa1/2, respectively. The solubility parameter differences between GF–Sol and GF–
HPC are 7.2 and 11.8 MPa1/2, respectively, which suggests that GF–Sol is borderline 
miscible (or at least partially miscible), whereas GF–HPC is most likely immiscible. 
While being useful, the solubility parameters do not account for all drug–polymer 
interactions such as contributions from hydrogen bonding, hydrophobic interactions, 
etc., and hence should be used with caution as rough estimates of drug–polymer 
miscibility. 
XRPD diffractograms (Figure 3.4b and Figure 3.4c) of the spray-dried 
powders prepared using the solution-based (S) feeds showed halo pattern instead of 
any characteristic diffraction peaks of GF (except S-HPC-1:1). These halo patterns 
confirm that amorphous GF dispersed molecularly into the polymer matrix forming 
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amorphous solid dispersions (ASDs). Despite the immiscibility of HPC with GF, fast 
drying of acetone–water in 1:3 GF–HPC solution led to molecular dispersion and 
arrested amorphous GF in the HPC matrix kinetically. On the other hand, the peaks in 
the XRPD diffractogram of S-HPC-1:1 and 6.5% crystalline GF could be explained 
by the insufficient HPC concentration to ensure complete dispersion of GF molecules 
in the polymer matrix; hence, recrystallization of GF during spray-drying occurred.  
The DSC thermograms in Figure 3.5a show an endothermic peak associated 
with melting of as-received GF, with a Tm of 220.1 °C and ΔHf of 101.8 J/g; a glass 
transition for Sol (amorphous) at 72.4 °C, and a slight endothermic event around 
170–200 °C for HPC likely due to the melting of the small crystalline domain of 
largely amorphous HPC (Sarode et al., 2013) (crystallinity was undetectable by 
XRPD). The Tg of HPC could not be measured (in the range of –25 to 0 °C (Sarode et 
al., 2013)) due to limitation of our equipment. For spray-dried powders prepared 
using solution-based (S) feeds, a single Tg was observed for all the formulations 
confirming the formation of molecular level dispersion (Luebbert et al., 2017; 
Wlodarski et al., 2015) (see Table 3.3 and ASD schematic in Figure 3.6c). While S-
Sol-1:3 exhibited only a glass transition, all other ASDs exhibited a glass transition 
followed by an exothermic event due to re-crystallization of amorphous GF followed 
by the melting of the recrystallized GF (Figure 3.5b and 3.5c). The (absolute value) 
enthalpy of recrystallization was lower for Sol than for HPC formulations and was 
lower when a higher polymer loading was used (in line with other studies e.g., 
(Wlodarski et al., 2015)). Recrystallization occurred during the heating step of DSC 
scan because above Tg amorphous drug molecules and amorphous polymer had 
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Figure 3.6  Schematic illustration of the solid state of the drug (GF) in (a) GF nanocomposite, (b) GF hybrid nanocrystal–
amorphous solid dispersion (HyNASD), and (c) GF amorphous solid dispersion (ASD). Figure is not drawn to scale.
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higher mobility, leading to GF recrystallization. Due to stronger molecular 
interactions and miscibility of Sol with GF, S-Sol-1:3 with high Sol loading was able 
to inhibit recrystallization even at high temperatures during the DSC scan.  
The spray-dried powders prepared using the suspension-based (W) feeds, i.e., 
the nanocomposites including HyNASDs, exhibited a melting endotherm only 
(Figure 3.5b and 3.5c). The Tm and fusion enthalpy ΔHf of these spray-dried powders 
were lower than those of the respective physical mixtures (Table 3.3). Moreover, 
higher polymer loading (1:3 vs. 1:1 W formulations) led to lower Tm and ΔHf, similar 
to the lower peaks and crystallinity in XRPD. The observed reduction in Tm and ΔHf 
of HyNASDs, as compared with the physical mixtures, may be partly attributed to 
defect formation and accumulation during milling. However, only a slight reduction 
in Tm and ΔHf occurred upon wet media milling of GF without stabilizers (Monteiro 
et al., 2013). Hence, the reduction in Tm and ΔHf was mostly attributed to 
amorphization of GF on the surface of the drug nanocrystals (Kayaert and Van den 
Mooter, 2012) or its solubilization in the polymer upon spray-drying as well as the 
solubilization during the DSC scan. Compared with the thermogram of as-received 
GF, the thermograms of the physical mixtures also show a significant reduction of Tm 
and ΔHf, which can be explained by the solubilization of GF in molten polymer at 
high temperatures during the DSC scan. Finally, the lower Tm and ΔHf of the W-Sol 
formulations than those for the W-HPC formulations could again be explained by the 
higher miscibility and stronger molecular interaction of Sol with GF than HPC with 
GF. 
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The observed Raman lines in Figure 3.7a for as-received GF and PMs of GF 
are largely in agreement with Fourier transform Raman data of ref. (Feng et al., 2008) 
and Raman data of ref. (Żarów et al., 2011) for crystalline GF. The Raman spectra of 
S-Sol-1:3 (Figure 3.7c) show that the GF line at 1606 cm–1 disappeared, and the lines 
at other characteristic frequencies shifted to new positions that are characteristic of 
amorphous GF, e.g., the line shift from 1712 to 1715 cm–1 (see Zarow et al. (Żarów et 
al., 2011)), signifying formation of amorphous GF and strong molecular interactions 
between GF and Sol in the ASD. While the GF line at 1606 cm–1 disappeared in the 
Raman spectra of S-HPC-1:3 (Figure 3.7b), the shifts in other lines were subtler than 
those for the Raman spectra of S-Sol-1:3, which could suggest stronger molecular 
interactions between GF and Sol than GF and HPC. While the W-Sol-1:3 and W-
HPC-1:3 powders (HyNASDs) did not show disappearance of lines or line shifts, 
unlike S-Sol-1:3 and S-HPC-1:3 powders (ASDs), their spectra clearly show 
broadening of the characteristic GF lines and peak intensity reduction as compared 
with the spectra of the respective PMs due to GF–polymer interactions and presence 
of amorphous domains in these powders. In contrast, the spectra of W-Sol-3:1 
(nanocomposite), having 1/9th of Sol content compared with W-Sol-1:3, did not show 
as much line broadening compared to the spectra of its respective PM.  
The XRPD, DSC, and Raman spectroscopy results overall suggest that spray-
drying of GF–polymer solutions (S feeds) led to formation of ASDs, whereas spray-
drying of GF–polymer nanosuspensions (W feeds) led to formation of drug 
nanocomposites/HyNASDs. Although a hard and crisp distinction between traditional 
nanocomposites and HyNASDs is not intended here, HyNASDs appear to have  
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Figure 3.7  Raman spectra of as-received GF, physical mixtures (PMs) of GF–Sol–
SDS at 3:1 and 1:3 GF:Sol mass ratios and GF–HPC–SDS at 1:3 GF:HPC mass ratio 
(a); physical mixtures of GF–polymer–SDS and the spray-dried powders prepared 
using the GF nanosuspension-based (W) feed and GF solution-based (S) feed with 1:3 
GF:polymer mass ratio: (b) HPC as the polymer and (c) Sol as the polymer. W-Sol-
3:1 stands for the spray-dried powder with 3:1 GF:Sol mass ratio. 
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notable amorphous content (>%10 in XRPD) and/or exhibit significant Tm 
depression–ΔHf reduction and GF Raman peak broadening as compared with the 
respective physical mixtures. As a general observation, we note that spray-drying a 
drug nanosuspension with a lower drug:polymer mass ratio (1:1, 1:3) than typically 
used (see e.g., Table 1.2) and the use of a miscible polymer, i.e., Sol, that interacts 
with the drug nanoparticles strongly and potentially solubilizes them during the spray 
drying favor the formation of HyNASDs vs. nanocomposites (W-Sol-1:3 vs. W-Sol-
3:1).  Moreover, as will be shown in Section 3.3.5, nanocomposites and HyNASDs 
may behave quite differently in their functional responses such as drug release in 
vitro. 
3.3.4  Impact of Drying Rate and Drug–Polymer Interactions/Miscibility  
In the solution-based (S) feeds, GF, polymer, and SDS were completely dissolved in 
acetone–water mixture, which allowed molecular level interaction in the solution 
before spray drying. Due to fast evaporation of the solvents in the spray dryer, 
viscosity increases rapidly causing entrapment of the drug molecules in the polymer 
matrices, which appears to have retarded phase separation even in the case of GF–
HPC (immiscible) and enables the ASD formation. In the nanosuspension-based (W) 
feeds, GF exists as nanocrystalline particles while polymer and SDS were dissolved 
in water. However, due to large surface area of GF nanocrystals and presence of 
relatively high polymer loading (1:1 and 1:3 GF:polymer), GF was partially 
solubilized or molecularly dispersed, especially in Sol, as the evaporation proceeds, 
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leading to formation of GF molecularly dispersed in the polymer matrix surrounding 
the GF nanocrystals (refer to Figure 3.6b). 
To demonstrate the criticality of drying rate and drug–polymer 
interactions/miscibility, we have devised a slower drying method: a single droplet of 
GF–HPC–SDS solution on a heated glass slide at 75 ºC, same temperature as that of 
hot air in the spray-drying. However, the droplet was dried in quiescent air, which 
makes external mass transfer of solvent vapor in air controlling the evaporation rate, 
making drying slower compared to spray drying. The drying took less than 40 s, 
whereas the drying occurred less than ~5 s in the spray dryer. The PLM images in 
Figure 3.8 illustrate that GF crystals formed during the slow drying of all solutions. 
On the other hand, the drying of S-Sol-1:3 solution yielded few small crystals, 
whereas that of S-Sol-1:1 solution yielded significant number of needle-shaped 
crystals. The extent of recrystallization was much higher in HPC than in Sol. HPC 
could not inhibit the nucleation/crystal growth of GF from the supersaturated solution 
as evaporation proceeded during the spray-drying. Since only S-HPC-1:1 spray-dried 
powder had 6.5% crystalline GF and others solution-based (S) spray-dried samples 
did not have detectable GF crystals, it is concluded that the relatively fast evaporation 
during the spray drying enabled ASD formation.  
It is known that the phase separation and recrystallization involve diffusion 
and nucleation of drug molecules, both of which require molecular mobility and can 
be restricted by polymer molecules as inhibitor (Baghel et al., 2016). Strong drug–
polymer interactions can reduce the molecular mobility and delay crystallization 
onset time and the extent of crystallization (Mistry et al., 2015). This is in line with 
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earlier work, e.g., (Kothari et al., 2015), where the recrystallization time of nifedipine 
increased with an increase in polymer (PVP) concentration. To gain additional 
insights into the GF recrystallization inhibition capability of Sol/HPC in solutions, 
desupersaturation experiments were performed. The GF desupersaturation curves 
indicate the superior GF recrystallization inhibition and supersaturation maintenance 
capability of Sol over HPC, and even at 1:1 drug:Sol mass ratio, Sol is an effective 
inhibitor (Figure 3.9). Figure 3.9 also corroborates the fast recrystallization tendency 
of GF (Baird et al., 2010) and establishes negligible role of SDS alone on 
supersaturation maintenance. Again, these findings from the desupersaturation 
experiments can be explained by adequate GF–Sol miscibility based on solubility 
parameter differences and stronger GF–Sol molecular interactions than GF–HPC 
interactions, based on Raman spectroscopy (Figure 3.7). 
 
 
Figure 3.8  Polarized light microscope images of a droplet of GF solution-based (S) 
feed, i.e., (a) S-Sol-1:3, (b) S-Sol-1:1, (c) S-HPC-1:3, and (d) S-HPC-1:1, dried on a 
hot glass slide at 75 °C. All images were taken at 5X zoom (scale bar: 200 µm). 
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Figure 3.9  GF desupersaturation curves for a supersaturated 20 mL GF–acetone 
solution mixed with 1000 mL aqueous solution of 300 µg/mL and 100 µg/mL of 
HPC/Sol–5 µg/mL SDS (equivalent to S-formulations with 1:3 and 1:1 drug:polymer 
mass ratios, respectively), 5 µg/mL SDS only, and in the absence of any 
recrystallization inhibitor. The initial GF concentration right after mixing ranged 
from 92–99 µg/mL. 
 
3.3.5  Dissolution Performance of the Spray-Dried Powders 
The temporal evolution of GF release from the spray-dried powders and their 
corresponding PMs containing 100 mg equivalent GF dose in 1000 mL deionized 
water was investigated. We note from Figures 3.10 and 3.11 that the mere presence of 
HPC/Sol–SDS could slightly increase the extent and rate of GF release without any 
prior processing of the as-received micronized GF particles. This could be partly 
explained by the wetting enhancement of the hydrophobic drug (GF) in the presence 
of HPC/Sol–SDS and deaggregation of the large drug aggregates present in the as-
received drug (Li et al., 2017) and partly by the higher solubility in the dissolution 
medium. The thermodynamic solubility of the GF microparticles at 37 °C was 
measured to be 14.2 mg/L, 17.8 mg/L, and 18.3 mg/L in the deionized water, aqueous 
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medium of Sol–SDS (1:3 drug:polymer ratio), and aqueous medium of HPC–SDS 
(1:3 drug:polymer ratio), respectively. 
 
 
Figure 3.10  Evolution of drug release from as-received GF, physical mixture (PM) of 
GF–HPC–SDS, and spray-dried powders with two different GF:HPC mass ratios: (a) 
1:1 GF:HPC and (b) 1:3 GF:HPC. Dissolution sample size is equivalent to 100 mg GF 
dose. 
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Figure 3.11  Evolution of drug release from as-received GF, physical mixture (PM) of 
GF–Sol–SDS, and spray-dried powders with two different GF:Sol mass ratios: (a) 1:1 
GF:Sol and (b) 1:3 GF:Sol. Dissolution sample size is equivalent to 100 mg GF dose. 
 
Figures 3.10 and 3.11 also show that both GF HyNASDs and ASDs prepared 
via spray-drying of the suspension-based (W) and solution-based (S) feeds, 
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respectively, enhanced the dissolution rate and the extent of GF release as compared 
to the as-received GF and the physical mixtures (PM). However, even a cursory look 
at the Figure 3.10 vs. Figure 3.11 reveals a drastic difference between HPC-based 
formulations and Sol-based formulations: the former provided an order of magnitude 
lower (relative) supersaturation than the latter, i.e., ~50% (for both HyNASDs and 
ASDs) vs. 360% (S-Sol-1:3, ASD) and 180% (W-Sol-1:3, HyNASD). Another 
interesting general observation is that there was little impact of polymer loading or 
drug:polymer ratio on the supersaturation for HPC-based formulations, whereas 
supersaturation significantly increased upon increase in polymer loading (lower 
drug:polymer ratio) for Sol-based formulations.  
HPC-based HyNASDs and ASDs performed equally poorly in enhancing 
supersaturation (Figure 3.10), but for different reasons, as compared with Sol-based 
HyNASDs and ASDs (Figure 3.11). S-HPC-1:1 and S-HPC-1:3 powders are ASDs 
that have respectively 94% and 100% XRPD-amorphous GF, which has order of 
magnitude higher apparent (kinetic) solubility than its crystalline counterpart. 
Unfortunately, depending on the polymer–drug miscibility and interactions, 
amorphous drugs may phase-separate and recrystallize upon contact of ASDs with 
water in the dissolution medium (Alonzo et al., 2011; Chen et al., 2015) because once 
imbibed into the ASD matrix, water acts as a plasticizing agent, reducing the Tg of the 
ASD and enhancing the mobility of the drug molecules (Chen et al., 2015). HPC-SSL 
has sub-ambient Tg (Sarode et al., 2013) (lower than Tg of Sol: 73 ± 2 °C) and its 
ASDs have lower Tg than Sol-based ASDs (see Table 3.3). Moreover, due to HPC 
immiscibility with GF, its relatively weak molecular interactions with GF as 
 117 
 
compared with Sol (miscible with GF), as well as its poor GF nucleation/crystal 
growth inhibition (refer to Figure 3.9), it is no surprise that the amorphous GF 
recrystallized from HPC-based ASDs during the dissolution test, which also explains 
the drastic differences between the HPC-based ASDs vs. Sol-based ASDs.  PLM 
images of a loose compact of the ASD particles in Figure 3.12 also corroborate the 
formation of GF crystals from S-HPC-1:3 ASD upon its exposure to water, whereas 
no recrystallization was observed for S-Sol-1:3. The HPC-based HyNASDs also 
performed poorly. Although they released GF nanocrystals upon redispersion (see 
Appendix B), these GF nanocrystals have limited supersaturation capability. 
Moreover, the small amorphous content of the HyNASDs probably recrystallized in 
water similar to amorphous GF in HPC-based ASDs. While HPC has been used in 
both marketed drug nanocrystal products and in academia for preparation of drug 
nanosuspensions and drug nanocomposites (Bhakay et al., 2018b; Li et al., 2016b), 
we find here that it is not a suitable polymer for preventing GF recrystallization and 
achieving high GF supersaturation. 
What is remarkable about the dissolution results in Figure 3.11 is neither the 
360% supersaturation obtained with the S-Sol-1:3 ASD nor the higher Sol loading 
(1:3 vs. 1:1 GF:Sol ratio) achieving higher supersaturation. ASDs are well-known to 
generate significant supersaturation (Alonzo et al., 2011; Jackson et al., 2015) due to 
amorphous nature of the molecularly dispersed drug, and the polymer provides 
solubilization of the drug within the swollen GF–Sol matrix and recrystallization 
inhibition. Sol has a Tg of 73 ± 2 °C and strong molecular interactions with GF (GF 
Raman line shifts in Figure 3.7); it is miscible with GF and is an excellent GF 
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nucleation/crystal growth inhibitor, as evidenced by the small desupersaturation after 
~3 h (Figure 3.9) and absence of crystals in the PLM image (Figure 3.12b). During 
the PLM imaging of S-Sol-1:3 (see Figure 3.12b), the compact with the Sol matrix 
got swollen after the addition of water while eroding slowly (not shown in the 
images). Even after 5 min of water imbibition, no recrystallization of the amorphous 
GF was observed, which supports how high supersaturation was reached in this ASD.  
What we found surprising is that W-Sol-1:3 provides 180% GF 
supersaturation (Figure 3.11). It is well-known that drug nanocomposites have limited 
supersaturation capability, typically up to 10–15% (Kesisoglou and Wu, 2008), and 
supersaturation capability of nanocomposites has not even been studied in depth 
(Azad et al., 2015b; Bhakay et al., 2014a; Shah et al., 2016). Note that W-Sol-1:3 is 
not a traditional nanocomposite: while largely composed of drug nanocrystals, it has 
about 20% amorphous GF and in water it provided 180% supersaturation. In this 
paper, we refer to such nanocomposites as HyNASDs (Figure 3.6b) to differentiate 
them from nanocomposites (Figure 3.6a) and ASDs (Figure 3.6b). Another 
remarkable finding is that W-Sol-1:3 (HyNASD) generated more supersaturation than 
S-Sol-1:1 (ASD), i.e., 180% vs. 130%. Although this mainly resulted from the 
HyNASD having more Sol than the ASD and this comparison is not head-to-head, 
there is no similar result in literature where a formulation consisting of ~80% 
nanocrystals outperforms an ASD with 100% amorphous drug. Clearly, HyNASDs 
boost the supersaturating capabilities of traditional nanocomposites.  
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Figure 3.12  Polarized light microscope images of a loose compact of the ASD particles (S-formulations) with (a) 1:3 GF:HPC 
mass ratio and (b) 1:3 GF:Sol mass ratio in 20 µL deionized water. The images were taken at 0 (before adding water), 1, 2, and 5 
min after the addition of deionized water addition. Except 0 min image (5X magnification, scale bar: 200 µm), which focused on 
the compact, all other images focused on particles that emanated from the surface, which were captured at 20X magnification 
(scale bar: 50 µm). 
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Additional dissolution experiments were carried out with various spray-dried 
powders prepared using suspension-based (W) feeds in order to elucidate the 
significant functional performance difference between traditional nanocomposites 
(e.g., W-Sol-3:1 with low Sol loading) and HyNASDs (W-Sol-1:1 and W-Sol-1:3 
with high Sol loading) (see Figure 3.13). W-Sol-3:1, like any traditional 
nanocomposite, provided low (30%) supersaturation, whereas the two HyNASDs, 
i.e., W-Sol-1:1 and W-Sol-1:3, provided 100% and 180% supersaturation, 
respectively. There is a clear trend: an increase in Sol loading led to higher 
amorphous content and higher GF supersaturation/drug release. During dissolution of 
the HyNASDs, the amorphous GF dissolves and diffuses through swollen Sol matrix 
(Li et al., 2017), while additional GF could dissolve into the swollen Sol matrix and 
supersaturate upon water imbibition. It is also likely that higher Sol loading helps the 
solubilization in the dissolution medium. Not only did the higher Sol content lead to 
HyNASDs having higher amorphous content upon spray drying (see Table 3.3), but 
also the higher Sol loading enabled solubilization of additional GF within the swollen 
Sol matrix and/or in the dissolution medium. Both mechanisms contributed to the 
high supersaturation from HyNASDs. The contribution of amorphous GF and GF 
solubilization by Sol within the swollen Sol matrix to supersaturation follows the 
order: W-Sol-1:3 (180%) > W-Sol-1:1 (eq. 1:3) (130%) > W-Sol-1:1 (100%). Note 
that W-Sol-1:1 (eq. 1:3) has the same total Sol content as in W-Sol-1:3, but 2/3rd of 
Sol was pre-dissolved in the dissolution medium and it was not part of the W-Sol-1:1 
matrix. Incorporating the whole Sol in the spray-dried matrix achieved higher 
supersaturation than keeping 1/3rd of Sol in the matrix and pre-dissolving 2/3rd in the 
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medium. Apparently, having all Sol in the spray-dried matrix allowed for more 
amorphous GF generated during the spray-drying, while also helping the 
solubilization of GF within the swollen Sol matrix. On the other hand, having 
additional Sol in the dissolution medium generated more supersaturation, as inferred 
from the dissolution of W-Sol-1:1 (eq. 1:3) vs. W-Sol-1:1.    
 
 
Figure 3.13  Evolution of GF dissolution from physical mixture (PM) of GF–Sol–
SDS with 1:3 GF:Sol, spray-dried W-formulations with 1:1, 1:3, and 3:1 GF:Sol, as 
well as W-Sol-1:1 (eq. 1:3),  which has the same total Sol content as in W-Sol-1:3, 
but 2/3rd of Sol was pre-dissolved in the dissolution medium and the remaining 1/3rd 
was in W-Sol-1:1 (eq. 1:3). W-M-Sol-1:3 stands for the spray-dried powder prepared 
using a suspension-based feed of as-received (micronized) GF. Dissolution sample 
size is equivalent to 100 mg GF dose.  
 
It may be argued that the higher supersaturation in HyNASDs as compared 
with traditional nanocomposites is solely about GF–Sol interactions/miscibility and 
GF solubilization by Sol. W-M-Sol-1:3 was prepared by spray-drying the aqueous 
suspension of as-received (micronized, d50: 9.74 µm) GF microcrystals with Sol–
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SDS. W-Sol-1:3 (HyNASD), which contains drug nanocrystals with d50: 0.14 µm and 
~20% amorphous GF, generated thrice as much supersaturation as W-M-Sol-1:3, 
demonstrating the importance of crystal size in HyNASD for supersaturation 
generation. The solubilization of GF particles (microparticles or nanoparticles) in the 
Sol matrix and supersaturation generation during the dissolution is a kinetically-
driven process, which is limited by the size of the particles: faster solubilization and 
higher supersaturation occurred when GF nanoparticles were encapsulated by the Sol 
matrix (HyNASD) as compared with the micronized GF particles owing to 
approximately 70-times larger surface area of the nanoparticles.  
 
3.4  Conclusions 
Spray-drying of an aqueous GF nanosuspension with 1:1 and 1:3 GF:Sol/HPC mass 
ratios in the presence of SDS led to formation HyNASDs, which have notable 
amorphous GF content  unlike traditional drug nanocomposites that typically have 
1:0.8 to 1:0.02 drug:polymer mass ratio. To ensure a fair, head-to-head comparison of 
HyNASDs to ASDs, ASDs with identical composition were prepared by spray-drying 
the organic solution of GF–Sol/HPC–SDS in acetone–water mixture. All spray-dried 
powders had acceptable content uniformity. XRPD–DSC–Raman spectroscopy shed 
light on the nanocomposite/HyNASD and ASD formation. HPC-based HyNASDs 
and ASDs performed equally poorly in enhancing GF supersaturation (50%) in 
dissolution tests, whereas Sol-based ones achieved significant supersaturation: up to 
360% for ASD and 180% for HyNASD. These results were explained by higher Tg of 
Sol than that of HPC, GF–Sol miscibility, stronger molecular interactions between 
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Sol–GF than HPC–GF, and excellent nucleation/crystal growth inhibition by Sol as 
compared to HPC. The supersaturation generation capability of HyNASDs is largely 
controlled by drug–polymer interactions/miscibility as well as the size of the drug 
(nano)crystals in the polymeric matrix. Overall, the most striking finding from this 
study is that despite having ~80% nanocrystals, HyNASDs provided fast drug 
supersaturation (~190% within 20 min) unlike traditional nanocomposites (30%), 
which could render nanoparticle formulations more attractive in bioavailability 
enhancement of poorly soluble drugs. While HyNASDs did not generate as high 
saturation as ASDs, they can be rendered competitive to ASDs upon further 
formulation–process optimization. Future research efforts will include  
(i) investigation of the storage stability of HyNASDs vs. ASDs under various 
environmental conditions, (ii) preparation of HyNASDs with various drug–polymer 
pairs and their comparative assessment, (iii) systematic examination of the impact of 
various surfactants, and (iv) impact of various drug nanoparticle sizes in the range of 
50–1000 nm on drug supersaturation.    
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CHAPTER 4 
DRUG RELEASE FROM SPRAY-DRIED HYBRID NANOCRYSTALS–
AMORPHOUS SOLID DISPERSIONS (HyNASDs): IMPACT OF SDS 
 
As discussed in Chapter 1, limited supersaturation generation capability is a major 
limitation of the drug nanocomposites compared to the ASD formulations. To address 
this limitation, a new class of drug nanocomposites called HyNASDs has been 
introduced in Chapter 3, which provided significant supersaturation generation in the 
dissolution medium. In Chapter 4, we prepared hybrid nanocrystal–amorphous 
solution dispersions (HyNASDs) in order to boost the drug release performance of 
traditional nanocomposites while elucidating the impact of a common anionic 
surfactant, sodium dodecyl sulfate (SDS), on drug release in dissolution tests. To this 
end, 2.5% wet-milled griseofulvin (GF, BCS Class II drug) suspensions containing 
1:1, 1:3, and 1:5 GF:polymer mass ratios, with 0.125% SDS (below CMC) and 
without SDS, were spray-dried. Hydroxypropyl cellulose (HPC) and Soluplus (Sol) 
were used as suspension stabilizers and matrix-forming polymers. Examination of 
particle sizes in the milled suspensions revealed the criticality of SDS in the 
synergistic stabilization of GF nanoparticles. XRPD and DSC results suggest that 
nanocomposites and nanocomposites with notable amorphous GF (>10%), 
HyNASDs, were formed upon spray-drying. Redispersion of the spray-dried powders 
revealed the criticality of SDS in nanoparticle recovery from the 
nanocomposites/HyNASDs, which could be explained by GF wettability 
enhancement by SDS, as inferred from the modified Washburn experiment. Results 
from in vitro dissolution tests with low (9 mg) GF dose suggest that enhanced 
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wettability with SDS and smaller spray-dried particle sizes led to faster GF release. 
For 100 mg GF dose (above thermodynamic solubility), Sol provided higher GF 
relative supersaturation, e.g., 250% for the HyNASDs (1:5 GF:Sol with SDS) vs. 
30% for the nanocomposites (3:1 GF:Sol with SDS), than HPC (up to 50%) owing to 
Sol’s stronger intermolecular interactions–miscibility with GF and its kinetic 
solubilization–recrystallization inhibition of GF. Higher polymer loading led to 
higher supersaturation. SDS provided Sol-based HyNASDs with enhanced wettability 
and augmented Sol in solubilizing SDS, leading to fast supersaturation (max. 300% 
within 20 min). This study demonstrates how drug release from traditional 
nanocomposites could be boosted upon incorporating a drug-miscible, solubilizing 
polymer with a low GF:polymer mass ratio and an anionic surfactant.     
 
4.1  Materials and Methods 
4.1.1  Materials 
BP/EP grade, micronized griseofulvin (GF) purchased from Letco Medical (Decatur, 
AL, USA) was used as a challenging Biopharmaceutics Classification System (BCS) 
Class II drug because GF nanocrystals exhibit severe aggregation in suspensions, if 
improperly stabilized (Bilgili and Afolabi, 2012), and it is known to be a fast 
crystallizing drug (Baird et al., 2010). Its solubility is ~8.9 mg/L at 25 °C and ~14.2 
mg/L at 37 °C, melting point Tm 220 °C, and a glass transition temperature Tg of 89 
°C (Baird et al., 2010). Hydroxypropyl cellulose (HPC, SSL grade, Nisso America 
Inc., New York, NY) is a semi-crystalline polymer with low crystallinity and 
amorphous domains of very low Tg. It is widely used as a stabilizer during milling 
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and matrix former in the nanocomposites (Azad et al., 2015b; Bhakay et al., 2014a). 
Soluplus® (Sol) is an amphiphilic graft copolymer produced from polyvinyl 
caprolactam–polyvinyl acetate–polyethylene glycol having a single glass transition 
temperature of 73 ± 2 °C (Terife et al., 2012). Even 15% w/v aqueous solutions of 
both polymers have less than 60 cP viscosity at 25 °C, which allowed us to perform 
milling and spray drying without any processing issue. Sodium dodecyl sulfate 
(SDS), an anionic surfactant with a CMC of 8.0 mM at ambient temperature, 
purchased from GFS Chemicals, Inc. (Columbus, OH) was used as a wetting agent, 
which also helps to stabilize GF nanosuspensions. Wear resistant yttrium zirconia 
beads (Zirmil Y, Saint Gobain ZirPro, Mountainside, NJ, USA) with a median size of 
430 µm was used as the milling media. 
4.1.2  Milling and Spray Drying of Drug Suspensions 
Aqueous suspension-based (W:water) feeds of GF prepared by wet milling were fed 
to the spray dryer for the preparation of drug nanocomposites. Table 4.1 presents the 
formulations used in the precursor feeds. The concentration of GF and SDS was kept 
at 2.5% w/v and 0.125% w/v, respectively, in all suspensions. The concentration was 
calculated with respect to the 240 mL suspension liquid (deionized water). GF 
suspensions were prepared with two polymers (HPC and Sol) with three 
drug:polymer mass ratios of 1:1, 1:3, and 1:5 to examine the impact of polymer type 
and polymer loading on GF release in the dissolution tests. To prepare a traditional 
nanocomposite, a GF nanosuspension with 3:1 GF:Sol (W-Sol-3:1, SDS) was also 
prepared. Finally, to investigate the impact of SDS in the stabilization of the milled 
GF suspensions and GF release during dissolution tests, surfactant-free suspensions 
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having the same drug:polymer mass ratios were also prepared for comparative 
analysis.  
 
Table 4.1  Formulations and Compositions of the Aqueous (W) Suspension-Based 
Feeds Used in Spray Drying Experiments 
ID Formulationa 
GF 
(% w/v)b 
Polymers 
(% w/v)b 
SDS 
(% w/v)b 
Water 
(mL) 
W1 W-Sol-1:5 2.5 12.5 0 240 
W2 W-Sol-1:3 2.5 7.5 0 240 
W3 W-Sol-1:1 2.5 2.5 0 240 
W4 W-Sol-1:5, SDS 2.5 12.5 0.125 240 
W5 W-Sol-1:3, SDS 2.5 7.5 0.125 240 
W6 W-Sol-1:1, SDS 2.5 2.5 0.125 240 
W7 W-HPC-1:5 2.5 12.5 0 240 
W8 W-HPC-1:3 2.5 7.5 0 240 
W9 W-HPC-1:1 2.5 2.5 0 240 
W10 W-HPC-1:5, SDS 2.5 12.5 0.125 240 
W11 W-HPC-1:3, SDS 2.5 7.5 0.125 240 
W12 W-HPC-1:1, SDS 2.5 2.5 0.125 240 
W13 W-Sol-3:1, SDS 2.5 0.8 0.125 240 
aW denotes suspension-based feed; Sol denotes Soluplus; the ratios refer to the drug:polymer mass 
ratios. 
b% w/v with respect to the volume (240 mL) of the deionized water. 
 
In each milling experiment, a shear mixer (Fisher Scientific Laboratory 
Stirrer, Catalog No. 14-503, Pittsburgh, PA) was used to disperse as-received GF 
particles in aqueous stabilizer (HPC/Sol) solutions with and w/o SDS. The resultant 
GF pre-suspensions were transferred to the holding tank of a Microcer wet stirred 
media mill (WSMM) (Netzsch Fine Particle Technology, LLC, Exton, PA, USA) 
having 80 mL chamber. Milling conditions were adapted from our prior work on wet 
media milling (Afolabi et al., 2014; Bilgili et al., 2016). 50 mL of the milling 
chamber was filled with zirconia beads, and a screen with 200 µm opening was used 
in the outlet of the chamber to hold the beads in the chamber. A peristaltic pump was 
used to recirculate the suspension through the chamber at a rate of 126 mL/min and 
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the suspension was milled for 64 min at a rotor speed of 3200 rpm. A chiller 
(Advantage Engineering Greenwood, IN, USA) was used to maintain the milling 
chamber temperature below 35 °C throughout the milling. A portion of each 
suspension was separated in a vial and stored for 7 days at 8 °C to assess the short-
term physical stability. Also, the milled suspensions were refrigerated at 8 °C 
overnight before spray drying.  
Milled GF suspensions were dried using a spray dryer (4M8-Trix, Procept, 
Zelzate, Belgium) having a co-current flow set-up. The total length and the diameter 
of the spray dryer are 1.59 and 0.15 m, respectively. To ensure complete drying, inlet 
temperature was selected above the boiling temperature of the water. Drying air at 
120 °C were fed at 0.37–0.40 m3/min at the top of the dryer column to dry the milled 
GF nanosuspensions, while 200 g milled suspension of each formulation was fed at 
2.0 g/min rate using a peristaltic pump (Make-it-EZ, Creates, Zelzate, Belgium) and 
atomized by a bi-fluidic nozzle at the top of the column concurrently to air flow.  A 
cyclone separator was used to separate the dried particles from the outlet stream into a 
glass jar. The residence time was calculated to be ~4.0 s for the feeds. Atomizing air 
pressure of 2.0 bar, a bi-fluidic nozzle with tip diameter of 0.6 mm, and cyclone 
pressure of 55–60 mbar were selected based on prior experience (Azad et al., 2015b) 
and exploratory experiments. The dried particles obtained from the collection jar were 
transferred into double plastic bag and stored into a vacuum-desiccator at room 
temperature for further characterizations.  
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4.2  Characterization Techniques 
4.2.1  Particle Size Measurement 
Drug particle size distributions (PSDs) in the suspensions were measured using a 
laser diffraction (LS 13 320, Beckman Coulter, Miami, FL) based on Mie scattering 
theory following the procedure described in Bilgili et al. (2016). Particle sizes were 
measured at various time points: right after milling, after 1-day and 7-day storage at 8 
°C to in a refrigerator. During the measurement, the intensity was maintained 40–
50% while the obscuration was maintained below 8.0%. Refractive index values are 
1.65 for GF (drug) and 1.33 for deionized water (medium). For each measurement, a 
2.0 mL suspension sample was diluted with 5.0 mL of the respective stabilizer 
solution and mixed using a vortex mixer (Fisher Scientific Digital Vortex Mixer, 
Model No: 945415, Pittsburgh, PA) at 1500 rpm for 1 min.  
The particle sizes of the spray-dried powders were measured by a 
Rodos/Helos laser diffraction system (Sympatec, NJ, USA) based on Fraunhofer 
theory following the procedure described in Li et al. (2016b). About 1 g of the 
powder sample was placed on top of the sample chute of the Rodos dispersing system 
and the sample chute was vibrated at a 100% setting, and 0.1 bar dispersion pressure 
was used to suck in the falling powder through the sample cell of the laser diffraction 
system. For further confirmation of the particle sizes, spray-dried particles were 
placed on a glass slide and observed by Axio Scope.A1 polarized light microscope 
(PLM, Carl Zeiss Microscopy GmbH, Göttingen, Germany). 
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4.2.2  Solid State Characterization and Drug–Polymer Interactions 
To analyze the crystallinity of the as-received GF, HPC, Sol, spray-dried powders, 
and physical mixtures of GF–polymer with or w/o SDS, X-ray powder diffraction 
(XRPD) (PANanalytical, Westborough, MA, USA), provided with Cu Kα radiation 
(λ= 1.5406 Å) was used. The samples were scanned at a rate of 0.165 s-1 for 2θ 
ranging from 5° to 40°. The total area under three distinct, non-overlapping peaks of 
GF at characteristic diffraction angles of 13.2, 14.6, and 16.5º was calculated for both 
the physical mixtures and the spray-dried powders using the equipment’s HighScore 
Plus software, which was then used to estimate the crystallinity. 
Differential scanning calorimetry (DSC) of the as-received GF, Sol, HPC, and 
spray-dried powders was performed using a Mettler-Toledo polymer analyzer 
(PolyDSC, Columbus, OH, USA) with integrated STARe 10 software. ~6.0–7.0 mg 
powder sample was placed in an aluminum pan with a hole in the lid and loaded into 
the DSC machine. As-received GF was heated at a rate of 10 °C/min from 25 °C to 
250 °C. All other samples were heated from 25 °C to 70 °C and the temperature was 
held for 2 min at 70 °C, then cooled back to 25 °C to remove any residual solvent in 
the sample. In the final step, the samples were heated from 25 °C to 250 °C at 10 
°C/min. Nitrogen gas was used as the purge gas and protective gas at a flow rate of 
50 mL/min and 150 mL/min, respectively. Thermogravimetric analysis (TGA) was 
performed to measure the residual water/solvent content using a TGA/DSC1/SF Stare 
system (Mettler Toledo, Inc., Columbus, OH). ~6.0–7.0 mg of each spray-dried 
sample was placed in a ceramic crucible and heated from 25 °C to 150 °C at a heating 
rate of 10 °C/min under nitrogen flow. 
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Raman spectroscopy was conducted using a Fergie Imaging Spectrometer 
System (Princeton Instruments, Trenton, NJ) with a 500-mW external diode laser 
processing at 785 nm wavelength. Data acquisition time for all spectra was 15 s per 
scanned spectrum (100–1800 cm-1) and each spectrum acquired was averaged over 
two scans. The data was presented for the range of 1550–1800 cm-1 wavenumber. 
4.2.3  Nanoparticle Recovery From the Nanocomposites 
Aqueous redispersion of the spray-dried powders was performed following the 
method in refs. (Bhakay et al., 2014a; Li et al., 2016b). About 0.5 g of the spray-dried 
powders produced from nanosuspension-based (W) feeds was dispersed in 30 mL of 
deionized water inside a 60 mL beaker and stirred at 500 rpm for 60 min with a 
paddle-stirrer (CAT R18, Scientific Instrument Center Limited, Winchester, UK). 
~1.0 mL aliquot of redispersed sample was collected at 2, 10 and 60 min while 
stirring, and particle size was measured using laser diffraction (LS 13 320, Beckman 
Coulter, Miami, FL). At the same time, a droplet of each redispersed sample was 
dried immediately by dropping on a preheated glass slide at 100 °C using a hot plate. 
After drying, the polarized light microscope (PLM) was used to capture the images of 
the redispersed particles. The details of the experimental methods and PLM images 
are presented in Section C.2 of the Appendix C. 
4.2.4  Drug Content in the Spray-Dried Powders and In Vitro Dissolution Tests 
The drug content in the dried powders varied based on the drug:polymer mass ratios. 
To measure the actual drug content, an assay testing was performed by dissolving 100 
mg of the sample powders in 20 mL methanol under 30 min of sonication, followed 
by overnight storage to ensure complete solubilization of the GF particles. An aliquot 
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of 100 µL was taken from the GF solution and diluted up to 10 mL using methanol. 
The absorbance of the samples was measured at 292 nm using UV spectrophotometer 
(Agilent, Santa Clara, CA, USA), and the drug concentration was calculated from a 
pre-established calibration curve. Six replicates were tested for each formulation to 
calculate the mean drug content along with the relative standard deviation (RSD). 
Drug release from the spray-dried powders and physical mixtures (PMs) 
prepared by blending was determined via a Distek 2100C dissolution tester (North 
Brunswick, NJ, USA), following the USP II paddle method. 1000 mL deionized 
water at 37 °C was selected as the dissolution medium and stirred at 50 rpm paddle 
speed. Considering the thermodynamic aqueous solubility of GF, i.e., 14.2 mg/L at 37 
°C, a typical low (8.9 mg) dose and high dose (100 mg) of GF would allow for non-
supersaturating and supersaturating dissolution conditions. Although the low dose 
may not arouse as much interest as the high dose, a low dose like 8.9 mg may 
emulate potent poorly soluble drugs. The spray-dried powders were poured into the 
dissolution medium and 4 mL samples were taken out manually at 1, 2, 5, 10, 20, 30, 
and 60 min. These aliquots were filtered with a 0.1 µm PVDF membrane-type 
syringe filter before UV-spectroscopy measurements to minimize any confounding 
effect of the undissolved coarse drug aggregates (Bhakay et al., 2014a; Li et al., 
2016b). In separate dissolution tests, 100 mg equivalent GF was used to allow for 
supersaturation in the bulk dissolution medium, which was conducted with additional 
sampling at 120, 180, and 210 min. The filtered samples were diluted with deionized 
water kept at 37 °C at a ratio of 1 to 5 before UV measurement. Dissolved GF 
amount was measured by UV-vis spectroscopy at 296 nm wavelength and calculated 
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using a pre-established calibration curve. Deionized water was used as blank before 
UV measurement, and six replicates were performed for each sample. In this paper, 
relative % supersaturation is reported based on GF concentration at 210 min and 
thermodynamic solubility of as-received GF particles, unless otherwise indicated. 
4.2.5  Drug Wettability Enhancement by Sol and HPC Solutions With or W/O 
SDS 
GF wettability was investigated by analyzing the penetration rate of stabilizer 
solutions into a packed bed of GF particles inside a cylindrical column according to 
the Washburn method (Hołownia et al., 2008; Washburn, 1921). Attension Sigma 
700 (Biolin Scientific, Linthicum, MD, USA) set-up was used to measure the mass of 
the liquid penetrated the GF powder bed as a function of time. Experimental methods 
were adapted from Bilgili et al. (2018) and Li et al. (2017) and the details can be 
found in Section C.1 of the Appendix C. In the current study, liquids and powder 
refer to GF-saturated aqueous solutions of 15% Sol/HPC with 0.125% SDS or w/o 
SDS and as-received GF, respectively. All percentages are (% w/w) with respective 
to deionized water. The aqueous solution of the stabilizers and deionized water were 
saturated with griseofulvin (GF) and stirred overnight. After overnight stirring, the 
saturated solutions were used for further characterization. The apparent shear 
viscosity and surface tension of the liquids were measured using R/S Plus Rheometer 
(Brookfield Engineering, Middleboro, MA, USA) and Attension Sigma 700 (Biolin 
Scientific, Linthicum, MD, USA), respectively. The ratio of the cosine of contact 
angles cosθss/cosθw was calculated using the modified Washburn equation and used as 
a wetting effectiveness factor. Here, θss is the contact angle between GF and the 
stabilizer solutions and θw is the contact angle between GF and deionized water. The 
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ratio was used as a rough measure of the drug wettability enhancement upon use of 
different stabilizers (HPC/Sol and HPC/Sol–SDS) in water with respect to the GF–
water wettability. 
 4.2.6  Drug Supersaturation Maintenance Ability of the Polymers 
Drug (GF) supersaturation maintenance ability of HPC/Sol with and w/o SDS was 
examined in separate desupersaturation tests (similar to Konno et al. (2008)). A 
concentrated solution of GF was prepared by dissolving 100 mg of as-received GF 
into 20 mL of acetone via sonication for 40 min. This solution was subsequently 
added to a 1000 mL of pre-dissolved HPC/Sol solution having 100 and 300 µg/mL 
concentrations to maintain 1:1 and 1:3 drug:polymer ratios (similar to the 
formulations in Table 4.1), respectively, with or w/o SDS in the USP II paddle type 
dissolution tester. The addition resulted in 92–99 µg/mL supersaturated solution of 
GF initially (target: 100 µg/mL, corresponding to complete dissolution of 100 mg 
drug during dissolution testing). Any subsequent desupersaturation during the 
following 210 min was tracked via GF concentration measurements. The 
experimental conditions and concentration measurements were identical to those in 
the dissolution test. All measurements were carried out in triplicate. 
 
4.3  Results and Discussion 
4.3.1  Properties of GF Suspensions Prepared via Wet Stirred Media Milling 
Twelve GF suspensions with HPC/Sol at 1:1, 1:3, and 1:5 drug:polymer mass ratios 
and 0.125% SDS and without SDS were wet media milled. Figure. 4.1 presents the 
characteristic particle sizes of the 64 min milled suspensions and the suspensions after 
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1-day and 7-day storage. As-received GF (unmilled) particles had d50: 9.74 ± 0.23 µm 
and d90: 27.4 ± 0.1 µm. After milling for 64 min, median particle sizes d50 were in the 
range of 0.146–0.155 µm for W4–W6 (Sol–SDS) and 0.166–0.184 µm for W10–W12 
(HPC–SDS) formulations. Unless properly stabilized, GF nanoparticles are known to 
form micron-sized aggregates in aqueous suspensions (Bilgili and Afolabi, 2012).  
Figure 4.1 suggests that only with SDS, GF nanosuspensions with median sizes d50 
less than 200 nm were formed, and the small changes in their d50 and d90 during the 7-
day storage suggest that these suspensions were physically stable. With SDS, Sol-
based suspensions were insensitive to Sol loading, whereas finer aggregates were 
formed with lower GF:HPC mass ratio (higher polymer loading). On the other hand, 
without SDS, Sol-based suspensions with 1:1 and 1:3 GF:Sol exhibited severe 
nanoparticle aggregation with a 4 µm median size, whereas submicron median sizes 
were observed for HPC-based suspensions. These suspensions also exhibited notable 
size increase upon 7-day storage. An increase in polymer concentration led to finer 
aggregates. 
Due to their relatively neutral charge, stabilizing capability of Sol/HPC solely 
depends on their steric effects, which in turn is modulated by their adsorption onto 
GF nanoparticle surfaces. The adsorption is dependent on free polymer concentration  
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Figure 4.1  Volume-based particle size statistics of the milled GF suspensions with 
1:1, 1:3, and 1:5 GF:polymer mass ratios and 0.125% SDS/without SDS after milling 
(64 min) as well as 7-day storage at 8 °C: (a) 10% cumulative passing size d10, (b) 
median particle size d50 and (c) 90% cumulative passing size d90.  
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in the suspension, and usually increases as polymer concentration increases. The finer 
aggregates and lower extent of aggregation can be explained by greater polymer 
adsorption at higher polymer adsorption, which was already established in an earlier 
HPC–GF adsorption study (Bilgili and Afolabi, 2012). Clearly, presence of 0.125% 
in the suspensions had the most dramatic effect on the extent of nanoparticle 
aggregation. HPC–SDS was reported to have synergistic stabilizing effect on GF 
suspensions during milling and storage (Konno et al., 2008) and stabilized multiple 
BCS Class II drug nanosuspensions (Bilgili et al., 2016). HPC and Sol imparted steric 
stabilization by adsorbing on drug nanoparticles (Bilgili and Afolabi, 2012; Yang et 
al., 2014), while the anionic surfactant (SDS) enhanced GF wettability/deaggregation 
and helped to stabilize the GF nanosuspensions via electrostatic repulsion (Bilgili and 
Afolabi, 2012; Bilgili et al., 2016). As can be seen from Table 4.2, both polymers and 
polymer–SDS reduced the surface tension and enhanced the GF wettability by water. 
As indicated by the higher wetting effectiveness factor, HPC (hydrophilic polymer) 
rendered GF more wettable by water than Sol (amphiphilic polymer), and SDS 
enhanced the wettability even further when used in combination with both polymers. 
The wettability is important to the deaggregation of the aggregates formed during 
milling, which allows for full exposure of GF particle surfaces for polymer 
adsorption. The lower wettability of GF by Sol as compared with HPC could be one 
reason for the large aggregates in Sol-based suspensions. On the other hand, with 
SDS, finer suspensions were obtained with Sol than with HPC, which suggests 
differing interactions between polymer–SDS. 
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Table 4.2  Properties of Drug-Saturated Deionized Water–Aqueous Stabilizer 
Solutions and Wetting Effectiveness Factor Determined Using the Modified 
Washburn Method 
Formulation η 
(cP) 
ρ 
(g/mL) 
γ 
(mN/m) 
Slope, 
(g2/s) 
R2  cosθss/cosθw 
Water 0.89 1.00 66.5 7.0×10-3 0.990  1.00a 
Sol 8.76 1.01 41.4 1.2×10-3 0.989  2.65 
Sol–SDS 13.5 1.01 40.5 1.5×10-3 0.991  4.65 
HPC 53.2 1.01 39.9 1.5×10-3 0.998  20.9 
HPC–SDS 58.3 1.01 34.8 2.4×10-3 0.999  42.1 
a
The slope of the water penetration data was used as reference for wettability enhancement by the 
stabilizer solutions. 
4.3.2  Size, Morphology, and Drug–Moisture Content of the Spray-Dried 
Powders 
Despite the relatively short residence time (4 s), the powders were completely dried, 
as indicated by TGA, which shows weight loss of 2.0 ± 0.3% for the samples. The 
extremely large surface area generated by atomization of the suspension feed coupled 
with the convective heat–mass transfer at high air temperature enabled fast drying of 
the droplets in the drying chamber. The mean (actual) drug content after spray-drying 
was higher for feeds with higher drug:polymer mass ratio (Table 4.3). All RSD values 
were below 6%: 0.51–4.71%, which signifies pharmaceutically acceptable content 
uniformity. The lower drug content as compared with the theoretical value can be 
attributed to preferential drug loss during handling/transfer of the suspensions after 
milling, poor separation of finer particles in the cyclone separator of the spray dryer, 
and presence of the residual moisture after drying (Azad et al., 2015b; Bilgili et al., 
2018). An increase in polymer loading (lower drug:polymer mass ratio) led to 
formation of coarser particles due to increase in total solids loading and higher 
viscosity of the precursor feed (Bilgili et al., 2018; Li et al., 2018b; Poozesh and 
Bilgili, 2019). Compared to the significant impact of polymer loading on particle size, 
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the impact of SDS was weak and did not exhibit a clear trend. The microscopic 
images (Figure 4.2) illustrate that spray-dried particles are somewhat aggregated due 
to their cohesive nature and individual particles have rounded–shriveled morphology.  
 
 
Figure 4.2  Polarized light microscope images of the spray-dried particles prepared 
using the GF suspension-based (W) feed with 1:3 GF:polymer mass ratios and 
0.125% SDS/without SDS: (a) W-HPC-1:3 (b) W-HPC-1:3, SDS, (c) W-Sol-1:3, and 
(d) W-Sol-1:3, SDS. All images were taken at 50X magnification (scale bar: 20 µm). 
 
4.3.3  Formation of Drug Nanocomposites/HyNASDs 
Figure 4.3 illustrates the XRPD diffractograms of the spray-dried powders, while 
Table 4.4 presents their crystallinity. X-ray diffractograms depict that as-received GF 
exhibited intense peak characteristics of a crystalline material, whereas HPC/Sol 
exhibited halo pattern indicating amorphous structure. The physical mixtures (PMs), 
prepared by blending of as-received GF with HPC/Sol or HPC/Sol–SDS powders,  
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Table 4.3  Particle Size Statistics of the Spray-Dried Powders and Their Drug Content 
ID Formulationa 
Particle size statistics of the spray-dried particles 
(µm) 
Theoretical drug 
content  
(% w/w)b 
Actual drug 
content, RSD              
(% w/w, %)b 
d10±SD d50±SD d90±SD 
W1 W-Sol-1:5 10.8±0.4 21.8±0.3 39.8±0.5 16.7 15.4, 2.34 
W2 W-Sol-1:3 5.68±0.1 16.2±0.0 31.9±0.1 25.0 22.3, 4.47 
W3 W-Sol-1:1 4.02±0.2 10.4±0.1 20.0±0.0 50.0 44.1, 4.31 
W4 W-Sol-1:5, SDS 10.3±0.1 20.3±0.1 36.4±0.3 16.5 14.9, 3.47 
W5 W-Sol-1:3, SDS 9.29±0.1 19.0±0.1 33.6±0.1 24.7 21.2, 1.50 
W6 W-Sol-1:1, SDS 4.48±0.1 10.1±0.1 21.9±0.2 48.8 42.0, 1.73 
W7 W-HPC-1:5 9.73±0.3 22.3±0.4 46.0±0.7 16.7 14.9, 4.71 
W8 W-HPC-1:3 6.41±0.1 20.3±0.1 41.8±0.3 25.0 22.8, 4.60 
W9 W-HPC-1:1 4.61±0.1 14.9±0.4 35.8±0.6 50.0 45.4, 1.77 
W10 W-HPC-1:5, SDS 8.32±0.2 21.0±0.8 44.3±0.8 16.5 15.3, 1.48 
W11 W-HPC-1:3, SDS 6.37±0.1 16.5±0.6 40.0±0.1 24.7 22.3, 3.14 
W12 W-HPC-1:1, SDS 5.24±0.1 12.9±0.1 34.2±0.1 48.8 42.5, 2.83 
W13 W-Sol-3:1, SDS 1.66±0.1 6.89±0.3 15.3±0.4 72.3 64.4, 0.51 
aW denotes suspension-based feed; Sol denotes Soluplus; the ratios refer to the drug:polymer mass ratios. 
b% w/w with respect to the total weight of the spray-dried powder. 
1
4
0
 
 
 141 
 
exhibited peaks at the same diffraction angles as those of as-received GF, albeit with 
reduced intensity. The diffractograms of the spray-dried powders without SDS 
(Figure 4.3a) and with SDS (Figure 4.3b) did not remarkably differ, except for peak 
intensities; they exhibit a similar pattern regarding the impact of polymer loading. 
The peak intensities of GF in the PMs were lower than those of the as-received GF 
powder, which can be attributed to the dilution and surface coverage of GF 
microparticles with HPC/Sol, and the reduction is more discernible with increasing 
polymer concentration. Similar XRPD diffractograms to those of the PMs were 
observed for the spray-dried powders confirming that spray-drying of the milled 
suspensions led to formation of nanocomposites that are largely crystalline. 
Interestingly, the diffractograms of the spray-dried powders displayed reduced peak 
intensities as compared with their respective PMs, beyond the aforementioned 
dilution effect of the polymer, which becomes more pronounced upon an increase in 
polymer loading (lower drug:polymer mass ratio). Surprisingly, wet milling followed 
by spray-drying led to reduction of crystallinity and formation of notable (up to 21%) 
amorphous GF (see Table 4.4). To the best knowledge of the authors, this level of 
amorphous content in drug nanocomposites is not common.  
It is well-known that wet media milling does not cause any detectable 
amorphization of as-received GF, in the absence of stabilizers, due to plasticization 
effect of water (Monteiro et al., 2013; Żarów et al., 2011). XRPD diffractograms of 
the wet-media milled GF and as-received GF were almost identical (Monteiro et al., 
2013) In the presence of high polymer loading in the suspensions here, however, 
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amorphization of GF took place during the spray drying. Table 4.4 shows that despite 
being largely crystalline, the spray-dried powders had higher amorphous GF when 
 
 
Figure 4.3  X-ray diffractograms of as-received GF, HPC, Sol, physical mixtures 
(PMs) of GF–HPC/Sol and the spray-dried powders prepared using the GF 
suspension-based (W) feed with 1:1, 1:3, and 1:5 drug:polymer mass ratios: (a) 
without SDS and (b) with 0.125% SDS in the suspension. W-Sol-3:1, SDS and PM-
Sol-3:1, SDS stand for the spray-dried powder prepared using a suspension-based 
feed with 3:1 GF:Sol mass ratio and 0.125% SDS and its corresponding physical 
mixture, respectively. 
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Table 4.4  Melting Point Temperature and Fusion Enthalpy of the Spray-Dried 
Powders Obtained From DSC Thermograms and Crystallinity Estimated From XRPD 
Diffractograms 
ID Formulationa Tm (ºC)
b Hf (J/g)b Tm (ºC)b Crystallinity (%) 
W1 W-Sol-1:5 171 1.56 49.1 80.3 
W2 W-Sol-1:3 181 3.23 39.1 86.8 
W3 W-Sol-1:1 205 19.6 15.1 93.9 
W4 W-Sol-1:5, SDS 168 2.46 52.1 78.8 
W5 W-Sol-1:3, SDS 186 7.37 34.1 81.3 
W6 W-Sol-1:1, SDS 204 22.7 16.1 86.3 
W7 W-HPC-1:5 189 8.34 31.1 80.8 
W8 W-HPC-1:3 199 12.0 21.1 82.7 
W9 W-HPC-1:1 211 28.0 9.1 99.2 
W10 W-HPC-1:5, SDS 172 3.54 48.1 81.8 
W11 W-HPC-1:3, SDS 198 12.7 22.1 86.5 
W12 W-HPC-1:1, SDS 211 28.7 9.1 95.5 
W13 W-Sol-3:1, SDS 212 47.0 8.1 92.1 
aW denotes nanosuspension-based feed, Sol denotes Soluplus; the ratios refer to the drug:polymer mass 
ratios.   
bTm stands for melting point temperature, Tm stands for melting point depression, and Hf stands for 
fusion enthalpy. 
 
the polymer loading in the precursor suspension was higher. In general, more 
amorphous GF formed in the Sol formulations than in the HPC formulations at the 
same drug:polymer mass ratio with/without SDS except for 1:3 GF:polymer without 
SDS. These findings imply that (i) amorphous GF formed due to GF–polymer 
molecular interactions and/or solubilization of the surface layer of nanoparticles by 
the polymer during the spray-drying and (ii) Sol appears to favor the amorphization 
of GF more than HPC, which implies stronger Sol–GF molecular 
interactions/miscibility than HPC–GF. It is likely that presence of GF nanoparticles 
and their aggregates with large surface area and higher polymer loading (more GF–
polymer interactions and higher GF solubilization in the polymer) could have favored 
the formation of amorphous GF. Based on these findings and ref. (Kayaert and Van 
den Mooter, 2012), it is proposed that the polymeric matrix of the spray-dried 
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particles encapsulates drug nanocrystals/aggregates, surrounded by a layer of 
amorphous GF molecularly dispersed in the polymer (see Figure 4.4b). Formation of 
amorphous content upon drying of drug nanosuspensions was first noted in (Kayaert 
and Van den Mooter, 2012), albeit to a lower extent, and was regarded as 
“unfavorable”. Nonetheless, the impact of such amorphous content on drug release 
from the nanocomposites has not been studied at all. As the dissolution tests will 
reveal, despite being largely crystalline, these nanocomposites with relatively high 
polymer loading (low drug:polymer ratio) allow for much higher supersaturation than 
traditional nanocomposites, similar to the supersaturation levels observed for ASDs; 
hence, we coin the term hybrid nanocrystal–ASD (HyNASD) for this special class of 
nanocomposites. 
The DSC thermograms in Figure 4.5 show an endothermic peak associated 
with melting of as-received GF, with a melting point temperature Tm of 220.1 °C and 
a fusion enthalpy ΔHf of 101.8 J/g; a glass transition for Sol (amorphous) at 72.4 °C; 
and a slight endothermic event around 170–200 °C for HPC likely due to the melting 
of the small crystalline domain of largely amorphous HPC (Sarode et al., 2013) 
(crystallinity was undetectable by XRPD). The Tg of HPC could not be measured (in 
the range of –25 to 0 °C (Sarode et al., 2013)) due to limitation of our equipment. The 
spray-dried powders exhibited a melting endotherm only, corresponding to the fusion 
of their GF crystals. The absence of any recrystallization event during the heating 
could suggest that the amorphous GF in HyNASDs did not recrystallize due to GF–  
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Figure 4.4  Schematic illustration of the solid state of the drug (GF) in (a) GF nanocomposite, (b) GF hybrid nanocrystal–
amorphous solid dispersion (HyNASD), and (c) GF amorphous solid dispersion (ASD). Figure is not drawn to scale. 
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polymer molecular interactions as the small amorphous GF was in the ASD 
surrounding the drug crystals (see Figure 4.4b). 
 
 
Figure 4.5  DSC thermograms of as-received GF, HPC, Sol, and the spray-dried 
powders prepared using the GF suspension-based (W) feed with 1:1, 1:3, and 1:5 
drug:polymer mass ratios: (a) without SDS and (b) with 0.125% SDS in the 
suspension. W-Sol-3:1, SDS stands for the spray-dried powder prepared using a 
suspension-based feed with 3:1 GF:Sol mass ratio and 0.125% SDS. 
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Wet media milling of as-received GF without any stabilizers depressed Tm by 
less than 1 ºC (Monteiro et al., 2013). On the other hand, Figure 4.5 and Table 4.4 
show that spray-drying of GF suspensions with polymers led to drastic melting point 
depression (high ΔTm), up to 52 ºC, and reduction of ΔHf even if the ΔHf values were 
corrected for dilution with polymer and reduced crystallinity (not shown for brevity). 
The significant melting point depression in drug–polymer mixtures is indicator of 
drug–polymer miscibility (Baird and Taylor, 2012; Newman et al., 2008). In general, 
higher polymer loading (lower GF:polymer mass ratio) led to lower Tm as compared 
with the as-received GF crystals, higher ΔTm, and lower ΔHf, regardless of the 
presence/absence of SDS, which signifies significant GF–polymer molecular 
interactions. Moreover, without exceptions, having identical polymer/SDS 
composition, the spray-dried powders with Sol had higher ΔTm and lower ΔHf than 
those with HPC, which could be explained by (i) stronger GF–Sol interactions and 
miscibility, (ii) higher initial amorphous content in the Sol-based spray-dried 
powders, and (iii) higher extent of solubilization of GF in the polymer melt at high 
temperatures due to the thermal treatment during the DSC scan. Compared with the 
clear trends regarding the impact of polymer loading for formulations with/without 
SDS, the trends for SDS impact were not as strong and as clear. For HPC-based 
formulations, the impact of SDS was small and only notable for the highest HPC 
loading (1:5), which exhibited higher ΔTm and lower ΔHf with SDS than without 
SDS, implying increased solubilization of GF in the presence of SDS. For Sol-based 
formulations, the impact of SDS was small at 1:1 GF:Sol loading. While lower ΔHf 
without SDS than with SDS was noted for all GF:Sol powders, ΔTm did not follow a 
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clear trend. The relatively low impact of SDS could be related to the small amount of 
SDS in the formulations (1:0.05 GF:SDS). 
4.3.4  Raman Spectroscopy and Drug–Polymer Miscibility 
The observed Raman lines in Figure 4.6 for as-received GF and PMs of GF are 
largely in agreement with Fourier transform Raman data of ref. (Feng et al., 2008) 
and Raman data of ref. (Żarów et al., 2011) for crystalline GF. While the W-Sol-1:3 
and W-HPC-1:3 powders did not show disappearance of any lines characteristic of 
GF, their spectra clearly show broadening of the characteristic GF lines, peak 
intensity reduction, and line shifts as compared with the spectra of the respective PMs 
due to GF–polymer interactions (Meng et al., 2015) and presence of amorphous 
domains in these powders (Baird et al., 2010). In contrast, the spectra of W-Sol-3:1 
with SDS, having 1/9th of Sol content compared with W-Sol-1:3 with SDS, did not 
show as much line broadening and line shift compared to the spectra of its respective 
PM. Finally, the line at 1606 cm-1 does not exist in amorphous GF (Żarów et al., 
2011); hence, intensity reduction and line broadening/slight line shift at 1606 cm-1 
could originate from the presence of amorphous GF content. 
It is suggested that if the solubility parameter difference between a drug and 
polymer is <7.0 MPa1/2, they are likely to be miscible; if the difference is >10 MPa1/2, 
they are considered immiscible (Forster et al., 2001; Greenhalgh et al., 1999). The 
solubility parameters of GF, HPC, and Sol are 12.2 (Thakral and Thakral, 2013), 24.0 
(Choi et al., 1994), and 19.4 (Kolter et al., 2012) MPa1/2, respectively. The solubility 
parameter differences between GF–Sol and GF–HPC are 7.2 and 11.8 MPa1/2, 
respectively, which suggests that GF–Sol is borderline miscible, whereas GF–HPC is 
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immiscible. Despite being useful, a caveat about the solubility parameters is worth- 
noting: the theoretical models of this approach are applicable for simple molecular 
 
 
Figure 4.6  Raman spectra of as-received GF, physical mixtures (PMs) of GF–
HPC/Sol at 1:3 drug:polymer ratio, and the spray-dried powders prepared using the 
GF suspension-based (W) feed with 1:3 GF:polymer mass ratio: (a) with SDS and (b) 
without SDS in the suspensiom. W-Sol-3:1, SDS and PM-Sol-3:1, SDS stand for the 
spray-dried powder prepared using a suspension-based feed with 3:1 GF:Sol mass 
ratio and 0.125% SDS and its corresponding physical mixture, respectively.  
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structures wherein van der Waals force plays a predominant role, while for drug–
polymer systems which are known to form highly directional interactions (e.g., 
hydrogen bonding) or long-range interactions (e.g., ionic interaction), this approach 
can be erroneous (Baird et al., 2010; Meng et al., 2015). Indeed, the formation of 
amorphous GF upon spray-drying with HPC-based suspensions, drastic melting point 
depression and reduced ΔHf in the spray-dried powders (even after corrected for 
crystallinity and GF loading) and the Raman spectroscopy results above suggest that 
HPC molecularly interacts with GF, resulting in partial miscibility unlike the 
prediction from the solubility parameters. However, the solubility parameters 
correctly predicted the higher Sol–GF–miscibility than the HPC–GF miscibility, 
which is in in line with the DSC and XRPD results. 
The XRPD, DSC, and Raman spectroscopy results overall suggest that spray-
drying of GF–polymer nanosuspensions with/without SDS led to formation of drug 
nanocomposites/HyNASDs. Although a hard and crisp distinction between traditional 
nanocomposites and HyNASDs is not intended here, HyNASDs appear to have 
notable amorphous content (>%10 in XRPD) and/or exhibit significant Tm 
depression–ΔHf reduction and GF Raman peak broadening as compared with the 
respective physical mixtures. As a general observation, we note that spray-drying a 
drug nanosuspension with a lower drug:polymer mass ratio (1:3 and 1:5) than 
typically used (see e.g., Table 1.3) and the use of a strongly miscible polymer that 
interacts with the drug nanoparticles and solubilizes them during the spray drying 
favor the formation of HyNASDs vs. nanocomposites (W-Sol-1:3 vs. W-Sol-3:1).  
Moreover, as will be shown in Section 4.3.7, nanocomposites and HyNASDs may 
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behave quite differently in their functional responses such as in vitro drug release. 
4.3.5  Redispersibility of the Spray-Dried Powders 
Spray-dried powders were dispersed in 30 mL of deionized water inside a 60 mL 
beaker and stirred at 500 rpm for 60 min, and particle sizes of the suspension samples 
taken 2, 10, and 60 min into redispersion are presented in Figures 4.7 and 4.8 for 
HPC-based and Sol-based formulations, respectively. Ideally, the redispersion of the 
powders should yield particles with sizes similar to those in the milled suspensions. A 
cursory look at these figures suggests that redispersion of the powders with SDS 
achieved this ideal expectation: fast recovery of the drug nanoparticles that have 
similar sizes to those in the precursor suspensions. The only exception was W-Sol-
1:1, SDS, which has the lowest Sol loading and had d90 above 1 µm. Without SDS, 
most spray-dried powders exhibited slow or incomplete redispersion. Among Sol-
based powders only W-Sol-1:5 (with the highest Sol loading) exhibited complete 
redispersion, whereas W-Sol-1:1 and W-Sol-1:3 redispersed extremely slowly 
(incomplete redispersion).  On the other hand, even without SDS, all HPC-based 
powders were able to redisperse to different extents. Note that GF is a relatively 
hydrophobic drug (Muster and Prestidge, 2005), while HPC is hydrophilic, and Sol is 
amphiphilic. Based on modified Washburn method and results presented in Table 4.2, 
we note (i) the higher wettability enhancement by HPC as compared with Sol in 
aqueous solutions and (ii) higher wettability enhancement when SDS was present 
along with the polymer in the aqueous solutions. Hence, the wettability of the spray-
dried powder largely controls the redispersion behavior. Although the spray-dried 
powders encapsulate the drug crystals/amorphous GF, depending on the polymer 
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loading, the surface will still have hydrophobic GF exposed to water. The dissolving 
polymer/SDS in the microenvironment of the particles enhances wettability of the 
hydrophobic drug and allows for faster imbibition/absorption of water in the particle, 
which facilitates the redispersion. 
 
 
Figure 4.7  Volume-based particle size statistics of the GF suspension-based (W) 
feeds with 1:1, 1:3, and 1:5 GF:HPC mass ratios and 0.125% SDS/without SDS 
before spray drying (SD) (after 1 day of milling), after spray drying (spray-dried 
powders), and the spray-dried particles after redispersion in deionized water for 2 
min, 10 min, and 60 min: (a) median particle size d50 and (b) 90% passing size d90. 
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Figure 4.8  Volume-based particle size statistics of the GF suspension-based (W) 
feeds with 1:1, 1:3, and 1:5 GF:Sol mass ratios and 0.125% SDS/without SDS before 
spray drying (SD) (after 1 day of milling), after spray drying (spray-dried powders), 
and the spray-dried particles after redispersion in deionized water for 2 min, 10 min, 
and 60 min: (a) median particle size d50 and (b) 90% passing size d90. 
 
4.3.6  Dissolution Performance of the Spray-Dried Powders in Non-
Supersaturating Condition 
The temporal evolution of GF release from the spray-dried powders and the PM with 
the highest polymer loading (1:5 GF:polymer) containing 8.9 mg equivalent GF dose 
in 1000 mL deionized water at 37 ºC was investigated. The bulk dissolution medium 
will not supersaturate for this low drug dose as the GF solubility is 14.2 mg/L. We 
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note from Figure 4.9 that the mere presence of HPC/Sol (1:5 GF:polymer mass 
ratio)/SDS could increase GF release rate without any wet-milling–spray drying of 
the as-received (micronized) GF particles. This could be partly explained by the 
wetting enhancement of the hydrophobic drug (GF) in the presence of HPC/Sol–SDS 
(Table 4.2), deaggregation of the large drug aggregates present in the as-received 
drug (Li et al., 2017b), and partly by the higher solubility of GF in the dissolution 
medium due to dissolution of PM’s polymer/SDS in the dissolution medium. For 
example, the thermodynamic solubility of the GF microparticles at 37 °C was 
measured to be 14.2 mg/L, 17.8 mg/L, and 18.3 mg/L in the deionized water, aqueous  
 
Figure 4.9  Evolution of drug release from as-received GF, physical mixture (PM) 
with 1:5 GF:polymer mass ratio, and spray-dried powders prepared using GF 
suspension-based (W) feeds with 1:1, 1:3, and 1:5 drug:polymer mass ratios: (a) HPC 
without SDS, (b) HPC with SDS, (c) Sol without SDS, and (d) Sol with SDS. 
Dissolution sample size equivalent to 8.9 mg GF dose (low dose, non-supersaturating 
condition in the bulk dissolution medium). 
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medium of 1:3 GF:Sol with SDS, and aqueous medium of 1:3 GF:HPC with SDS, 
respectively. However, the spray-dried powders released GF faster than the PM 
owing to the presence of GF nanoparticles/aggregates with larger surface area than 
drug microcrystals and amorphous GF that has higher kinetic solubility than 
crystalline GF. 
A quick comparison of Figure 4.9b to 4.9a and Figure 4.9d to 4.9c reveals that 
the spray-dried powders with SDS dissolved faster than those without SDS, which is 
in accordance with the expectations from the redispersion results and the wetting 
effectiveness factors presented in Table 4.2. The dissolution profiles of the powders 
with SDS all exhibited fast, immediate drug release (>80% GF release in 20 min) and 
their dissolution profiles are hard to differentiate. The presence of SDS imparted 
wettability enhancement to the spray-dried powders, allowed for their faster 
redispersion and recovery of the nanoparticles with small extent of aggregation, and 
ultimately faster GF release. For powders with SDS, wettability may not be the rate-
limiting process in drug dissolution; hence, other factors such as spray-dried particle 
size might have played a role.  For example, the fastest-dissolving powder, i.e., W-
HPC-1:1, SDS in Figure 4.9b had the smallest spray-dried particles. Without SDS, 
the HPC-based powders exhibited faster GF release at higher HPC loading despite 
larger size of the particles; whereas such monotonic behavior was not observed for 
the Sol-based powders: 1:1 GF:Sol released GF faster than 1:3 GF:Sol, while 1:5 
GF:Sol achieved the fastest drug release. These somewhat nuanced trends resulted 
from differing spray-dried particle sizes, redispersibility, and drug particle sizes in the 
precursor suspensions, and cannot be predicted by the redispersion results in Figure 
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4.7 and Figure 4.8 also because of the different volume and microhydrodynamics in 
the redispersion and dissolution tests. Owing to 1000 mL volume in the dissolution 
test vs. 30 mL in the redispersion test, drug dissolution simultaneously occurred along 
with erosion of the polymeric matrix in the dissolution test, which allowed 
redispersion of 1:1 and 1:3 GF:Sol particles without SDS in the dissolution test, 
whereas these powders did not redisperse much over 60 min in the redispersion test. 
4.3.7  Dissolution Performance of the Spray-Dried Powders in Supersaturating 
Condition 
The temporal evolution of GF release from the spray-dried powders and the PM with 
the highest polymer loading (1:5 GF:polymer) containing 100 mg equivalent GF dose 
in 1000 mL deionized water at 37 ºC was investigated. The bulk dissolution medium 
could supersaturate for this high drug dose as the GF solubility is 14.2 mg/L. Unless 
otherwise specified, all supersaturation values are relative to aqueous thermodynamic 
solubility of GF and calculated at 210 min. Considering that the major shortcoming of 
traditional drug nanocomposites with low polymer loading (like W-Sol-3:1, SDS) as 
compared with amorphous solid dispersions (ASDs) is their limited supersaturation 
capability in dissolution media, the examination of drug dissolution under 
supersaturating condition is critical. A cursory look at Figure 4.10 reveals 
immediately various general trends: (i) the spray-dried powder could generate GF 
superstation more than the corresponding PM for 1:5 GF:polymer, (ii) the GF 
supersaturation was higher for spray-dried powders with SDS than those without 
SDS, and (iii) Sol-based formulations generated much higher supersaturation than 
HPC-based formulations especially when the formulation included SDS. These 
results point to the criticality of the wet-media milling in preparing drug nanoparticles 
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especially in the presence of SDS, wettability of the spray-dried powder, which was 
enhanced by SDS (Table 4.2), GF–polymer miscibility (refer to Section 4.3.4), and 
solubilization of the GF by the polymer/SDS. 
 
 
Figure 4.10  Evolution of drug release from as-received GF, physical mixture (PM) 
with 1:5 GF:polymer mass ratio, and spray-dried powders prepared using GF 
suspension-based (W) feeds with 1:1, 1:3, and 1:5 drug:polymer mass ratios: (a) HPC 
without SDS, (b) HPC with SDS, (c) Sol without SDS, and (d) Sol with SDS. 
Dissolution sample size equivalent to 100 mg GF dose (high dose, supersaturating 
condition in the bulk dissolution medium). W-Sol-3:1, SDS stands for the spray-dried 
powder prepared using a suspension-based feed with 3:1 GF:Sol mass ratio with 
0.125% SDS. 
 
During the dissolution test, as water wets and imbibes into the spray-dried 
particles, their polymer dissolves and the particles redisperse into smaller GF–
polymer/SDS clusters depending on the wettability, while their amorphous GF 
fraction contributes to the dissolution fast. In the polymer/SDS-rich 
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microenvironment of the particles and clusters released, GF could be solubilized by 
the polymer/SDS, and the rate of this process depends on the cluster/particle size, GF 
particle size inside these clusters as well as the drug:polymer mass ratio and 
presence/absence of SDS. Unfortunately, depending on the polymer–drug miscibility 
and interactions, amorphous content of the HyNASDs (see Table 4.4 for the 
crystallinity) may phase-separate and recrystallize upon contact with water in the 
dissolution medium (Alonzo et al., 2011; Chen et al., 2015) because water acts as a 
plasticizing agent, reducing the glass transition of the ASD component of HyNASDs 
and enhancing the mobility of the drug molecules (Chen et al., 2015).  Finally, the 
supersaturated GF in the dissolution medium and the released drug nanoparticles 
form a metastable system, and GF could recrystallize on existing GF nanoparticles 
and cause their growth, with ensuing GF desupersaturation in time. Strong drug–
polymer interactions can reduce the drug molecular mobility and delay 
recrystallization onset time and the extent of recrystallization (Mistry et al., 2015). 
Similarly, ref. (Kothari et al., 2015) found that the recrystallization time of nifedipine 
increased with an increase in polymer (PVP) concentration. To gain additional 
insights into the GF recrystallization inhibition capability of Sol/HPC–SDS in 
solutions, independent desupersaturation experiments were performed. Figure 4.11 
presents the GF desupersaturation curves. Supersaturation was attained fast upon 
mixing a GF solution with deionized water and aqueous HPC/Sol/SDS solutions. The 
supersaturation was largely maintained up to ~210 min with Sol and Sol–SDS, 
signifying the superior inhibition capability of Sol. GF without any inhibitor and with 
SDS alone recrystallized fast as GF is a fast recrystallizing compound (Baird et al., 
 159 
 
2010). HPC and HPC–SDS could not maintain supersaturation long unlike Sol. 
 
 
Figure 4.11  GF desupersaturation curves for a supersaturated 20 mL GF–acetone 
solution mixed with 1000 mL aqueous solutions of 300 µg/mL and 100 µg/mL of 
HPC/Sol–5 µg/mL SDS or w/o SDS (corresponding to 1:3 and 1:1 polymer:drug 
formulations), 5 µg/mL SDS only, and deionized water (without any recrystallization 
inhibitor). The initial concentration of GF right after mixing was targeted at 100 
µg/mL.  
 
A comparison of Figure 4.10a vs. 4.10b and wetting effectiveness factors in 
Table 2.2 suggest that wetting enhancement with SDS helped to increase the GF 
release, but even with SDS, the HPC-based spray-dried powders did not generate 
more than ~50% supersaturation. HPC-SSL has sub-ambient glass transition 
temperature Tg (Sarode et al., 2013) (much lower than Tg of Sol: 73 ± 2 °C) and the 
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amorphous GF molecularly dispersed in HPC matrix of the HyNASDs may have 
recrystallized due to plasticizing action of water. Moreover, due to HPC’s partial 
miscibility with GF, its relatively weak molecular interactions with GF as compared 
with Sol, as well as its poor GF nucleation/crystal growth inhibition (refer to Figure 
4.11), HPC-based HyNASDs did not generate significant supersaturation even at 1:5 
GF:HPC with SDS. While HPC has been used in both marketed drug nanocrystal 
products and in academic research for preparation of drug nanosuspensions and drug 
nanocomposites (Bhakay et al., 2018b; Li et al., 2016a), we find here that its SSL 
grade is not effective in solubilizing GF, preventing GF recrystallization, and 
achieving high GF supersaturation. 
What is remarkable about the dissolution results in Figure 4.10c and 4.10d is 
that Sol-based HyNASDs with SDS could generate high GF supersaturation fast (up 
to 300% within 20 min), which is not common in pharmaceutical nanotechnology 
literature. HyNASDs (1:5 GF:Sol with SDS) achieved 250% GF supersaturation vs. 
30% achieved by the traditional nanocomposites with low polymer loading (3:1 
GF:Sol with SDS). Traditional nanocomposites with drug:polymer mass ratios in the 
1:0.8–1:0.02 range usually generate supersaturation up to 50% (see e.g., (Bhakay et 
al., 2014a; Müller et al., 2011; Zuo et al., 2013)). The high supersaturation achieved 
by HyNASDs was not possible without SDS because HyNASDs without SDS 
exhibited retarded release of GF nanoparticles due to poor wettability (see Table 4.2) 
and they had significant fraction of GF nanoparticle aggregates; both can be inferrred 
from the poorer redispersibility (Figures 4.7 and 4.8) and the coarser GF particle sizes 
in the precursor suspensions without SDS (Figure 4.1). Sol was responsible for the 
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high supersaturation owing to its stronger intermolecular interactions–miscibility with 
GF affording kinetic solubilization of GF and its inhibition of GF recrystallization 
(refer to Figure 4.11). Finally, with a Tg of 73 ± 2 °C, Sol prevented recrystallization 
of amorphous GF molecularly dispersed in the HyNASD during the dissolution test. 
Another trend in Figure 4.10d was evident: an increase in Sol loading led to higher 
GF supersaturation/drug release. One reason for this is the higher amorphous content 
in HyNASDs at higher polymer loading (Table 4.4), which contributed to the faster 
supersaturation generation, as in ASDs. Moreover, higher Sol loading with respect to 
GF helped the solubilization of smaller GF nanocrystals within the Sol matrix of the 
spray-dried particles and drug–Sol clusters emanating from them in the dissolution 
medium. 
Besides its drastic effect on wettability and drug particle size in Sol-based 
formulations, SDS also helped to delay GF crystallization, despite the fact that SDS 
alone could not suppress GF recrystallization (Figure 4.11). Presence of SDS might 
have contributed to the solubilization of GF in the Sol–SDS matrix during the spray 
drying and the dissolution. To better elucidate the roles of SDS, SDS was added to 
the dissolution medium to form 0.0005% and 0.125% w/v solutions. Then, the spray-
dried powder without SDS (W-Sol-1:5) was dissolved in such media and its 
dissolution was compared with that of W-Sol-1:5, SDS in water. Here, 0.0005% 
corresponds to SDS level that would be achieved upon complete dissolution of W-
Sol-1:5, SDS powder, while 0.125% (still below CMC) was present in the precursor 
drug nanosuspensions, whose examination may reveal the impact of high SDS within 
or in the neighborhood of the swollen spray-dried particles. The analysis of external 
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addition of SDS to the dissolution medium vs. internal addition of SDS to the 
formulation allowed us to elucidate if there is any other effect of SDS besides its 
wettability enhancement. Figure 4.12 shows that adding SDS externally to the 
dissolution medium improved the GF release from W-Sol-1:5 significantly and higher 
SDS concentration achieved higher supersaturation, which can be explained by 
wettability enhancement and redispersion of the GF nanoparticle aggregates of W-
Sol-1:5 in the dissolution medium. On the other hand, W-Sol-1:5, SDS (SDS 
internally added as part of the formulation) achieved the highest GF supersaturation 
 
 
Figure 4.12  Evolution of drug release from spray-dried powders prepared using GF 
suspension-based (W) feeds with 1:5 drug:polymer mass ratio and SDS and without 
SDS in the formulation. Deionized water was used as the dissolution medium for the 
formulation with SDS (W-Sol-1:5, SDS). For the formulation without SDS (W-Sol-
1:5), aqueous solution of 0.125% w/v SDS, aqueous solution of 0.0005% w/v SDS, 
and deionized water were used as dissolution media. Dissolution sample size 
equivalent to 100 mg GF dose (high dose, supersaturating condition in the bulk 
dissolution medium). 
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in water, implying that internal addition of SDS helped Sol in solubilizing GF during 
the spray-drying and dissolution besides its favorable effect on the 
wetting/deaggregation of GF aggregates. Such solubilizing effect of SDS has been 
reported in earlier studies on drug ASDs (Lu et al., 2014; Sjökvist et al., 1991).  
 
4.4  Conclusions 
Spray-drying of wet-milled GF suspensions with high polymer loading (1:1 to 1:5 
GF:polymer mass ratio) with HPC/Sol as polymer and with/without SDS led to 
formation of a special class of nanocomposites, HyNASDs, which contain drug 
nanocrystals and aggregates surrounded by notable amorphous content (5%–21%) 
molecularly dispersed in the polymeric matrix. All spray-dried powders had 
acceptable content uniformity. XRPD–DSC–Raman spectroscopy shed light on the 
nanocomposite/HyNASD formation and revealed higher GF miscibility–stronger 
molecular interactions for Sol–GF than for HPC–GF. Redispersion of the HyNASD 
powders indicated the critical need for wettability enhancement by SDS. The 
HyNASDs with SDS exhibited fast, immediate release in non-supersaturating 
dissolution condition; the ones without SDS exhibited slower GF release, whose 
profile depended on polymer loading and spray-dried particle size. Under 
supersaturating dissolution conditions (high GF dose), HPC-based HyNASDs 
performed poorly in enhancing GF supersaturation (up to 50% even with SDS), 
whereas Sol-based ones with SDS achieved fast supersaturation: up to 300% within 
20 min and maintained supersaturation at 250% after 3 h. These results were 
explained by higher Tg of Sol than that of HPC, higher GF–Sol miscibility, stronger 
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molecular interactions between Sol–GF than HPC–GF, excellent nucleation/crystal 
growth inhibition by Sol as compared to HPC as well as wettability–solubilization 
enhancement by SDS. The supersaturation generation capability of HyNASDs was 
largely controlled by presence of SDS either in the formulation or in the dissolution 
medium, drug–polymer interactions/miscibility as well as the size of the drug 
(nano)crystals in the polymeric matrix. Overall, the most striking finding from this 
study is that despite having ~80% nanocrystals, Sol-based HyNASDs with SDS 
provided fast drug supersaturation and maintained it at 250% unlike traditional 
nanocomposites (10%–60%), which could render nanoparticle formulations more 
attractive in bioavailability enhancement of poorly soluble drugs. In a forthcoming 
paper, we will compare the dissolution performance of HyNASDs with ASDs having 
identical formulation. Future research efforts will include investigation of the storage 
stability of HyNASDs under various environmental conditions and preparation of 
HyNASDs with various drug–polymer–surfactants and their comparative assessment.    
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CHAPTER 5 
IMPACT OF SDS ON GRISEOFULVIN RELEASE FROM SPRAY-DRIED 
AMORPHOUS SOLID DISPERSIONS WITH HPC–SOLUPLUS  
 
In Chapter 4, impact of an anionic surfactant, sodium dodecyl sulphate (SDS) was 
investigated in the stabilization of GF nanosuspensions and production of HyNASDs 
and dissolution enhancement under supersaturating condition. Significant 
improvement in the drug release rate and in supersaturation generation was achieved 
while using SDS in the formulation. Since the mechanism of drug release and 
supersaturation generation–maintenance mechanisms are different from drug 
nanocomposites and ASDs, it is important to investigate the impact of surfactant in 
the production and dissolution performance of ASDs. The goal of this chapter was to 
elucidate the impact of a common anionic surfactant, sodium dodecyl sulfate (SDS), 
on drug release from amorphous solution dispersions (ASDs) while elucidating its 
roles in wettability enhancement and recrystallization inhibition along with polymers. 
To this end, hydroxypropyl cellulose (HPC) and Soluplus (Sol) were used as matrix-
forming polymers of the ASDs. 2.5% griseofulvin (GF, BCS Class II drug) and 
HPC/Sol with 1:1, 1:3, and 1:5 GF:polymer mass ratios, along with  0.125% SDS and 
without SDS, were dissolved in acetone–water and spray-dried. XRPD, DSC, and 
Raman spectroscopy results suggest that Sol had stronger interactions and better 
miscibility with GF than HPC and formed XRPD-amorphous GF, while HPC-based 
ASDs, except the ASD with1:5 GF:HPC/SDS, had crystalline GF. SDS helped to 
reduce the fraction of GF crystals in HPC-based ASDs, suggesting its role in GF 
solubilization within the polymer matrix. Modified Washburn experiments revealed 
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significant wettability enhancement when SDS was used along with the polymer and 
better wettability enhancement by HPC (hydrophilic) than Sol (amphiphilic). Results 
from in vitro dissolution tests with low (9 mg) GF dose suggest that enhanced 
wettability with SDS led to faster GF release. For 100 mg GF dose (above 
thermodynamic solubility), without SDS, ASDs provided limited GF supersaturation 
due to poor wettability of Sol-based ASDs (max. 250%) and extensive GF 
recrystallization in HPC-based ASDs (max. 50%). Microscopic imaging of a loose 
ASD compact imbibed with water confirmed formation of GF crystals in HPC-based 
ASDs. Incorporating even 0.83% SDS in Sol-based ASDs led to dramatic increase in 
supersaturation (max. 570%), but it had no notable improvement for HPC-based 
ASDs. SDS provided Sol-based ASDs with enhanced wettability and augmented Sol 
in solubilizing GF, without interfering with Sol’s ability to inhibit GF 
recrystallization, as confirmed by desupersaturation experiments. While elucidating 
the roles of SDS, this study demonstrates the dramatic positive impact of 
incorporating SDS as a minor component of ASDs unlike its common use as a carrier 
for solubilization in most recent studies.     
 
5.1  Materials and Methods 
5.1.1  Materials 
BP/EP grade, micronized griseofulvin (GF) purchased from Letco Medical (Decatur, 
AL, USA) was used as a challenging Biopharmaceutics Classification System (BCS) 
Class II drug, which is known to be a fast crystallizing drug (Baird et al. 2010). Its 
aqueous solubility is ~8.9 mg/L at 25 °C and ~14.2 mg/L at 37 °C, and has a melting 
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point temperature Tm of 220 °C and a glass transition temperature Tg of 89 °C (Baird 
et al., 2010). Hydroxypropyl cellulose (HPC, SSL grade, Nisso America Inc., New 
York, NY) is a semi-crystalline polymer with low crystallinity and amorphous 
domains of very low Tg (Sarode et al., 2013) Soluplus® (Sol) is an amphiphilic graft 
copolymer produced from polyvinyl caprolactam–polyvinyl acetate–polyethylene 
glycol having a single glass transition temperature of 73 ± 2 °C (Terife et al., 2012). 
Sodium dodecyl sulfate (SDS), an anionic surfactant, purchased from GFS 
Chemicals, Inc. (Columbus, OH) was used as a surface-active agent. Acetone (ACS 
reagent, ≥ 99.5%) was purchased from BDH Analytical chemicals, (VWR, GA) and 
used as a solvent to prepare solution-based feed to the spray dryer 
5.1.2  Preparation of Spray-Dried Powders 
Organic solution-based (S:solvent) feeds of GF were fed to the spray dryer for the 
preparation of drug ASDs. Table 5.1 presents the formulations used in the precursor 
feeds. The drug concentration was kept constant at 2.5% (w/v) in all formulations. 
The drug concentration was calculated with respect to the total volume of the solvent 
mixture (acetone–water) in the solution-based feeds, which was fixed at 240 mL. A 
mixture of acetone–water was purposefully selected to dissolve all components of the 
formulation. 2.5% griseofulvin (GF, BCS Class II drug) and HPC/Sol with 1:1, 1:3, 
and 1:5 GF:polymer mass ratios, along with  0.125% SDS (20:1 GF:SDS mass ratio) 
and without SDS, were dissolved in acetone–water using a magnetic stirrer and spray-
dried to prepare the ASDs. The rationale for selecting of 0.125% SDS is as follows: 
when fully dissolved, ASD will provide 0.0005% SDS in the dissolution medium, i.e., 
water, which is well below the critical micelle concentration of SDS (8 mM, 0.23% 
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w/v at 25 ºC) (Sharma et al., 1996). Hence, the micellar solubilization of GF by SDS 
in the dissolution medium is purposefully avoided. After dissolving the drug–
polymer–surfactant into the binary solvent mixture, the solutions were sonicated for 
30 min before feeding to the spray dryer. 
Table 5.1  Formulations of the GF–HPC/Sol Solutions With or Without SDS Fed to 
the Spray Dryer  
ID Formulationa 
GF 
(% w/v)b 
Polymers 
(% w/v)b 
SDS 
(% w/v)b 
Water 
(mL) 
 
Acetone 
(mL) 
S1 S-Sol-1:5 2.5 12.5 0 40 200 
S2 S-Sol-1:3 2.5 7.5 0 40 200 
S3 S-Sol-1:1 2.5 2.5 0 40 200 
S4 S-Sol-1:5, SDS 2.5 12.5 0.125 40 200 
S5 S-Sol-1:3, SDS 2.5 7.5 0.125 40 200 
S6 S-Sol-1:1, SDS 2.5 2.5 0.125 40 200 
S7 S-HPC-1:5 2.5 12.5 0 40 200 
S8 S-HPC-1:3 2.5 7.5 0 40 200 
S9 S-HPC-1:1 2.5 2.5 0 40 200 
S10 S-HPC-1:5, SDS 2.5 12.5 0.125 40 200 
S11 S-HPC-1:3, SDS 2.5 7.5 0.125 40 200 
S12 S-HPC-1:1, SDS 2.5 2.5 0.125 40 200 
aS denotes solution-based feed; Sol denotes Soluplus; the ratios refer to the drug:polymer mass ratios. 
b% w/v with respect to the total volume (240 mL) of the solvent mixture (acetone + deionized water). 
c% w/w with respect to the total weight of the solid content. 
 
Using a spray dryer (4M8-Trix, Procept, Zelzate, Belgium) having a co-
current flow set-up, solution-based feeds were dried. The total length and the 
diameter of the spray dryer are 1.59 m and 0.15 m, respectively. To ensure complete 
drying, inlet temperature was selected above the boiling temperature of the respective 
pure liquids. Drying air at 75 °C flowing at a rate of 0.27–0.30 m3/min were fed co-
currently at the top of the dryer column to dry the solution-based feeds. 200 g solution 
of each formulation was sprayed at 2.0 g/min rate using a peristaltic pump (Make-it-
EZ, Creates, Zelzate, Belgium). A cyclone separator was used to separate the dried 
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particles from the outlet stream into a glass jar.  Atomizing air pressure of 2.0 bar, a 
bi-fluidic nozzle with tip diameter of 0.6 mm, and cyclone pressure of 55–60 mbar 
were selected based on prior experience (Azad et al., 2015b) and exploratory 
experiments. The dried particles obtained from the collection jar were transferred into 
double plastic bags and stored in a vacuum-desiccator at room temperature for further 
characterization. 
5.1.3  Particle Size and Morphology of the Spray-Dried Powders      
The particle size of the spray-dried powders was measured by a Rodos/Helos laser 
diffraction system (Sympatec, NJ, USA) based on Fraunhofer theory following the 
procedure described in Li et al. (2016b). About 1 g of the powder sample was placed 
on top of the sample chute of the Rodos dispersing system and the sample chute was 
vibrated at a 100% setting, and 0.1 bar dispersion pressure was used to suck in the 
falling powder through the sample cell of the laser diffraction system. Spray-dried 
particles were placed on a glass slide and observed by Axio Scope.A1 polarized light 
microscope (PLM, Carl Zeiss Microscopy GmbH, Göttingen, Germany). 
5.1.4  Solid Sate Characterization and Drug–polymer Interactions      
To analyze the crystallinity of the as-received GF, HPC, Sol, spray-dried powders, 
and physical mixtures of GF–polymer with or w/o SDS (same formulation as stated 
in Table 5.1), XRPD (PANanalytical, Westborough, MA, USA), provided with Cu Kα 
radiation (λ= 1.5406 Å), was used. The samples were scanned at a rate of 0.165 s-1 for 
2θ ranging from 5° to 40°. The total area under three distinct, non-overlapping peaks 
of GF at characteristic diffraction angles of 13.2, 14.6, and 16.5º was calculated for 
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both the physical mixtures and the spray-dried powders using the equipment’s 
HighScore Plus software, which was then used to estimate the crystallinity. 
DSC of the as-received GF, Sol, HPC, and spray-dried powders was 
performed using a Mettler-Toledo polymer analyzer (PolyDSC, Columbus, OH, 
USA) with integrated STARe 10 software. ~6.0–7.0 mg powder sample was placed in 
an aluminum pan with a hole in the lid and loaded into the DSC machine. As-
received GF was heated at a rate of 10 °C/min from 25 °C to 250 °C. All other 
samples were heated from 25 °C to 70 °C and the temperature was held for 2 min at 
70 °C, then cooled back to 25 °C to remove any residual solvent in the sample. In the 
final step, the samples were heated from 25 °C to 250 °C at 10 °C/min. Nitrogen gas 
was used as the purge gas and protective gas at a flow rate of 50 mL/min and 150 
mL/min, respectively. Thermogravimetric analysis (TGA) was performed to measure 
the residual water/solvent content using a TGA/DSC1/SF Stare system (Mettler 
Toledo, Inc., Columbus, OH). ~6.0–7.0 mg of each spray-dried sample was placed in 
a ceramic crucible and heated from 25 °C to 150 °C at a heating rate of 10 °C/min 
under nitrogen flow. 
Raman spectroscopy was conducted using a Fergie Imaging Spectrometer 
System (Princeton Instruments, Trenton, NJ) with a 500-mW external diode laser 
processing at 785 nm wavelength. Data acquisition time for all spectra was 15 s per 
scanned spectrum (100–1800 cm-1) and each spectrum acquired was averaged over 
two scans. The data was presented for the range of 1550–1800 cm-1 wavenumber. 
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5.1.5  Drug Content in the Spray-Dried Powders and In Vitro Dissolution Tests  
The drug content in the dried powders varied based on the drug:polymer mass ratios. 
To measure the actual drug content in the spray-dried powders, an assay testing was 
performed by dissolving 100 mg of the sample powders in 20 mL methanol under 30 
min of sonication, followed by overnight storage to ensure complete solubilization of 
the GF particles. An aliquot of 100 µL was taken from the GF solution and diluted up 
to 10 mL using methanol. The absorbance of the samples was measured at 292 nm 
using UV spectrophotometer (Agilent, Santa Clara, CA, USA), and the drug 
concentration was calculated from a pre-established calibration curve. Six replicates 
were tested for each formulation to calculate mean drug content along with the 
relative standard deviation (RSD).   
Drug release from the spray-dried powders and physical mixtures (PMs) 
prepared by blending was determined via a Distek 2100C dissolution tester (North 
Brunswick, NJ, USA), following the USP II paddle method. 1000 mL deionized 
water at 37 °C was stirred at 50 rpm paddle speed during the test. Two different doses 
i.e., 8.9 mg (non-supersaturating condition) and 100 mg (supersaturating condition) 
were tested for the dissolution performance of the spray-dried powders. Since the 
solubility of GF is 14.2 mg/L in water at 37 °C, a relatively low dose, i.e., 8.9 mg was 
selected to ensure non-supersaturating condition in the dissolution medium, which 
also could emulate low-dose (potent) drugs. The spray-dried powders were poured 
into the dissolution medium and 4 mL samples were taken out manually at 1, 2, 5, 10, 
20, 30, and 60 min. These aliquots were filtered with a 0.1 µm PVDF membrane-type 
syringe filter before UV-spectroscopy measurements to minimize any confounding 
effect of undissolved drug. In a separate dissolution tests, 100 mg equivalent GF was 
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used to allow for supersaturation in the bulk dissolution medium, which was 
conducted for 210 min with additional sampling at 120, 180, and 210 min. The 
filtered samples were diluted with deionized water kept at 37 ºC at a ratio of 1 to 5 
before UV measurement. Dissolved GF amount was measured by UV-vis 
spectroscopy at 296 nm wavelength and calculated using a pre-established calibration 
curve. Deionized water was used as blank before UV measurement, and six replicates 
were performed for each sample. In this paper, relative % supersaturation is reported 
based on GF concentration at 210 min and thermodynamic solubility of as-received 
GF particles, unless otherwise indicated. 
5.1.6  Drug Wettability Enhancement by Sol and HPC Solutions With or W/O 
SDS      
GF wettability by water, the dissolution medium, was investigated by analyzing the 
penetration rate of aqueous polymer/SDS solutions into a packed bed of GF particles 
inside a cylindrical column according to the modified Washburn method (Hołownia et 
al., 2008; Washburn, 1921). An Attension Sigma 700 (Biolin Scientific, Linthicum, 
MD, USA) was used to measure the mass of test liquid penetrated into the GF powder 
bed as a function of time. Experimental methods were adapted from Bilgili et al. (2018) 
and Li et al. (2017) (refer to Appendix D for details). In the current study, liquids and 
powder refer to GF-saturated aqueous solutions of 15% Sol/HPC with 0.125% SDS–
w/o SDS, 0.125% SDS alone and as-received GF, respectively. All percentages are (% 
w/w) with respective to deionized water. The aqueous solution of the stabilizers and 
deionized water were saturated with griseofulvin (GF) and stirred overnight. After 
overnight stirring, the saturated solutions were used for further characterization. The 
apparent shear viscosity and surface tension of the liquids were measured using R/S 
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Plus Rheometer (Brookfield Engineering, Middleboro, MA, USA) and Attension Sigma 
700 (Biolin Scientific, Linthicum, MD, USA), respectively. The ratio of the cosine of 
contact angles cosθss/cosθw was calculated using the modified Washburn equation and 
used as a wetting effectiveness factor. Here, θss is the contact angle between GF and the 
GF-saturated polymer/SDS solutions and θw is the contact angle between GF and GF-
saturated deionized water. This ratio was used as a rough measure of the drug 
wettability enhancement upon use of polymers (HPC/Sol) and SDS in water taking 
water as a basis of comparison. 
5.1.7  Characterization of Drug Recrystallization in the Presence of Aqueous 
Medium     
To elucidate GF recrystallization in the presence of water, a small portion of the spray-
dried powders prepared using the solution-based (S) feed (S-HPC-1:3 and S-Sol-1:3) 
with and w/o SDS was gently pressed to form a loose compact, which was then 
mounted onto a microscopic glass slide, and placed under the polarized light 
microscope (PLM). 20 µL of deionized water was added to the sample and the PLM 
images were captured at 0, 1, 2, and 5 min from the moment of water addition. 
 
5.2  Results and Discussion 
We present and discuss the properties of the spray-dried powders (Section 5.2.1), 
solid state characterization of the drug and ASD formation in spray-dried powders 
(Section 5.2.2), as well as in vitro drug release from the ASDs and impact of SDS–
polymer loading under non-supersaturating (Section 5.2.3) and supersaturating 
dissolution conditions (Section 5.2.4). 
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5.2.1  Size, Morphology, and Drug–Moisture Content of the Spray-Dried 
Powders 
Although the residence time in the spray dryer is short, complete drying of the feed is 
expected due to the fast evaporation of the solvents from fine droplets, which 
originated from atomization of the feed suspension/solution at a higher temperature 
than the boiling point of the liquid at the inlet. Residual moisture content in the spray-
dried powders was measured by TGA based on weight loss. Weight loss of 2.0 ± 
0.3% was measured with TGA for all the samples, which confirmed that most of the 
solvents were removed during the spray drying. The actual (mean) drug content after 
spray-drying ranged from 14.6–15.1% for 1:5 GF:polymer powders, 21.5–24.4% for 
1:3 GF:polymer powders, and 42.3–44.9% for 1:1 GF:polymer powder (refer to Table 
5.2). As expected, an increase in polymer loading in the feed solutions led to lower 
drug content in the powders. The slight variation in the theoretical and actual drug 
content can be attributed to preferential drug loss during handling, poor separation of 
finer particles in the cyclone separator of the spray dryer, and presence of some 
residual moisture after drying (Azad et al., 2015b; Bilgili et al., 2018). The relative 
standard deviation (RSD) of drug content in all powders was less than 6.0%, 
signifying pharmaceutically acceptable content uniformity. The median sizes d50 of 
the spray-dried powders ranged from 10.9–22.6 µm (Table 5.2). An increase in 
polymer loading led to formation of coarser particles due to increase in total solids 
loading and higher viscosity of the feed (Bilgili et al., 2018; Li et al., 2018b; Poozesh 
and Bilgili, 2019). Unlike this clear and strong impact of polymer loading, the impact 
of SDS was weak: for a given polymer type/loading, the powders with SDS had 
slightly greater median sizes than the powders without SDS, except for S:Sol-1:3. 
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The microscopic images (Figure 5.1) illustrate that spray-dried particles have 
rounded–donut shapes, and their sizes are in rough agreement with the ranges 
mentioned in Table 5.2. 
 
 
Figure 5.1  Light microscope images of the spray-dried particles prepared using the 
GF solution-based (S) feed with 1:3 GF:polymer mass ratio and 0.125% SDS/without 
SDS: (a) S-HPC-1:3, (b) S-HPC-1:3, SDS, (c) S-Sol-1:3, and (d) S-Sol-1:3, SDS. All 
images were taken at 50X magnification (scale bar: 20 µm). 
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Table 5.2  Particle Size Statistics of the Spray-Dried Powders and Their Drug Content 
ID Formulationa 
Particle size statistics of the spray-dried particles 
(µm) 
Theoretical 
drug content  
(% w/w)b 
Actual drug 
content, RSD              
(% w/w, %)b 
d10±SD d50±SD d90±SD 
S1 S-Sol-1:5 7.03±0.2 18.3±0.2 38.3±0.1 16.7 14.8, 1.79 
S2 S-Sol-1:3 6.08±0.1 14.3±0.0 32.4±0.1 25.0 22.1, 1.76 
S3 S-Sol-1:1 3.46±0.2 10.9±0.1 21.5±0.0 50.0 44.8, 3.46 
S4 S-Sol-1:5, SDS 6.23±0.1 20.8±0.1 40.1±0.2 16.5 14.6, 4.45 
S5 S-Sol-1:3, SDS 4.11±0.0 12.3±0.0 33.2±0.1 24.7 21.5, 2.02 
S6 S-Sol-1:1, SDS 5.03±0.1 11.0±0.1 20.2±0.0 48.8 42.3, 2.21 
S7 S-HPC-1:5 6.48±0.2 21.5±0.4 42.3±0.2 16.7 15.0, 2.65 
S8 S-HPC-1:3 5.87±0.1 15.4±0.3 33.5±0.1 25.0 24.0, 1.51 
S9 S-HPC-1:1 5.28±0.1 12.7±0.2 30.3±1.2 50.0 44.9, 1.67 
S10 S-HPC-1:5, SDS 7.10±0.2 22.6±0.2 40.3±0.3 16.5 15.1, 3.30 
S11 S-HPC-1:3, SDS 6.48±0.0 15.8±0.6 31.3±1.0 24.7 24.4, 2.56 
S12 S-HPC-1:1, SDS 7.05±0.2 13.0±0.9 26.9±0.8 48.8 42.7, 0.73 
aS denotes solution-based feed; Sol denotes Soluplus; the ratios refer to the drug:polymer mass ratios. 
b% w/w with respect to the total weight of the solid content. 
 
 
 
 
 
1
7
6
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5.2.2  Formation of Drug ASDs Upon Spray Drying 
To confirm the crystalline state of the drug (GF) in the final spray-dried powders, as-
received GF (microparticles), polymers (HPC/Sol), spray-dried powders, and 
corresponding physical mixtures (PM) of the spray-dried powders were analyzed 
using XRPD (Figure 5.2) and DSC (Figure 5.3). Table 5.3 presents the summary of 
DSC thermal events and estimated crystallinity via XRPD. X-ray diffractograms 
(Figure 5.2) depict that as-received GF (microparticles) exhibited intense peak 
characteristics of a crystalline material, whereas HPC/Sol exhibited halo pattern 
indicating amorphous structure. The physical mixtures (PMs), prepared by blending, 
exhibited peaks at the same diffraction angles as those of as-received GF, albeit with 
reduced peak intensity, which can be attributed to the dilution and surface coverage 
of GF microparticles with HPC/Sol/SDS. On the other hand, XRPD diffractograms of 
all Sol-based spray-dried powders with and without SDS, regardless of polymer 
loading, showed halo pattern instead of any characteristic peaks of GF. These halo 
patterns confirm the formation of amorphous solid dispersion (ASD). Small peaks 
were visible in the XRPD diffractograms of S-HPC-1:3, S-HPC-1:1, and S-HPC-1:1, 
SDS powders, which had 27.7%, 11.5%, and 6.5% crystallinity, respectively (Table 
5.3). Despite being largely amorphous, strictly speaking, these powders should be 
referred to as solid dispersions; but, for the sake of simplicity, we call all powders 
ASDs recognizing that some of them had notable crystalline content. The XRPD 
results overall suggest that (i) amorphous GF was molecularly dispersed in or 
solubilized by Sol matrix owing to their good miscibility even at 1:1 mass ratio 
 regardless of the presence/absence of SDS, (ii) GF was only partially miscible with 
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Figure 5.2  X-ray diffractograms of as-received GF, HPC, Sol, physical mixtures 
(PMs) of GF–HPC/Sol and the spray-dried powders prepared using the GF solution-
based (S) feed with 1:1, 1:3, and 1:5 drug:polymer mass ratios: (a) without SDS and 
(b) with 0.125% SDS in the solution. 
 
HPC, and required a high HPC loading (1:5 GF:HPC) to ensure formation of ASD; 
lower HPC loading could not prevent GF recrystallization during or right after spray 
drying, and (iii) SDS helped to disperse or solubilize GF in the HPC matrix, thus 
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allowing ASD formation at lower HPC loading (1:3 GF:HPC ratio). However, SDS 
could not prevent recrystallization when the GF:HPC mass ratio was 1:1. During 
spray drying, rapid evaporation of the solvents in the spray dryer increased viscosity 
instantaneously, resulting in kinetic arrest of the drug molecules in the amorphous 
polymer matrices, thus forming ASD (Baghel et al., 2016). Therefore, besides drug–
polymer miscibility, fast drying kinetics in the spray dryer played a substantial role to 
produce ASD from solution-based (S) feeds, even for a partially miscible (GF–HPC) 
system. 
The DSC thermograms in Figure 5.3 show an endothermic peak associated 
with melting of as-received GF, with a Tm of 220.1 °C and ΔHf of 101.8 J/g; a glass 
transition for Sol (amorphous) at 72.4 °C, and a slight endothermic event around 
170–200 °C for HPC likely due to the melting of the small crystalline domain of 
largely amorphous HPC (Sarode et al., 2013) (crystallinity was undetectable by 
XRPD). The Tg of HPC could not be measured (in the range of –25 to 0 °C (Sarode et 
al., 2013)) due to limitation of our equipment. A single Tg was observed confirming 
the formation of molecular level dispersion (Luebbert et al., 2017; Wlodarski et al., 
2015) in all powders except S-HPC-1:1 with 28% GF crystallinity (see Table 5.3). 
While S-Sol-1:3, SDS, S-Sol-1:5, SDS, and S-Sol-1:5 exhibited only a glass 
transition, all other ASDs exhibited a glass transition followed by an exothermic 
event due to re-crystallization of amorphous GF, which was followed by the melting 
of the recrystallized GF (Figure 5.3a and Figure 5.3b). Recrystallization of GF from 
ASDs can occur during the heating step of DSC scan because above Tg amorphous 
drug molecules and amorphous polymer had higher mobility. The absence of 
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recrystallization and higher temperature of recrystallization transition Trc (if it 
occurred at all) in the Sol-based powders than HPC-based powders suggest better 
miscibility and stronger molecular interactions between Sol–HPC than HPC–GF.     
                                  
 
Figure 5.3  DSC thermograms of as-received GF, HPC, Sol, and the spray-dried 
powders prepared using the GF solution-based (S) feed with 1:1, 1:3, and 1:5 
drug:polymer mass ratios: (a) without SDS and (b) with 0.125% SDS in the solution. 
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Table 5.3  Characteristic Temperatures–Enthalpy Values Obtained From DSC Thermograms and Crystallinity Estimated From 
XRPD Diffractograms 
ID Formulationa Tg (ºC)
a,b Trc (ºC)
 a,b Hrc (J/g) a,b Tm (ºC)
 a,b Hf (J/g) a,b Crystallinity (%)
b 
S1 S-Sol-1:5 80.6 ND ND ND ND ND 
S2 S-Sol-1:3 80.4 ND ND 189 0.64 ND 
S3 S-Sol-1:1 77.7 131 –14.1 209 23.2 ND 
S4 S-Sol-1:5, SDS 77.4 ND ND ND ND ND 
S5 S-Sol-1:3, SDS 80.0 ND ND ND ND ND 
S6 S-Sol-1:1, SDS 74.6 127 –9.26 206 25.4 ND 
S7 S-HPC-1:5 52.9 139 –3.35 192 6.64 ND 
S8 S-HPC-1:3 53.2 122 –4.36 201 13.2 11.5 
S9 S-HPC-1:1 ND 111 –8.90 213 34.3 27.7 
S10 S-HPC-1:5, SDS 51.7 130 –2.43 191 5.68 ND 
S11 S-HPC-1:3, SDS 57.7 124 –1.71 200 10.5 ND 
S12 S-HPC-1:1, SDS 58.9 109 –20.0 213 40.6 6.5 
aS denotes solution-based feed, Sol denotes Soluplus; the ratios refer to the drug:polymer mass ratios. Other symbols: Tg, Trc, and Tm stand for temperature 
for glass transition, recrystallization transition, and melting point, respectively, while Hrc and Hf respectively stand for recrystallization enthalpy and 
fusion enthalpy.    
bND: not detected. 
 
1
8
1
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For HPC-based powders, Trc increased (recrystallization delayed to higher 
temperature) and Hrc decreased when a higher polymer loading was used, which is 
in line with other studies (e.g., Wlodarski et al., 2015). 
GF crystals have a Tm of 220.1 °C. The powders, whose DSC thermograms 
exhibited an endotherm due to melting of the existing GF crystals and/or GF crystals 
formed during the heat treatment of the DSC scan, also exhibited significant melting 
point depression (Figure 5.3). The significant melting point depression in drug–
polymer mixtures is an indicator of drug–polymer miscibility (Baird et al., 2012; 
Newman et al., 2008). Table 5.3 indicates that higher polymer loading (lower 
GF:polymer mass ratio) led to lower Tm as compared with the as-received GF 
crystals, higher melting point depression, and lower ΔHf, regardless of the 
presence/absence of SDS. Moreover, without exceptions, having identical 
polymer/SDS composition, the spray-dried powders with Sol had either no melting 
point or had a higher melting point depression and lower ΔHf than those with HPC, 
which could be explained by (i) stronger molecular interactions and better miscibility 
for GF–Sol than GF–HPC, (ii) higher initial amorphous content in the Sol-based 
powders than in the HPC-based powders, and (iii) higher extent of drug solubilization 
during the thermal treatment when the polymer loading was higher. Compared with 
the clear trends regarding the impact of polymer loading for formulations 
with/without SDS, the trends for SDS impact were not as strong. At the same loading 
for a given polymer, the presence of SDS either led to disappearance of the melting 
point or slightly higher melting point depression, which suggests that SDS appears to 
help GF molecular dispersion or solubilization. These findings from DSC 
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thermograms are largely in agreement with the findings from the XRPD 
diffractograms regarding the impacts of GF–polymer miscibility and the impact of 
polymer loading and presence of SDS on the solid state of GF.   
The observed Raman spectra in Figure 5.4 for as-received GF and PMs of GF 
are largely in agreement with Fourier transform Raman data of ref. (Feng et al., 2008) 
and Raman data of ref. (Żarów et al., 2011) for crystalline GF. The Raman spectra of 
all the spray-dried samples (Figure 5.4) show that the GF line at 1606 cm–1 
disappeared, and the peaks at other characteristic frequencies shifted to new positions 
that are characteristic of amorphous GF, e.g., the peak shift from 1623 to 1620 cm–1 
(see Żarów et al., 2011), signifying formation of amorphous GF and molecular level 
interactions between GF and polymers in the ASD. While the GF line at 1606 cm–1 
disappeared in the Raman spectra of S-HPC-1:3 with and w/o SDS (Figure 5.4a and 
Figure 5.4b), the shifts in other peaks were subtler than those for the Raman spectra 
of S-Sol-1:3 with and w/o SDS, which could suggest stronger molecular interactions 
between GF–Sol than GF–HPC.  
It is suggested that if the solubility parameter difference between a drug and 
polymer is <7.0 MPa1/2, they are likely to be miscible; if the difference is >10 MPa1/2, 
they are considered immiscible, and if the difference is in between 7.0 and 10, they 
exhibit partial miscibility (Forster et al., 2001; Greenhalgh et al., 1999). The 
solubility parameters of GF, HPC, and Sol are 12.2 (Thakral and Thakral, 2013), 24.0 
(Choi et al., 1994), and 19.4 (Kolter et al., 2012) MPa1/2, respectively. The solubility 
parameter differences between GF–Sol and GF–HPC are 7.2 and 11.8 MPa1/2, 
respectively, which suggests that GF–Sol is borderline miscible, whereas GF–HPC is 
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immiscible.  The solubility parameter prediction is fairly accurate for Sol–GF as 
XRPD, DSC, and Raman spectroscopy results suggests GF–Sol are miscible and 
molecularly interact more than GF–HPC. However, GF–HPC exhibits partial 
miscibility unlike what the solubility parameters of GF–HPC suggest. As the 
 
Figure 5.4  Raman spectra of as-received GF, physical mixtures (PMs) of GF–
HPC/Sol at 1:3 drug:polymer ratio, and the spray-dried powders prepared using the 
GF solution-based (S) feed with 1:3 GF:polymer mass ratio: (a) with 0.125% SDS 
and (b) without SDS in the solution.  
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theoretical models behind the solubility parameter prediction are applicable for 
simple molecular structures wherein van der Waals force plays a predominant role, 
while for drug–polymer systems which are known to form highly directional 
interactions (e.g., hydrogen bonding) or long range interactions (e.g., ionic 
interaction), this approach can be erroneous (Ambike et al., 2005; Forster et al., 
2001). Indeed, the absence of diffraction peaks in XRPD in several HPC-based 
powders and significant melting depression in DSC along with the Raman line shifts 
suggest that HPC molecularly interacts with GF, resulting in partial miscibility unlike 
the prediction from the solubility parameters. 
5.2.3  Dissolution Performance of the Spray-Dried Powders Under Non-
Supersaturating Condition 
The temporal evolution of GF release from the spray-dried powders and the PM with 
the highest polymer loading (1:5 GF:polymer) containing 8.9 mg equivalent GF dose 
in 1000 mL deionized water at 37 ºC was investigated. The bulk dissolution medium 
will not supersaturate for this low drug dose as the GF solubility is 14.2 mg/L. We 
note from Figure 5.5 that as-received (micronized) GF microparticles with d50: 9.74 ± 
0.23 µm and d90: 27.4 ± 0.1 µm dissolved very slowly: <20% GF dissolved at 20 min 
and <33% at 60 min. The mere blending of as-received GF particles with HPC/Sol 
(1:5 GF:polymer mass ratio) with and without SDS, i.e., led to the physical mixture, 
which enhanced GF release rate. This could be partly explained by the wetting 
enhancement of the hydrophobic drug (GF) in the presence of dissolved HPC/Sol–
SDS (see Table 5.4) and deaggregation of the large drug aggregates present in the as-
received drug (Letchford and Burt, 2007), and partly by the higher solubility of GF in 
the dissolution medium. For example, the thermodynamic solubility of the GF 
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microparticles at 37 °C was measured to be 14.2 mg/L, 17.8 mg/L, and 18.3 mg/L in 
the deionized water, aqueous medium of 1:3 GF:Sol with SDS, and aqueous medium 
of 1:3 GF:HPC with SDS, respectively.  
 
 
Figure 5.5  Evolution of drug release from as-received GF, physical mixture (PM) 
with 1:5 GF:polymer mass ratio, and spray-dried powders prepared using GF 
solution-based (S) feeds with 1:1, 1:3, and 1:5 drug:polymer mass ratios: (a) HPC 
without SDS, (b) HPC with SDS, (c) Sol without SDS, and (d) Sol with SDS. 
Dissolution sample size equivalent to 8.9 mg GF dose (low dose, non-supersaturating 
condition in the bulk dissolution medium). 
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Table 5.4  Properties of Drug-Saturated Deionized Water and Aqueous Polymer–
SDS Solutions and Wetting Effectiveness Factor Determined Using the Modified 
Washburn Method 
Formulation η (cP) ρ (g/mL) γ (mN/m) Slope, (g2/s) R2   cosθss/cosθw 
Water 0.89 1.00 66.5 7.0×10-3 0.990   1.00 
SDS 0.94 1.00 37.1 7.2×10-3 0.975   1.94 
Sol 8.76 1.01 41.4 1.2×10-3 0.989   2.65 
Sol–SDS 13.5 1.01 40.5 1.5×10-3 0.991   4.65 
HPC 53.2 1.01 39.9 1.5×10-3 0.998   20.9 
HPC–SDS 58.3 1.01 34.8 2.4×10-3 0.999   42.1 
 
The spray-dried powders released GF faster than the PM (except S-Sol 
powders without SDS, see Figure 5.5c) owing to the presence of amorphous GF in 
the former that has higher kinetic solubility than crystalline GF in the PM. The poor 
wettability of S-Sol formulation hindered the dissolution of Sol and erosion of the 
spray-dried particles, which in turn retarded the drug release. Inclusion of SDS in the 
ASDs led to significant increase in the rate of GF release, but the increase was more 
notable for the Sol-based ASDs than the HPC-based ASDs. The analysis of the 
wetting effectiveness factors obtained from the modified Washburn method (Table 
5.4) shed some light on this observation. Presence of SDS has almost doubled the 
wetting effectiveness of the dissolved polymer in water and the rank order of 
wettability enhancement is HPC–SDS > HPC > Sol–SDS > Sol > SDS, which is in 
accordance with the hydrophilic nature of HPC and amphiphilic nature of Sol. Hence, 
poor wettability of Sol-based ASDs was mitigated upon incorporation of SDS, which 
led to significant dissolution improvement. On the other hand, HPC-based ASDs did 
not significantly benefit from the incorporation of SDS as HPC is hydrophilic. The 
initial fast GF release within 10 min followed by a much slower dissolution in the 
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following 50 min for S-HPC-1:1 (Figure 5.5a) and S-HPC-1:1, SDS (Figure 5.5b) 
could be explained by their smallest particle sizes among the S-HPC formulations 
(see Table 5.1), which led to initial fast release of amorphous GF followed by the 
slow dissolution of their crystalline component, i.e.,  27.7%  and 6.5%, respectively 
(see Table 5.2). 
5.2.4  Dissolution Performance of the Spray-Dried Powders Under 
Supersaturating Condition 
The temporal evolution of GF release from the spray-dried powders and the PM with 
the highest polymer loading (1:5 GF:polymer) containing 100 mg equivalent GF dose 
in 1000 mL deionized water at 37 ºC was investigated. The bulk dissolution medium 
could supersaturate for this high drug dose as the GF solubility is 14.2 mg/L. Unless 
otherwise specified, all supersaturation values are relative to aqueous thermodynamic 
solubility of GF and calculated at 210 min. Figure 5.6 shows that only slight 
supersaturation (max. ~50%) was achieved fast upon dissolution of HPC-based 
ASDs. An increase in polymer loading (lower GF:HPC mass ratio) led to slight 
increase in the supersaturation attained. Similarly, presence of SDS only increased 
supersaturation for the lowest HPC S-HPC-1:1; at higher polymer loadings, the effect 
of SDS was not notable. A cursory look at Figure 5.7 and Figure 5.6 suggests that 
Sol-based ASDs exhibited higher GF supersaturation than HPC-based ASDs, and 
inclusion of SDS as a minor component of ASD had a drastic impact on the 
attainment of high supersaturation fast: e.g., 430% supersaturation at 30 min for S-
Sol-1:5, SDS, which attained 570% supersaturation at 180 min. In fact, that ASD 
maintained supersaturation way above 430% for 180 min. 
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Figure 5.6  Evolution of drug release from as-received GF, physical mixture (PM) with 1:5 GF:HPC mass ratio, and spray-dried 
powders prepared using GF solution-based (S) feeds with 1:1, 1:3, and 1:5 GF:HPC mass ratios: (a) HPC without SDS, (b) HPC 
with SDS. Dissolution sample size equivalent to 100 mg GF dose (high dose, supersaturating condition in the bulk dissolution 
medium).  
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Figure 5.7  Evolution of drug release from as-received GF, physical mixture (PM) with 1:5 GF:Sol mass ratio, and spray-dried 
powders prepared using GF solution-based (S) feeds with 1:1, 1:3, and 1:5 GF:Sol mass ratios: (a) Sol without SDS, (b) Sol with 
SDS. Dissolution sample size equivalent to 100 mg GF dose (high dose, supersaturating condition in the bulk dissolution 
medium).  
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Maintaining the API in its amorphous state without precipitation during the intestinal 
transit time (>180 min) would often be sufficient for achieving the necessary 
bioavailability (Matsui et al., 2016).  
The remarkably high GF supersaturation achieved by Sol-based ASDs as 
compared with HPC-based ASDs can be explained by the higher GF solubilization in 
Sol micelles, which increased with a higher Sol loading, and excellent GF 
recrystallization inhibition imparted by Sol as compared with HPC. To make the 
latter point more lucid, let us examine the PLM images (Figure 5.8) of loose ASD 
compacts imbibed with a 20 µL deionized water droplet.  The addition of water to S-
HPC-1:3, SDS compact (Figure 5.8a) and S-HPC-1:3 compact (Figure 5.8c) resulted 
in immediate dissolution of the compact and recrystallization of amorphous GF (see 
the shiny crystals in the respective images). On the other hand, for S-Sol-1:3, SDS 
compact (Figure 5.8b) and S-Sol-1:3 (Figure 5.8d), the swollen ASD particles eroded 
from the compact gradually released amorphous GF from the Sol matrix. The images 
show spherical, swollen ASD particles. Even after 5 min of water addition, no 
recrystallization of the amorphous GF observed, which implies that the phase 
separation did not occur and the undissolved ASD powders stayed in the amorphous 
form and facilitated the supersaturation generation of GF (Figure 5.8b and Figure 
5.8c). It is inferred from these observations that due to fast and extensive 
recrystallization of GF in HPC-based ASDs upon exposure to water and low 
thermodynamic solubility of the GF crystals, only limited supersaturation was 
achieved by HPC-based ASDs.  
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Figure 5.8  PLM images of a loose compact of the spray-dried ASD particles with 1:3 drug:polymer mass ratio in 20 µL deionized 
water: (a) HPC with SDS, (b) Sol with SDS, (c) HPC without SDS, and (d) Sol without SDS. The images were taken at 0 (before 
adding water), 1, 2, and 5 min after the addition of deionized water addition. Except 0 min image (5X magnification, scale bar: 
200 µm), which focused on the compact, all other images focused on particles that emanated from the surface, which were 
captured at 20X magnification (scale bar: 50 µm). 
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To gain further insights into the GF recrystallization and supersaturation 
maintenance, desupersaturation experiments were performed via the solvent-shift 
method. 20 mL of 5 mg/mL GF solution in acetone was mixed with 1000 mL of 
aqueous solutions of 100 µg/mL, 300 µg/mL, and 500 µg/mL polymer with 
0.0005%/0.125% SDS or without SDS. These concentrations and volume correspond 
to the formulation of fully dissolved ASDs with 1:1, 1:3, and 1:5 GF:polymer mass 
ratio, respectively, and SDS in the dissolution medium or in the initial solution fed to 
the spray dryer. The addition of GF solution led to a supersaturation spike; 76–99 
µg/mL GF dissolved within 2 min (see Figure 5.9). HPC with or w/o SDS could not 
prevent depletion of supersaturation (desupersaturation) due to recrystallization of 
GF. It appears that for HPC-based ASDs, SDS promoted nucleation (earlier 
commencement of desupersaturation), but led to slower GF desupersaturation. In the 
absence of polymers, SDS alone also promoted nucleation, but appeared to cause 
slightly slower desupersaturation compared to the desupersaturation without any 
inhibitor. Finally, Sol was able to maintain high GF supersaturation for at least 180 
min with a small drop at 210 min. The presence of SDS and higher Sol led to slightly 
higher supersaturation; but, these differences are small and within the experimental 
errors. In the presence of 0.125% SDS alone or with 500 µg/mL Sol in the dissolution 
medium, very fast nucleation and recrystallization occurred (see Figure 5.9b), which 
confirms that high concertation of SDS promotes recrystallization from the 
supersaturated GF solution. In summary, no adverse impact of SDS on GF 
recrystallization was observed when it was used along with Sol as a minor component 
(e.g., 1:3:0.05 GF:Sol:SDS). SDS promoted drug recrystallization in the presence of 
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PVP-VA (Liu et al., 2016) and crystal growth in the presence of PVP (Mosquera-
Giraldo et al., 2014). These adverse effects could be absent partly due to low SDS 
concentration in the desupersaturation and dissolution tests (SDS being a minor 
component in the ASD) besides the specific interactions among GF–Sol–SDS. 
 
 
Figure 5.9  GF desupersaturation curves for a supersaturated 20 mL GF–acetone 
solution mixed with 1000 mL aqueous solution of 500 µg/mL, 300 µg/mL, and 100 
µg/mL of HPC/Sol–SDS or w/o SDS (corresponding to 1:5, 1:3, and 1:1 
drug:polymer formulations), SDS only, and deionized water without any 
recrystallization inhibitor: (a) HPC, and (b) Sol. Unless otherwise indicated, 0.0005% 
w/v (5 µg/mL) SDS was used for the formulation with SDS. With 500 µg/mL Sol, 
both 0.0005% w/v and 0.125% w/v SDS were used. The initial concentration of GF 
right after mixing was targeted at 100 µg/mL. 
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It is well-established that depending on the drug–polymer miscibility and 
interactions, amorphous drug may phase-separate and recrystallize upon contact of 
ASDs with water in the dissolution medium (Alonzo et al., 2011; Chen et al., 2015). 
Once imbibed into the ASD matrix, water acts as a plasticizing agent, enhancing the 
mobility of the drug molecules by reducing the Tg of the ASD (Chen et al., 2015). 
HPC-SSL has sub-ambient Tg (Sarode et al., 2013) (lower than Tg of Sol: 73 ± 2 °C) 
and its ASDs have lower Tg than Sol-based ASDs (see Table 5.3). Moreover, due to 
partial immiscibility of HPC with GF, its relatively weak molecular interactions with 
GF as compared with Sol (miscible with GF), as well as its poor GF 
nucleation/crystal growth inhibition (refer to Figure 5.9), it is no surprise that the 
amorphous GF recrystallized from HPC-based ASDs during the dissolution test, 
which also explains the drastically lower supersaturation generated by HPC-based 
ASDs than by Sol-based ASDs.  PLM images of a loose compact of the ASD 
particles in Figure 5.8 corroborated the formation of GF crystals from S-HPC-1:3 
ASD upon its exposure to water, whereas no recrystallization was observed for S-Sol-
1:3.  
To further elucidate the impact of SDS in Sol-based ASDs, S-Sol-1:5 (without 
SDS) was dissolved in 1000 mL of deionized water, aqueous solution of 0.0005% 
SDS solution, aqueous solution of 0.125% SDS solution. In these cases, SDS was 
introduced to ASDs externally, outside the ASD particles. In S-Sol-1:5, SDS, the 
SDS was in the ASD particles, whose dissolution in water would yield a 0.0005% 
SDS. Figure 5.10 shows that the external addition of 0.0005% SDS significantly 
improved the GF release of S-Sol-1:5, which corroborates the wettability 
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enhancement mechanism. Adding 0.125% SDS led to even faster supersaturation due 
to faster wettability; however, the released GF recrystallized, which is in line with the 
desupersaturation test (Figure 5.9b). When too much surfactant is used either in the 
ASD or in the dissolution medium, SDS molecules compete with drug molecules to 
interact with Sol molecules, which interferes with the crystallization inhibiting 
capability of Sol, leading to GF recrystallization (Liu et al., 2016). The fastest 
supersaturation occurred when SDS was internally added or incorporated into the 
ASD (S-Sol-1:5, SDS dissolution in water). It is likely that the presence of SDS in the 
ASD particle led to faster wettability enhancement as the GF is already available at 
the surface locally obviating the need for SDS molecules adsorbing onto ASD 
microparticles from the dissolution medium. Also, the higher local SDS concentration 
in the ASD particle and its boundary layer will facilitate water imbibition into Sol 
matrix and its faster erosion, leading to faster release of GF. Interestingly, despite 
exhbiting a much slower build-up of superstation in 0.0005% SDS solution, S-Sol-1:5 
ASD (without SDS) tend to a plateau supersaturation at 210 min, which is slightly 
below the supersaturation achieved by S-Sol-1:5, SDS ASD (with SDS) in water. 
This finding suggests that having the SDS along with GF–Sol in the ASD led to 
slightly higher kinetic solubility of GF in Sol–SDS of the ASD. 
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Figure 5.10  Evolution of drug release from physical mixture (PM) with SDS and 
spray-dried powders prepared using GF solution-based (S) feeds with 1:5 
drug:polymer mass ratio with and without SDS in the formulation. Deionized water 
was used as the medium for the formulation with SDS (S-Sol-1:5, SDS) and physical 
mixture. For the formulation without SDS (S-Sol-1:5), aqueous solution of 0.125% 
w/v SDS, aqueous solution of 0.0005% w/v SDS, and deionized water were used as 
dissolution media. Dissolution sample size equivalent to 100 mg GF dose (high dose, 
supersaturating condition in the bulk dissolution medium).  
 
5.3 Conclusions 
We have demonstrated that the use of SDS as a minor component along with a drug-
miscible polymer (Sol) as major component, which provides significant solubilization 
of the drug (GF) and supersaturation maintenance via recrystallization inhibition, 
could boost drug supersaturation from the ASDs via mainly wettability enhancement 
and some additional drug solubilization. The ASD with 1:5:0.05 GF:Sol:SDS 
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composition achieved 430% GF supersaturation within 30 min and maintained it for 3 
h. Unlike the use of SDS as carriers/solubilizers, the use of SDS as a minor 
component dramatically improved the wettability of the ASD, without having any 
deleterious impact on drug recrystallization, which is a common problem in polymer–
surfactant carrier systems. Also, the use of such low concentrations of SDS even in 
high-dose applications of ASDs alleviates any concern associated with the toxicity of 
anionic surfactants.  
The high GF supersaturation was only possible owing to the highly favorable 
properties of Sol because very limited supersaturation was achieved by HPC-based 
ASDs with or without SDS. Sol-based ASDs have higher Tg owing to higher Tg of Sol 
(73 ± 2 °C) than HPC-SSL; Sol has greater miscibility and stronger molecular 
interactions with GF, as revealed by XRPD, DSC, and Raman spectroscopy analysis; 
and it is an excellent GF recrystallization inhibitor, as suggested by the 
desupersaturation experiments. The only drawback of Sol was its amphiphilic nature, 
and ensuing poor wettability of the Sol-based ASDs that contain a hydrophobic drug. 
Adding SDS as a minor component alleviated that problem, which enabled fast 
supersaturation from Sol-based ASDs. A future study entails examining the stability 
of these ASD formulations and optimizing the SDS concentration for various high 
drug doses. Also, the generality of the use of anionic surfactants as a minor 
component will be tested with other drug–polymer–surfactants to assess 
supersaturation generation–maintenance benefits.    
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CHAPTER 6 
SYNERGISTIC EFFECTS OF HYDROPHILIC POLYMER–AMPHIPHILIC 
POLYMER COMBINATION IN ENHANCING GRISEOFULVIN RELEASE 
FROM AMORPHOUS SOLID DISPERSIONS 
 
As discussed in Chapter 1, formulating an amorphous solid dispersion (ASD) with 
high drug loading that releases drug rapidly, while generating and maintaining high 
supersaturation over at least three hours is challenging. To overcome this challenge in 
this study, we prepared ternary drug ASDs using a combination of a hydrophilic 
polymer that provides significant wettability enhancement to drug and an amphiphilic 
polymer that provides supersaturation maintenance and compared their in vitro 
dissolution release to binary drug ASDs prepared using each polymer separately. 
Griseofulvin (GF) was selected as a challenging, fast-crystallizing poorly soluble 
drug; hydroxypropyl cellulose (HPC) and Kollidon VA64 (VA64) were the 
hydrophilic polymers, while Soluplus® (Sol) was the amphiphilic polymer. In the 
ASDs, GF:total polymer mass ratio was fixed at 1:3 to yield 25% GF loading. XRPD, 
DSC, and Raman spectroscopy confirmed the formation of ASDs from GF–Sol, GF–
HPC, and GF–VA64 and their binary polymer combinations. Sol-based ASD 
generated supersaturation very slowly and achieved 170% supersaturation in 210 min. 
HPC-based ASD exhibited fast recrystallization in the matrix; whereas VA64-based 
ASD achieved 220% supersaturation in 10 min followed by rapid desupersaturation 
due to recrystallization in the medium. The modified Washburn experiments revealed 
the significant wettability enhancement of GF by HPC/VA64 and inadequate 
enhancement by Sol, which explains the rapid burst in VA64-based ASD and slow 
supersaturation build-up in Sol-based ASD. Slow drying of a droplet of GF–
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polymer(s) solutions and desupersaturation experiments revealed the poor 
recrystallization inhibition by the hydrophilic polymers. In most cases, combination 
of Sol with HPC/VA64 led to a trade-off between rapid drug release and high 
supersaturation. A strong synergistic effect emerged for the ASD with 11:1 
Sol:VA64, which led to 230% supersaturation within 30 min and maintained it over 
three hours. Contrary to existing literature, the inclusion of a hydrophilic polymer as a 
minor component in an amphiphilic, precipitation-inhibiting polymer of a ternary 
ASD exhibited optimal drug release. 
 
6.1  Materials and Methods 
6.1.1  Materials 
BP/EP grade, micronized griseofulvin (GF) purchased from Letco Medical (Decatur, 
AL, USA) was used as a challenging Biopharmaceutics Classification System (BCS) 
Class II drug because it is a fast-crystallizing poorly soluble drug (Baird et al., 2010). 
Its solubility is ~8.9 mg/L at 25 °C and ~14.2 mg/L at 37 °C, melting point Tm 220 
°C, and a glass transition temperature Tg of 89 °C (Baird et al., 2010). Hydroxypropyl 
cellulose (HPC, SSL grade, Nisso America Inc., New York, NY) and PVP-VA64 
(Kollidon VA64) were used as the hydrophilic polymers, while Soluplus® (Sol) was 
used as the amphiphilic polymer. HPC is a semi-crystalline polymer with low 
crystallinity and amorphous domains of very low Tg (Sarode et al., 2013). It has been 
widely used as a matrix polymer in drug nanocomposites (solid nanodispersions) that 
allows for fast drug nanoparticle recovery and rapid drug release (Bhakay et al., 
2018). Kollidon VA64 (VA64) is a vinylpyrrolidone-vinyl acetate copolymer with a 
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glass transition temperature of 101 °C (Kolter et al., 2012). Soluplus® (Sol, BASF, 
Tarrytown, NY) is an amphiphilic graft copolymer produced from polyvinyl 
caprolactam–polyvinyl acetate–polyethylene glycol having a single glass transition 
temperature of 73 ± 2 °C (Terife et al., 2012). Acetone (ACS reagent, ≥ 99.5%) and 
ethanol (reagent alcohol, ≥ 95%) were purchased from BDH Analytical chemicals 
(VWR, GA) and used as solvent to prepare drug–polymer solutions.  
6.1.2  Drug–Polymer Solution Preparation and Spray Drying 
The formulations of the solution-based (S) feeds to the spray dryer are provided in 
Table 6.1. The drug concentration was set at 2.5% (w/v), which was measured with 
respect to the total volume (240 mL) of the solution (mixture of acetone–
water/acetone–ethanol–water), in all formulations. For both binary and tertiary ASDs, 
the drug:total polymer mass ratio was kept constant at 1:3. To prepare the solution-
based (S) feed, a common solvent mixture was selected where drug, and polymers 
(HPC/Sol/VA64) can be dissolved completely. A mixture of acetone–water was used 
for dissolving GF–HPC/Sol, whereas a ternary solvent mixture (acetone–water–
ethanol) was used to dissolve formulations with VA64. After dissolving the drug–
polymer(s) into the solvent mixture using a magnetic stirrer, the solutions were 
sonicated for 30 min to ensure complete solubilization of the solid components before 
feeding to the spray dryer.  
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Table 6.1  Formulations and Compositions of the Drug–Polymer Solutions (S) Used in Spray Drying Experiments 
ID Formulationa GF  
(% w/v)b 
Polymers (% w/v)b Water 
(mL) 
Acetone 
(mL) 
Ethanol 
(mL) HPC Sol VA64 
S1 S-Sol 2.5 - 7.5 - 40 200 0 
S2 S-HPC 2.5 7.5 - - 40 200 0 
S3 S-VA64 2.5  - - 7.5 40 140 60 
S4 S-Sol-HPC-1:1 2.5  3.75 3.75 - 40 200 0 
S5 S-Sol-HPC-5:1 2.5 1.25 6.25 - 40 200 0 
S6 S-Sol-HPC-9:1 2.5  0.75 6.75 - 40 200 0 
S7 S-VA64-HPC-1:1 2.5  3.75 - 3.75 40 140 60 
S8 S-VA64-HPC-5:1 2.5 1.25 - 6.25 40 140 60 
S9 S-VA64-HPC-9:1 2.5  0.75 - 6.75 40 140 60 
S10 S-Sol-VA64-1:5 2.5  - 1.25 6.25 40 140 60 
S11 S-Sol-VA64-1:1 2.5 - 3.75 3.75 40 140 60 
S12 S-Sol-VA64-3:1 2.5 - 5.62 1.88 40 140 60 
S13 S-Sol-VA64-5:1 2.5 - 6.25 1.25 40 140 60 
S14 S-Sol-VA64-11:1 2.5 - 6.87 0.63 40 140 60 
aS denotes solution-based feed. Sol denotes Soluplus; VA64 denotes polyvinylpyrrolidone vinyl-acetate (6:4). The ratios refer to the 
polymer1:polymer2 mass ratio. 
b% w/v, with respect to the total solvent volume (240 mL). All formulations had a drug:total polymer mass ratio of 1:3. 
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6.2  Characterization Techniques 
6.2.1  Particle Size Measurement 
The particle sizes of the spray-dried powders were measured by a Rodos/Helos laser 
diffraction system (Sympatec, NJ, USA) based on Fraunhofer theory following the 
procedure described in Li et al. (2016b). About 1 g of the powder sample was placed 
on top of the sample chute of the Rodos dispersing system and the sample chute was 
vibrated at a 100% setting, and 0.1 bar dispersion pressure was used to suck in the 
falling powder through the sample cell of the laser diffraction system. For further 
confirmation of the particle sizes, spray-dried particles were placed on a glass slide 
and observed by Axio Scope.A1 polarized light microscope (PLM, Carl Zeiss 
Microscopy GmbH, Göttingen, Germany). 
6.2.2  Solid State Characterization and Drug–Polymer Interactions 
To analyze the crystallinity of the as-received GF, HPC, Sol, VA64, spray-dried 
powders with single and binary polymers, and physical mixtures of GF–
HPC/Sol/VA64, X-ray powder diffraction (XRPD) (PANanalytical, Westborough, 
MA, USA), provided with Cu Kα radiation (λ= 1.5406 Å) was used. The samples 
were scanned at a rate of 0.165 s-1 for 2θ ranging from 5° to 40°. The total area under 
three distinct, non-overlapping peaks of GF, if they exist, at characteristic diffraction 
angles of 13.2o, 14.6o, and 16.5o was calculated for both the physical mixtures and the 
spray-dried powders using the equipment’s HighScore Plus software, which was then 
used to estimate the crystallinity. 
Differential scanning calorimetry (DSC) of the as-received GF, Sol, HPC, 
VA64, and spray-dried powders with single and binary polymers was performed 
 204 
 
using a Mettler-Toledo polymer analyzer (PolyDSC, Columbus, OH, USA) with 
integrated STARe 10 software. ~6.0–7.0 mg powder sample was placed in an 
aluminum pan with a hole in the lid and loaded into the DSC machine. As-received 
GF was heated at a rate of 10 °C/min from 25 °C to 250 °C. All other samples were 
heated from 25 °C to 70 °C and the temperature was held for 2 min at 70 °C, then 
cooled back to 25 °C to remove any residual solvent in the sample. In the final step, 
the samples were heated from 25 °C to 250 °C at 10 °C/min. Nitrogen gas was used 
as the purge gas and protective gas at a flow rate of 50 mL/min and 150 mL/min, 
respectively. Thermogravimetric analysis (TGA) was performed to measure the 
residual water/solvent content using a TGA/DSC1/SF Stare system (Mettler Toledo, 
Inc., Columbus, OH). ~6.0–7.0 mg of each spray-dried sample was placed in a 
ceramic crucible and heated from 25 °C to 150 °C at a heating rate of 10 °C/min 
under nitrogen flow. 
Raman spectroscopy was conducted using a Fergie Imaging Spectrometer 
System (Princeton Instruments, Trenton, NJ) with a 500-mW external diode laser 
processing at 785 nm wavelength. Data acquisition time for all spectra was 15 s per 
scanned spectrum (100–1800 cm-1) and each spectrum acquired was averaged over 
two scans. The data was presented for the range of 1550–1800 cm-1 wavenumber. 
6.2.3  Characterization of Drug Recrystallization 
To assess the recrystallization inhibition capability of the polymer(s) qualitatively, a 
droplet of 20 µL of the GF–polymer(s) solutions was put onto a hot glass slide at 75 
°C and kept for drying in quiescent air. After about one min drying, the slides were 
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placed under the polarized light microscope (PLM) to observe if any drug 
recrystallization occurred. 
6.2.4  Drug Content in the Spray-Dried Powders and In Vitro Dissolution Tests 
The drug content in the dried powders varied based on the drug:polymer mass ratios. 
To measure the actual drug content, an assay testing was performed by dissolving 100 
mg of the sample powders in 20 mL methanol under 30 min of sonication, followed 
by overnight storage to ensure complete solubilization of the drug. An aliquot of 100 
µL was taken from the GF solution and diluted up to 10 mL using methanol. The 
absorbance of the samples was measured at 292 nm using UV spectrophotometer 
(Agilent, Santa Clara, CA, USA), and the drug concentration was calculated from a 
pre-established calibration curve. Six replicates were tested for each formulation to 
calculate the mean drug content along with the relative standard deviation (RSD).   
Drug release from the as-received GF, various physical mixtures (PMs) 
prepared by blending, and spray-dried powders was determined via a Distek 2100C 
dissolution tester (North Brunswick, NJ, USA), following the USP II paddle method. 
1000 mL deionized water at 37 °C was stirred at 50 rpm paddle speed. Spray-dried 
powder samples containing 100 mg GF (above the thermodynamic solubility of as-
received GF particles) were weighed and added to the dissolution medium and 4 mL 
samples were taken out manually at 1, 2, 5, 10, 20, 30, 60, 120, 180, and 210 min. 
These aliquots were filtered with a 0.1 µm PVDF membrane-type syringe filter 
before UV-spectroscopy measurements to minimize any confounding effect of the 
undissolved drug clusters (Bhakay et al., 2014; Li et al., 2016b). The filtered samples 
were diluted with 37 °C deionized water at a ratio of 1 to 5 before UV measurement. 
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Dissolved GF amount was measured by UV spectroscopy at 296 nm wavelength and 
calculated using a pre-established calibration curve. Deionized water was used as the 
blank before UV measurement and six replicates of each sample were performed. In 
this paper, relative % supersaturation is reported based on GF concentration at 210 
min and thermodynamic solubility of as-received GF particles, unless otherwise 
indicated. 
6.2.5  Drug Wettability Enhancement by Single and Binary Polymer Solutions 
Aqueous wettability of GF particles was investigated by analyzing the penetration 
rate of drug-saturated polymer solutions into a packed bed of GF particles inside a 
cylindrical column according to the Washburn method (Hołownia et al., 2008; 
Washburn, 1921). Attension Sigma 700 (Biolin Scientific, Linthicum, MD, USA) set-
up was used to measure the mass of the liquid penetrated the GF powder bed as a 
function of time. Experimental methods were adapted from Bilgili et al. (2018) and Li 
et al. (2017) and the details can be found in Section E.1 of the Appendix E. In the 
current study, liquids and powder refer to GF-saturated aqueous solutions of 15% 
polymer (single or binary polymer) and as-received GF, respectively. All percentages 
are (% w/w) with respective to deionized water. The aqueous polymer(s) solution and 
deionized water were saturated with griseofulvin (GF) and stirred overnight. After 
overnight stirring, the saturated solutions were used for further characterization. The 
apparent shear viscosity and surface tension of the liquids were measured using R/S 
Plus Rheometer (Brookfield Engineering, Middleboro, MA, USA) and Attension 
Sigma 700 (Biolin Scientific, Linthicum, MD, USA), respectively. The ratio of the 
cosine of contact angles cosθss/cosθw was calculated using the modified Washburn 
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equation and used as a wetting effectiveness factor. Here, θss is the contact angle 
between GF and the polymer(s) solutions and θw is the contact angle between GF and 
deionized water. The ratio was used as a rough measure of the drug wettability 
enhancement upon use of different polymer (HPC/Sol/VA64 and their combinations) 
in water with respect to the GF–water wettability. 
6.2.6  Drug Supersaturation Maintenance Ability of the Polymers 
Drug (GF) supersaturation maintenance ability of HPC/Sol/VA64 and their 
combination was examined in separate desupersaturation tests (similar to Konno et al. 
(2008)) based on the solvent-shift method. A GF solution was prepared by dissolving 
100 mg of as-received GF into 20 mL of acetone via sonication for 40 min. This 
solution was subsequently added to a 1000 mL of pre-dissolved HPC/Sol/VA64 
solution having 300 µg/mL total polymer concentrations to mimic 1:3 drug:polymer 
mass ratio in the USP II paddle type dissolution tester. In the case of binary polymers, 
polymer concentrations were adjusted following the formulation compositions in 
Table 6.1, while keeping the total polymer concentration fixed at 300 µg/mL. The 
addition resulted in 92–98 µg/mL supersaturated solution of GF initially (target: 100 
µg/mL, corresponding to complete dissolution of 100 mg drug during dissolution 
testing). Any subsequent desupersaturation during the following 210 min was tracked 
via GF concentration measurements. The experimental conditions and concentration 
measurements were identical to those in the dissolution test. All measurements were 
carried out in triplicate. 
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6.3  Results and Discussion 
6.3.1  Size, Morphology, and Drug–Moisture Content of the Spray-Dried 
Powders 
Drug–polymer solutions with single and binary polymers were dried using a spray 
dryer. Despite the relatively short residence time in the spray dryer (5.0 s), the spray-
dried powders were completely dried, as indicated by the TGA, which shows weight 
loss of ~2.0% for the samples. The extremely large surface area generated by 
atomization of the feed coupled with the fast convective heat–mass transfer at high 
air temperature enabled fast drying of the droplets. The slightly lower drug content as 
compared with the theoretical value can be attributed to preferential drug loss during 
handling, poor separation of finer particles in the cyclone separator of the spray dryer, 
and presence of the residual moisture after drying (Azad et al., 2015b; Bilgili et al., 
2018). RSD values of drug content were below 6%, which signifies pharmaceutically 
acceptable content uniformity. The median sizes of the spray-dried powders were 
measured to be in the range of 8.69–15.4 µm (Table 6.2). The microscopic images 
(Figure 6.1) illustrate that spray-dried particles have rounded–donut shapes, and their 
sizes are in rough agreement with the size ranges presented in Table 6.2.  
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Table 6.2  Particle Size Statistics of the Spray-Dried Powders and Their Drug 
Content 
ID Formulationa Size of the spray-dried powders 
(µm) 
Actual drug 
content, RSD 
(%w/w, %)b d10 ± SD d50 ± SD d90 ± SD 
S1 S-Sol 6.08±0.1 14.3±0.0 32.4±0.1 22.1, 1.76 
S2 S-HPC 5.87±0.1 15.4±0.3 33.5±0.1 24.0, 1.51 
S3 S-VA64 4.21±0.1 10.3±0.2 21.3±0.2 22.5, 2.15 
S4 S-Sol-HPC-1:1 4.01±0.0 10.9±0.0 22.7±0.0 22.4, 3.85 
S5 S-Sol-HPC-5:1 4.52±0.1 11.2±0.1 24.3±0.6 21.7, 1.60 
S6 S-Sol-HPC-9:1 4.21±0.0 11.5±0.0 27.7±0.1 21.7, 3.93 
S7 S-VA64-HPC-1:1 4.35±0.0 9.90±0.5 21.6±0.7 22.1, 2.15  
S8 S-VA64-HPC-5:1 4.11±0.1 9.34±0.2 19.7±0.2 22.6, 1.76 
S9 S-VA64-HPC-9:1 3.27±0.1 8.69±0.1 17.4±0.1 22.3, 1.42 
S10 S-Sol-VA64-1:5 4.40±0.0 12.1±0.1 27.3±0.1 20.9, 1.12 
S11 S-Sol-VA64-1:1 4.61±0.1 10.2±0.2 20.6±0.1 21.3, 3.14 
S12 S-Sol-VA64-3:1 3.71±0.1 9.76±0.3 22.8±0.2 23.1, 1.22 
S13 S-Sol-VA64-5:1 4.58±0.0 12.0±0.0 28.9±0.1 22.8, 1.48 
S14 S-Sol-VA64-11:1 3.47±0.1 13.0±0.1 30.9±0.2 22.3, 2.57 
aS denotes solution-based feed. Sol denotes Soluplus; VA64 denotes polyvinylpyrrolidone vinyl- 
acetate (6:4). The ratios refer to the polymer1:polymer2 mass ratio. 
b% w/v, with respect to the total solvent volume (240 mL). All formulations had a drug:total  
polymer mass ratio of 1:3. 
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Figure 6.1  Microscope images of the spray-dried powders prepared using GF 
solution-based (S) feeds with a single polymer and binary polymers with various 
polymer1:polymer2 mass ratios: (a) S-HPC, (b) S-Sol, (c) S-VA64, (d) S-Sol-HPC-
9:1, (e) S-VA64-HPC-9:1, (f) S-Sol-VA64-1:5, (g) S-Sol-VA64-1:1, (h) S-Sol-VA64-
5:1, and (i) S-Sol:VA64-15:1. All formulations had 1:3 drug:polymer mass ratio. The 
images were taken at 50X magnification (scale bar: 20 µm). 
 
6.3.2  Formation of Drug ASDs Upon Spray Drying 
The solid state of GF in the spray-dried powders was investigated via XRPD (see 
Figure 6.2) and DSC (see Figure 6.3). Table 6.3 presents the summary of DSC 
thermal events and estimated crystallinity via XRPD. X-ray diffractograms depict that 
as-received GF exhibited intense peak characteristics of a crystalline material, 
whereas HPC/Sol/VA64 exhibited halo pattern indicating amorphous structure  
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Figure 6.2  X-ray diffractograms of (a) as-received GF, HPC, Sol, VA64, and 
physical mixtures (PMs) of GF–HPC/Sol/VA64; (b) spray-dried powders prepared 
using the GF solution-based (S) feeds with a single polymer and binary polymers 
with various polymer1:polymer2 mass ratios. All formulations had 1:3 drug:polymer 
mass ratio. 
 
(Figure 6.2a). The physical mixtures (PMs), prepared by blending, exhibited peaks at 
the same diffraction angles as those of as-received GF, albeit with reduced peak 
intensity (Figure 6.2a), which can be attributed to the dilution and surface coverage of 
GF microparticles with HPC/Sol/VA64. XRPD diffractograms (Figure 6.2b) of the 
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spray-dried powders prepared using the drug–polymer solutions showed halo pattern 
instead of any characteristic diffraction peaks of GF (except S-HPC). These halo 
patterns confirm that amorphous GF dispersed molecularly into the polymer matrix 
forming amorphous solid dispersions (ASDs). On the other hand, the peaks in the 
XRPD diffractogram of S-HPC and 11.5% crystalline GF could be explained by the 
partial miscibility of GF–HPC and insufficient HPC concentration to ensure complete 
dispersion of GF molecules in the polymer matrix; hence, recrystallization of GF 
during spray-drying occurred. 
The DSC thermograms in Figure 6.3a show an endothermic peak associated 
with melting of as-received GF, with a Tm of 220.1 °C and ΔHf of 101.8 J/g; a glass 
transition for Sol (amorphous) at 72.4 °C, a glass transition for VA64 (amorphous) at 
102 °C and a slight endothermic event around 170–200 °C for HPC likely due to the 
melting of the small crystalline domain of largely amorphous HPC (Sarode et al., 
2013) (crystallinity was undetectable by XRPD). The Tg of HPC could not be 
measured (in the range of –25 to 0 °C (Sarode et al., 2013)) due to limitation of our 
equipment. For the spray-dried powders prepared from the drug–polymer solutions, a 
single Tg was observed for all the formulations confirming the formation of molecular 
level dispersion (Luebbert et al., 2017; Wlodarski et al., 2015) (see Table 6.3). All 
spray-dried powders exhibited a glass transition and a small endothermic melting 
peak for GF. S-HPC had the highest value of fusion enthalpy due to presence of 12% 
crystals, as measured by XRPD. The small endothermic event for all other samples 
could be due to small amount of nuclei/crystals in the prepared ASDs, which could 
not be detected by XRPD or crystals generated during the heat treatment of DSC.  
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Figure 6.3  DSC thermograms of (a) as-received GF, HPC, Sol, and VA64; (b) spray-
dried powders prepared using the GF solution-based (S) feeds with a single polymer 
and binary polymers with various polymer1:polymer2 mass ratios. All formulations 
had 1:3 drug:polymer mass ratio. 
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Table 6.3  Characteristic Temperatures–Enthalpy Values Obtained From DSC Thermograms and Crystallinity Estimated From 
XRPD Diffractograms 
ID Formulationa Tg (ºC)
a,b Trc (ºC)
 a,b Hrc (J/g) a,b Tm (ºC)
 a,b Hf (J/g) a,b Crystallinity (%)
b 
S1 S-Sol 80.4 ND ND 189 0.64 ND 
S2 S-HPC 53.2 122 –4.36 201 13.2 11.5 
S3 S-VA64 100.4 ND ND 184 0.94 ND 
S4 S-Sol-HPC-1:1 77.6 135 –6.38 195 7.45 ND 
S6 S-Sol-HPC-9:1 75.1 ND ND 191 4.64 ND 
S7 S-VA64-HPC-1:1 93.7 ND ND 187 2.26 ND 
S9 S-VA64-HPC-9:1 94.1 ND ND 188 1.11 ND 
S10 S-Sol-VA64-1:5 85.9 ND ND 185 1.06 ND 
S11 S-Sol-VA64-1:1 86.1 ND ND 186 1.31 ND 
S12 S-Sol-VA64-3:1 82.8 ND ND 186 0.62 ND 
S13 S-Sol-VA64-5:1 82.7 ND ND 188 0.74 ND 
aS denotes solution-based feed, Sol denotes Soluplus; the ratios refer to the polymer1:polymer2 mass ratio. Other symbols: Tg, Trc, and Tm stand for 
temperature for glass transition, recrystallization transition, and melting point, respectively, while Hrc and Hf respectively stand for recrystallization 
enthalpy and fusion enthalpy.    
bND: not detected. 
 
 
 
2
1
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However, significant depression in the melting point of the spray-dried samples 
compared to the respective physical mixtures confirm the miscibility of the drug–
polymers. S-HPC and S-Sol-HPC-1:1 exhibited a glass transition followed by an 
exothermic event due to the recrystallization of amorphous GF followed by the 
melting of the existing crystals and/or recrystallized GF (Figure 6.3c). 
Recrystallization occurred during the heating step of DSC scan because above Tg 
amorphous drug molecules and amorphous polymer had higher mobility, which may 
cause GF recrystallization. Since GF–HPC are partially miscible, above Tg GF 
molecules can easily phase separate and recrystallize. Due to strong molecular 
interactions and good miscibility of GF–Sol and GF–VA64, recrystallization event at 
high temperature was not observed for the formulations with Sol, VA64, and their 
combinations during the DSC scan.  
The observed Raman spectra in Figure 6.4a for as-received GF and PMs of 
GF are largely in agreement with Fourier transform Raman data of ref. (Feng et al., 
2008) and Raman data of ref. (Żarów et al., 2011) for crystalline GF. The Raman 
spectra of all the spray-dried samples (Figure 6.4b) show that the GF line at 1606  
cm-1 disappeared, and the peaks at other characteristic frequencies shifted to new 
positions that are characteristic of amorphous GF, e.g., the peak shift from 1623 to 
1620 cm–1 (see (Żarów et al., 2011)), signifying formation of amorphous GF and 
molecular level interactions between GF and polymers in the ASD. While the GF line 
at 1606 cm–1 disappeared in the Raman spectra of S-HPC (Figure 6.4b), the shifts in 
other peaks were subtler than those for the Raman spectra of S-Sol and S-VA64, 
which could suggest stronger molecular interactions between GF–Sol and GF–VA64 
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than GF–HPC. For all the spray-dried formulations produced from binary polymers, 
noticeable peaks shift also suggest stronger molecular interactions between GF–
binary polymers (Figure 6.5).  
 
 
Figure 6.4  Raman spectra of (a) as-received GF, physical mixtures (PMs) of GF–
HPC, GF–Sol, and GF–VA64 at 1:3 drug:polymer mass ratio; (b) physical mixtures 
(PMs) and spray-dried powders prepared using GF solution-based (S) feeds of GF–
HPC, GF–Sol, and GF–VA64 with 1:3 drug:polymer mass ratio.  
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Figure 6.5  Raman spectra of (a) as-received GF, physical mixtures (PMs) of GF–
binary polymers at various polymer1:polymer2 mass ratios; (b) physical mixtures 
(PMs) of GF–Sol–HPC and GF–VA64–HPC and their respective spray-dried 
powders with 9:1 mass ratio of Sol:HPC and VA64:HPC, respectively; (c) physical 
mixtures (PMs) of GF–Sol–VA64 and their respective spray-dried powders with 5:1 
and 1:5 mass ratios of Sol:VA64. All formulations had 1:3 drug:polymer mass ratio. 
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Overall, XRPD, DSC, and Raman spectroscopy results (i) confirm that the 
spray-drying of drug–polymer(s) solutions produced ASDs and (ii) suggest stronger 
GF–polymer interactions and miscibility for GF–Sol and GF–VA64 than GF–HPC. It 
is suggested that if the solubility parameter difference between a drug and polymer is 
<7.0 MPa1/2, they are likely to be miscible; if the difference is >10 MPa1/2, they are 
considered immiscible; and if the difference is in between 7.0 and 10, they exhibit 
partial miscibility (Forster et al., 2001; Greenhalgh et al., 1999). The solubility 
parameters of GF, HPC, Sol, and VA64 are 12.2 (Thakral and Thakral, 2013), 24.0 
(Choi et al., 1994), 19.4, and 19.7 (Kolter et al., 2012) MPa1/2, respectively. The 
solubility parameter differences between GF–Sol and GF–VA64, and GF–HPC are 
7.2, 7.5, and 11.8 MPa1/2, respectively, which suggests that GF–Sol is borderline 
miscible, GF–VA64 is partially miscible, whereas GF–HPC is most likely 
immiscible. While being useful, the solubility parameters do not account for all drug–
polymer interactions such as contributions from hydrogen bonding, hydrophobic 
interactions, etc., and hence should be used with caution as rough estimates of drug–
polymer miscibility. The solubility parameter prediction appears to be accurate for 
GF–Sol and GF–VA64 as XRPD, DSC, and Raman spectroscopy results suggests 
GF–Sol and GF–VA64 are miscible and molecularly interact more than GF–HPC. 
However, GF–HPC exhibits partial miscibility unlike what the solubility parameters 
of GF–HPC suggest. As the theoretical models behind the solubility parameter 
prediction are applicable for simple molecular structures wherein van der Waals force 
plays a predominant role, while for drug–polymer systems which are known to form 
highly directional interactions (e.g., hydrogen bonding) or long range interactions 
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(e.g., ionic interaction), this approach can be erroneous (Baird et al., 2010; Meng et 
al., 2015). Indeed, the absence of diffraction peaks in XRPD for 1:5 GF:Sol ASD (not 
shown) and significant melting point depression with respect to physical mixtures 
based on DSC (not shown) along with the Raman line shifts suggest that HPC 
molecularly interacts with GF, resulting in partial miscibility unlike the prediction 
from the solubility parameters.  
6.3.3  Assessment of the Recrystallization Inhibition Capability of the Polymers 
In the drug–polymer solutions, GF and polymer (s) were completely dissolved in 
acetone–water/acetone–water–ethanol mixture, which allowed molecular level 
interaction in the solution before spray drying. Due to fast evaporation of the solvents 
in the spray dryer, viscosity increases rapidly causing entrapment of the drug 
molecules in the polymer matrices, which appears to have retarded phase separation 
even in the case of GF–HPC (immiscible or partially miscible) and enables the ASD 
formation. 
To assess the recrystallization inhibition capability of the polymers 
qualitatively, we have devised a slower drying method: a single droplet of GF–
polymer (s) solution was dried on a heated glass slide at 75 ºC, i.e, the same 
temperature as that of hot air in the spray-drying. However, the droplet was dried in 
quiescent air, which makes external mass transfer of solvent vapor in air controlling 
the evaporation rate, making drying slower compared to spray drying. This slow 
drying is quite conservative regarding the crystallization inhibition capability of the 
polymers as it gives ample time for dissolved drug to precipitate and form crystals. 
The drying took less than 40 s, whereas the drying occurred less than ~5 s in the 
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spray dryer. The PLM images in Figure 6.6 illustrate that GF crystals formed during 
the slow drying of all solutions. On the other hand, the slow drying of S-Sol and S-
VA64 solution yielded few small crystals, whereas that of S-HPC solution yielded 
significant number of long needle-shaped crystals. The extent of recrystallization was 
much higher in HPC than in Sol or VA64. HPC could not inhibit the 
nucleation/crystal growth of GF from the supersaturated solution as evaporation 
proceeded during the spray-drying. Figure 6.6d and 6.6e show that Sol is a better 
precipitation inhibitor than VA64 in the presence of HPC. An increase in Sol:VA64 
mass ratio led to smaller and fewer crystals suggesting that Sol could be a good GF 
crystal inhibitor. While all images in Figure 6.6 shows presence of crystals due to 
slow drying, fast spray-drying did not allow much time for precipitation; thus, all 
GF–polymer(s) led to ASD, except ASD with 1:3 GF:HPC mass ratio.  
It is known that the phase separation and recrystallization involve diffusion 
and nucleation of drug molecules, both of which require molecular mobility and can 
be restricted by polymer molecules as inhibitor (Baghel et al., 2016). Strong drug–
polymer interactions can reduce the molecular mobility and delay crystallization 
onset time and the extent of crystallization (Mistry et al., 2015). To gain additional 
insights into the GF recrystallization inhibition capability of Sol/HPC in 
supersaturated drug solutions, desupersaturation experiments were performed. In the 
desupersaturation tests (Figure 6.7a), only Sol was able to maintain the GF 
supersaturation for ~3 h, whereas GF concentration drastically decreased after 10 min 
in the case of VA64 or HPC upon GF recrystallization. These results suggest that the     
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Figure 6.6  Polarized light microscope images of a droplet of GF solution-based (S) 
feed of (a) S-Sol, (b) S-HPC, (c) S-VA64, (d) S-VA64-HPC-9:1, (e) S-Sol-HPC-9:1, 
(f) S-Sol-VA64-1:1, (g) S-Sol-VA64-1:5, (h) S-Sol-VA64-5:1, and (i) S-Sol-VA64-
15:1 after slow drying. The droplets were dried on a glass slide at room temperature. 
All formulations had 1:3 drug:polymer mass ratio. The images were taken at 5X 
zoom (scale bar: 200 µm). 
 
superior GF recrystallization inhibition and supersaturation maintenance capability of 
Sol over HPC and VA64 (Figure 6.7a). Excellent nucleation inhibition and 
supersaturation maintenance capability of Sol was reported earlier (Guan et al., 
2019a; Guan et al., 2019b). Figure 6.7 also corroborates the fast recrystallization 
tendency of GF (Baird et al., 2010) without inhibitors. Among binary polymers, Sol–
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VA64 and Sol–HPC were able to maintain the supersaturation, whereas VA64–HPC 
could not maintain the supersaturation. In other words, the ASDs without Sol, as the 
 
 
Figure 6.7  GF desupersaturation curves for a 20 mL GF–acetone solution mixed 
with (a) 1000 mL aqueous solutions of 300 µg/mL Sol/VA64/HPC and deionized 
water and (b) 1000 mL aqueous solutions of 250 µg/mL Sol–50 µg/mL VA64, 50 
µg/mL Sol–250 µg/mL VA64, 150 µg/mL Sol–150 µg /mL HPC, 270 µg/mL Sol–30 
µg/mL HPC, 270 µg/mL VA64–30 µg/mL HPC, and deionized water. Deionize water 
has no recrystallization inhibitor. The initial concentration of GF right after mixing 
was targeted at 100 µg/mL.  
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crystallization inhibitor is not expected to provide or maintain a high supersaturation. 
These findings suggest that having an amphiphilic polymer like Sol as the 
crystallization inhibitor is a must as the rather hydrophilic polymers like VA64–HPC 
do not have much inhibitory effect. 
6.3.4  Dissolution Performance of the Spray-Dried Powders 
The temporal evolution of GF release from the binary ASDs with single polymer and 
ternary ASDs with binary polymers combinations and the PM with the binary 
polymer combinations containing 100 mg equivalent GF dose in 1000 mL deionized 
water at 37 ºC was investigated. The bulk dissolution medium could supersaturate for 
this high drug dose as the GF solubility is 14.2 mg/L. Unless otherwise specified, all 
supersaturation values are relative to aqueous thermodynamic solubility of GF and 
calculated at 210 min. 
Figure 6.8 shows that the GF ASDs prepared via spray-drying of the drug–
polymer solutions with single polymer enhanced the dissolution rate and extent of GF 
release compared to the as-received GF. The initial drug release rate was significantly 
higher for S-HPC ASD and S-VA64 ASD than S-Sol ASD. At 10 min, 220% and 
40% GF supersaturation were achieved by S-VA64 and S-HPC, respectively, whereas 
S-Sol could not even reach the saturation solubility (14 mg/L). These observations 
can be explained by the hydrophilicity of the polymers and their relative wetting 
effectiveness (see Table 6.4). The relative wetting effectiveness factor for HPC, 
VA64, and Sol measured to be 20.9, 16.1, and 2.65, respectively, which is in line 
with the relatively more hydrophilic nature of HPC/VA64 than Sol, based on the 
functional groups of the respective groups (not shown). Therefore, in the aqueous 
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dissolution medium, HPC and VA64 allowed for excellent wetting of hydrophobic 
GF molecules and their ASDs exhibited rapid release of GF and the hydrophilic 
polymer.  Unlike HPC/VA64, Sol does not allow for good wetting of the GF 
particles, which hinders Sol/GF dissolution. 
 
 
Figure 6.8  Evolution of drug release from as-received GF and spray-dried powders 
prepared using solution-based (S) feeds of GF–HPC, GF–Sol, and GF–VA64 with 
1:3 drug:polymer mass ratio. 
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Table 6.4  Properties of Drug-Saturated Deionized Water–Aqueous Polymer 
Solutions and Wetting Effectiveness Factor Determined Using the Modified 
Washburn Method 
a
The slope of the water penetration data was used as reference for wettability enhancement by the 
stabilizer solutions. 
 
There is a drastic difference between S-HPC and S-VA64 in their GF release 
(Figure 6.8): after S-VA64 achieved 220% GF supersaturation at 10 min, the GF 
concentration displayed exponential decay in time due to recrystallization of the drug 
in the supersaturated dissolution medium because VA64 is not a good crystallization 
inhibitor (refer to Section 6.3.3 for recrystallization inhibition). On the other hand, S-
HPC could not provide any further supersaturation after 10 min. It is well-established 
that depending on the drug–polymer miscibility and interactions, amorphous drug in 
an ASD may phase-separate and recrystallize upon contact of ASDs with water in the 
dissolution medium (Alonzo et al., 2011; Chen et al., 2015). Once imbibed into the 
ASD matrix, water acts as a plasticizing agent, enhancing the mobility of the drug 
molecules by reducing the Tg of the ASD (Chen et al., 2015). HPC-SSL has sub-
ambient Tg (Sarode et al., 2013) (lower than Tg of Sol: 73 °C and Tg of VA64: 101 °C, 
Formulation η (cP) ρ (g/mL) γ (mN/m) Slope, (g2/s) R2 cosθss/cosθw 
Water 0.89 1 66.5 7.0×10-3 0.990 1a 
HPC 53.2 1.01 39.9 1.5×10
-3
 0.998 20.9 
Sol 8.76 1.01 41.4 1.2×10
-3
 0.989 2.65 
VA64 7.80 1.01 39.6 7.8×10
-3
 0.999 16.1 
Sol-HPC-1:1 35.0 0.98 41.0 7.3×10
-4
 0.997 6.93 
Sol-HPC-9:1 10.9 1.01 41.9 2.0×10
-3
 0.989 5.44 
Sol-VA64-1:5 7.41 1.01 40.8 6.1×10
-3
 0.996 11.6 
Sol-VA64-5:1 8.05 1.01 41.9 2.9×10
-3
 0.993 5.83 
VA64-HPC-1:1 23.0 1.01 38.9 4.2×10
-3
 0.999 26.9 
VA64-HPC-9:1 10.6 1.01 36.8 7.3×10
-3
 0.999 22.0 
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Kolter et al., 2012) and its ASDs have lower Tg than Sol-based and VA64-based 
ASDs (see Table 6.3). Moreover, due to partial immiscibility of HPC with GF, its 
relatively weak molecular interactions with GF as compared with Sol/VA64 (miscible 
with GF), as well as its poor GF nucleation/crystal growth inhibition, it is likely that 
the amorphous GF most likely crystallized in the S-HPC matrix rather than in the 
dissolution medium, unlike the case for S-VA64 ASD. Interestingly, at the end of the 
dissolution test (210 min), S-Sol was able to reach higher supersaturation (170%) 
compared to S-VA64 (110%) and S-HPC (40%). Owing to the high Tg of Sol and its 
ASD (see Table 6.3), its strong intermolecular interactions and relatively good 
miscibility with GF, Sol could achieve high GF supersaturation; however, the GF 
release rate from S-Sol is controlled by the relatively poor wettability, which led to 
slow, monotonic build-up of supersaturation, eventually after 210 min leading to the 
highest GF supersaturation in Figure 6.8. 
Analysis of Figure 6.7 and Figure 6.8 and Table 6.4 overall suggests that 
binary polymers Sol–VA64 in a ternary ASD could potentially complement each 
other in achieving rapid drug release by VA64 and maintenance of high GF 
supersaturation by Sol, which will be evaluated via dissolution tests with ternary 
ASDs. Since HPC could not generate or maintain high extent of supersaturation, it 
was not used as a major component in the ternary ASDs. For both VA64–HPC and 
Sol–HPC combinations, 1:1, 5:1, and 9:1 VA64/Sol:HPC mass ratios were used. Due 
to its unfavorable characteristics mentioned earlier, using HPC either with VA64 or 
Sol did not appear to improve desirable dissolution performance (Figure 6.9a and 
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Figure 6.9b). The extent of supersaturation at 210 min for all ternary ASDs with HPC 
was lower than those for the binary ASDs: S-VA64 and S-Sol. Augmenting HPC with 
 
 
Figure 6.9  Evolution of drug release from physical mixture (PM) of GF–binary 
polymers and spray-dried powders prepared using GF–polymer solutions with a 
single polymer and binary polymers with various polymer1:polymer2 mass ratios: (a) 
VA64/HPC was each used as a single polymer and as binary polymers with 1:1, 5:1, 
and 9:1 VA64:HPC mass ratios; (b) Sol/HPC was each used as a single polymer and 
as binary polymers with 1:1, 5:1, and 9:1 Sol:HPC mass ratios. All formulations had 
1:3 drug:polymer mass ratio. 
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VA64 deteriorated extent of supersaturation drastically (Figure 6.9a). For the Sol–
HPC binary blends, the ternary ASDs had slightly faster initial GF release than the 
S-Sol, but this benefit came at the expense of reduced extent of supersaturation at 
longer times. These poor drug dissolution performance of the ternary ASDs with 
HPC stems from the rapid matrix crystallization of GF caused by low Tg of HPC and 
its relatively poor miscibility with GF. The detrimental impact of HPC was more 
marked for its ternary ASD with VA64 than that with Sol because Sol could at least 
inhibit recrystallization in the matrix to a certain extent, however, VA64 could not.  
Ternary ASD of GF with Sol–VA64 exhibited desirable GF release 
characteristics such as initial, rapid GF release and build-up of supersaturation and its 
prolonged maintenance over 3 h when Sol was used as the major polymer component 
and VA64 as the minor component, i.e., 5:1 Sol:VA64 mass ratio (Figure 6.10). At 
210 min, 230% relative supersaturation was achieved from S-Sol-VA64-5:1, whereas 
the relative supersaturation was 170% and 110% from S-Sol and S-VA64, 
respectively. It is inferred that ternary ASD with 5:1 Sol-VA64 exhibited significant 
synergistic enhancement upon combined use of an amphiphilic polymer (Sol, 
crystallization inhibitor) as a major component and the hydrophilic polymer (VA64) 
as a minor component. Apparently, this is contrary to the strategy proposed by Xie 
and Taylor, (2016a, b) based on their work on celecoxib. In fact, following their 
strategy, one would expect S-Sol-VA64-1:5 ASD to perform the best; yet, it led to the 
lowest extent of supersaturation among all ASDs with Sol–VA64 (Figure 6.10). 
Apparently, due to the obvious complexity of ternary ASDs, a “universal” 
formulation strategy is not likely to apply to all drugs because of the specificity of 
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drug–polymer1–polymer2 molecular interactions and their relative impact on 
wettability, drug recrystallization inhibition within the ASD matrix and in the 
dissolution medium, their diffusivities and dissolution rates relative to the drug, etc.   
Although increasing Sol concentration helped to improve the extent of 
supersaturation, there is a Sol:VA64 ratio after which the improvement is trivial, e.g., 
relative supersaturation 130%, 210%, 230%, and 260% was achieved at 210 min by 
varying Sol:VA64 mass ratio 1:1, 3:1, 5:1, and 11:1, respectively.  
 
 
Figure 6.10  Evolution of drug release from physical mixture (PM) of GF–binary 
polymers and spray-dried powders prepared using GF–polymer solutions with a 
single polymer and binary polymers with different Sol:VA64 mass ratios: Sol/VA64 
was each used as a single polymer and as binary polymers with 1:1, 5:1, 11:1, and 1:5 
Sol:VA64 mass ratios. 
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6.4  Conclusions 
Ternary ASDs of a poorly soluble fast crystallizing drug (GF) with binary 
combinations of HPC/VA64/Sol and binary ASDs of GF with the corresponding 
individual polymers, all having 1:3 GF:total polymer mass ratio, were prepared using 
spray-drying. XRPD, DSC, and Raman spectroscopy confirmed the molecular 
dispersion of GF in the matrices of single or binary polymers. Although binary ASDs 
with single polymer showed dissolution enhancement compared to as-received GF 
and physical mixtures, a desirable dissolution profile, i.e., rapid GF release 
concurrently generating fast supersaturation that lasts 3 hours, was not achieved. 
Despite being an excellent crystallization inhibitor, Sol did not allow for good 
wettability and hence its ASD could not achieve rapid drug release. Moreover, owing 
to its strong intermolecular interactions and miscibility with GF, it could generate a 
high GF supersaturation, albeit slowly. VA64, on the other hand, provided excellent 
wettability to the hydrophobic drug within the ASD and thus its ASD achieved fast 
initial release of the drug/polymer, with a burst. However, it is a poor crystallization 
inhibitor and could not sustain the initial high supersaturation. Unfortunately, having 
a sub-ambient Tg with low partial miscibility with GF, HPC (SSL grade) could not 
suppress the mobility of amorphous GF molecules upon contact of ASD with water, 
and fast recrystallization within the ASD matrix occurred. 
The dissolution profiles of the ternary ASDs of binary polymers were mostly 
reflective of the deficiencies of the polymers in terms of wettability enhancement and 
recrystallization inhibition in the ASD matrix and the dissolution medium. As 
expected, the combination of the two hydrophilic polymers HPC–VA64 without an 
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amphiphilic crystal-inhibiting polymer (Sol) led to low supersaturation, below 80%. 
Being an effective crystallization inhibitor Sol compensated for HPC’s inability to 
prevent recrystallization; but there was no synergistic positive impact.  Any increase 
in initial drug release rate upon use of HPC was nullified by lower extent of 
supersaturation. Finally, based on the results regarding GF release from ternary ASDs 
with Sol-VA64, we conclude that a ternary ASD of GF could exhibit synergistic 
enhancement of drug release rate and its extent upon combined use of an amphiphilic 
polymer (Sol, as a crystallization inhibitor) as a major component and the hydrophilic 
polymer (VA64) as a minor component that provides wettability enhancement. Future 
work will focus on the application of such strategy to other poorly water-soluble 
drugs.
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CHAPTER 7 
RELEASE OF ITRACONAZOLE FROM SPRAY-DRIED NANOCRYSTAL–
AMORPHOUS SOLID DISPERSIONS (HyNASDs) and ASDs 
 
To elucidate the generality of the findings from the research on GF regarding 
HyNASDs formation and impact of SDS in the dissolution enhancement, here 
another BCS Class II drug, Itraconazole (ITZ) is selected, which has very low 
aqueous solubility (0.002 µg/mL). Hydroxypropyl cellulose (HPC), Kollidon VA64 
(VA64), and Soluplus® (Sol) were used as suspension stabilizers and matrix-forming 
polymers. To elucidate the impact of a surfactant in on drug release from HyNASDs, 
an anionic surfactant, sodium dodecyl sulfate (SDS), was selected. 2.5% wet-milled 
ITZ suspensions containing 1:5 GF:polymer mass ratios, with 0.125% SDS (below 
CMC) and without SDS, were spray-dried. Hydroxypropyl cellulose (HPC) and 
Soluplus (Sol) were used as suspension stabilizers and matrix-forming polymers. To 
prepare ASDs, ITZ–Sol/HPC/VA64 solutions having identical composition to the 
nanosuspensions were spray dried. Examination of particle sizes in the milled 
suspensions revealed the criticality of SDS in the synergistic stabilization of GF 
nanoparticles. XRPD and DSC results suggest that nanocomposites and 
nanocomposites with notable amorphous ITZ, HyNASDs, were formed upon spray-
drying. For 100 mg ITZ dose (above thermodynamic solubility), up to 840% relative 
supersaturation was achieved from Sol-based HyNASDs at 210 min, whereas with 
SDS, this value went up to 1230%. Sol-based HyNASDs outperformed HPC and 
VA64, which could be explained partly by the stronger molecular interaction between 
ITZ–Sol than ITZ–HPC/VA64 and partly by the micellar solubilization by Sol as well 
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as its recrystallization inhibition in the superstrated drug solutions. ITZ-Sol-ASD 
generated ~2000% supersaturation, which is higher that generated by HyNASDs 
(1230%). Nonetheless, such high supersaturation from nanoparticle-based 
formulation has not been achieved in literature before. So, HyNASDs boost the 
performance drug nanoparticle-based formulations and render them competitive to 
ASDs. Therefore, this study demonstrates the generality of the findings in Chapter 3 
and Chapter 4, by using another poorly soluble drug, ITZ and the presence of SDS in 
the formulation significantly improved the extent of supersaturation in the dissolution 
medium, similar to the GF-HyNASDs.   
 
7.1  Materials and Methods 
7.1.1  Materials 
Itraconazole (ITZ) was used as Biopharmaceutics Classification System (BCS) Class 
II drug and was purchased from Jai Radhe Sales (Ahmedabad, India). Solubility of 
pure ITZ in deionized water and 0.1 N HCl are around 0.002 µg/mL and ~ 4 µg/mL, 
respectively (Ghazal et al., 2009) at 37 ºC. The glass transition and melting 
temperature of ITZ are reported to be 59 ºC (Zhang et al., 2016) and 171 ºC (Bilgili et 
al., 2018), respectively. Hydroxypropyl cellulose (HPC, SSL grade, Nisso America 
Inc., New York, NY) is a semi-crystalline polymer with low crystallinity and 
amorphous domains of very low Tg. It is widely used as a stabilizer during milling 
and matrix former in the nanocomposites (Azad et al., 2015b; Bhakay et al., 2014a). 
Soluplus® (Sol) is an amphiphilic graft copolymer produced from polyvinyl 
caprolactam–polyvinyl acetate–polyethylene glycol having a single glass transition 
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temperature of 73 ± 2 °C (Terife et al., 2012). Kollidon VA64 (VA64) is a 
hydrophilic polymer produced from the combination of vinylpyrrolidone (hydrophilic 
in nature) and vinyl acetate (lyophilic in nature) and has a single glass transition 
temperature of 101 °C (Kolter et al., 2012). Even 15% w/v aqueous solutions of all 
three polymers have less than 60 cP viscosity at 25 °C, which allowed us to perform 
milling and spray drying without any likely processing issues such as pressure build-
up in wet media milling and nozzle clogging in spray drying. Sodium dodecyl sulfate 
(SDS), an anionic surfactant with a CMC of 8.0 mM, purchased from GFS 
Chemicals, Inc. (Columbus, OH) was used as a wetting agent, which also helps to 
stabilize GF nanosuspensions. Dichloromethane, DCM (ACS reagent, ≥ 99.5%) was 
purchased from BDH Analytical chemicals (VWR, GA) and used as the solvent to 
prepare drug–polymer solutions. Wear resistant yttrium zirconia beads (Zirmil Y, 
Saint Gobain ZirPro, Mountainside, NJ, USA) with a median size of 430 µm was 
used as the milling media. 
7.1.2  Preparation of Suspension-Based (W) and Solution-Based (S) feeds of ITZ 
and Their Spray Drying  
Aqueous suspension-based (W:water) feeds of ITZ prepared by wet milling were fed 
to the spray dryer for the preparation of drug nanocomposites. Table 7.1 presents the 
formulations used in the precursor feeds. The concentration of ITZ and SDS was kept 
at 2.5% w/v and 0.125% w/v, respectively, in all suspensions. The concentration was 
calculated with respect to the 240 mL suspension liquid (deionized water). ITZ 
suspensions were prepared with three different polymers (HPC, Sol, and VA64) with 
drug:polymer mass ratios of 1:5 to examine the impact of polymer type on ITZ 
release in the dissolution tests. Finally, to investigate the impact of SDS in the 
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stabilization of the milled ITZ suspensions and ITZ release during dissolution tests, 
surfactant-free suspensions having the same drug:polymer mass ratios were also 
prepared for comparative analysis.  
 
Table 7.1  Formulations and Compositions of the Suspension-Based (W) Feeds Used 
in Spray Drying Experiments 
ID Formulationa GF  
(% w/v)b 
SDS 
(% w/v)b 
Polymers (% w/v)b Water 
(mL) Sol HPC VA64 
W1 W-Sol 2.5 0 12.5 - - 240 
W2 W-HPC 2.5 0  12.5 - 240 
W3 W-VA64 2.5  0 - - 12.5 240 
W4 W-Sol-SDS 2.5  0.125 12.5 - - 240 
W5 W-HPC-SDS 2.5 0.125  12.5 - 240 
W6 W-VA64-SDS 2.5  0.125 - - 12.5 240 
aW denotes suspension-based feed; drug:polymer mass ratio was fixed at 1:5 in all the formulations; 
Sol denotes Soluplus; VA64 denotes polyvinylpyrrolidone vinyl-acetate (6:4).  
b% w/v, with respect to the total solvent volume (240 mL). 
 
In each milling experiment, a shear mixer (Fisher Scientific Laboratory 
Stirrer, Catalog No. 14-503, Pittsburgh, PA) was used to disperse as-received ITZ 
particles in aqueous stabilizer (HPC/Sol/VA64) solutions with and w/o SDS. The 
resultant GF pre-suspensions were transferred to the holding tank of a Microcer wet 
stirred media mill (WSMM) (Netzsch Fine Particle Technology, LLC, Exton, PA, 
USA) having 80 mL chamber. Milling conditions were adapted from our prior work 
on wet media milling (Afolabi et al., 2014; Bilgili et al., 2016; Bilgili et al., 2018). 50 
mL of the milling chamber was filled with zirconia beads, and a screen with 200 µm 
opening was used at the outlet of the chamber to hold the beads in the chamber. A 
peristaltic pump was used to recirculate the suspension through the chamber at a rate 
of 126 mL/min and the suspension was milled for 64 min at a rotor speed of 4000 
rpm. A chiller (Advantage Engineering Greenwood, IN, USA) was used to maintain 
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the milling chamber temperature below 35 °C throughout the milling. A portion of 
each suspension was separated in a vial and stored for 7-days at 8 °C to assess the 
short-term physical stability. Also, the milled suspensions were refrigerated at 8 °C 
overnight before spray drying. 
The formulations of the solution-based (S) feeds to the spray dryer are 
provided in Table 7.2. The drug concentration was kept constant at 2.5% (w/v) in all 
the formulations, which was measured with respect to the total volume of the DCM 
(240 mL). ITZ solutions were prepared with three polymers (HPC, Sol, and VA64), 
while keeping the drug:polymer mass ratio constant at 1:5. After dissolving the drug–
polymer into DCM using a magnetic stirrer, the solutions were sonicated for 30 min 
to ensure complete solubilization of the solid components before feeding to the spray 
dryer. 
 
Table 7.2  Formulations and Compositions of the Solution-Based (S) Feeds Used in 
Spray Drying Experiments 
ID Formulationa GF  
(% w/v)b 
Polymers (% w/v)b DCM (mL) 
Sol HPC VA64  
S1 S-Sol 2.5 12.5 - - 240 
S2 S-HPC 2.5 - 12.5 - 240 
S3 S-VA64 2.5  - - 12.5 240 
a S denotes solution-based feed; drug:polymer mass ratio was fixed at 1:5 in all the formulations; the 
ratios refer to the polymer:polymer mass ratio; Sol denotes Soluplus; VA64 denotes 
polyvinylpyrrolidone vinyl-acetate (6:4).  
b % w/v, with respect to the total solvent volume (240 mL). 
 
7.2  Characterization Techniques 
7.2.1  Particle Size Measurement 
Drug particle size distributions (PSDs) in the suspensions were measured using a 
laser diffraction (LS 13 320, Beckman Coulter, Miami, FL) based on Mie scattering 
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theory following the procedure described in (Bilgili et al., 2016). Particle sizes were 
measured at various time points: right after milling, after 1-day and 7-day storage at 8 
°C in a refrigerator. During the measurement, the intensity was maintained 40–50% 
while the obscuration was maintained below 8.0%. Refractive index values are 1.68 
for ITZ (drug) and 1.33 for deionized water (medium). For each measurement, a 2.0 
mL suspension sample was diluted with 5.0 mL of the respective stabilizer solution 
and mixed using a vortex mixer (Fisher Scientific Digital Vortex Mixer, Model No: 
945415, Pittsburgh, PA) at 1500 rpm for 1 min.  
The particle sizes of the spray-dried powders were measured by a 
Rodos/Helos laser diffraction system (Sympatec, NJ, USA) based on Fraunhofer 
theory following the procedure described in (Li et al., 2016b). About 1 g of the 
powder sample was placed on top of the sample chute of the Rodos dispersing system 
and the sample chute was vibrated at a 100% setting, and 0.1 bar dispersion pressure 
was used to suck in the falling powder through the sample cell of the laser diffraction 
system.  
7.2.2  Solid State Characterization and Drug –Polymer Interactions 
To analyze the crystallinity of the as-received ITZ, HPC, Sol, VA64, spray-dried 
powders, and physical mixtures of ITZ–polymer with or w/o SDS, X-ray powder 
diffraction (XRPD) (PANanalytical, Westborough, MA, USA), provided with Cu Kα 
radiation (λ= 1.5406 Å) was used. The samples were scanned at a rate of 0.165 s-1 for 
2θ ranging from 5° to 40°.  
Differential scanning calorimetry (DSC) of the as-received ITZ, Sol, HPC, 
VA64, spray-dried powders, and physical mixtures (PM) was performed using a 
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Mettler-Toledo polymer analyzer (PolyDSC, Columbus, OH, USA) with integrated 
STARe 10 software. ~6.0–7.0 mg powder sample was placed in an aluminum pan 
with a hole in the lid and loaded into the DSC machine. All the samples were heated 
at a rate of 10 °C/min from 25 °C to 200 °C. Nitrogen gas was used as the purge gas 
and protective gas at a flow rate of 50 mL/min and 150 mL/min, respectively. 
Thermogravimetric analysis (TGA) was performed to measure the residual 
water/solvent content using a TGA/DSC1/SF Stare system (Mettler Toledo, Inc., 
Columbus, OH). ~6.0–7.0 mg of each spray-dried sample was placed in a ceramic 
crucible and heated from 25 °C to 150 °C at a heating rate of 10 °C/min under 
nitrogen flow. 
7.2.3  Drug Content in the Spray-Dried Powders and In Vitro Dissolution Tests 
To measure the actual drug content, an assay testing was performed by dissolving 100 
mg of the sample powders in 20 mL DCM under 30 min of sonication, followed by 
overnight storage to ensure complete solubilization of the GF particles. An aliquot of 
100 µL was taken from the ITZ solution and diluted up to 10 mL using DCM. The 
absorbance of the samples was measured at 260 nm using UV spectrophotometer 
(Agilent, Santa Clara, CA, USA), and the drug concentration was calculated from a 
pre-established calibration curve. Six replicates were tested for each formulation to 
calculate the mean drug content along with the relative standard deviation (RSD).   
Drug release from the spray-dried powders and physical mixtures (PMs) 
prepared by blending was determined via a Distek 2100C dissolution tester (North 
Brunswick, NJ, USA), following the USP II paddle method. 1000 mL of 0.1 N HCl 
solution at 37 °C was selected as the dissolution medium and stirred at 50 rpm paddle 
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speed. Considering the thermodynamic aqueous solubility of ITZ in 0.1 N HCl, i.e., 
4.0 µg/mL at 37 °C (Ghazal et al., 2009), a high dose (100 mg) of ITZ would allow 
for supersaturating dissolution conditions. 100 mg ITZ equivalent spray-dried 
powders were poured into the dissolution medium and 4 mL samples were taken out 
manually at 1, 2, 5, 10, 20, 30, 60, 120, 180, and 210 min. These aliquots were 
filtered with a 0.1 µm PVDF membrane-type syringe filter before UV-spectroscopy 
measurements to minimize any confounding effect of the undissolved coarse drug 
aggregates (Bhakay et al., 2014a; Li et al., 2016b). The filtered samples were diluted 
with 0.1 N HCl solution kept at 37 ºC at a ratio of 1 to 10 before UV measurement. 
Dissolved GF amount was measured by UV-vis spectroscopy at 255 nm wavelength 
and calculated using a pre-established calibration curve. 0.1 N HCl solution was used 
as blank before UV measurement, and three replicates were performed for each 
sample. In this chapter, relative % supersaturation is reported based on GF 
concentration at 210 min and thermodynamic solubility of as-received ITZ particles, 
unless otherwise indicated. 
7.2.4  Drug Wettability Enhancement by Sol and HPC Solutions With or W/O 
SDS 
ITZ wettability was investigated by analyzing the penetration rate of stabilizer solutions 
into a packed bed of ITZ particles inside a cylindrical column according to the 
Washburn method (Hołownia et al., 2008; Washburn, 1921). Attension Sigma 700 
(Biolin Scientific, Linthicum, MD, USA) set-up was used to measure the mass of the 
liquid penetrated the ITZ powder bed as a function of time. Experimental methods were 
adapted from Bilgili et al. (2018) and Li et al. (2017) and the details can be found in 
Section F.1 of the Appendix F. In the current study, liquids and powder refer to 
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aqueous solutions of 15% Sol/HPC/VA64 with 0.125% SDS or w/o SDS and as-
received ITZ, respectively. All percentages are (% w/w) with respective to deionized 
water. The apparent shear viscosity and surface tension of the liquids were measured 
using R/S Plus Rheometer (Brookfield Engineering, Middleboro, MA, USA) and 
Attension Sigma 700 (Biolin Scientific, Linthicum, MD, USA), respectively. The ratio 
of the cosine of contact angles cosθss/cosθw was calculated using the modified 
Washburn equation and used as a wetting effectiveness factor. Here, θss is the contact 
angle between ITZ and the stabilizer solutions and θw is the contact angle between ITZ 
and deionized water. This ratio or its logarithmic value provides a rough measure of the 
drug wettability enhancement upon use of various stabilizers in water.  
7.2.5  Drug Supersaturation Maintenance Ability of the Polymers 
Drug (ITZ) supersaturation maintenance ability of HPC/Sol/VA64 with or w/o SDS 
was examined in separate desupersaturation tests (similar to Konno et al., 2008). A 
concentrated solution of ITZ was prepared by adding 100 mg of as-received ITZ into 
60 mL of methanol via sonication for 40 min. Unfortunately, 60 mL methanol did not 
completely dissolve 100 mg ITZ and a turbid solution was formed. The turbid 
solution was subsequently added to a 1000 mL of pre-dissolved HPC/Sol/VA64 in 
aqueous solution of 0.1 N HCl solution having 500 µg/mL concentrations to maintain 
1:5 drug:polymer ratios (similar to the formulations in Table 7.1 and 7.2), 
respectively, with or w/o SDS in the USP II paddle type dissolution tester. The 
addition resulted in 69–78 µg/mL supersaturated solution of ITZ initially. This lower 
concentration of ITZ as compared with the targeted (100 µg/mL) resulted from both 
incomplete dissolution of IZT in methanol and inhomogeneous mixing of methanol 
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solution with the aqueous solution. Any subsequent desupersaturation during the 
following 210 min was tracked via ITZ concentration measurements. The 
experimental conditions and concentration measurements were identical to those in 
the dissolution test. All measurements were carried out in triplicate.    
 
7.3  Results and Discussion 
7.3.1  Properties of ITZ Suspensions Prepared via Wet Stirred Media Milling 
Six ITZ suspensions with HPC/Sol/VA64 with 1:5 drug:polymer mass ratios and 
0.125% SDS (W4–W6) and without SDS (W1–W3) were wet media milled. Table 
7.3 shows the characteristic particle sizes of the 64 min milled suspensions and after 
7-day storage. As-received ITZ particles had d50: 15.5 µm and d90: 45.8 µm, 
measured via Rodos/Helos laser diffraction system. After milling for 64 min, median 
particle sizes d50 were in the range of 0.16–0.24 µm for W4–W6 (Sol/HPC/VA64–
SDS) and 0.21–0.80 µm for W1–W3 (Sol/HPC/VA64) formulations. Unless properly 
stabilized, milled drug nanoparticles are known to form micron-sized aggregates in 
aqueous suspensions (Bilgili and Afolabi, 2012; Bilgili et al., 2018). Table 7.3 
suggests that only the formulations with SDS, ITZ nanosuspensions with median 
sizes d50 less than 200 nm were formed (except for W-VA64-SDS, W6), and the 
small changes in their d50 and d90 during the 7-day storage suggest that these 
suspensions were physically stable. Among the suspensions with the three polymers, 
VA64-based suspension had the coarsest particles in the presence/absence of SDS. 
Also, VA64-based suspension exhibited notable size increase upon 7-day storage, 
which resulted in d90 greater than 1 µm even in the presence of SDS (see Table 7.3).  
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Due to their relatively neutral charge, stabilizing capability of Sol/HPC/VA64 solely 
depends on their steric effects, which in turn is modulated by their adsorption onto 
ITZ nanoparticle surfaces. The adsorption is dependent on free polymer concentration 
in the suspension, and usually the adsorption is higher at high polymer concentrations 
until a saturation point is reached (Bilgili and Afolabi, 2012; Knieke et al., 2013).  
 
Table 7.3  Particle Size Statistics of the Milled GF Suspensions After 64 min and 7-
day Storage at 8 ºC 
ID Formulationa After 64 min (µm)  After 7-day storage 
d50 ± SD d90 ± SD d50 ± SD d90 ± SD 
W1 W-Sol 0.26±0.0 
0.21±0.0 
0.80±0.1 
0.16±0.0 
0.18±0.0 
0.24±0.0 
1.85±0.1  0.37±0.0 
0.23±0.0 
0.96±0.1 
0.18±0.0 
0.18±0.0 
0.27±0.0 
2.16±0.2 
W2 W-HPC 0.32±0.0  0.35±0.0 
W3 W-VA64 2.19±0.1  2.18±0.2 
W4 W-Sol-SDS 0.25±0.0  0.25±0.0 
W5 W-HPC-SDS 0.25±0.0  0.25±0.0 
W6 W-VA64-SDS 0.45±0.0  1.81±0.1 
a W denotes solution-based feed; drug:polymer mass ratio was fixed at 1:5 in all the formulations; the 
ratios refer to the polymer:polymer mass ratio; Sol denotes Soluplus; VA64 denotes Kollidon VA64. 
 
Clearly, presence of 0.125% in the suspensions had the most dramatic effect 
on the stabilization and extent of nanoparticle aggregation. HPC–SDS was reported to 
have synergistic stabilizing effect on multiple BCS Class II drug nanosuspensions 
during milling and storage (Bilgili et al., 2016). HPC, Sol, and VA64 imparted steric 
stabilization by adsorbing on drug nanoparticles (Bilgili and Afolabi, 2012; Bilgili et 
al., 2018; Yang et al., 2014), while the anionic surfactant (SDS) enhanced ITZ 
wettability/deaggregation and helped to stabilize the ITZ nanosuspensions via 
electrostatic repulsion. As can be seen from Table 7.4, polymers alone and polymer–
SDS combination reduce the surface tension and enhanced the ITZ wettability by 
water. As indicated by the higher wetting effectiveness factor, HPC (hydrophilic 
polymer) renders ITZ more wettable by water than VA64 and Sol (amphiphilic 
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polymer), and SDS enhances the wettability even further when used in combination 
with both polymers. The wettability is important to deggregation of the aggregates 
formed during milling, which allows for full exposure of ITZ particle surfaces for 
polymer adsorption. The lower wettability of ITZ by Sol and VA64 as compared with 
HPC could be another reason for the large aggregates in VA64 and Sol-based 
suspensions. On the other hand, with SDS, finer suspensions were obtained with Sol 
than with HPC, which suggests differing interaction between polymer–SDS. While 
wettability results here helped us to explain  the milling results,  they should be used 
with caution for interpreting the impact of  polymers/surfactant on the wettability 
enhancement because the dissolution medium was 0.1 N HCl whereas the modified 
Washburn experiment was conducted with deionzied water as the penetrating liquid.
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Table 7.4  Properties of Deionized Water–Aqueous Stabilizer Solutions and Wetting Effectiveness Factor Determined Using the 
Modified Washburn Method 
a
The slope of the water penetration data was used as reference for wettability enhancement by the stabilizer solution. 
Formulation η, (cP) ρ, (g/mL) γ, (mN/m) Slope, (g2/s) R2 (-) cosθss/cosθw log(cosθss/cosθw) 
Water 0.89
a
 1 70.8 6.5×10
-6
 0.995 1 0 
Sol 8.21 1.02 41.6 1.9×10
-3
 0.996 4430 3.65 
HPC  54.4 1.02 40.5 7.0×10
-4
 0.999 11120 4.01 
VA64 6.75 1.02 40.0 4.1×10
-3
 0.998 8180 3.91 
Sol–SDS 13.3 1.01 38.6 2.0×10
-3
 0.999 8310 3.92 
HPC–SDS 63.2 1.01 39.4 9.0×10
-4
 0.999 17410 4.24 
VA64-SDS 8.76 1.01 38.2 4.9×10
-3
 0.999 13550 4.13 2
4
4
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7.3.2  Size, Morphology, and Drug–Moisture Content of the Spray-Dried 
Powders 
Despite the relatively short residence time (4 s and 5 s), the powders produced form 
both suspension-based (W) and solution-based (S) feeds were completely dried, as 
indicated by TGA, which shows weight loss of 2.0 ± 0.3% for the samples. The high 
surface area generated by atomization of the feed coupled with the convective heat–
mass transfer at high air temperature enabled fast drying of the droplets in the drying 
chamber. The mean (actual) drug content after spray-drying was close or slightly 
higher than the theoretical drug content; all RSD values were below 6%: 0.49–5.23%, 
which signifies pharmaceutically acceptable content uniformity (see Table 7.5). Table 
7.5 shows that for a given polymer, the ITZ suspension without SDS (W1–W3) had 
smaller particles than that with SDS (W4–W6) and the ITZ solution (S1–S3). The 
presence of aggregated ITZ particles and the aqueous viscosity–surface tension of the 
base-polymer/SDS appeared to have a joint effect on the particle size of the 
suspension-based spray-dried powders.  Despite an increase in base viscosity, the 
presence of SDS resulted in lower surface tension (Table 7.4) and smaller ITZ 
aggregates (Table 3), which could explain the smaller spray-dried particles in the 
presence of SDS.  
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Table 7.5  Particle Size Statistics of the Spray-Dried Powders and Their Drug 
Content 
ID Formulationa Size of the spray-dried 
powders (µm) 
Theoretical 
drug content 
(%w/w)b 
Actual drug 
content, 
RSD 
(%w/w, %)b 
d10±SD d50±SD d90±SD 
W1 W-Sol 9.65±0.1 28.8±0.0 57.9±0.1 16.7 16.7, 0.49 
W2 W-HPC 7.33±0.1 23.0±0.3 56.4±0.1 16.7 17.2, 3.56 
W3 W-VA64 3.20±0.1 18.7±0.2 41.5±0.2 16.7 16.9, 4.31 
W4 W-Sol-SDS 5.20±0.0 13.5±0.0 38.2±0.0 16.5 16.8, 5.10 
W5 W-HPC-SDS 7.93±0.1 14.7±0.1 35.9±0.6 16.5 16.7, 4.37 
W6 W-VA64-SDS 4.21±0.0 11.5±0.0 37.7±0.1 16.5 16.9, 1.93 
S1 S-Sol 4.20±0.0 15.8±0.5 48.6±0.7 16.7 17.1, 2.02  
S2 S-HPC 4.90±0.1 12.3±0.2 39.7±0.2 16.7 16.9, 5.23 
S3 S-VA64 3.27±0.1 5.1±0.1 37.6±0.1 16.7 17.0, 3.41 
aS denotes solution-based feed; W denotes suspensions-based feed; drug:polymer mass ratio was fixed 
at 1:5 in all the formulations; the ratios in the formulations refer to the polymer:polymer mass ratio; 
Sol denotes Soluplus; VA64 denotes polyvinylpyrrolidone vinyl-acetate (6:4).  
b%w/w with respect to the total weight of the solid content. 
 
7.3.3  Formation of Drug HyNASDs and ASDs Upon Spray Drying 
Figures 7.1 and 7.2 illustrate the XRPD diffractograms of the spray-dried powders. 
X-ray diffractograms depict that as-received ITZ exhibited intense peak 
characteristics of a crystalline material. The physical mixtures (PMs), prepared by 
blending of as-received ITZ with HPC/Sol/VA64 or HPC/Sol/VA64–SDS powders, 
exhibited peaks at the same diffraction angles as those of as-received ITZ, albeit with 
reduced intensity. The diffractograms of the spray-dried powders with SDS (Figure 
7.1a) and without SDS (Figure 7.1b) did not remarkably differ, except for peak 
intensities; they exhibit patterns similar to those of the physical mixtures. The peak 
intensities of ITZ in the PMs were lower than those of the as-received ITZ powder, 
which can be attributed to the dilution and surface coverage of ITZ microparticles 
with HPC/Sol/VA64. Similar XRPD diffractograms to those of the PMs were 
observed for the spray-dried powders produced from suspension-based feeds 
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confirming that spray-drying of the milled suspensions led to formation of 
nanocomposites that are crystalline in nature. Interestingly, the diffractograms of the 
spray-dried powders show significant peak broadening and reduction in intensities as 
compared with their respective PMs, beyond the aforementioned dilution effect of the 
polymers. This peak reduction points to the possibility that wet media milling 
followed by spray-drying led to reduction of crystallinity and formation of notable 
amorphous ITZ (similar to the observations in Chapter 3 and Chapter 4 for GF). 
However, unlike for the GF nanocomposites, the crystallinity has not been quantified 
here for the ITZ nanocomposites. It is conjectured that wet media milling does not 
cause any detectable amorphization of as-received ITZ, in the absence of stabilizers, 
due to plasticization effect of water (Bilgili et al., 2018; Li et al., 2018b). In the 
presence of high polymer loading in the suspensions here, however, amorphization of 
ITZ seemed to have taken place during the spray drying. Looking at the XRPD 
diffractograms (Figure 7.1a and 7.1b), the reduction in the peak intensity and peaks 
broadening confirm some extent of amorphization of ITZ occurred. Taking a close 
look, it is visible that the reduction in peak intensity is more pronounced for the ITZ–
Sol formulation than for the ITZ–HPC/VA64 formulations with/without SDS. 
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Figure 7.1  X-ray diffractograms of as-received ITZ, physical mixtures (PMs) of GF–
HPC/Sol/VA64 and the spray-dried powders prepared using the ITZ suspension-
based (W) feed with 1:5 drug:polymer mass ratios: (a) without SDS and (b) with 
0.125% SDS in the suspension. 
 
These findings imply that (i) amorphous ITZ formed due to ITZ–polymer 
molecular interactions and/or solubilization of the surface layer of nanoparticles by 
the polymer during the spray-drying and (ii) Sol appears to favor the amorphization 
of ITZ more than HPC and VA64, which implies stronger Sol–ITZ molecular 
interactions/miscibility than HPC/VA64–ITZ. It is likely that presence of ITZ 
nanoparticles and their aggregates with large surface area and higher polymer loading 
(more ITZ–polymer interactions and higher ITZ solubilization in the polymer) could 
have favored the formation of amorphous GF. Based on our findings and Kayaert and 
Van den Mooter, 2012, it is proposed that the polymeric matrix of the spray-dried 
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particles encapsulates drug nanocrystals/aggregates, surrounded by a layer of 
amorphous ITZ molecularly dispersed in the polymer. Formation of amorphous 
content upon drying of drug nanosuspensions was first noted by Kayaert and Van den 
Mooter, 2012, albeit to a lower extent, and was regarded as “unfavorable”. 
Nonetheless, the impact of such amorphous content on drug release from the 
nanocomposites has not been studied at all. As the dissolution tests will reveal, 
despite being crystalline in nature, these nanocomposites with relatively high polymer 
loading (low drug:polymer ratio) allow for much higher supersaturation than 
traditional nanocomposites, similar to the supersaturation levels observed for ASDs; 
hence, we coin the term hybrid nanocrystal–ASD (HyNASD) for this special class of 
nanocomposites. 
XRPD diffractograms (Figure 7.2) of the spray-dried powders produced from 
solution-based (S) feeds showed halo pattern instead of any characteristic diffraction 
peaks of ITZ. These halo patterns confirm that amorphous ITZ dispersed molecularly 
into the polymer matrix forming amorphous solid dispersions (ASDs).  
Generally, it is suggested that if the solubility parameter difference between a 
drug and polymer is <7.0 MPa1/2, they are likely to be miscible; if the difference is 
>10 MPa1/2, they are considered immiscible (Forster et al., 2001; Greenhalgh et al., 
1999). The solubility parameters of ITZ, HPC, Sol, and VA64 are 22.6 (Kolter et al., 
2012), 24.0 (Choi et al., 1994), 19.4, and 19.7 (Kolter et al., 2012) MPa1/2, 
respectively. The solubility parameter differences between ITZ–Sol and ITZ–VA64, 
and ITZ–HPC are 3.2, 2.9, and 1.4 MPa1/2, respectively, which suggests that ITZ–
Sol/VA64/HPC all are miscible based on the solubility parameter difference and very 
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likely to produce amorphous solid dispersions of ITZ. While being useful, the 
solubility parameters do not account for all drug–polymer interactions such as 
contributions from hydrogen bonding, hydrophobic interactions, etc., and hence 
should be used with caution as rough estimates of drug–polymer miscibility. 
 
 
Figure 7.2  X-ray diffractograms of as-received ITZ, and physical mixtures (PMs) of 
GF–HPC/Sol/VA64 (a); spray-dried powders prepared using the ITZ solution-based (S) 
feeds with 1:5 drug:polymer mass ratio (b). 
 
The DSC thermograms in Figure 7.3 show an endothermic peak associated 
with melting of as-received ITZ, with a melting point temperature Tm of 171 °C and a 
fusion enthalpy ΔHf of 70.9 J/g; a glass transition for Sol (amorphous) at 72.4 °C, a 
glass transition for VA64 (amorphous) at 102 °C and a slight endothermic event 
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around 170–200 °C for HPC likely due to the melting of the small crystalline domain 
of largely amorphous HPC (Sarode et al., 2013) (crystallinity was undetectable by 
XRPD). The Tg of HPC could not be measured as it is in the range of –25 to 0 °C 
(Sarode et al., 2013) and our DSC equipment is limited. The spray-dried powders 
exhibited a melting endotherm only, corresponding to the fusion of their ITZ crystals. 
The absence of any recrystallization event during the heating could suggest that the 
amorphous ITZ in HyNASDs did not recrystallize due to ITZ–polymer molecular 
interactions as the amorphous content was in the ASD surrounding the drug crystals.  
The DSC thermograms in Figure 7.3 and the data in Table 7.6 show that 
spray-drying of ITZ suspensions led to drastic melting point depression (high ΔTm), 
up to 37 ºC, and reduction of ΔHf even if the values were corrected for dilution with 
polymer and reduced crystallinity (not shown for brevity). Higher ΔTm and lower ΔHf 
of the spray-dried powders than those of the PMs suggest that the amorphous ITZ 
content of the spray-dried powders was lower. The significant melting point 
depression in drug–polymer mixtures is indicator of drug–polymer miscibility (Baird 
and Taylor, 2012; Newman et al., 2008). Moreover, without exceptions, having 
identical polymer/SDS composition, the spray-dried powders with Sol had higher 
ΔTm and lower ΔHf than those with HPC and VA64, which could be explained by (i) 
stronger ITZ–Sol interactions, (ii) higher initial amorphous content in the Sol-based 
spray-dried powders, and (iii) higher extent of solubilization of ITZ in the polymer 
melt at high temperatures due to the thermal treatment during the DSC scan. 
Compared with the clear trends regarding the impact of different polymers for 
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formulations with/without SDS, the trends for SDS impact were not as strong and as 
clear. 
 
Table 7.6  Characteristic Temperatures–Enthalpy Values Obtained From DSC 
Thermograms  
ID Formulationa Tg (ºC)
a,b Tm (ºC)
 a,b Hf (J/g) a,b 
ITZ As-received ITZ ND 171 70.9 
W1 W-Sol ND 134 1.02 
W2 W-HPC ND 160 6.32 
W3 W-VA64 ND 141 3.00 
W4 W-Sol-SDS ND 137 1.35 
W5 W-HPC-SDS ND 159 4.91 
W6 W-VA64-SDS ND 141 5.17 
S1 S-Sol 72.3 ND ND 
S2 S-HPC ND ND ND 
S3 S-VA64 99.6 ND ND 
aS denotes solution-based feed, Sol denotes Soluplus; the ratios refer to the polmer:polymer mass 
ratios. Other symbols: Tg, Trc, and Tm stand for temperature for glass transition, recrystallization 
transition, and melting point, respectively, while Hrc and Hf respectively stand for recrystallization 
enthalpy and fusion enthalpy.    
bND: not detected. 
 
For the spray-dried powders prepared from the drug–polymer solutions 
(Figure 7.4), a single Tg was observed for all the formulations confirming the 
formation of molecular level dispersion (Luebbert et al., 2017; Wlodarski et al., 2015) 
(Table 7.6). Due to strong molecular interactions and good miscibility of ITZ–Sol, 
ITZ–HPC, and ITZ–VA64, recrystallization event at high temperature was not 
observed for the any of the formulations during the DSC scan. However, for S-VA64 
formulation, at higher temperature (around 170 ºC) there was a thermal event 
observed, which might be due to phase separation of the drug and the polymer. 
Overall, the XRPD and DSC results suggest that spray-drying of ITZ–polymer  
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Figure 7.3  DSC thermograms of as-received ITZ, HPC, Sol, and VA64 (a); physical 
mixtures (PMs), and spray-dried powders prepared using the ITZ suspension-based 
(W) feed with 1:5 drug:polymer mass ratio: (b) without SDS and (c) with 0.125% 
SDS in the suspension. 
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nanosuspensions with/without SDS led to formation of drug HyNASDs and ITZ–
polymer solutions led to formation of ASDs. Therefore, as a general observation, 
similar to Chapter 3 and Chapter 4, we note that spray-drying of a drug 
nanosuspension with a lower drug:polymer mass ratio (high polymer concertation) 
than typically used (see e.g., Table 1.2) and the use of a strongly miscible polymer 
that interacts with the drug nanoparticles and solubilizes them during the spray drying 
favor the formation of HyNASDs.  
 
 
Figure 7.4  DSC thermograms of spray-dried powders prepared using the ITZ 
solution-based (S) feed with 1:5 drug:polymer mass ratio. 
 
7.3.4  Dissolution performance of the Spay-Dried Powders in Supersaturating 
Condition 
The temporal evolution of ITZ release from the spray-dried powders and the PM with 
the highest polymer loading (1:5 ITZ:polymer) containing 100 mg equivalent ITZ 
dose in 1000 mL 0.1 N HCl solution at 37 ºC was investigated. The bulk dissolution 
medium could supersaturate for this high drug dose as the ITZ solubility is ~4.0 
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mg/L. Unless otherwise specified, all supersaturation values are relative to aqueous 
thermodynamic solubility of ITZ and calculated at 210 min.  
Considering that the major shortcoming of traditional drug nanocomposites 
with low polymer loading as compared with amorphous solid dispersions (ASDs) is 
their limited supersaturation capability in dissolution media, the examination of drug 
dissolution under supersaturating condition is critical. The most striking feature of 
Figure 7.5a and 7.5b is that Sol-based HyNASDs, nanocomposites with notable 
amorphous content, achieved 840% and 1230% ITZ supersaturation without SDS and 
with SDS, respectively. Such high supersaturation has not been reported for drug 
nanocomposites before, but for ASDs. A cursory look at Figure 7.5 also reveals some 
general trends: (i) the spray-dried powder could generate ITZ superstation more than 
the corresponding PM for 1:5 GF:Sol with and w/o SDS, (ii) the ITZ supersaturation 
was higher for spray-dried powders with SDS than those without SDS, and (iii) Sol-
based formulations generated much higher supersaturation than HPC/VA64-based 
formulations especially when the formulation included SDS. These results point to 
the criticality of the wettability of the spray-dried powder, which is enhanced by SDS, 
ITZ–polymer interaction and solubilization of the ITZ by the polymer. The smaller 
ITZ nanoparticle sizes and the smaller spray-dried particle sizes in the presence of 
SDS could explain why the powders with SDS released ITZ faster besides the 
obvious wettability enhancement imparted by SDS (see Table 7.4).  
During the dissolution test, as water wets and imbibes into the spray-dried 
particles, their polymer dissolves and the particles redisperse into smaller ITZ–
polymer/SDS clusters depending on the wettability, while their amorphous ITZ 
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fraction contributes to the dissolution. In the polymer/SDS-rich microenvironment of 
the particles and releases clusters, ITZ could be solubilized by the polymer/SDS, and 
the rate of this process depends on the cluster/particle size as well as ITZ particle size 
inside these clusters as well as the drug:polymer mass ratio and presence/absence of 
SDS. Unfortunately, depending on the polymer–drug miscibility and interactions, 
amorphous content of the HyNASDs may phase-separate and recrystallize upon 
contact with water in the dissolution medium (Alonzo et al., 2011; Chen et al., 2015)  
 
 
Figure 7.5  Evolution of drug release from as-received ITZ, physical mixture (PM) 
with 1:5 ITZ:Sol mass ratio, and spray-dried powders prepared using GF suspension-
based (W) feeds with 1:5 drug:polymer mass ratios: (a) with 0.125% SDS in the ITZ 
suspensions and (b) without SDS. Dissolution sample size equivalent to 100 mg ITZ 
dose. 
 
because water acts as a plasticizing agent, reducing the glass transition of the ASD 
component of HyNASDs and enhancing the mobility of the drug molecules (Chen et 
al., 2015).  Finally, the supersaturated ITZ in the dissolution medium and the released 
drug nanoparticles form a metastable system, and ITZ could recrystallize on existing 
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ITZ nanoparticles and cause their growth in time, which in turn could cause reduced 
supersaturation. Strong drug–polymer interactions can reduce the molecular mobility 
and delay recrystallization onset time and the extent of recrystallization (Mistry et al., 
2015). 
With the hope of additional insights into the ITZ recrystallization inhibition 
capability of Sol/HPC/VA64 with and w/o SDS in supersaturated ITZ solutions, 
desupersaturation experiments were performed during which the dissolved ITZ shifts 
from methanol (high solubility) to methanol–water mixture (low solubility), thus 
creating supersaturation (see Figure 7.6). A peak ITZ supersaturation was attained 
fast upon mixing the ITZ solution with deionized water, and it was maintained up to 
~210 min with all the polymers with and w/o SDS. SDS did not in the supersaturation 
maintenance is not significant compared to the polymers. In the absence of any 
inhibitor, ITZ recrystallized fast and its concentration exponentially decayed to an 
equilibrium concentration in 60 mL methanol–1000 mL water mixture (~21 µg/mL). 
Unfortunately, methanol volume was so high to affect the solubility in the 
desupersaturation experiment. Moreover, to be more predictive of the dissolution test, 
0.1 N HCl rather than deionized water should have been used. Unfortunately, these 
results do not discern the inhibition capability of the polymers, nor do they 
confidently suggest that all polymers were good crystallization inhibitors of ITZ 
because a high supersaturation that mimics the saturation level in the dissolution 
vessel could not be achieved using 60 mL methanol in the desupersaturation 
experiment. It appears that a better solvent than methanol for ITZ is required and that 
solvent must be miscible with water and should be used at a lower solvent:antisolvent 
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mass ratio to generate high supersaturation. With such a caveat in mind, it may be fair 
to assert that in the presence of the polymers, ITZ recrystallization did not occur from 
the solutions with the specific supersaturation levels studied here. 
 
 
Figure 7.6  ITZ desupersaturation curves for a 60 mL ITZ–methanol solution mixed 
with 940 mL aqueous solutions of 500 µg/mL of HPC/Sol/VA64–5 µg/mL SDS or 
w/o SDS (corresponding to 1:5 drug:polymer formulations). The initial concentration 
of GF right after mixing was targeted at 100 µg/mL. 
 
A comparison of Figure 7.7a (ASDs) and Figure 7.7b (HyNASDs) indicates 
that ASDs outperform HyNASDs owing to the presence of 100% amorphous ITZ in 
the former. However, it is amazing to see such high supersaturation (up to 840%) 
from the HyNASDs/ Figure 7.7a also shows that 1220%, 1340%, and 1980% relative 
supersaturation was achieved by HPC-based, VA64-based, and Sol-based ASDs with 
SDS, respectively, at 210 min. Interestingly, even after 210 min of dissolution, the 
profile is still rising, which signifies that if the dissolution test was run longer than 
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210 min, the extent of supersaturation would be even higher. Before an attempt is to 
be made to explain these results, some caveats regarding the interpretation of 
dissolution results in view of the desupersaturation and wettability results must be 
mentioned. It is speculated based on the somewhat inconclusive desupersaturation 
test results (refer to Figure 7.6) that all three polymers are capable of maintaining the 
supersaturation in the dissolution medium. Also, since the Washburn experiments 
were carried out with deionized water rather than 0.1 N HCl, relating the ITZ 
wettability enhancement to the dissolution results are somewhat confounded due to 
the pH effect. Since the reduced pH in the acidic media results in ionization of ITZ 
(weak base), it is likely that surface properties and wettability changed with the pH. It 
should also be noted that the dissolution profiles in Figure 7.7a did not plateau within 
210 min; hence, longer dissolution time is needed to glean the impact of potential 
recrystallization. 
The solubility parameter differences suggest all polymers are miscible with 
ITZ, while the melting point depression results (refer to Table 7.6) suggest the 
miscibility of ITZ with Sol > VA64 > HPC. The supersaturation generation in Figure 
7.7a correlated positively with the ITZ–polymer miscibility inferred from DSC. The 
remarkably high ITZ supersaturation achieved by Sol-based ASDs as compared with 
HPC/VA64-based ASDs can be explained by the greater miscibility with ITZ and 
higher ITZ solubilization in Sol micelles in the dissolution medium. It is well-
established that depending on the drug–polymer miscibility and interactions, 
amorphous drug may phase-separate and recrystallize upon contact of ASDs with 
water in the dissolution medium (Alonzo et al., 2011; Chen et al., 2015). Once 
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imbibed into the ASD matrix, water acts as a plasticizing agent, enhancing the 
mobility of the drug molecules by reducing the Tg of the ASD (Chen et al., 2015). 
HPC-SSL has sub-ambient Tg (Srode et al., 2013) (lower than Tg of Sol: 73 ± 2 °C 
and VA64: 101 ºC) and its ASDs have lower Tg (was not possible to detect) than Sol-
based ASDs (Table 7.6). Owing to good miscibility of ITZ–HPC, no phase separation 
and recrystallization appeared in Figure 7.7a within 210 min (rising profile).  
 
 
Figure 7.7  Evolution of drug release from as-received ITZ, physical mixture (PM) 
with 1:5 ITZ:Sol mass ratio, and spray-dried powders prepared from: (a) ITZ 
solution-based (S) feeds and (b) ITZ suspension-based (W) feeds with 1:5 
drug:polymer mass ratios. Dissolution sample size equivalent to 100 mg ITZ dose.  
 
7.4  Conclusion 
Spray-drying of wet-milled ITZ suspensions with high polymer loading (1:5 
ITZ:polymer mass ratio) with HPC/Sol/VA64 and with/without SDS led to formation 
of a special class of nanocomposites, HyNASDs, which contain drug nanocrystals 
and aggregates surrounded by notable amorphous content molecularly dispersed in 
the polymeric matrix. XRPD and DSC thermogram shed light on the HyNASD 
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formation and revealed miscibility of ITZ with Sol/HPC/VA64. However, the 
interaction seems to be stronger in the case of ITZ–Sol than ITZ–HPC/VA64 from 
XRPD and DSC results. Presence of SDS in the formulation enhanced the relative 
wetting effectiveness of the polymers significantly and in the dissolution test helped 
to reach higher extent of supersaturation. This higher extent of supersaturation may 
be explained by the solubilizing effect of SDS, but due to the inconclusive nature of 
the Washburn experiments and desupersaturation experiments in deionized water, the 
roles of SDS could not be well-elucidated. Without SDS in the formulation, 480%, 
430%, and 840% relative supersaturation was achieved from HPC, VA64, and Sol-
based formulation, respectively, at 210 min. On the other hand, presence of SDS in 
the formulation resulted 720%, 470%, and 1230% relative supersaturation from HPC, 
VA64, and Sol-based formulation, respectively. Therefore, the results here for ITZ 
are in line with our previous observations in Chapter 2 and Chapter 3, where 
significant supersaturation generation from drug nanocomposites was possible by 
forming HyNASDs and presence of SDS boosted up the supersaturation level. 
Although ASD formulations generated higher extent of supersaturation (up to 1980%) 
than HyNASDs, 840% relative supersaturation from a largely crystalline formulation 
is an interesting, novel, and impactful finding.  
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CHAPTER 8 
CONCLUSIONS AND FUTURE WORK 
 
8.1  Conclusions 
This thesis research has identified two major challenges in the bioavailability 
enhancement of BCS Class II drugs via drug nanocomposites and amorphous solid 
dispersions (ASDs): (i) the major drawback of nanocomposites is their inability to 
attain high drug supersaturation during in vitro (<50% relative supersaturation) and in 
vivo dissolution; (ii) formulating an amorphous solid dispersion (ASD) with high 
drug loading (>20%) that releases drug rapidly, while generating and maintaining 
high supersaturation over at least three hours is challenging. The goal of this thesis 
was to develop a fundamental understanding of the impact of anionic surfactants–
polymers on in vitro drug release from nanocomposites and ASDs, while addressing 
the aforementioned challenges. This dissertation has developed a processing–
formulation approach to produce both nanocomposites and ASDs with identical 
formulation, which has allowed us to have a true head-to-head comparison of 
nanocomposites and ASDs.  
Spray drying of milled drug nanosuspensions with high polymer loading 
(unlike traditional drug nanosuspension formulations) enabled us to produce a new 
class of drug nanocomposites titled hybrid nanocrystal–ASD (HyNASD). HyNASDs 
contain a notable fraction (5–22%) of amorphous drug molecularly dispersed in the 
polymeric matrix that encapsulates drug nanoparticles. They generated high drug 
supersaturation rapidly (~300% within 20 min) in the dissolution tests unlike 
traditional nanocomposites (max. 50%), which could render nanoparticle 
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formulations more competitive to ASDs in bioavailability enhancement of poorly 
soluble drugs. The supersaturation generation capability of HyNASDs is largely 
controlled by drug–polymer interactions/miscibility as well as the size of the drug 
(nano)crystals in the polymeric matrix. While HyNASDs did not generate as high 
saturation as ASDs (480%), they can be rendered competitive to ASDs upon further 
formulation–process optimization. 
In wet media milling of drugs, various hydrophilic/amphiphilic polymers 
along with an anionic surfactant provided excellent physical stability to drug 
nanoparticles via electrosteric mechanisms. In the absence of the surfacatant, large 
aggregates of the drug nanoparticles formed. Significant supersaturation generation 
and maintenance was achieved by HyNASDs for high drug dose (100 mg). On the 
other hand, the supersaturation generation capability of HyNASDs was largely 
controlled by the anionic surfactant either in the formulation or in the dissolution 
medium, drug–polymer interactions/miscibility as well as the size of the drug 
(nano)crystals in the polymeric matrix. 
Inclusion of an anionic surfactant as a minor component along with a drug-
miscible polymer (major component), which can provide significant solubilization of 
the drug and supersaturation maintenance via recrystallization inhibition, could boost 
drug supersaturation from the ASDs via mainly wettability enhancement and some 
additional drug solubilization. Unlike the use of surfactant as carriers/solubilizers, the 
use of an anionic surfactant as a minor component dramatically improved the 
wettability of the drug ASDs, without having any deleterious impact on drug 
recrystallization, which is a common problem in polymer–surfactant carrier systems. 
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Also, the use of low concentrations of an anionic surfactant even in high-dose 
applications of ASDs alleviates any concern associated with the toxicity of anionic 
surfactants.  
Ternary ASDs of a poorly soluble fast crystallizing drug (GF) with binary 
combinations of HPC/VA64/Sol and binary ASDs of GF with the corresponding 
individual polymers, all having 1:3 GF:total polymer mass ratio, were prepared using 
spray-drying. Although binary ASDs with single polymer showed dissolution 
enhancement compared to as-received GF and physical mixtures, a desirable 
dissolution profile, i.e., rapid GF release concurrently generating fast supersaturation 
that lasts 3 hours, was not achieved. The dissolution profiles of the ternary ASDs of 
binary polymers were mostly reflective of the deficiencies of the polymers in terms of 
wettability enhancement and recrystallization inhibition in the ASD matrix and the 
dissolution medium. As expected, the combination of the two hydrophilic polymers 
HPC–VA64 without an amphiphilic crystal-inhibiting polymer (Sol) led to low 
supersaturation, below 80%. Being an effective crystallization inhibitor, Sol 
compensated for HPC’s inability to prevent recrystallization; but there was no 
synergistic positive impact.  Any increase in initial drug release rate upon use of HPC 
was nullified by lower extent of supersaturation. Finally, based on the results 
regarding GF release from ternary ASDs with Sol-VA64, we conclude that a ternary 
ASD of GF could exhibit synergistic enhancement of drug release rate and its extent 
upon combined use of an amphiphilic polymer (Sol, as a crystallization inhibitor) as a 
major component and the hydrophilic polymer (VA64) as a minor component that 
provides wettability enhancement. 
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General findings from the research on GF regarding HyNASD formation and 
impact of SDS were applicable to another poorly water-soluble, BCS Class II drug, 
Itraconazole (ITZ) as well. Spray drying of wet media milled drug nanosuspensions 
with high polymer loading led to formation of ITZ HyNASDs, which exhibited high 
supersaturation, and the presence of the anionic surfactant favored the ITZ 
supersaturation generation. Based on the success of the HyNASDs for two 
completely different BCS Class II drugs, i.e., GF and ITZ, Figure 8.1 presents a 
preliminary decision tree for the selection of nanocomposites, HyNASDs, and ASDs 
for BCS Class II drugs based on the current knowledge-base generated in this thesis. 
Obviously, the construction of this decision tree presumes that the physical stability 
of the HyNASDs is not worse than ASDs of the same drug, and the stability aspects 
of HyNASDs will be examined in future work. 
 
 
Figure 8.1  A preliminary decision tree for the selection of drug nanocomposites, 
HyNASDs, and ASDs based on the aqueous and dose of the drug. 
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Overall, this dissertation has established a platform approach (spray-drying) 
for a scientific comparison of drug nanocomposites vs. ASDs and generated the 
prerequisite processing–materials knowledge and methodology needed. The 
following objectives have been realized: (i) drug release from drug (GF) 
nanocomposites and ASDs with identical formulation, i.e., low drug GF:polymer 
(HPC/Soluplus) mass ratios (1:1 to 1:5) and an anionic surfactant (SDS),  were 
examined,  (2) the impact of anionic surfactant on drug release from hybrid 
nanocrystal–amorphous solution dispersions (HyNASDs) has been investigated, (3) 
rapidly supersaturating ternary ASDs of GF with HPC/Sol and SDS as a minor 
component were prepared, and (4) GF release from ternary ASDs of GF with a 
hydrophilic, wettability-enhancing polymer (HPC/PVP-VA64) as a minor component 
and an amphiphilic polymer as drug precipitation inhibitor was examined, and (5) the 
fundamental knowledge generated on GF was applied to another drug, itraconazole 
(ITZ). While this dissertation addressed the major shortcoming of the drug 
nanocomposites, i.e., limited supersaturation capability in the dissolution media 
compared with ASDs, elucidated the roles/impact of anionic surfactants and binary 
polymers on drug release from ASDs, there are still various areas for further research 
and investigation, which are summarized below.  
 
8.2  Future Work 
8.2.1  Investigation on Storage Stability of HyNASDs vs. ASDs Under Various 
Environmental Conditions  
In current dissertation, we have introduced a new class of particles called Hybrid 
Nanocrystals–Amorphous Solid Dispersions (HyNASDs) by spray-drying an aqueous 
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GF nanosuspension with higher polymer concertation (1:1–1:5 drug:polymer mass 
ratio) than conventional drug nanosuspensions, where 1:0.02–1:0.8 drug:polymer 
mass ratio is used. This special class of nanoparticles has significant amount of 
amorphous content (>10%), which allowed us to increase the apparent solubility of 
the poorly water-soluble drugs significantly and achieve supersaturation during 
dissolution. Also, significant improvement in the drug release rate was achieved by 
producing ASDs of the poorly soluble drugs. Since amorphous drugs are 
thermodynamically unstable in nature, they can recrystallize during storage and 
dissolution. Therefore, investigation into the storage stability of HyNASDs vs. ASDs 
should be conducted under various environmental (RH, T) conditions. 
8.2.2  Production of HyNASDs with Various Drug–Polymer Pairs and Their 
Comparative Assessment 
In the current dissertation, HyNASDs of GF (griseofulvin) and ITZ (itraconazole) 
were produced using HPC, Sol, and VA64, which worked as stabilizer/carrier/matrix 
formers. Dissolution enhancement of a poorly soluble drug from HyNASDs requires 
some extent of drug–polymer miscibility or interactions. As shown in Chapter 4, due 
its good miscibility with GF and higher glass transition temperature, Sol achieved 
significant supersaturation from HyNASDs, whereas due to the low glass transition 
temperature and poor miscibility, HyNASDs with GF–HPC could not provide high 
GF supersaturation. In Chapter 7, HyNASDs of ITZ were also produced using HPC, 
Sol, and VA64, where very high extent of supersaturation was attained in the 
dissolution tests. To generalize the concept of supersaturation generation from drug 
nanoparticle-based formulation using HyNASDs, multiple drug–polymer pairs should 
be used. 
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8.2.3  Systematic Investigation of the Impact of Various Surfactants for 
HyNASDs vs. ASDs 
In Chapters 4, 5, and 7, the impact of an anionic surfactant, sodium dodecyl sulfate 
(SDS) has been studied in the production and dissolution performance of GF and ITZ 
from HyNASDs and ASDs. It was found that the inclusion of a surfactant at low 
concentration in the formulation can significantly improve the stabilization of drug 
nanosuspensions during milling and it has remarkable impact in the drug release rate 
due to the wettability enhancement. However, the role of SDS in the HyNASDs and 
ASDs was different. Investigation on various surfactants and their impact in the 
production of HyNASDs/ASDs and drug release performance should be conducted 
for better understanding of the roles of surfactants. This understanding can help the 
formulation scientist in the selection of surfactant for the development of drug ASDs 
vs. HyNASDs formulations. 
8.2.4  Investigating the Impact of Various Drug Nanoparticle Sizes in the Range 
of 50–1000 nm on Drug Supersaturation from HyNASDs   
As shown in Chapters 3, 4, and 7, drug median particle sizes in the nanosuspensions 
were less than 200 nm when SDS was included in the formulation. In the absence of 
SDS, the particles were severely aggregated during milling (depending on the 
stabilizers type and concertation) and the size of the particles varied up to few 
microns in the final milled drug suspensions. Also, it was very evident from the 
studies in Chapters 4 and 7 that the final milled particles sizes played a significant 
role in the supersaturation generation besides the amorphous content of the drug in 
the final spray-dried powders. Consequently, a systematic study in the impact of drug 
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nanoparticles sizes in the range of 50–1000 nm will provide better understanding 
about the drug particle size impact in the supersaturation generation.   
8.2.5  Characterize the Thermodynamic Solubility of Crystalline Drug and 
Kinetic Solubility of the Amorphous Drug in the ASD and Drug Nanoparticles 
The thermodynamic solubility of the as-received crystalline drug particles in the 
presence of various polymers/surfactants must be determined. Kinetic solubility of 
the amorphous drug in different ASD formulation as well as drug nanoparticles must 
be measured separately.  
8.2.6  Detailed Characterization of HyNASDs and ASDs 
Drug–polymer intermolecular interactions should be studied via FTIR spectroscopy. 
Miscibility of polymer1–polymer2 in ternary ASDs should be studied by preparing 
films of pure polymer1, polymer2, and their known mixtures and using such films in 
FTIR spectroscopy. Modulated DSC should be used to determine glass transition 
temperature more accurately.  
8.2.7  Study of High Dose Effects in Drug Release from HyNASDs and ASDs 
In this thesis research, only 9 mg and 100 mg drug doses were considered in the 
dissolution testing. Hence, at least two other higher drug doses (200 mg and 400 mg) 
should be used in dissolution testing to address the needs of pharmaceutical industry.  
8.2.8  Characterization of the Dissolution/Redispersion Medium after Testing of 
HyNASDs and ASDs 
Characterization of particle sizes in the dissolution vessel following a dissolution 
experiment with HyNASDs and ASDs could provide significant insights as to the size 
of drug nanoparticles in HyNASDs. Similar information can be gleaned from 
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redispersion medium following the test. Also, any residue from the dissolution or 
redispersion should be characterized using polarized light microscopy, DSC, and 
XRPD.  
8.2.9  Development of a Decision Tree for Process–Formulation Selection 
As the invention of HyNASDs has been shown the performance of drug 
nanocomposites, it is likely that HyNASDs will be competitive to ASDs in the future 
upon for development and optimization. While in Section 8.1 has presented a 
preliminary decision tree for HyNASDs vs. ASDs, a more streamlined and robust 
decision tree should be developed based on the storage stability of HyNASDs in 
comparison to ASDs.  
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APPENDIX A 
IMPACT OF POLYMERS ON THE AGGREGATION OF WET-MILLED 
ITRACONAZOLE AND THEIR DISSOLUTION FROM SPRAY-DRIED 
NANOCOMPOSITES 
 
 
In appendix A, detail of the modified Washburn method to measure the relative 
wetting effectiveness of the stabilizer/dispersant solutions are provided. Also, to 
confirm the size of the redispersed drug particles form the drug the polymeric matrix 
of the drug nanocomposites, microscopic images are also shown here.  
A.1  Experimental Details of the Drug Wettability Measurements 
Penetration of a liquid into a packed powder bed of drug particles inside a cylindrical 
column allows for measurement of the drug powder wettability, based on the 
modified Washburn method (Hołownia et al., 2008; Washburn, 1921). In the current 
study, liquids and powder refers to aqueous solutions of dispersants (HPC, PVP K30, 
HPMC E3, SDS, HPC SL–SDS) and Itraconazole (ITZ), respectively. All percentages 
are w/w with respective to deionized water. Dispersant concentrations in the solutions 
were identical to those in the respective wet-milled suspensions in Table 2.1 of main 
text. The apparent shear viscosity and surface tension of the solutions were measured 
as described below. Then, the drug wettability was quantified based on fitting of the 
experimental data on the temporal evolution of the liquid mass penetrated into the 
drug powder bed by the modified Washburn equation.  
A.1.1  Apparent Shear Viscosity and Surface Tension of the Dispersant Solutions  
The apparent shear viscosity of the aqueous dispersant solutions was measured using 
an R/S Plus Rheometer (Brookfield Engineering, Middleboro, MA, USA) with a 
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water jacket assembly Lauda Eco (Lauda-Brinkmann LP, Delran, NJ, USA). A 
coaxial cylinder (CC40) was used to provide a controlled shear rate on the samples 
from 0 to 1000 1/s for 60 s. The temperature of the jacket was kept constant at 25 ± 
0.5 °C. The raw data were analyzed using the Rheo 3000 software (Brookfield 
Engineering, Middleboro, MA, USA) of the equipment to obtain the apparent shear 
viscosity as a function of the shear rate. For solutions with low viscosities (< 10 cP) 
such as 2.5% HPC SL, 4.5% HPC SSL, and 4.5% PVP solutions, a Kinexus Ultra 
Plus Rotational Rheometer (Malvern Panalytical, Southborough, MA, USA) with 
higher sensitivity/accuracy was used. 40 mm rotational parallel plates with 0.75 mm 
gap were used to provide a controlled shear rate on the samples from 0 to 1000 1/s. 
The viscosity value at ~100 1/s shear rate was used in the wetting effectiveness factor 
calculations. The viscosities of water and the 0.2% SDS solution were taken from 
Korson et al. (1969) and Kushner et al. (1952), respectively.   
The surface tension of deionized water and the aforementioned solutions was 
measured using Attension Sigma 700 (Biolin Scientific, Linthicum, MD, USA). The 
Attention software calculates surface tension from force measurements of interaction 
of a probe (Wilhelmy plate) at the boundary between air and a liquid, i.e., the 
deionized water or the dispersant solution.  
A.1.2  Drug Wettability with the Dispersant Solutions  
Attension Sigma 700 set-up (Biolin Scientific, Linthicum, MD, USA) was used to 
study the penetration of water/aforementioned dispersant solutions into a packed 
powder bed of drug (ITZ) particles inside a cylindrical column and determine the 
drug powder wettability, based on the Washburn method. The assembly consists of a 
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sample holder in the form of a cylindrical metallic tube with small holes at the bottom 
as well as a hook at the top of the cover equipped with screw threads. About 0.8 g of 
ITZ powder was packed uniformly into the tube before each measurement. A filter 
paper was placed at the perforated end of the sample holder to support the drug 
powder sample. A petri dish containing deionized water/dispersant solution was 
placed below the perforated end of the holder on the mechanical platform.  
Upon contact of the sample holder with deionized water/dispersant solution, 
the liquid penetrated into the drug powder bed, while Attension Sigma 700 recorded 
the mass of liquid penetrated into the drug powder bed as a function of time. The 
contact angle for the deionized water/dispersant solution and drug can be determined 
using the modified Washburn equation, which provides a relationship between mass 
of liquid penetrated and contact angle θ, i.e., ( )TCM  cos
22 = , where T, M, η, ρ, 
and γ are time after contact, mass of the liquid penetrated into the drug powder bed, 
viscosity of the liquid, density of the liquid, and surface tension of the liquid, 
respectively. C is a characteristic parameter of the powder sample (ITZ powder in the 
current study), which could have been determined independently using a completely 
wetting liquid such as hexane, heptane, etc. Since ITZ was used as the only powder 
sample and C depends only on powder packing (identical packing procedure used), C 
is assumed to remain invariant for various dispersant solutions and deionized water 
studied. This approach allows us to eliminate C and calculate the ratio of cosθds/cosθw 
as a wetting effectiveness factor, in which θds is the contact angle between ITZ and 
the dispersant solution and θw is the contact angle between ITZ and deionized water. 
The wettability enhancement upon use of different dispersants (polymers/surfactant) 
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on the wetting of ITZ particles can be assessed by using this ratio or its logarithmic 
value, taking the wettability by water as a basis of comparison.  
Experimental liquid penetration data (M2 vs. T) for water and various 
dispersant solutions are presented in Figure A.1. Penetration of water into ITZ bed is 
extremely slow because of the highly hydrophobic (lipophilic) nature of ITZ, which 
is indicated by the log-partition coefficient (logP) value of 7.3. The use of dispersant 
in water increased the penetration rate (slope) markedly with respect to that of water. 
The slope was obtained by fitting the linear region of liquid penetration curve. Initial 
~20 s was not considered due to transient behavior, and data points that deviated from 
the linear region, which may correspond to structural change in the bed, were 
excluded. The modified Washburn equation fitted the data almost perfectly (R2 ≥ 
0.995). Using the slope, η, ρ, and γ for different dispersant solutions and water, 
log(cosθds/cosθw) was calculated. 
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Figure A.1   Temporal evolution of the liquid mass penetrated into a packed bed of 
as-received ITZ particles for (a) water only and (b) various dispersant solutions such 
as 0.2% SDS, 2.5% HPC SL, 2.5% HPC SL–SDS, 4.5% HPC SL, 4.5% HPC SSL, 
4.5% HPC L, 4.5% HPMC E3, and 4.5% PVP K30, as well as water. 
 
A.2. Impact of the Nanocomposite Particle Size on the ITZ Release 
 
We spray-dried the milled 4.5% HPC SL suspension (F4) using a larger nozzle tip 
size (1.2 mm vs. 0.6 mm) at a lower atomization pressure (1.5 bar vs. 2 bar) as 
compared with the baseline drying conditions. The so-formed nanocomposite 
particles were coarser (d50: 20.7 µm and d90: 40.6 µm) than the baseline 
nanocomposites (d50: 16.2 µm and d90: 32.3 µm). The dissolution profiles (Figure 
A.2) suggest that despite ~30% increase in d50 and d90, (i) both the coarser and 
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baseline nanocomposites exhibited fast, immediate release and (ii) there is no 
statistically significant impact of the nanocomposite particle size on ITZ release (ƒ1 = 
0.93 and ƒ2 = 91.8) within the particle size range studied. The differences are within 
the variability of drug assay and dissolution measurements.  
 
 
Figure A.2  Drug dissolution from the nanocomposites prepared via spray-drying 
with different processing conditions for the same milled ITZ suspension with 4.5% 
HPC SL (F4). 
 
A.3. Optical Microscopic Images of Redispersed Nanocomposites 
In the redispersion test, about 0.5 g of nanocomposites was weighed and dispersed in 
30 mL of 3 g/L aqueous SDS solution inside a 60 mL beaker and stirred at 400 rpm 
for 60 min with a paddle-stirrer (CAT R18, Scientific Instrument Center Limited, 
Winchester, UK). ~0.5 mL aliquot of redispersed sample was taken at 2, 10 and 60 
min while stirring, and particle size was measured using laser diffraction. At the same 
time, a droplet of each sample was dropped on a glass slide and dried immediately 
using a hot air gun (Steinel Professional, Bloomington, MN, USA). After drying, 
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Axio Scope.A1 polarizing microscope (Carl Zeiss Microscopy GmbH, Göttingen, 
Germany) was used to capture images of redispersed particles (Figure A3).  
When redispersion was slow and incomplete, the rounded/spherical 
nanocomposite particles appeared in the images even after 60 min (e.g., 2.5% HPC 
SL) because the nanocomposite matrix slowly eroded or did not erode at all, keeping 
the shape/morphology intact. On the other hand, fast redispersion was associated with 
complete erosion of the nanocomposite matrix, leading to disappearance of the 
nanocomposite particles in the images (e.g., 2.5% HPC SL–0.2% SDS). In the latter 
case, ITZ nanoparticles/clusters, whose sizes are mostly below the detection limit of 
the optical microscope, were released upon disappearance of the matrix. These 
findings are in good agreement with the laser diffraction measurements of the 
redispersed nanocomposites (see Figure 2.9 of the main text). 
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Figure A.3  Optical microscope images of the nanocomposites with various 
dispersants redispersed in 3 g/L SDS solution at 2 min, 10 min, and 60 min (marker 
size: 20 µm). 
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A.4 Difference (f1) and similarity (f2) factors for dissolution profiles of ITZ 
nanocomposites 
Table A.1  Difference (f1) and similarity (f2) factors for dissolution profiles of ITZ 
nanocomposites with various dispersants (F1, F2, F4‒F8) as compared with that of F3 
Difference and 
similarity factors 
Formulation ID 
F1 F2 F4* F5 F6 F7 F8 
f
1
 68.6 71.7 3.73 48.2 24.5 44.7 41.5 
f
2
 29.0 28.0 83.5 36.2 54.4 37.7 38.1 
*This formulation had statistically similar dissolution profile to that of F3. 
 
Table A.2  Difference (f1) and similarity (f2) factors for dissolution profiles of ITZ 
nanocomposites with various dispersants (F1, F2, F4‒F8) as compared with that of F4 
Difference and 
similarity factors 
Formulation ID 
F1 F2 F3* F5 F6 F7 F8 
f
1
 67.4 70.6 3.88 46.2 21.4 42.5 39.2 
f
2
 30.4 29.2 83.5 38.0 58.0 39.6 40.0 
*This formulation had statistically similar dissolution profile to that of F4. 
 
 
 280 
 
APPENDIX B 
DISSOLUTION ENHANCEMENT VIA DRUG HYBRID NANOCRYSTALS–
AMORPHOUS SOLID DISPERSIONS (HyNASDs) VS. ASDs DISSOLUTION  
 
In appendix B, particle size statistics of the spray-dried powders before and after 
redispersions is shown. To confirm the size of the redispersed drug particle, 
microscopic images are also shown here.  
B.1. Redispersion of the Spray-Dried Powders 
Aqueous redispersion of the spray-dried powders prepared using the nanosuspension-
based (W) feeds, i.e., the HyNASD particles, was performed following a previously 
established method (Bhakay et al., 2014; Li et al., 2016; Bilgili et al., 2018). About 
0.5 g spray-dried powder was weighed and dispersed in 30 mL of deionized water 
inside a 60 mL beaker and stirred at 500 rpm for 60 min with a paddle-stirrer (CAT 
R18, Scientific Instrument Center Limited, Winchester, UK). ~1.0 mL aliquot of 
redispersed sample was taken at 2, 10 and 60 min while stirring, and particle size was 
measured using laser diffraction (LS 13 320, Beckman Coulter, Miami, FL). At the 
same time, a droplet of each redispersed sample was dried immediately by dropping 
on a preheated glass slide on a hot plate at 100 °C. After drying, Zeiss Axio Scope.A1 
polarizing microscope (Carl Zeiss Microscopy GmbH, Göttingen, Germany) was 
used to capture images of the redispersed particles (Figure B.2). 30 mL of deionized 
water was selected purposefully so that the polymer in the sample dissolved fully, 
while releasing the GF nanoparticles/clusters with minimal dissolution. Indeed, the 
maximum amount of GF that can dissolve was estimated to be small (e.g., 1.1% of 
GF from W-Sol-1-3).  
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In general, GF nanoparticles with sizes similar to those particles in the milled 
suspensions were recovered within 2 min upon redispersion of the spray-dried 
powders (Figure B.1). Since the spray-dried powders contain SDS, they got wetted 
fast and their polymer content dissolved quickly, thus releasing GF 
nanoparticles/clusters. The particles released are mostly below the detection limit of 
the optical microscope; hence, they are barely discernible in the optical microscope 
images (see Figure B.2). Overall, both the laser diffraction measurements and the 
optical microscope images suggest that HyNASDs release drug nanoparticles fast 
upon redispersion in water.  
 
 
Figure B.1  Volume-based particle size statistics of the nanosuspension-based (W) 
feeds of GF–Sol and GF–HPC before spray drying (SD) (after 1 day of milling), after 
spray drying (HyNASDs), and the HyNASD particles redispersed in deionized water 
at 2 min, 10 min, and 60 min: (a) Median particle size d50, and (b) 90% passing size 
d90. All feeds have 2.5% w/v GF and 0.125% w/v SDS. 
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Figure B.2  Optical microscope images of the HyNASD particles, prepared using the 
nanosuspension-based (W) feeds, after redispersion in deionized water at 2 min, 10 
min, and 60 min (marker size: 20 µm). All feeds have 2.5% w/v GF and 0.125% w/v 
SDS. 
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APPENDIX C 
DRUG RELEASE FROM SPRAY-DRIED HYBRID NANOCRYSTAL–
AMORPHOUS SOLID DISPERSIONS (HyNASDs): IMPACT OF SDS 
 
In appendix C, detail of the modified Washburn method to measure the relative 
wetting effectiveness of the stabilizer/dispersant solutions are provided. Also, to 
confirm the size of the redispersed drug particles form the drug the polymeric matrix 
of the drug nanocomposites, microscopic images are also shown here.  
C.1  Details of the Characterization Methods Used for Drug Wettability 
Measurements 
Penetration of a liquid into a packed powder bed of a drug inside a cylindrical column 
allows for measurement of the drug powder wettability, based on the Washburn 
method (Hołownia et al., 2008; Washburn, 1921). The method presented here was 
adapted from Bilgili et al. (2018) and Li et al. (2017). In the current study, liquids and 
powder refer to GF (griseofulvin)-saturated aqueous solutions of 15% Soluplus 
(Sol)/HPC with 0.125% SDS or w/o SDS and GF powder, respectively. All 
percentages are (% w/w) with respective to deionized water. This polymer 
concentration was selected to measure the viscosity accurately in our viscometer set-
up instead of the maximum viscosity of 12.5% used in the stabilizer solutions. The 
solutions and deionized water were saturated with griseofulvin (GF) and stirred 
overnight. After overnight stirring, the saturated solutions were used for further 
characterization. The apparent shear viscosity and surface tension of the solutions 
were measured using R/S Plus Rheometer (Brookfield Engineering, Middleboro, MA, 
USA) and Attension Sigma 700 (Biolin Scientific, Linthicum, MD, USA) 
respectively, as described below; then, the drug wettability by the drug-saturated 
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solutions was quantified via a wetting effectiveness factor using the modified 
Washburn equation.  
C.1.1  Apparent Shear Viscosity of the Solutions 
The apparent shear viscosity of the GF-saturated aqueous solutions of the stabilizers 
was measured using an R/S Plus Rheometer (Brookfield Engineering, Middleboro, 
MA, USA) with a water jacket assembly Lauda Eco (Lauda-Brinkmann LP, Delran, 
NJ, USA). A coaxial cylinder (CC40) was used to provide a controlled shear rate on 
the samples and shear rate 0 to 1000 1/s for 60 s was used for all the samples. The 
temperature of the jacket was kept constant at 25 ± 0.5 °C. The raw data were 
analyzed using the Rheo 3000 software (Brookfield Engineering, Middleboro, MA, 
USA) of the equipment to obtain the apparent shear viscosity as a function of the 
shear rate. The apparent shear viscosity at ~100 1/s was used as a representative low 
shear rate value. The viscosity of water was taken from Korson et al. (1969).   
C.1.2  Surface Tension of the Solutions 
The surface tension of the GF-saturated deionized water and the GF-saturated 
aqueous solutions of the stabilizers was measured using Attension Sigma 700 (Biolin 
Scientific, Linthicum, MD, USA). The Attention software calculates surface tension 
from force measurements of interaction of a probe (Wilhelmy plate) at the boundary 
between air and a liquid.  
C.1.3  Drug Wettability with the Solutions 
Attension Sigma 700 set-up (Biolin Scientific, Linthicum, MD, USA) was used to 
study the penetration of GF-saturated deionized water/GF-saturated aqueous solutions 
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of the stabilizers into a packed powder bed of GF inside a cylindrical column and 
determine the GF wettability, based on the modified Washburn method. The 
assembly consists of a sample holder in the form of a cylindrical metallic tube with 
small holes at the bottom as well as a hook at the top of the cover equipped with 
screw threads. About 0.8 g of GF powder was packed uniformly into the tube before 
each measurement. A filter paper was placed at the perforated end of the sample 
holder to support the GF powder sample. A petri dish containing deionized 
water/stabilizer solution was placed below the perforated end of the holder on the 
mechanical platform.  
Upon contact of the sample holder with the liquid, the liquid penetrated the GF 
powder bed, while Attension Sigma 700 recorded the mass M of the liquid penetrated 
as a function of time T. The cosine of the contact angle θ for the GF-saturated 
deionized water/GF-saturated aqueous stabilizer solution and drug can be determined 
using the modified Washburn equation, which provides a relationship between liquid 
penetration rate and contact angle, via , where η, ρ, and γ stand for 
viscosity of the liquid, density of the liquid, and surface tension of the liquid, 
respectively. C is a characteristic parameter of the powder sample, which could have 
been determined independently using a completely wetting liquid such as hexane, 
heptane, etc. Since the same drug powder (GF) was used as the powder sample and C 
depends only on powder packing–size, C remained invariant for different liquids 
studied here. This allows us to calculate the ratio of cosθss/cosθw as a wetting 
effectiveness factor from the slopes of M2 vs. T for deionized water and the stabilizer 
solution. Here, θss is the contact angle between GF and the polymer–SDS stabilizer 
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solution and θw is the contact angle between GF and deionized water. The wettability 
enhancement upon the use of different stabilizers (polymers/surfactant) on the wetting 
of GF particles can be assessed by using this ratio, taking the wettability by water as a 
basis for comparison.    
Experimental liquid penetration data (M2 vs. T) for various liquids are presented 
in Figure C.1. The slope of the modified Washburn equation, i.e., , was 
obtained by fitting the linear region of the liquid penetration curve. Initial ~20 s was 
not considered due to transient behavior; data points that deviated from the linear 
region, which may correspond to structural change in the bed, were excluded. The 
modified Washburn equation fitted the data well (R2 ≥ 0.990). Using the slope for the 
different stabilizer solutions and water, cosθss/cosθw was calculated. The viscosity, 
surface tension, and calculated wetting effectiveness factor are reported in Table 4.3 
of the main text. 
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Figure C.1  Temporal evolution of the liquid mass penetrated into a packed bed of 
as-received GF particles for GF-saturated deionized (DI) water and various GF-
saturated aqueous solutions of 15% HPC/Sol with 0.125% SDS and without SDS.  
 
C.2  Optical Microscopic Images of the Spray-Dried Particles Redispersed in 
Deionized Water 
The redispersion test method was adapted from Bhakay et al. (2014) and Li et al. 
(2016). About 0.5 g of nanocomposites was weighed and dispersed in 30 mL of 
deionized water inside a 60 mL beaker and stirred at 500 rpm for 60 min with a 
paddle-stirrer (CAT R18, Scientific Instrument Center Limited, Winchester, UK). 30 
mL of deionized water was selected purposefully so that the polymer could dissolve 
fully, while releasing the GF nanoparticles/clusters with minimal GF dissolution. 
~1.0 mL aliquot of redispersed sample was taken at 2, 10 and 60 min while stirring, 
and particle size was measured using laser diffraction (see Figure 4.7 and 4.8 of the 
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main text). At the same time, a droplet of each redispersed sample was dried 
immediately by dropping on a preheated glass slide at 100 °C using a hot plate. After 
drying, Zeiss Axio Scope.A1 polarizing microscope (Carl Zeiss Microscopy GmbH, 
Göttingen, Germany) was used to capture images of the redispersed particles (Figure 
C.2).  
Since only few images were taken per sample during the redispersion, the 
microscopic imaging of the redispersion should could only provide qualitative 
information. When redispersion was slow and incomplete due to poor wettability of 
the spray-dried particles as in most W-formulations without SDS, the 
rounded/spherical particles with some aggregates appeared in the images even after 
60 min redispersion. The matrix of such particles appears to be slowly eroded, 
keeping the shape/morphology somewhat intact. On the other hand, fast redispersion 
was associated with complete erosion of the spray-dried particles (W-formulations 
with SDS), leading to their disappearance from the images. Note that due to inability 
of the microscope to detect nanoparticles, some images do not have many particles. 
The microscopic imaging of the redispersion shows that presence of SDS imparts 
excellent wettability to the spray-dried particles and helped to release drug 
nanoparticles faster than the particles w/o SDS. These findings are largely in good 
agreement with the laser diffraction measurements presented in Figure 4.7 and 4.8 of 
the main text.  
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Figure C.2  Microscopic images of the spray-dried particles with 1:1, 1:3, and 1:5 
GF:polymer (Sol/HPC) mass ratios having SDS and no SDS after redispersion in DI 
water at 2 min, 10 min, and 60 min (marker size: 20 µm). 
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APPENDIX D 
IMPACT OF SDS ON GRISEOFULVIN RELEASE FROM SPRAY-DRIED 
AMORPHOUS SOLID DISPERSIONS WITH HPC–SOLUPLUS  
 
In appendix D, detail of the modified Washburn method to measure the relative 
wetting effectiveness of the stabilizer/dispersant solutions are provided.  
D.1  Details of the Characterization Methods Used for Drug Wettability 
Measurements 
Penetration of a liquid into a packed powder bed of a drug inside a cylindrical column 
allows for measurement of the drug powder wettability, based on the Washburn 
method (Hołownia et al., 2008; Washburn, 1921). The method presented here was 
adapted from Bilgili et al. (2018) and Li et al. (2017). In the current study, liquids and 
powder refer to GF (griseofulvin)-saturated aqueous solutions of 15% Soluplus 
(Sol)/HPC with 0.125% SDS or w/o SDS and GF powder, respectively. All 
percentages are (% w/w) with respective to deionized water. This polymer 
concentration was selected to measure the viscosity accurately in our viscometer set-
up instead of the maximum viscosity of 12.5% used in the solutions. The solutions 
and deionized water were saturated with griseofulvin (GF) and stirred overnight. 
After overnight stirring, the saturated solutions were used for further characterization. 
The apparent shear viscosity and surface tension of the solutions were measured 
using R/S Plus Rheometer (Brookfield Engineering, Middleboro, MA, USA) and 
Attension Sigma 700 (Biolin Scientific, Linthicum, MD, USA) respectively, as 
described below; then, the drug wettability by the drug-saturated solutions was 
quantified via a wetting effectiveness factor using the modified Washburn equation.  
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D.1.1  Apparent Shear Viscosity of the Solutions 
The apparent shear viscosity of the GF-saturated aqueous solutions of the 
polymer/surfactant was measured using an R/S Plus Rheometer (Brookfield 
Engineering, Middleboro, MA, USA) with a water jacket assembly Lauda Eco 
(Lauda-Brinkmann LP, Delran, NJ, USA). A coaxial cylinder (CC40) was used to 
provide a controlled shear rate on the samples and shear rate 0 to 1000 1/s for 60 s 
was used for all the samples. The temperature of the jacket was kept constant at 25 ± 
0.5 °C. The raw data were analyzed using the Rheo 3000 software (Brookfield 
Engineering, Middleboro, MA, USA) of the equipment to obtain the apparent shear 
viscosity as a function of the shear rate. The apparent shear viscosity at ~100 1/s was 
used as a representative low shear rate value. The viscosity of water was taken from 
Korson et al. (1969).  
D.1.2  Surface Tension of the Solutions 
The surface tension of the GF-saturated deionized water and the GF-saturated aqueous 
solutions of the polymer/surfactant was measured using Attension Sigma 700 (Biolin 
Scientific, Linthicum, MD, USA). The Attention software calculates surface tension 
from force measurements of interaction of a probe (Wilhelmy plate) at the boundary 
between air and a liquid.  
D.1.3  Drug Wettability with the Solutions 
Attension Sigma 700 set-up (Biolin Scientific, Linthicum, MD, USA) was used to 
study the penetration of GF-saturated deionized water/GF-saturated aqueous solutions 
of the polymer/surfactant into a packed powder bed of GF inside a cylindrical column 
and determine the GF wettability, based on the modified Washburn method. The 
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assembly consists of a sample holder in the form of a cylindrical metallic tube with 
small holes at the bottom as well as a hook at the top of the cover equipped with 
screw threads. About 0.8 g of GF powder was packed uniformly into the tube before 
each measurement. A filter paper was placed at the perforated end of the sample 
holder to support the GF powder sample. A petri dish containing deionized water or 
polymer/surfactant solution was placed below the perforated end of the holder on the 
mechanical platform.  
Upon contact of the sample holder with the liquid, the liquid penetrated the 
GF powder bed, while Attension Sigma 700 recorded the mass M of the liquid 
penetrated as a function of time T. The cosine of the contact angle θ for the GF-
saturated deionized water/GF-saturated aqueous polymer/surfactant solution and drug 
can be determined using the modified Washburn equation, which provides a 
relationship between liquid penetration rate and contact angle, via , where η, ρ, and γ 
stand for viscosity of the liquid, density of the liquid, and 
surface tension of the liquid, respectively. C is a characteristic parameter of the 
powder sample, which could have been determined independently using a completely 
wetting liquid such as hexane, heptane, etc. Since the same drug powder (GF) was 
used as the powder sample and C depends only on powder packing–size, C remained 
invariant for different liquids studied here. This allows us to calculate the ratio of 
cosθss/cosθw as a wetting effectiveness factor from the slopes of M2 vs. T for 
deionized water and the polymer/surfactant solution. Here, θss is the contact angle 
between GF and the polymer–surfactant solution and θw is the contact angle between 
GF and deionized water. The wettability enhancement upon the use of different 
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polymers/surfactant on the wetting of GF particles can be assessed by using this ratio, 
taking the wettability by water as a basis for comparison.    
Experimental liquid penetration data (M2 vs. T) for various liquids are 
presented in Figure D.1. The slope of the modified Washburn equation, i.e., 
2 cosc    , was obtained by fitting the linear region of the liquid penetration 
curve. Initial ~20 s was not considered due to transient behavior; data points that 
deviated from the linear region, which may correspond to structural change in the 
bed, were excluded. The modified Washburn equation fitted the data well (R2 ≥ 
0.990). Using the slope for the different polymer/surfactant solutions and water, 
cosθss/cosθw was calculated. The viscosity, surface tension, and calculated wetting 
effectiveness factor are reported in Table 5.5 of the main text. 
 
 
Figure D.1  Temporal evolution of the liquid mass penetrated into a packed bed of as-
received GF particles for GF-saturated deionized (DI) water and various GF-saturated 
aqueous solutions of 15% HPC/Sol with 0.125% SDS and without SDS.  
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APPENDIX E 
SYNERGISTIC EFFECTS OF HYDROPHILIC POLYMER–AMPHIPHILIC 
POLYMER COMBINATION IN ENHANCING GRISEOFULVIN RELEASE 
FROM AMORPHOUS SOLID DISPERSIONS 
 
In appendix E, detail of the modified Washburn method to measure the relative 
wetting effectiveness of the stabilizer/dispersant solutions are provided.  
E.1  Details of the Characterization Methods used for Drug Wettability 
Measurements 
Penetration of a liquid into a packed powder bed of a drug inside a cylindrical column 
allows for measurement of the drug powder wettability, based on the Washburn 
method (Hołownia et al., 2008; Washburn, 1921). The method presented here was 
adapted from Bilgili et al. (2018) and Li et al. (2017). In the current study, liquids and 
powder refer to GF (griseofulvin)-saturated aqueous solutions of 15% single or 
binary polymers and GF powder, respectively. Single polymer includes Soluplus 
(Sol)/HPC/Kollidon VA64 (VA64). In the preparation of aqueous solutions of binary 
polymers, Sol–HPC were combined at 1:1 and 9:1 mass ratio, Sol–VA64 were 
combined at 1:5 and 5:1 ratio, and VA64–HPC were combined at 1:1 and 9:1 ratio. 
All percentages are (% w/w) with respective to deionized water. This polymer 
concentration was selected to measure the viscosity accurately in our viscometer set-
up instead of the maximum viscosity of 7.5% used in the polymer solutions. The 
solutions and deionized water were saturated with griseofulvin (GF) and stirred 
overnight. After overnight stirring, the saturated solutions were used for further 
characterization. The apparent shear viscosity and surface tension of the solutions 
were measured using R/S Plus Rheometer (Brookfield Engineering, Middleboro, MA, 
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USA) and Attension Sigma 700 (Biolin Scientific, Linthicum, MD, USA) 
respectively, as described below; then, the drug wettability by the drug-saturated 
solutions was quantified via a wetting effectiveness factor using the modified 
Washburn equation. 
E.1.1  Apparent Shear Viscosity of the Solutions 
The apparent shear viscosity of the GF-saturated aqueous solutions of the polymers 
was measured using an R/S Plus Rheometer (Brookfield Engineering, Middleboro, 
MA, USA) with a water jacket assembly Lauda Eco (Lauda-Brinkmann LP, Delran, 
NJ, USA). A coaxial cylinder (CC40) was used to provide a controlled shear rate on 
the samples and shear rate 0 to 1000 1/s for 60 s was used for all the samples. The 
temperature of the jacket was kept constant at 25 ± 0.5 °C. The raw data were 
analyzed using the Rheo 3000 software (Brookfield Engineering, Middleboro, MA, 
USA) of the equipment to obtain the apparent shear viscosity as a function of the 
shear rate. The apparent shear viscosity at ~100 1/s was used as a representative low 
shear rate value. The viscosity of water was taken from Korson et al. (1969). 
E.1.2  Surface Tension of the Solutions 
The surface tension of the GF-saturated deionized water and the GF-saturated 
aqueous solutions of the polymers was measured using Attension Sigma 700 (Biolin 
Scientific, Linthicum, MD, USA). The Attention software calculates surface tension 
from force measurements of interaction of a probe (Wilhelmy plate) at the boundary 
between air and a liquid.   
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E.1.3  Drug Wettability with the Solutions 
Attension Sigma 700 set-up (Biolin Scientific, Linthicum, MD, USA) was used to 
study the penetration of GF-saturated deionized water/GF-saturated aqueous solutions 
of the polymers into a packed powder bed of GF inside a cylindrical column and 
determine the GF wettability, based on the modified Washburn method. The 
assembly consists of a sample holder in the form of a cylindrical metallic tube with 
small holes at the bottom as well as a hook at the top of the cover equipped with 
screw threads. About 0.8 g of GF powder was packed uniformly into the tube before 
each measurement. A filter paper was placed at the perforated end of the sample 
holder to support the GF powder sample. A petri dish containing deionized 
water/polymer solution was placed below the perforated end of the holder on the 
mechanical platform.  
Upon contact of the sample holder with the liquid, the liquid penetrated the 
GF powder bed, while Attension Sigma 700 recorded the mass M of the liquid 
penetrated as a function of time T. The cosine of the contact angle θ for the GF-
saturated deionized water/GF-saturated aqueous polymer solution and drug can be 
determined using the modified Washburn equation, which provides a relationship 
between liquid penetration rate and contact angle, via , where η, 
ρ, and γ stand for viscosity of the liquid, density of the liquid, and surface tension of 
the liquid, respectively. C is a characteristic parameter of the powder sample, which 
could have been determined independently using a completely wetting liquid such as 
hexane, heptane, etc. Since the same drug powder (GF) was used as the powder 
sample and C depends only on powder packing–size, C remained invariant for 
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different liquids studied here. This allows us to calculate the ratio of cosθss/cosθw as a 
wetting effectiveness factor from the slopes of M2 vs. T for deionized water and the 
polymer solution. Here, θss is the contact angle between GF and the polymer/SDS 
solution and θw is the contact angle between GF and deionized water. The wettability 
enhancement upon the use of different polymers on the wetting of GF particles can be 
assessed by using this ratio, taking the wettability by water as a basis for comparison. 
Experimental liquid penetration data (M2 vs. T) for various liquids are 
presented in Figure E.1. The slope of the modified Washburn equation, i.e., 
2 cosc    , was obtained by fitting the linear region of the liquid penetration 
curve. Initial ~20 s was not considered due to transient behavior; data points that 
deviated from the linear region, which may correspond to structural change in the 
bed, were excluded. The modified Washburn equation fitted the data well (R2 ≥ 
0.990). Using the slope for various polymer solutions and water, cosθss/cosθw was 
calculated. The viscosity, surface tension, and calculated wetting effectiveness factor 
are reported in Table 6.4 of the main text. 
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Figure E.1  Temporal evolution of the liquid mass penetrated into a packed bed of as-
received GF particles for GF-saturated deionized (DI) water and various GF-saturated 
aqueous solutions of 15% HPC/Sol/VA64 (single polymer) and 15% Sol–HPC/VA64–
HPC/Sol–VA64 (binary polymer) with varied polymer1:polymer2 mass ratios.   
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APPENDIX F 
RELEASE OF ITRACONAZOLE FROM SPRAY-DRIED NANOCRYSTAL–
AMORPHOUS SOLID DISPERSIONS (HyNASDs) AND ASDs 
 
In appendix F, detail of the modified Washburn method to measure the relative 
wetting effectiveness of the stabilizer/dispersant solutions are provided.  
F.1  Details of the Characterization Methods used for Drug Wettability 
Measurements 
Penetration of a liquid into a packed powder bed of a drug inside a cylindrical column 
allows for measurement of the drug powder wettability, based on the Washburn 
method (Hołownia et al., 2008; Washburn, 1921). The method presented here was 
adapted from Bilgili et al. (2018) and Li et al. (2017). In the current study, liquids and 
powder refer to aqueous solutions of 15% polymers (Soluplus (Sol)/HPC/Kollidon 
VA64 (VA64)) and ITZ powder, respectively. All percentages are (% w/w) with 
respective to deionized water. This polymer concentration was selected to measure 
the viscosity accurately in our viscometer set-up instead of the maximum viscosity of 
7.5% used in the polymer solutions. After dissolving the polymers, the solutions were 
stirred overnight. After overnight stirring, the solutions were used for further 
characterization. The apparent shear viscosity and surface tension of the solutions 
were measured using R/S Plus Rheometer (Brookfield Engineering, Middleboro, MA, 
USA) and Attension Sigma 700 (Biolin Scientific, Linthicum, MD, USA) 
respectively, as described below; then, the drug wettability by the drug-saturated 
solutions was quantified via a wetting effectiveness factor using the modified 
Washburn equation. 
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F.1.1  Apparent Shear Viscosity of the Solutions 
The apparent shear viscosity of the aqueous solutions of the polymers was measured 
using an R/S Plus Rheometer (Brookfield Engineering, Middleboro, MA, USA) with 
a water jacket assembly Lauda Eco (Lauda-Brinkmann LP, Delran, NJ, USA). A 
coaxial cylinder (CC40) was used to provide a controlled shear rate on the samples 
and shear rate 0 to 1000 1/s for 60 s was used for all the samples. The temperature of 
the jacket was kept constant at 25 ± 0.5 °C. The raw data were analyzed using the 
Rheo 3000 software (Brookfield Engineering, Middleboro, MA, USA) of the 
equipment to obtain the apparent shear viscosity as a function of the shear rate. The 
apparent shear viscosity at ~100 1/s was used as a representative low shear rate value. 
The viscosity of water was taken from Korson et al. (1969). 
F.1.2  Surface Tension of the Solutions 
The surface tension of the water and the aqueous solutions of the polymers was 
measured using Attension Sigma 700 (Biolin Scientific, Linthicum, MD, USA). The 
Attention software calculates surface tension from force measurements of interaction 
of a probe (Wilhelmy plate) at the boundary between air and a liquid.   
F.1.3  Drug Wettability with the Solutions 
Attension Sigma 700 set-up (Biolin Scientific, Linthicum, MD, USA) was used to 
study the penetration of deionized water/ aqueous solutions of the polymers into a 
packed powder bed of ITZ inside a cylindrical column and determine the ITZ 
wettability, based on the modified Washburn method. The assembly consists of a 
sample holder in the form of a cylindrical metallic tube with small holes at the bottom 
as well as a hook at the top of the cover equipped with screw threads. About 0.8 g of 
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ITZ powder was packed uniformly into the tube before each measurement. A filter 
paper was placed at the perforated end of the sample holder to support the ITZ 
powder sample. A petri dish containing deionized water/polymer solution was placed 
below the perforated end of the holder on the mechanical platform.  
Upon contact of the sample holder with the liquid, the liquid penetrated the 
ITZ powder bed, while Attension Sigma 700 recorded the mass M of the liquid 
penetrated as a function of time T. The cosine of the contact angle θ for the deionized 
water/ aqueous polymer solution and drug can be determined using the modified 
Washburn equation, which provides a relationship between liquid penetration rate 
and contact angle, via , where η, ρ, and γ stand for viscosity of the 
liquid, density of the liquid, and surface tension of the liquid, respectively. C is a 
characteristic parameter of the powder sample, which could have been determined 
independently using a completely wetting liquid such as hexane, heptane, etc. Since 
the same drug powder (ITZ) was used as the powder sample and C depends only on 
powder packing–size, C remained invariant for different liquids studied here. This 
allows us to calculate the ratio of cosθss/cosθw as a wetting effectiveness factor from 
the slopes of M2 vs. T for deionized water and the polymer solution. Here, θss is the 
contact angle between ITZ and the polymer/SDS solution and θw is the contact angle 
between ITZ and deionized water. The wettability enhancement upon the use of 
different polymers on the wetting of ITZ particles can be assessed by using this ratio, 
taking the wettability by water as a basis for comparison. 
Experimental liquid penetration data (M2 vs. T) for various liquids are 
presented in Figure F.1. The slope of the modified Washburn equation, i.e., 
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2 cosc    , was obtained by fitting the linear region of the liquid penetration 
curve. Initial ~20 s was not considered due to transient behavior; data points that 
deviated from the linear region, which may correspond to structural change in the 
bed, were excluded. The modified Washburn equation fitted the data well (R2 ≥ 
0.990). Using the slope for various polymer solutions and water, cosθss/cosθw was 
calculated. The viscosity, surface tension, and calculated wetting effectiveness factor 
are reported in Table 7.4 of the main text. 
 
 
 
Figure F.1  Temporal evolution of the liquid mass penetrated into a packed bed of as-
received ITZ particles for (a) water only and (b) various aqueous solutions of 15% 
HPC/Sol/VA64–0.125% SDS or w/o SDS.  
 
(a) 
(b) 
 305 
 
REFERENCES  
Abdelwahed, W., Degobert, G., Fessi, H., 2006. Investigation of nanocapsules 
stabilization by amorphous excipients during freeze-drying and storage. Eur. 
J. Pharm. Biopharm. 63, 87–94. 
Adamson, A., Gast, A., 1997. Physical chemical of surfaces. John Wiley & Son, Inc., 
New York. 
Afolabi, A., Akinlabi, O., Bilgili, E., 2014. Impact of process parameters on the 
breakage kinetics of poorly water-soluble drugs during wet stirred media 
milling: a microhydrodynamic view. Eur. J. Pharm. Sci. 51, 75–86. 
Albadarin, A.B., Potter, C.B., Davis, M.T., Iqbal, J., Korde, S., Pagire, S., Paradkar, 
A., Walker, G., 2017. Development of stability-enhanced ternary solid 
dispersions via combinations of HPMCP and Soluplus® processed by hot 
melt extrusion. Int. J. Pharm. 532, 603–611. 
Aleandri, S., Schönenberger, M., Niederquell, A., Kuentz, M., 2018. Temperature-
induced surface effects on drug nanosuspensions. Pharm. Res. 35, 69. 
Aleem, O., Kuchekar, B., Pore, Y., Late, S., 2008. Effect of β-cyclodextrin and 
hydroxypropyl β-cyclodextrin complexation on physicochemical properties 
and antimicrobial activity of cefdinir. J. Pharm. Biomed. Anal. 47, 535–540. 
Alhalaweh, A., Alzghoul, A., Mahlin, D., Bergström, C.A., 2015. Physical stability of 
drugs after storage above and below the glass transition temperature: 
Relationship to glass-forming ability. Int. J. Pharm. 495, 312–317. 
Alonzo, D.E., Gao, Y., Zhou, D., Mo, H., Zhang, G.G., Taylor, L.S., 2011. 
Dissolution and precipitation behavior of amorphous solid dispersions. J. 
Pharm. Sci. 100, 3316–3331. 
Alonzo, D.E., Zhang, G.G., Zhou, D., Gao, Y., Taylor, L.S., 2010. Understanding the 
behavior of amorphous pharmaceutical systems during dissolution. Pharm. 
Res. 27, 608–618. 
Ambike, A.A., Mahadik, K., Paradkar, A., 2005. Spray-dried amorphous solid 
dispersions of simvastatin, a low T g drug: in vitro and in vivo evaluations. 
Pharm. Res. 22, 990–998. 
Azad, M., Afolabi, A., Bhakay, A., Leonardi, J., Davé, R., Bilgili, E., 2015a. 
Enhanced physical stabilization of fenofibrate nanosuspensions via wet co-
milling with a superdisintegrant and an adsorbing polymer. Eur. J. Pharm. 
Biopharm. 94, 372–385. 
 306 
 
Azad, M., Arteaga, C., Abdelmalek, B., Davé, R., Bilgili, E., 2015b. Spray drying of 
drug-swellable dispersant suspensions for preparation of fast-dissolving, high 
drug-loaded, surfactant-free nanocomposites. Drug Dev. Ind. Pharm. 41, 
1617–1631. 
Azad, M., Moreno, J., Bilgili, E., Davé, R., 2016. Fast dissolution of poorly water 
soluble drugs from fluidized bed coated nanocomposites: Impact of carrier 
size. Int. J. Pharm. 513, 319–331. 
Baghel, S., Cathcart, H., O'Reilly, N.J., 2016. Polymeric amorphous solid dispersions: 
a review of amorphization, crystallization, stabilization, solid-state 
characterization, and aqueous solubilization of biopharmaceutical 
classification system class II drugs. J. Pharm. Sci. 105, 2527–2544. 
Baird, J.A., Taylor, L.S., 2012. Evaluation of amorphous solid dispersion properties 
using thermal analysis techniques. Adv. Drug Delivery Rev. 64, 396-421. 
Baird, J.A., Van Eerdenbrugh, B., Taylor, L.S., 2010. A classification system to 
assess the crystallization tendency of organic molecules from undercooled 
melts. J. Pharm. Sci. 99, 3787–3806. 
Barthelmes, G., Pratsinis, S.E., Buggisch, H., 2003. Particle size distributions and 
viscosity of suspensions undergoing shear-induced coagulation and 
fragmentation. Chem. Eng. Sci. 58, 2893–2902. 
Basa, S., Muniyappan, T., Karatgi, P., Prabhu, R., Pillai, R., 2008. Production and in 
vitro characterization of solid dosage form incorporating drug nanoparticles. 
Drug Dev. Ind. Pharm. 34, 1209–1218. 
BASF, 2019. Crystallization inhibition for enhanced bioavailability – BASF 
functional solutions for solid and liquid formulations. 
Berglund, K.D., Przybycien, T.M., Tilton, R.D., 2003a. Coadsorption of sodium 
dodecyl sulfate with hydrophobically modified nonionic cellulose polymers. 
1. Role of polymer hydrophobic modification. Langmuir 19, 2705–2713. 
Berglund, K.D., Przybycien, T.M., Tilton, R.D., 2003b. Coadsorption of sodium 
dodecyl sulfate with hydrophobically modified nonionic cellulose polymers. 
2. Role of surface selectivity in adsorption hysteresis. Langmuir 19, 2714–
2721. 
Bernhardt, C., Reinsch, E., Husemann, K., 1999. The influence of suspension 
properties on ultra-fine grinding in stirred ball mills. Powder Technol. 105, 
357–361. 
Bhakay, A., Merwade, M., Bilgili, E., Dave, R.N., 2011. Novel aspects of wet milling 
for the production of microsuspensions and nanosuspensions of poorly water-
soluble drugs. Drug Dev. Ind. Pharm. 37, 963–976. 
 307 
 
Bhakay, A., Davé, R., Bilgili, E., 2013. Recovery of BCS Class II drugs during 
aqueous redispersion of core–shell type nanocomposite particles produced via 
fluidized bed coating. Powder Technol. 236, 221–234. 
Bhakay, A., Azad, M., Bilgili, E., Dave, R., 2014a. Redispersible fast dissolving 
nanocomposite microparticles of poorly water-soluble drugs. Int. J. Pharm. 
461, 367–379. 
Bhakay, A., Azad, M., Vizzotti, E., Dave, R.N., Bilgili, E., 2014b. Enhanced recovery 
and dissolution of griseofulvin nanoparticles from surfactant-free 
nanocomposite microparticles incorporating wet-milled swellable dispersants. 
Drug Dev. Ind. Pharm. 40, 1509–1522. 
Bhakay, A., Vizzotti, E., Li, M., Davé, R., Bilgili, E., 2016. Incorporation of 
fenofibrate nanoparticles prepared by melt emulsification into polymeric 
films. J. Pharm. Innovation 11, 53–63. 
Bhakay, A., Davé, R., Bilgili, E., 2018a. Quiescent and agitated redispersion as a tool 
for evaluating dispersant effectiveness in dissolution enhancement of drug-
laden nanocomposites. AAPS PharmSciTech 19, 436–447. 
Bhakay, A., Rahman, M., Dave, R.N., Bilgili, E., 2018b. Bioavailability enhancement 
of poorly water-soluble drugs via nanocomposites: Formulation processing 
aspects and challenges. Pharmaceutics 10. 
Bilgili, E., Hamey, R., Scarlett, B., 2004. Production of pigment nanoparticles using a 
wet stirred mill with polymeric media. China Particuology 2, 93–100. 
Bilgili, E., Afolabi, A., 2012. A combined microhydrodynamics–polymer adsorption 
analysis for elucidation of the roles of stabilizers in wet stirred media milling. 
Int. J. Pharm. 439, 193–206. 
Bilgili, E., Li, M., Afolabi, A., 2016. Is the combination of cellulosic polymers and 
anionic surfactants a good strategy for ensuring physical stability of BCS 
Class II drug nanosuspensions? Pharm. Dev. Technol. 21, 499–510. 
Bilgili, E., Rahman, M., Palacios, D., Arevalo, F., 2018. Impact of polymers on the 
aggregation of wet-milled itraconazole particles and their dissolution from 
spray-dried nanocomposites. Adv. Powder Technol. 9, 2941–2956. 
Bitterlich, A., Laabs, C., Busmann, E., Grandeury, A., Juhnke, M., Bunjes, H., 
Kwade, A., 2014. Challenges in nanogrinding of active pharmaceutical 
ingredients. Chem. Eng. Technol. 37, 840-846. 
Boateng, J.S., Matthews, K.H., Auffret, A.D., Humphrey, M.J., Stevens, H.N., 
Eccleston, G.M., 2009. In vitro drug release studies of polymeric freeze-dried 
wafers and solvent-cast films using paracetamol as a model soluble drug. Int. 
J. Pharm. 378, 66–72. 
 308 
 
Bose, S., Schenck, D., Ghosh, I., Hollywood, A., Maulit, E., Ruegger, C., 2012. 
Application of spray granulation for conversion of a nanosuspension into a 
dry powder form. Eur. J. Pharm. Sci. 47, 35–43. 
Brough, C., Williams, R., 2013. Amorphous solid dispersions and nano-crystal 
technologies for poorly water-soluble drug delivery. Int. J. Pharm. 453, 157–
166. 
Cerdeira, A.M., Mazzotti, M., Gander, B., 2010. Miconazole nanosuspensions: 
influence of formulation variables on particle size reduction and physical 
stability. Int. J. Pharm. 396, 210–218. 
Cerdeira, A.M., Mazzotti, M., Gander, B., 2013. Formulation and drying of 
miconazole and itraconazole nanosuspensions. Int. J. Pharm. 443, 209–220. 
Chang, T.-L., Zhan, H., Liang, D., Liang, J.F., 2015. Nanocrystal technology for drug 
formulation and delivery. Frontiers of Chemical Science and Engineering 9, 
1–14. 
Chaubal, M.V., Popescu, C., 2008. Conversion of nanosuspensions into dry powders 
by spray drying: a case study. Pharm. Res. 25, 2302–2308. 
Chen, Y., Liu, C., Chen, Z., Su, C., Hageman, M., Hussain, M., Haskell, R., 
Stefanski, K., Qian, F., 2015. Drug–polymer–water interaction and its 
implication for the dissolution performance of amorphous solid dispersions. 
Molecular Pharmaceutics 12, 576–589. 
Cheow, W.S., Ng, M.L.L., Kho, K., Hadinoto, K., 2011. Spray freeze-drying 
production of thermally sensitive polymeric nanoparticle aggregates for 
inhaled drug delivery: effect of freeze-drying adjuvants. Int. J. Pharm. 404, 
289–300. 
Chin, W.W.L., Parmentier, J., Widzinski, M., Tan, E.H., Gokhale, R., 2014. A brief 
literature and patent review of nanosuspensions to a final drug product. J. 
Pharm. Sci. 103, 2980–2999. 
Choi, J.-Y., Park, C.H., Lee, J., 2008. Effect of polymer molecular weight on 
nanocomminution of poorly soluble drug. Drug Delivery 15, 347–353. 
Choi, P., Kavassalis, T.A., Rudin, A., 1994. Estimation of Hansen solubility 
parameters for (hydroxyethyl) and (hydroxypropyl) cellulose through 
molecular simulation. Industrial & Engineering Chemistry Research 33, 
3154–3159. 
Costa, P., Lobo, J.M.S., 2001. Modeling and comparison of dissolution profiles. Eur. 
J. Pharm. Sci. 13, 123–133. 
 309 
 
Craig, D.Q., 2002. The mechanisms of drug release from solid dispersions in water-
soluble polymers. Int. J. Pharm. 231, 131–144. 
Crowley, K.J., Zografi, G., 2002. Water vapor absorption into amorphous 
hydrophobic drug/poly (vinylpyrrolidone) dispersions. J. Pharm. Sci. 91, 
2150-2165. 
Cui, Y., 2007. A material science perspective of pharmaceutical solids. Int. J. Pharm. 
339, 3-18. 
Dave, R.H., Patel, H.H., Donahue, E., Patel, A.D., 2013. To evaluate the change in 
release from solid dispersion using sodium lauryl sulfate and model drug 
sulfathiazole. Drug Dev. Ind. Pharm. 39, 1562–1572. 
Davis, M.T., Potter, C.B., Walker, G.M., 2018. Downstream processing of a ternary 
amorphous solid dispersion: The impacts of spray drying and hot melt 
extrusion on powder flow, compression and dissolution. Int. J. Pharm. 544, 
242–253. 
De Smet, L., Saerens, L., De Beer, T., Carleer, R., Adriaensens, P., Van Bocxlaer, J., 
Vervaet, C., Remon, J.P., 2014. Formulation of itraconazole nanococrystals 
and evaluation of their bioavailability in dogs. Eur. J. Pharm. Biopharm. 87, 
107–113. 
De Waard, H., Hinrichs, W., Frijlink, H., 2008. A novel bottom–up process to 
produce drug nanocrystals: controlled crystallization during freeze-drying. J. 
Controlled Release 128, 179–183. 
Di, L., Kerns, E.H., Carter, G.T., 2009. Drug-like property concepts in 
pharmaceutical design. Current Pharmaceutical Design 15, 2184–2194. 
Duddu, S.P., Sokoloski, T.D., 1995. Dielectric analysis in the characterization of 
amorphous pharmaceutical solids. 1. Molecular mobility in poly 
(vinylpyrrolidone)–water systems in the glassy state. J. Pharm. Sci. 84, 773-
776. 
Elder, D.P., Holm, R., de Diego, H.L., 2013. Use of pharmaceutical salts and 
cocrystals to address the issue of poor solubility. Int. J. Pharm. 453, 88–100. 
Eskin, D., Zhupanska, O., Hamey, R., Moudgil, B., Scarlett, B., 2005. 
Microhydrodynamics of stirred media milling. Powder Technol. 156, 95-102. 
Evertsson, H., Nilsson, S., 1997. Microviscosity in clusters of ethyl hydroxyethyl 
cellulose and sodium dodecyl sulfate formed in dilute aqueous solutions as 
determined with fluorescence probe techniques. Macromolecules 30, 2377–
2385. 
 310 
 
Ewing, A.V., Clarke, G.S., Kazarian, S.G., 2014. Stability of indomethacin with 
relevance to the release from amorphous solid dispersions studied with ATR-
FTIR spectroscopic imaging. Eur. J. Pharm. Sci. 60, 64-71. 
Fakes, M.G., Vakkalagadda, B.J., Qian, F., Desikan, S., Gandhi, R.B., Lai, C., Hsieh, 
A., Franchini, M.K., Toale, H., Brown, J., 2009. Enhancement of oral 
bioavailability of an HIV-attachment inhibitor by nanosizing and amorphous 
formulation approaches. Int. J. Pharm. 370, 167–174. 
Fasano, A., 1998. Innovative strategies for the oral delivery of drugs and peptides. 
Trends Biotechnol. 16, 152–157. 
Feng, T., Pinal, R., Carvajal, M.T., 2008. Process induced disorder in crystalline 
materials: differentiating defective crystals from the amorphous form of 
griseofulvin. J. Pharm. Sci. 97, 3207–3221. 
Forster, A., Hempenstall, J., Rades, T., 2001. Characterization of glass solutions of 
poorly water‐soluble drugs produced by melt extrusion with hydrophilic 
amorphous polymers. J. Pharm. Pharmacol. 53, 303–315. 
França, M.T., Pereira, R.N., Riekes, M.K., Pinto, J.M.O., Stulzer, H.K., 2018. 
Investigation of novel supersaturating drug delivery systems of 
chlorthalidone: The use of polymer-surfactant complex as an effective carrier 
in solid dispersions. Eur. J. Pharm. Sci. 111, 142–152. 
Galli, C., 2006. Experimental determination of the diffusion boundary layer width of 
micron and submicron particles. Int. J. Pharm. 313, 114–122. 
Ghazal, H.S., Dyas, A.M., Ford, J.L., Hutcheon, G.A., 2009. In vitro evaluation of the 
dissolution behaviour of itraconazole in bio-relevant media. Int. J. Pharm. 
366, 117–123. 
Ghosh, I., Bose, S., Vippagunta, R., Harmon, F., 2011. Nanosuspension for 
improving the bioavailability of a poorly soluble drug and screening of 
stabilizing agents to inhibit crystal growth. Int. J. Pharm. 409, 260–268. 
Greenhalgh, D.J., Williams, A.C., Timmins, P., York, P., 1999. Solubility parameters 
as predictors of miscibility in solid dispersions. J. Pharm. Sci. 88, 1182–1190. 
Gupta, R.B., Kompella, U.B., 2006. Nanoparticle technology for drug delivery. 
Taylor & Francis, New York, USA. 
Gupta, S., Kesarla, R., Omri, A., 2013. Formulation strategies to improve the 
bioavailability of poorly absorbed drugs with special emphasis on self-
emulsifying systems. ISRN Pharmaceutics 2013, 848043. 
 311 
 
Ha, E.-S., Baek, I.-h., Cho, W., Hwang, S.-J., Kim, M.-S., 2014. Preparation and 
evaluation of solid dispersion of atorvastatin calcium with Soluplus® by spray 
drying technique. Chem. Pharm. Bull. 62, 545–551. 
Hancock, B.C., Parks, M., 2000. What is the true solubility advantage for amorphous 
pharmaceuticals? Pharm. Res. 17, 397–404. 
Hancock, B.C., Zografi, G., 1994. The relationship between the glass transition 
temperature and the water content of amorphous pharmaceutical solids. 
Pharm. Res. 11, 471-477. 
Hauss, D.J., Fogal, S.E., Ficorilli, J.V., Price, C.A., Roy, T., Jayaraj, A.A., Keirns, 
J.J., 1998. Lipid‐based delivery systems for improving the bioavailability 
and lymphatic transport of a poorly water‐soluble LTB4 inhibitor. Journal of 
pharmaceutical sciences 87, 164-169. 
Hecq, J., Deleers, M., Fanara, D., Vranckx, H., Amighi, K., 2005. Preparation and 
characterization of nanocrystals for solubility and dissolution rate 
enhancement of nifedipine. Int. J. Pharm. 299, 167–177. 
Hoffman, J.D., 1958. Thermodynamic driving force in nucleation and growth 
processes. The Journal of Chemical Physics 29, 1192-1193. 
Hołownia, D., Kwiatkowska, I., Hupka, J., 2008. An investigation on wetting of 
porous materials. Physicochem. Prob. Miner. Process. 42, 251–262. 
Hou, Y., Shao, J., Fu, Q., Li, J., Sun, J., He, Z., 2017. Spray-dried nanocrystals for a 
highly hydrophobic drug: Increased drug loading, enhanced redispersity, and 
improved oral bioavailability. Int. J. Pharm. 516, 372–379. 
Huang, S., Williams, R.O., 2018. Effects of the preparation process on the properties 
of amorphous solid dispersions. AAPS PharmSciTech 19, 1971–1984. 
Humberstone, A.J., Charman, W.N., 1997. Lipid-based vehicles for the oral delivery 
of poorly water soluble drugs. Adv. Drug Delivery Rev. 25, 103–128. 
Ilevbare, G.A., Taylor, L.S., 2013. Liquid–liquid phase separation in highly 
supersaturated aqueous solutions of poorly water-soluble drugs: implications 
for solubility enhancing formulations. Crystal Growth & Design 13, 1497–
1509. 
Iurian, S., Bogdan, C., Tomuță, I., Szabó-Révész, P., Chvatal, A., Leucuța, S.E., 
Moldovan, M., Ambrus, R., 2017. Development of oral lyophilisates 
containing meloxicam nanocrystals using QbD approach. Eur. J. Pharm. Sci. 
104, 356–365. 
Jackson, M.J., Kestur, U.S., Hussain, M.A., Taylor, L.S., 2015. Dissolution of 
danazol amorphous solid dispersions: supersaturation and phase behavior as a 
 312 
 
function of drug loading and polymer type. Molecular Pharmaceutics 13, 223–
231. 
Janssens, S., Van den Mooter, G., 2009. Physical chemistry of solid dispersions. J. 
Pharm. Pharmacol. 61, 1571-1586. 
Jermain, S.V., Brough, C., Williams III, R.O., 2018. Amorphous solid dispersions 
and nanocrystal technologies for poorly water-soluble drug delivery–An 
update. Int. J. Pharm. 535, 379–392. 
Jung, H.J., Ahn, H.I., Park, J.Y., Ho, M.J., Lee, D.R., Cho, H.R., Park, J.S., Choi, 
Y.S., Kang, M.J., 2016. Improved oral absorption of tacrolimus by a solid 
dispersion with hypromellose and sodium lauryl sulfate. Int. J. Biol. 
Macromol. 83, 282–287. 
Jung, J.-Y., Yoo, S.D., Lee, S.-H., Kim, K.-H., Yoon, D.-S., Lee, K.-H., 1999. 
Enhanced solubility and dissolution rate of itraconazole by a solid dispersion 
technique. Int. J. Pharm. 187, 209–218. 
Junghanns, J.-U.A., Müller, R.H., 2008a. Nanocrystal technology, drug delivery and 
clinical applications. Int. J. Nanomed. 3, 295–309. 
Kagotani, R., Kinugawa, K., Nomura, M., Imanaka, H., Ishida, N., Imamura, K., 
2013. Improving the physical stability of freeze‐dried amorphous sugar 
matrices by compression at several hundreds MPa. Journal of pharmaceutical 
sciences 102, 2187-2197. 
Kayaert, P., Van den Mooter, G., 2012. Is the amorphous fraction of a dried 
nanosuspension caused by milling or by drying? A case study with Naproxen 
and Cinnarizine. Eur. J. Pharm. Biopharm. 81, 650–656. 
Keck, C.M., Müller, R.H., 2006. Drug nanocrystals of poorly soluble drugs produced 
by high pressure homogenisation. Eur. J. Pharm. Biopharm. 62, 3–16. 
Kemp, I.C., 2011. Fundamentals of energy analysis of dryers, Modern Drying 
Technology. WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim, 
Germany, pp. 1–46. 
Knieke, C., Azad, M., Davé, R., Bilgili, E., 2013. A study of the physical stability of 
wet media-milled fenofibrate suspensions using dynamic equilibrium curves. 
Chem. Eng. Res. Des. 91, 1245–1258. 
Kesisoglou, F., Panmai, S., Wu, Y., 2007. Nanosizing—oral formulation 
development and biopharmaceutical evaluation. Adv. Drug Delivery Rev. 59, 
631–644. 
Kesisoglou, F., Wu, Y., 2008. Understanding the effect of API properties on 
bioavailability through absorption modeling. AAPS J. 10, 516–525. 
 313 
 
Kim, D.S., Choi, H.G., Jin, S.G., 2018. Influence of Hydroxypropylmethylcellulose 
and Sodium Lauryl Sulfate on the Solubility and Dissolution of Sirolimus in 
Solvent‐evaporated Solid Dispersions. Bull. Korean Chem. Soc. 39, 778–
783. 
Kim, D.S., Choi, J.S., Kim, D.W., Kim, K.S., Seo, Y.G., Cho, K.H., Kim, J.O., Yong, 
C.S., Youn, Y.S., Lim, S.-J., 2016. Comparison of solvent⿿ wetted and 
kneaded l-sulpiride⿿ loaded solid dispersions: Powder characterization and in 
vivo evaluation. Int. J. Pharm. 511, 351–358. 
Kim, S., Lee, J., 2010. Effective polymeric dispersants for vacuum, convection and 
freeze drying of drug nanosuspensions. Int. J. Pharm. 397, 218–224. 
Kipp, J., 2004. The role of solid nanoparticle technology in the parenteral delivery of 
poorly water-soluble drugs. Int. J. Pharm. 284, 109–122. 
Knieke, C., Azad, M., Davé, R., Bilgili, E., 2013. A study of the physical stability of 
wet media-milled fenofibrate suspensions using dynamic equilibrium curves. 
Chem. Eng. Res. Des. 91, 1245–1258. 
Knieke, C., Rawtani, A., Davé, R.N., 2014. Concentrated fenofibrate nanoparticle 
suspensions from melt emulsification for enhanced drug dissolution. Chem. 
Eng. Technol. 37, 157–167. 
Kolter, K., Karl, M., Gryczke, A., Ludwigshafen am Rhein, B., 2012. Hot-melt 
extrusion with BASF pharma polymers: extrusion compendium. BASF. 
Konnerth, C., Braig, V., Ito, A., Schmidt, J., Lee, G., Peukert, W., 2017. Formation of 
mefenamic acid nanocrystals with improved dissolution characteristics. Chem. 
Ing. Tech. 89, 1060–1071. 
Konno, H., Handa, T., Alonzo, D.E., Taylor, L.S., 2008. Effect of polymer type on 
the dissolution profile of amorphous solid dispersions containing felodipine. 
Eur. J. Pharm. Biopharm. 70, 493–499. 
Korson, L., Drost-Hansen, W., Millero, F.J., 1969. Viscosity of water at various 
temperatures. J. Phys. Chem. 73, 34–39. 
Kothari, K., Ragoonanan, V., Suryanarayanan, R., 2015. The role of polymer 
concentration on the molecular mobility and physical stability of nifedipine 
solid dispersions. Molecular Pharmaceutics 12, 1477–1484. 
Krull, S.M., Ma, Z., Li, M., Davé, R.N., Bilgili, E., 2016. Preparation and 
characterization of fast dissolving pullulan films containing BCS class II drug 
nanoparticles for bioavailability enhancement. Drug Dev. Ind. Pharm. 42, 
1073–1085. 
 314 
 
Krull, S.M., Susarla, R., Afolabi, A., Li, M., Ying, Y., Iqbal, Z., Bilgili, E., Davé, 
R.N., 2015. Polymer strip films as a robust, surfactant-free platform for 
delivery of BCS Class II drug nanoparticles. Int. J. Pharm. 489, 45–57. 
Kumar, S., Jog, R., Shen, J., Zolnik, B., Sadrieh, N., Burgess, D.J., 2015a. In vitro 
and in vivo performance of different sized spray-dried crystalline itraconazole. 
J. Pharm. Sci. 104, 3018–3028. 
Kumar, S., Shen, J., Zolnik, B., Sadrieh, N., Burgess, D.J., 2015b. Optimization and 
dissolution performance of spray-dried naproxen nano-crystals. Int. J. Pharm. 
486, 159–166. 
Kumar, S., Xu, X., Gokhale, R., Burgess, D.J., 2014. Formulation parameters of 
crystalline nanosuspensions on spray drying processing: a DoE approach. Int. 
J. Pharm. 464, 34–45. 
Kushner, L.M., Duncan, B.C., Hoffman, J.I., 1952. A viscometric study of the 
micelles of sodium dodecyl sulfate in dilute solutions. J. Res. Nat. Bur. Stand. 
49, 85–90. 
Lakshmi, P., Kumar, G.A., 2010. Nanosuspension technology: A review. Int. J. 
Pharm. Sci. 2, 35–40. 
Langham, Z.A., Booth, J., Hughes, L.P., Reynolds, G.K., Wren, S.A., 2012. 
Mechanistic insights into the dissolution of spray‐dried amorphous solid 
dispersions. Journal of pharmaceutical sciences 101, 2798-2810. 
Layre, A.-M., Couvreur, P., Richard, J., Requier, D., Eddine Ghermani, N., Gref, R., 
2006. Freeze-drying of composite core-shell nanoparticles. Drug Dev. Ind. 
Pharm. 32, 839–846. 
Lebhardt, T., Roesler, S., Uusitalo, H.P., Kissel, T., 2011. Surfactant-free 
redispersible nanoparticles in fast-dissolving composite microcarriers for dry-
powder inhalation. Eur. J. Pharm. Biopharm. 78, 90–96. 
Lee, J., 2003. Drug nano‐and microparticles processed into solid dosage forms: 
physical properties. J. Pharm. Sci. 92, 2057–2068. 
Lee, J., Choi, J.-Y., Park, C., 2008. Characteristics of polymers enabling nano-
comminution of water-insoluble drugs. Int. J. Pharm. 355, 328–336. 
Lee, M.K., Kim, M.Y., Kim, S., Lee, J., 2009. Cryoprotectants for freeze drying of 
drug nano‐suspensions: Effect of freezing rate. J. Pharm. Sci. 98, 4808–
4817. 
Leleux, J., Williams, R.O., 2014. Recent advancements in mechanical reduction 
methods: particulate systems. Drug Dev. Ind. Pharm. 40, 289–300. 
 315 
 
Letchford, K., Burt, H., 2007. A review of the formation and classification of 
amphiphilic block copolymer nanoparticulate structures: micelles, 
nanospheres, nanocapsules and polymersomes. Eur. J. Pharm. Biopharm. 65, 
259–269. 
Leuner, C., Dressman, J., 2000. Improving drug solubility for oral delivery using 
solid dispersions. Eur. J. Pharm. Biopharm. 50, 47-60. 
Li, M., Yaragudi, N., Afolabi, A., Dave, R., Bilgili, E., 2015. Sub-100 nm drug 
particle suspensions prepared via wet milling with low bead contamination 
through novel process intensification. Chem. Eng. Sci. 130, 207–220. 
Li, M., Azad, M., Davé, R., Bilgili, E., 2016a. Nanomilling of drugs for 
bioavailability enhancement: a holistic formulation-process perspective. 
Pharmaceutics 8, 27. 
Li, M., Lopez, N., Bilgili, E., 2016b. A study of the impact of polymer–surfactant in 
drug nanoparticle coated pharmatose composites on dissolution performance. 
Adv. Powder Technol. 27, 1625–1636. 
Li, M., Zhang, L., Davé, R.N., Bilgili, E., 2016c. An intensified vibratory milling 
process for enhancing the breakage kinetics during the preparation of drug 
nanosuspensions. AAPS PharmSciTech 17, 389–399. 
Li, M., Ioannidis, N., Gogos, C., Bilgili, E., 2017. A comparative assessment of 
nanocomposites vs. amorphous solid dispersions prepared via nanoextrusion 
for drug dissolution enhancement. Eur. J. Pharm. Biopharm. 119, 68–80. 
Li, M., Alvarez, P., Orbe, P., Bilgili, E., 2018a. Multi-faceted characterization of wet-
milled griseofulvin nanosuspensions for elucidation of aggregation state and 
stabilization mechanisms. AAPS PharmSciTech 19, 1789–1801. 
Li, M., Suriel, I., Vekaria, J., Proske, J., Orbe, P., Armani, M., Dave, R., Bilgili, E., 
2018b. Impact of dispersants on dissolution of itraconazole from drug-loaded, 
surfactant-free, spray-dried nanocomposites. Powder Technol. 339, 281–295. 
Lipinski, C., 2002. Poor aqueous solubility—an industry wide problem in drug 
discovery. Am. Pharm. Rev. 5, 82–85. 
Liu, C., Chen, Z., Chen, Y., Lu, J., Li, Y., Wang, S., Wu, G., Qian, F., 2016. 
Improving oral bioavailability of sorafenib by optimizing the “Spring” and 
“Parachute” based on molecular interaction mechanisms. Molecular 
Pharmaceutics 13, 599–608. 
Liu, T., Müller, R.H., Möschwitzer, J.P., 2018. Production of drug nanosuspensions: 
effect of drug physical properties on nanosizing efficiency. Drug Dev. Ind. 
Pharm. 44, 233–242. 
 316 
 
Liversidge, G.G., Cundy, K.C., 1995. Particle size reduction for improvement of oral 
bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of 
nanocrystalline danazol in beagle dogs. Int. J. Pharm. 125, 91–97. 
Lu, Y., Tang, N., Lian, R., Qi, J., Wu, W., 2014. Understanding the relationship 
between wettability and dissolution of solid dispersion. Int. J. Pharm. 465, 25–
31. 
Luebbert, C., Huxoll, F., Sadowski, G., 2017. Amorphous-amorphous phase 
separation in API/polymer formulations. Molecules 22, 296. 
Malamatari, M., Taylor, K.M., Malamataris, S., Douroumis, D., Kachrimanis, K., 
2018. Pharmaceutical nanocrystals: prodcution by wet media milling and 
applications. Drug Discovery Today 23, 534–547. 
Marsac, P.J., Konno, H., Taylor, L.S., 2006. A comparison of the physical stability of 
amorphous felodipine and nifedipine systems. Pharm. Res. 23, 2306-2316. 
Matsui, K., Tsume, Y., Amidon, G.E., Amidon, G.L., 2016. The evaluation of in vitro 
drug dissolution of commercially available oral dosage forms for itraconazole 
in gastrointestinal simulator with biorelevant media. J. Pharm. Sci. 105, 2804–
2814. 
Medarević, D., Djuriš, J., Ibrić, S., Mitrić, M., Kachrimanis, K., 2018. Optimization 
of formulation and process parameters for the production of carvedilol 
nanosuspension by wet media milling. Int. J. Pharm. 540, 150–161. 
Meng, F., Trivino, A., Prasad, D., Chauhan, H., 2015. Investigation and correlation of 
drug polymer miscibility and molecular interactions by various approaches for 
the preparation of amorphous solid dispersions. Eur. J. Pharm. Sci. 71, 12–24. 
Merisko-Liversidge, E., Liversidge, G.G., 2011. Nanosizing for oral and parenteral 
drug delivery: a perspective on formulating poorly-water soluble compounds 
using wet media milling technology. Adv. Drug Delivery Rev. 63, 427–440. 
Merisko-Liversidge, E., Liversidge, G.G., Cooper, E.R., 2003. Nanosizing: a 
formulation approach for poorly-water-soluble compounds. Eur. J. Pharm. 
Sci. 18, 113–120. 
Merisko-Liversidge, E.M., Liversidge, G.G., 2008. Drug nanoparticles: formulating 
poorly water-soluble compounds. Toxicologic Pathology 36, 43–48. 
Mistry, P., Mohapatra, S., Gopinath, T., Vogt, F.G., Suryanarayanan, R., 2015. Role 
of the strength of drug–polymer interactions on the molecular mobility and 
crystallization inhibition in ketoconazole solid dispersions. Molecular 
Pharmaceutics 12, 3339–3350. 
 317 
 
Mittal, G., Sahana, D., Bhardwaj, V., Kumar, M.R., 2007. Estradiol loaded PLGA 
nanoparticles for oral administration: effect of polymer molecular weight and 
copolymer composition on release behavior in vitro and in vivo. J. Controlled 
Release 119, 77–85. 
Monteiro, A., Afolabi, A., Bilgili, E., 2013. Continuous production of drug 
nanoparticle suspensions via wet stirred media milling: a fresh look at the 
Rehbinder effect. Drug Dev. Ind. Pharm. 39, 266–283. 
Moroi, Y., Motomura, K., Matuura, R., 1974. The critical micelle concentration of 
sodium dodecyl sulfate-bivalent metal dodecyl sulfate mixtures in aqueous 
solutions. J. Colloid Interface Sci. 46, 111–117. 
Morrison, I.D., Ross, S., 2002. Colloidal Dispersions. Wiley-Interscience, New York, 
USA. 
Müller, R.H., Gohla, S., Keck, C.M., 2011. State of the art of nanocrystals–special 
features, production, nanotoxicology aspects and intracellular delivery. Eur. J. 
Pharm. Biopharm. 78, 1–9. 
Müller, R.H., Benita, S., Böhm, B.H., 1998. Nanosuspensions, in: Benita, S., Böhm, 
B.H. (Ed.), Emulsions and nanosuspensions for the formulation of poorly 
soluble drugs. Medpharm Scientific, Stuttgart, Germany, pp. 149–173. 
Müller, R.H., Peters, K., 1998. Nanosuspensions for the formulation of poorly soluble 
drugs: I. Preparation by a size-reduction technique. Int. J. Pharm. 160, 229–
237. 
Müllertz, A., Ogbonna, A., Ren, S., Rades, T., 2010. New perspectives on lipid and 
surfactant based drug delivery systems for oral delivery of poorly soluble 
drugs. J. Pharm. Pharmacol. 62, 1622–1636. 
Muster, T.H., Prestidge, C.A., 2005. Water adsorption kinetics and contact angles of 
pharmaceutical powders. J. Pharm. Sci. 94, 861–872. 
Nakagami, H., 1991. Solid dispersions of indomethacin and griseofulvin in non-
porous fumed silicon dioxide, prepared by melting. Chem. Pharm. Bull. 39, 
2417–2421. 
Newman, A., Engers, D., Bates, S., Ivanisevic, I., Kelly, R.C., Zografi, G., 2008. 
Characterization of amorphous API: Polymer mixtures using X‐ray powder 
diffraction. J. Pharm. Sci. 97, 4840–4856. 
Niwa, T., Danjo, K., 2013. Design of self-dispersible dry nanosuspension through wet 
milling and spray freeze-drying for poorly water-soluble drugs. Eur. J. Pharm. 
Sci. 50, 272–281. 
 318 
 
Niwa, T., Miura, S., Danjo, K., 2011. Design of dry nanosuspension with highly 
spontaneous dispersible characteristics to develop solubilized formulation for 
poorly water-soluble drugs. Pharm. Res. 28, 2339–2349. 
Noyes, A.A., Whitney, W.R., 1897a. The rate of solution of solid substances in their 
own solutions. J. Am. Chem. Soc. 19, 930–934. 
Paradkar, A., Ambike, A.A., Jadhav, B.K., Mahadik, K., 2004. Characterization of 
curcumin–PVP solid dispersion obtained by spray drying. Int. J. Pharm. 271, 
281–286. 
Parmentier, J., Tan, E.H., Low, A., Möschwitzer, J.P., 2017. Downstream drug 
product processing of itraconazole nanosuspension: Factors influencing drug 
particle size and dissolution from nanosuspension-layered beads. Int. J. 
Pharm. 524, 443–453. 
Peeters, J., Neeskens, P., Tollenaere, J.P., Van Remoortere, P., Brewster, M.E., 2002. 
Characterization of the interaction of 2‐hydroxypropyl‐β‐cyclodextrin 
with itraconazole at pH 2, 4, and 7. J. Pharm. Sci. 91, 1414–1422. 
Peltonen, L., Hirvonen, J., 2010. Pharmaceutical nanocrystals by nanomilling: 
Critical process parameters, particle fracturing and stabilization methods. J. 
Pharm. Pharmacol. 62, 1569–1579. 
Peltonen, L., Hirvonen, J., 2018. Drug nanocrystals–Versatile option for formulation 
of poorly soluble materials. Int. J. Pharm. 537, 73–83. 
Peppas, N., 1985. Analysis of Fickian and non-Fickian drug release from polymers. 
Pharm. Acta Helv. 60, 110–111. 
Ploehn, H.J., Russel, W.B., 1990. Interactions between colloidal particles and soluble 
polymers. Adv. Chem. Eng. 15, 137–228. 
Poozesh, S., Bilgili, E., 2019. Scale-up of pharmaceutical spray drying using scale-up 
rules: A review. Int. J. Pharm. 562, 271–292. 
Prasad, D., Chauhan, H., Atef, E., 2016. Role of molecular interactions for synergistic 
precipitation inhibition of poorly soluble drug in supersaturated drug–
polymer–polymer ternary solution. Molecular Pharmaceutics 13, 756–765. 
Qian, F., Huang, J., Hussain, M.A., 2010. Drug–polymer solubility and miscibility: 
stability consideration and practical challenges in amorphous solid dispersion 
development. J. Pharm. Sci. 99, 2941–2947. 
Rabinow, B.E., 2004. Nanosuspensions in drug delivery. Nature reviews. Drug 
discovery 3, 785. 
 319 
 
Raghavan, S., Trividic, A., Davis, A., Hadgraft, J., 2001. Crystallization of 
hydrocortisone acetate: influence of polymers. Int. J. Pharm. 212, 213–221. 
Rahman, Z., Zidan, A.S., Samy, R., Sayeed, V.A., Khan, M.A., 2012. Improvement 
of physicochemical properties of an antiepileptic drug by salt engineering. 
AAPS PharmSciTech 13, 793–801. 
Riddick, T.M., 1968. Control of colloid stability through zeta potential. Zeta-Meter 
Inc. via Livingston Publishing Company, Lynnewood, PA, USA. 
Ritger, P.L., Peppas, N.A., 1987a. A simple equation for description of solute release 
I. Fickian and non-fickian release from non-swellable devices in the form of 
slabs, spheres, cylinders or discs. J. Controlled Release 5, 23–36. 
Ritger, P.L., Peppas, N.A., 1987b. A simple equation for description of solute release 
II. Fickian and anomalous release from swellable devices. J. Controlled 
Release 5, 37–42. 
Rowe, R., 1986. The effect of the molecular weight of ethyl cellulose on the drug 
release properties of mixed films of ethyl cellulose and 
hydroxypropylmethylcellulose. Int. J. Pharm. 29, 37–41. 
Rumondor, A.C., Stanford, L.A., Taylor, L.S., 2009. Effects of polymer type and 
storage relative humidity on the kinetics of felodipine crystallization from 
amorphous solid dispersions. Pharm. Res. 26, 2599–2606. 
Rumondor, A.C., Dhareshwar, S.S., Kesisoglou, F., 2016. Amorphous solid 
dispersions or prodrugs: complementary strategies to increase drug 
absorption. J. Pharm. Sci. 105, 2498–2508. 
Ryde, N.P., Ruddy, S.B., 2002. Solid dose nanoparticulate compositions comprising a 
synergistic combination of a polymeric surface stabilizer and dioctyl sodium 
sulfosuccinate. Google Patents. 
Sarnes, A., Kovalainen, M., Häkkinen, M.R., Laaksonen, T., Laru, J., Kiesvaara, J., 
Ilkka, J., Oksala, O., Rönkkö, S., Järvinen, K., 2014. Nanocrystal-based per-
oral itraconazole delivery: Superior in vitro dissolution enhancement versus 
Sporanox® is not realized in in vivo drug absorption. J. Controlled Release 
180, 109–116. 
Sarode, A., Wang, P., Cote, C., Worthen, D.R., 2013. Low-viscosity 
hydroxypropylcellulose (HPC) grades SL and SSL: versatile pharmaceutical 
polymers for dissolution enhancement, controlled release, and pharmaceutical 
processing. AAPS PharmSciTech 14, 151–159. 
Schersch, K., Betz, O., Garidel, P., Muehlau, S., Bassarab, S., Winter, G., 2010. 
Systematic investigation of the effect of lyophilizate collapse on 
 320 
 
pharmaceutically relevant proteins I: Stability after freeze‐drying. Journal of 
pharmaceutical sciences 99, 2256-2278. 
Schönert, K., 1988. Size Reduction (Fundamentals)—Chap. 1, Ullmann’s 
Encyclopedia of Industrial Chemistry, vol. B2. Vch Verlagsgesellschaft, 
Weinheim. 
Sepassi, S., Goodwin, D., Drake, A., Holland, S., Leonard, G., Martini, L., Lawrence, 
M., 2007. Effect of polymer molecular weight on the production of drug 
nanoparticles. J. Pharm. Sci. 96, 2655–2666. 
Serajuddin, A., 1999. Solid dispersion of poorly water‐soluble drugs: Early 
promises, subsequent problems, and recent breakthroughs. J. Pharm. Sci. 88, 
1058–1066. 
Shah, D.A., Patel, M., Murdande, S.B., Dave, R.H., 2016. Influence of spray drying 
and dispersing agent on surface and dissolution properties of griseofulvin 
micro and nanocrystals. Drug Dev. Ind. Pharm. 42, 1842–1850. 
Shah, N., Iyer, R.M., Mair, H.J., Choi, D.S., Tian, H., Diodone, R., Fähnrich, K., 
Pabst‐Ravot, A., Tang, K., Scheubel, E., 2013. Improved human 
bioavailability of vemurafenib, a practically insoluble drug, using an 
amorphous polymer‐stabilized solid dispersion prepared by a 
solvent‐controlled coprecipitation process. J. Pharm. Sci. 102, 967-981. 
Shamblin, S.L., Tang, X., Chang, L., Hancock, B.C., Pikal, M.J., 1999. 
Characterization of the time scales of molecular motion in pharmaceutically 
important glasses. The Journal of Physical Chemistry B 103, 4113-4121. 
Sharma, V., Yadav, O., Singh, J., 1996. Physicochemical studies of aqueous sodium 
dodecyl sulphate solutions in pyridine and isomeric picolines. Colloids and 
Surfaces A: Physicochemical and Engineering Aspects 110, 23–35. 
Shchekin, A., Rusanov, A., 2008. Generalization of the Gibbs–Kelvin–Köhler and 
Ostwald–Freundlich equations for a liquid film on a soluble nanoparticle. The 
Journal of chemical physics 129, 154116. 
Shegokar, R., Müller, R.H., 2010. Nanocrystals: industrially feasible multifunctional 
formulation technology for poorly soluble actives. Int. J. Pharm. 399, 129–
139. 
Shete, G., Jain, H., Punj, D., Prajapat, H., Akotiya, P., Bansal, A.K., 2016. Stabilizers 
used in nano-crystal based drug delivery systems. J. Excipients and Food 
Chem. 5, 184–200. 
 321 
 
Shibata, Y., Fujii, M., Suzuki, A., Koizumi, N., Kanada, K., Yamada, M., Watanabe, 
Y., 2014. Effect of storage conditions on the recrystallization of drugs in solid 
dispersions with crospovidone. Pharm. Dev. Technol. 19, 468–474. 
Sievens-Figueroa, L., Bhakay, A., Jerez-Rozo, J.I., Pandya, N., Romañach, R.J., 
Michniak-Kohn, B., Iqbal, Z., Bilgili, E., Davé, R.N., 2012. Preparation and 
characterization of hydroxypropyl methyl cellulose films containing stable 
BCS Class II drug nanoparticles for pharmaceutical applications. Int. J. 
Pharm. 423, 496–508. 
Singh, A., Van den Mooter, G., 2016. Spray drying formulation of amorphous solid 
dispersions. Adv. Drug Delivery Rev. 100, 27–50. 
Singh, S.K., Srinivasan, K., Gowthamarajan, K., Singare, D.S., Prakash, D., Gaikwad, 
N.B., 2011. Investigation of preparation parameters of nanosuspension by top-
down media milling to improve the dissolution of poorly water-soluble 
glyburide. Eur. J. Pharm. Biopharm. 78, 441–446. 
Six, K., Verreck, G., Peeters, J., Brewster, M., Van den Mooter, G., 2004. Increased 
physical stability and improved dissolution properties of itraconazole, a class 
II drug, by solid dispersions that combine fast‐and slow‐dissolving 
polymers. J. Pharm. Sci. 93, 124–131. 
Sjökvist, E., Nyström, C., Aldén, M., 1991. Physicochemical aspects of drug release. 
XIII. The effect of sodium dodecyl sulphate additions on the structure and 
dissolution of a drug in solid dispersions. Int. J. Pharm. 69, 53–62. 
Sommer, M., Stenger, F., Peukert, W., Wagner, N., 2006. Agglomeration and 
breakage of nanoparticles in stirred media mills—a comparison of different 
methods and models. Chem. Eng. Sci. 61, 135–148. 
Srinarong, P., de Waard, H., Frijlink, H.W., Hinrichs, W.L., 2011. Improved 
dissolution behavior of lipophilic drugs by solid dispersions: the production 
process as starting point for formulation considerations. Expert Opin. Drug 
Delivery 8, 1121–1140. 
Srivalli, K.M.R., Mishra, B., 2016. Improved aqueous solubility and 
antihypercholesterolemic activity of ezetimibe on formulating with 
hydroxypropyl-β-cyclodextrin and hydrophilic auxiliary substances. AAPS 
PharmSciTech 17, 272–283. 
Sun, W., Ni, R., Zhang, X., Li, L.C., Mao, S., 2015. Spray drying of a poorly water-
soluble drug nanosuspension for tablet preparation: formulation and process 
optimization with bioavailability evaluation. Drug Dev. Ind. Pharm. 41, 927–
933. 
 322 
 
Susarla, R., Afolabi, A., Patel, D., Bilgili, E., Davé, R.N., 2015. Novel use of 
superdisintegrants as viscosity enhancing agents in biocompatible polymer 
films containing griseofulvin nanoparticles. Powder Technol. 285, 25–33. 
Suzuki, H., Sunada, H., 1998. Influence of water-soluble polymers on the dissolution 
of nifedipine solid dispersions with combined carriers. Chem. Pharm. Bull. 
46, 482–487. 
Suzuki, M., Machida, M., Adachi, K., Otabe, K., Sugimoto, T., Hayashi, M., Awazu, 
S., 2000. Histopathological study of the effects of a single intratracheal 
instillation of surface active agents on lung in rats. J. Toxicol. Sci. 25, 49–55. 
Tanaka, Y., Inkyo, M., Yumoto, R., Nagai, J., Takano, M., Nagata, S., 2012. 
Nanoparticulation of probucol, a poorly water-soluble drug, using a novel 
wet-milling process to improve in vitro dissolution and in vivo oral 
absorption. Drug Dev. Ind. Pharm. 38, 1015–1023. 
Terife, G., Wang, P., Faridi, N., Gogos, C.G., 2012. Hot melt mixing and foaming of 
soluplus® and indomethacin. Polymer Engineering & Science 52, 1629–1639. 
Thakral, S., Thakral, N.K., 2013. Prediction of drug–polymer miscibility through the 
use of solubility parameter based Flory–Huggins interaction parameter and the 
experimental validation: PEG as model polymer. J. Pharm. Sci. 102, 2254–
2263. 
Toziopoulou, F., Malamatari, M., Nikolakakis, I., Kachrimanis, K., 2017. Production 
of aprepitant nanocrystals by wet media milling and subsequent solidification. 
Int. J. Pharm. 533, 324–334. 
Truong, D.H., Tran, T.H., Ramasamy, T., Choi, J.Y., Choi, H.-G., Yong, C.S., Kim, 
J.O., 2015. Preparation and characterization of solid dispersion using a novel 
amphiphilic copolymer to enhance dissolution and oral bioavailability of 
sorafenib. Powder Technol. 283, 260–265. 
Tuomela, A., Liu, P., Puranen, J., Rönkkö, S., Laaksonen, T., Kalesnykas, G., Oksala, 
O., Ilkka, J., Laru, J., Järvinen, K., 2014. Brinzolamide nanocrystal 
formulations for ophthalmic delivery: reduction of elevated intraocular 
pressure in vivo. Int. J. Pharm. 467, 34–41. 
Van Drooge, D.J., Braeckmans, K., Hinrichs, W.L., Remaut, K., De Smedt, S.C., 
Frijlink, H.W., 2006. Characterization of the mode of incorporation of 
lipophilic compounds in solid dispersions at the nanoscale using fluorescence 
resonance energy transfer (FRET). Macromol. Rapid Commun. 27, 1149-
1155. 
Van Eerdenbrugh, B., Froyen, L., Martens, J., Blaton, N., Augustijns, P., Brewster, 
M., Van den Mooter, G., 2007. Characterization of physico-chemical 
properties and pharmaceutical performance of sucrose co-freeze–dried solid 
 323 
 
nanoparticulate powders of the anti-HIV agent loviride prepared by media 
milling. Int. J. Pharm. 338, 198–206. 
Van Eerdenbrugh, B., Froyen, L., Van Humbeeck, J., Martens, J.A., Augustijns, P., 
Van Den Mooter, G., 2008a. Alternative matrix formers for nanosuspension 
solidification: dissolution performance and X-ray microanalysis as an 
evaluation tool for powder dispersion. Eur. J. Pharm. Sci. 35, 344–353. 
Van Eerdenbrugh, B., Froyen, L., Van Humbeeck, J., Martens, J.A., Augustijns, P., 
Van den Mooter, G., 2008b. Drying of crystalline drug nanosuspensions—the 
importance of surface hydrophobicity on dissolution behavior upon 
redispersion. Eur. J. Pharm. Sci. 35, 127–135. 
Van Eerdenbrugh, B., Van den Mooter, G., Augustijns, P., 2008c. Top-down 
production of drug nanocrystals: nanosuspension stabilization, miniaturization 
and transformation into solid products. Int. J. Pharm. 364, 64–75. 
Van Eerdenbrugh, B., Vercruysse, S., Martens, J., Vermant, J., Froyen, L., Van, J.H., 
den Mooter Van, G., Augustijns, P., 2008d. Microcrystalline cellulose, a 
useful alternative for sucrose as a matrix former during freeze-drying of drug 
nanosuspensions-a case study with itraconazole. Eur. J. Pharm. Biopharm. 70, 
590–596. 
Vasconcelos, T., Marques, S., das Neves, J., Sarmento, B., 2016. Amorphous solid 
dispersions: Rational selection of a manufacturing process. Adv. Drug 
Delivery Rev. 100, 85-101. 
Vasconcelos, T., Sarmento, B., Costa, P., 2007. Solid dispersions as strategy to 
improve oral bioavailability of poor water soluble drugs. Drug Discovery 
Today 12, 1068–1075. 
Vatanara, A., 2015. Spray drying of nanoparticles to form fast dissolving glipizide. 
Asian J. Pharm. 9, 213–218. 
Vehring, R., 2008. Pharmaceutical particle engineering via spray drying. Pharm. Res. 
25, 999–1022. 
Verma, S., Kumar, S., Gokhale, R., Burgess, D.J., 2011. Physical stability of 
nanosuspensions: investigation of the role of stabilizers on Ostwald ripening. 
Int. J. Pharm. 406, 145–152. 
Vo, C.L.-N., Park, C., Lee, B.-J., 2013. Current trends and future perspectives of solid 
dispersions containing poorly water-soluble drugs. Eur. J. Pharm. Biopharm. 
85, 799-813. 
Wang, B., Zhang, W., Zhang, W., Mujumdar, A.S., Huang, L., 2005. Progress in 
drying technology for nanomaterials. Drying Technol. 23, 7–32. 
 324 
 
Wang, Y., Kho, K., Cheow, W.S., Hadinoto, K., 2012. A comparison between spray 
drying and spray freeze drying for dry powder inhaler formulation of drug-
loaded lipid–polymer hybrid nanoparticles. Int. J. Pharm. 424, 98–106. 
Wang, Y., Zheng, Y., Zhang, L., Wang, Q., Zhang, D., 2013. Stability of 
nanosuspensions in drug delivery. J. Controlled Release 172, 1126–1141. 
Washburn, E.W., 1921. The dynamics of capillary flow. Phys. Rev. 17, 273–283. 
Winnik, F.M., Winnik, M.A., 1990. The interaction of sodium dodecylsulfate with 
(hydroxypropyl) cellulose. Polym. J. 22, 482–488. 
Wlodarski, K., Sawicki, W., Kozyra, A., Tajber, L., 2015. Physical stability of solid 
dispersions with respect to thermodynamic solubility of tadalafil in PVP-VA. 
Eur. J. Pharm. Biopharm. 96, 237–246. 
Wu, L., Zhang, J., Watanabe, W., 2011. Physical and chemical stability of drug 
nanoparticles. Adv. Drug Delivery Rev. 63, 456–469. 
Wu, T., Yu, L., 2006. Surface crystallization of indomethacin below T g. Pharm. Res. 
23, 2350-2355. 
Wu, W., Nancollas, G.H., 1998. A new understanding of the relationship between 
solubility and particle size. J. Solution Chem. 27, 521–531. 
Xia, D., Yu, H., Tao, J., Zeng, J., Zhu, Q., Zhu, C., Gan, Y., 2016. Supersaturated 
polymeric micelles for oral cyclosporine A delivery: the role of Soluplus–
sodium dodecyl sulfate complex. Colloids Surf. B Biointerfaces 141, 301–
310. 
Yalkowsky, S.H., Roseman, T.J., 1981. Techniques of solubilization of drugs. M. 
Dekker, New York. 
Yamashita, K., Nakate, T., Okimoto, K., Ohike, A., Tokunaga, Y., Ibuki, R., Higaki, 
K., Kimura, T., 2003. Establishment of new preparation method for solid 
dispersion formulation of tacrolimus. Int. J. Pharm. 267, 79–91. 
Yan, Y.-D., Sung, J.H., Kim, K.K., Kim, D.W., Kim, J.O., Lee, B.-J., Yong, C.S., 
Choi, H.-G., 2012. Novel valsartan-loaded solid dispersion with enhanced 
bioavailability and no crystalline changes. Int. J. Pharm. 422, 202–210. 
Yang, H., Teng, F., Wang, P., Tian, B., Lin, X., Hu, X., Zhang, L., Zhang, K., Zhang, 
Y., Tang, X., 2014. Investigation of a nanosuspension stabilized by Soluplus® 
to improve bioavailability. Int. J. Pharm. 477, 88–95. 
Yu, L., 2001. Amorphous pharmaceutical solids: preparation, characterization and 
stabilization. Adv. Drug Delivery Rev. 48, 27-42. 
 325 
 
Żarów, A., Zhou, B., Wang, X., Pinal, R., Iqbal, Z., 2011. Spectroscopic and X-ray 
diffraction study of structural disorder in cryomilled and amorphous 
griseofulvin. Appl. Spectrosc. 65, 135–143. 
Zhang, S., Lee, T.W., Chow, A.H., 2016. Crystallization of itraconazole polymorphs 
from melt. Crystal Growth & Design 16, 3791–3801. 
Zhang, X., Guan, J., Ni, R., Li, L.C., Mao, S., 2014. Preparation and solidification of 
redispersible nanosuspensions. J. Pharm. Sci. 103, 2166–2176. 
Zhang, X., Xing, H., Zhao, Y., Ma, Z., 2018. Pharmaceutical dispersion techniques 
for dissolution and bioavailability enhancement of poorly water-soluble drugs. 
Pharmaceutics 10, 74. 
 
Zuo, B., Sun, Y., Li, H., Liu, X., Zhai, Y., Sun, J., He, Z., 2013. Preparation and in 
vitro/in vivo evaluation of fenofibrate nanocrystals. Int. J. Pharm. 455, 267–
275. 
 
 
 
 
 
 
 
 
